Generated by All in One SEO Pro v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# The Clinical Trial Vanguard

Your premier source for the latest clinical trial news

## Sitemaps

- [XML Sitemap](https://www.clinicaltrialvanguard.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [AI and ML in Predicting Biopharmaceutical Product Profile Approvability](https://www.clinicaltrialvanguard.com/conference-coverage/ai-and-ml-in-predicting-biopharmaceutical-product-profile-approvability/) - Explore how AI and machine learning transform pharmaceutical regulatory processes at the 2024 DIA conference. Legal dimensions in AI and ML in clinical trials.
- [In-Silico Breakthrough: EMA’s Shift from Animal Testing](https://www.clinicaltrialvanguard.com/conference-coverage/in-silico-breakthrough-emas-shift-from-animal-testing/) - Advance drug development with Organ-on-Chip technologies, reducing reliance on Animal Testing at the DIA 2024 European conference.
- [FDA On Clinical Trial Innovation and Regulatory Evolution](https://www.clinicaltrialvanguard.com/conference-coverage/fda-on-clinical-trial-innovation-and-regulatory-evolution/) - FDA accelerates access to treatments for rare diseases, clinical trial innovation and novel regulatory approaches at the Duke Margolis conference.
- [How Practical Is FDA's HCP Approach in DCTs?](https://www.clinicaltrialvanguard.com/article/how-practical-is-fdas-hcp-approach-in-dcts/) - FDA's latest guidance on DCTs marks a pivotal shift in the clinical research landscape. But is it truly feasible to integrate local HCPs into clinical trials?
- [When the Trial Ends, the Data Work Begins](https://www.clinicaltrialvanguard.com/executiveinterviews/when-the-trial-ends-the-data-work-begins/) - Dr. Olga Kubassova, Founder and CEO of Image Analysis Group (IAG), discusses how AI-driven imaging biomarkers extend the value of clinical trial data beyond database lock, from IAG's real-world validation work with Ferring Pharmaceuticals in fertility trials to what it takes to scale an AI imaging pilot into a global rollout.
- [When the Trial Fails, Was It the Drug or the Design?](https://www.clinicaltrialvanguard.com/executiveinterviews/when-the-trial-fails-was-it-the-drug-or-the-design/) - NetraMark's Chief Innovation and Regulatory Officer Luca Pani, MD, on why broad enrollment can obscure treatment effects, what makes an AI-derived subgroup credible, and how Phase 2 should inform Phase 3.
- [The CRO Isn't Failing Your Trial. Your Governance Model Is.](https://www.clinicaltrialvanguard.com/clinical-bellwether/the-cro-isnt-failing-your-trial-your-governance-model-is/) - Sponsors treat CRO contract signing as a handoff. Three independent clinical ops leaders say that abdication, not bad molecules, is killing small biotech…
- [The 90% Automation Promise Means Nothing to a Coordinator Running 12 Systems](https://www.clinicaltrialvanguard.com/clinical-bellwether/the-90-automation-promise-means-nothing-to-a-coordinator-running-12-systems/) - Medable's CEO wants 90% of clinical trials automated by 2030. Site coordinators are still manually bridging 12 disconnected systems. Both are true, and that's…
- [Asia Pacific Is No Longer a Backup Plan. Sponsors Who Still Treat It That Way Are Falling Behind.](https://www.clinicaltrialvanguard.com/executiveinterviews/asia-pacific-is-no-longer-a-backup-plan-sponsors-who-still-treat-it-that-way-are-falling-behind/) - Precision for Medicine's James Cheong and JingPing Yeo on what has actually changed in APAC clinical operations, and what biotechs still get wrong when they arrive.
- [The Protocol-Only Coverage Analysis: What a Site Can Defend Before the Budget Arrives](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/the-protocol-only-coverage-analysis-what-a-site-can-defend-before-the-budget-arrives/) - A protocol-scoped MCA is a real deliverable, but it has hard limits. Here is what you can and cannot defend at feasibility.
- [FDA's 2026 Single-Trial Default Standard Reframes the Dual-Pivotal Debate for Sponsors Still Designing Phase 3](https://www.clinicaltrialvanguard.com/opinion/fdas-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sponsors-still-designing-phase-3/) - FDA's 2026 shift to a single pivotal trial as the default approval standard forces sponsors to rethink Phase 3 design before the next IND meeting.
- [Risk-Based Source Data Verification Adoption Rises to 96% in Clinical Trials](https://www.clinicaltrialvanguard.com/news/risk-based-source-data-verification-adoption-rises-to-96-in-clinical-trials/) - Risk-based source data verification adoption reaches 96% in clinical trials, reshaping how monitors prioritize verification intensity across sites and data fiel
- [Merry Life Biomedical Starts Phase 2 Trial of TML-6 for Early Alzheimer's](https://www.clinicaltrialvanguard.com/news/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimers/) - Merry Life Biomedical starts Phase 2 trial of TML-6, an oral drug targeting autophagy-lysosomal pathways in early Alzheimer's disease across 20 global sites.
- [Ivonescimab beats durvalumab in biliary tract cancer Phase III trial](https://www.clinicaltrialvanguard.com/news/ivonescimab-beats-durvalumab-in-biliary-tract-cancer-phase-iii-trial/) - Ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit over durvalumab in biliary tract cancer Phase III trial HARMONi-GI1.
- [EC Approves Obicetrapib as Oral CETP Inhibitor for Hypercholesterolemia](https://www.clinicaltrialvanguard.com/news/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia/) - European Commission approves obicetrapib, a CETP inhibitor for hypercholesterolemia, offering oral dosing and 41% LDL-C reduction in Phase 3 trials.
- [Roche's Enicepatide Meets Phase II Endpoints in Type 2 Diabetes Trial](https://www.clinicaltrialvanguard.com/news/roches-enicepatide-meets-phase-ii-endpoints-in-type-2-diabetes-trial/) - Roche's enicepatide met Phase II endpoints in type 2 diabetes trial, demonstrating dose-dependent reductions in HbA1c and body weight over 48 weeks.
- [What Radial's 27-Site Brain Medicine Network Actually Means for EEG Endpoint Standardization](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/what-radials-27-site-brain-medicine-network-actually-means-for-eeg-endpoint-standardization/) - Radial's FDA-cleared Evoke EEG integration across 27 brain medicine clinics tests whether distributed neuroimaging endpoints can survive real-world site…
- [The Liquid Biopsy That Found Pancreatic Cancer Early Has a Bigger Regulatory Problem Than Its Science](https://www.clinicaltrialvanguard.com/opinion/the-liquid-biopsy-that-found-pancreatic-cancer-early-has-a-bigger-regulatory-problem-than-its-science/) - PANXEON detects stage 1-2 pancreatic cancer with 87% sensitivity, but FDA's companion diagnostic pathway may be the bigger obstacle to clinical adoption.
- [FDA Part 11 Compliance: Audit Trails and Electronic Signatures](https://www.clinicaltrialvanguard.com/news/fda-part-11-compliance-audit-trails-and-electronic-signatures/) - FDA Part 11 Compliance requires validated systems, audit trails, and electronic signatures linked to individual users. Learn what triggers 483 observations.
- [Phase III Clinical Trials Now Generate 5.9M Data Points Annually, Growing 11% Yearly](https://www.clinicaltrialvanguard.com/news/phase-iii-clinical-trials-now-generate-5-9m-data-points-annually-growing-11-yearly/) - Phase III Clinical Trials now generate 5.9M data points annually with 11% yearly growth, raising questions about managing protocol complexity and data quality.
- [Wearable neuromodulation reduces AF recurrence after ablation in pilot trial](https://www.clinicaltrialvanguard.com/news/wearable-neuromodulation-reduces-af-recurrence-after-ablation-in-pilot-trial/) - Wearable neuromodulation reduces AF recurrence after ablation in pilot trial, with 90% freedom from arrhythmias at six months versus 80.8% with sham.
- [Accro Bioscience Doses First Patient in AC-101 Phase IIb Trial for Ulcerative Colitis](https://www.clinicaltrialvanguard.com/news/accro-bioscience-doses-first-patient-in-ac-101-phase-iib-trial-for-ulcerative-colitis/) - Accro Bioscience doses first patient in AC-101 Phase IIb trial for ulcerative colitis, targeting the NOD/RIPK2 pathway with a 12-week clinical remission endpoin
- [Antengene Starts Phase III CLINCH-3 Trial of ATG-022 in Advanced Gastric Cancer](https://www.clinicaltrialvanguard.com/news/antengene-starts-phase-iii-clinch-3-trial-of-atg-022-in-advanced-gastric-cancer/) - Antengene launches Phase III CLINCH-3 Trial of ATG-022 in advanced gastric cancer, building on 46.7% response rates from Phase I/II data.
- [Lavengratinib Shows 100% Response Rate in Lowest Dose Achondroplasia Cohort](https://www.clinicaltrialvanguard.com/news/lavengratinib-shows-100-response-rate-in-lowest-dose-achondroplasia-cohort/) - Lavengratinib achondroplasia trial shows 100% responder rate in lowest dose cohort with 2.4 cm/year growth improvement and clean safety profile.
- [AbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancer](https://www.clinicaltrialvanguard.com/executiveinterviews/abbvies-bet-on-biology-why-one-modality-is-never-enough-in-lung-cancer/) - Daejin Abidoye, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology at AbbVie, discusses new data from ABBV-1480 (RC148) and ABBV-706 being presented at IASLC 2026 World Conference on Lung Cancer (WCLC), how AbbVie is advancing their programs and where biomarkers and AI could shape the future of oncology development.
- [What the Lancet Psychiatry Mania Data Gets Right, and What It Still Can't Tell Us](https://www.clinicaltrialvanguard.com/article/psych-pulse/what-the-lancet-psychiatry-mania-data-gets-right-and-what-it-still-cant-tell-us/) - A new target trial emulation in Lancet Psychiatry challenges antipsychotic-first strategies in early psychotic mania. Here's what it means for continuation…
- [Velocity Clinical Research appoints Justin Starzyk as CEO](https://www.clinicaltrialvanguard.com/news/velocity-clinical-research-appoints-justin-starzyk-as-ceo/) - Velocity Clinical Research appoints Justin Starzyk as CEO to lead its 70+ research sites across the U.S. and Europe.
- [Teva Study: Providers Prioritize Tolerability Over Efficacy in Tardive Dyskinesia](https://www.clinicaltrialvanguard.com/news/teva-study-providers-prioritize-tolerability-over-efficacy-in-tardive-dyskinesia/) - Teva study reveals healthcare providers prioritize tolerability and dosing convenience over efficacy when treating tardive dyskinesia in older patients.
- [Teva's TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trial](https://www.clinicaltrialvanguard.com/news/tevas-tev-749-olanzapine-lai-shows-80-stabilization-rate-in-schizophrenia-trial/) - TEV-749 olanzapine LAI achieved 80% clinical stabilization in schizophrenia patients during the SOLARIS Phase 3 trial, with durability sustained in open-label e
- [CHMP Recommends Ocrevus Approval for Pediatric Relapsing MS](https://www.clinicaltrialvanguard.com/news/chmp-recommends-ocrevus-approval-for-pediatric-relapsing-ms/) - CHMP recommends Ocrevus pediatric relapsing MS approval for children aged 10+, advancing toward European Commission authorization within two months.
- [FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer](https://www.clinicaltrialvanguard.com/news/fda-approves-imlunestrant-plus-abemaciclib-for-esr1-mutated-breast-cancer/) - FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 trials.
- [The RIO Trial's Viral Rebound Data Just Complicated Every HIV Functional Cure Strategy on the Market](https://www.clinicaltrialvanguard.com/article/article-deep-dive/the-rio-trials-viral-rebound-data-just-complicated-every-hiv-functional-cure-strategy-on-the-market/) - Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise hard questions for…
- [Certara Launches External Data Accelerator for CDISC Standards Compliance](https://www.clinicaltrialvanguard.com/news/certara-launches-external-data-accelerator-for-cdisc-standards-compliance/) - Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of clinical study data from external source
- [Boehringer Ingelheim launches PED Essentials for patient data collection](https://www.clinicaltrialvanguard.com/news/boehringer-ingelheim-launches-ped-essentials-for-patient-data-collection/) - Boehringer Ingelheim's PED Essentials teaches patient organizations to collect and structure patient experience data for regulatory submissions and advocacy.
- [SkinCure Analysis: Nonmelanoma Skin Cancer Cases 42% Higher Than Official Count](https://www.clinicaltrialvanguard.com/news/skincure-analysis-nonmelanoma-skin-cancer-cases-42-higher-than-official-count/) - New analysis suggests nonmelanoma skin cancer cases are 42% higher than official counts, with annual patient numbers reaching 4.7 million.
- [CDC Reports 17% Surge in Rabies Inquiries; Kamada Confirms KedRAB Supply](https://www.clinicaltrialvanguard.com/news/cdc-reports-17-surge-in-rabies-inquiries-kamada-confirms-kedrab-supply/) - Kamada confirms KedRAB supply meets surge in rabies inquiries. CDC reports 17% increase in rabies-related cases through summer 2026.
- [MIRA Pharmaceuticals Initiates Phase 2a Study of Ketamir-2 for Chemotherapy-Induced Peripheral Neuropathy](https://www.clinicaltrialvanguard.com/news/mira-pharmaceuticals-initiates-phase-2a-study-of-ketamir-2-for-chemotherapy-induced-peripheral-neuropathy/) - MIRA Pharmaceuticals initiates Phase 2a study of Ketamir-2 for chemotherapy-induced peripheral neuropathy, targeting an undertreated condition affecting over ha
- [PEDMARK Hearing Protection Shows No Cancer Efficacy Compromise in Study](https://www.clinicaltrialvanguard.com/news/pedmark-hearing-protection-shows-no-cancer-efficacy-compromise-in-study/) - PEDMARK hearing protection met its primary endpoint in a Phase 2 study, showing significant ototoxicity reduction without compromising cisplatin's anticancer ef
- [The Screen Failure You Can Prevent Before the Patient Leaves Home](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/the-screen-failure-you-can-prevent-before-the-patient-leaves-home/) - Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's trial pre-screening operations.
- [Medpace Expands Phase I Unit With On-Site Imaging and Specialized Assessments](https://www.clinicaltrialvanguard.com/news/medpace-expands-phase-i-unit-with-on-site-imaging-and-specialized-assessments/) - Medpace expands Phase I Unit with on-site imaging and specialized assessments to reduce participant dropout and keep trial endpoints aligned.
- [RBQM vs. RBDM: Data Teams Must Link Quality Plans to Management Protocols](https://www.clinicaltrialvanguard.com/news/rbqm-vs-rbdm-data-teams-must-link-quality-plans-to-management-protocols/) - Risk-based quality management requires linking quality plans to data management protocols. EU regulators now expect documented traceability between RBQM strateg
- [Coya Therapeutics Enrolls 100th Patient in ALSTARS Trial of COYA 302 for ALS](https://www.clinicaltrialvanguard.com/news/coya-therapeutics-enrolls-100th-patient-in-alstars-trial-of-coya-302-for-als/) - Coya Therapeutics enrolls 100th patient in ALSTARS trial of COYA 302 for ALS, reaching a key recruitment milestone for the Phase 2/3 study.
- [BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients](https://www.clinicaltrialvanguard.com/news/bh-30643-achieves-45-response-rate-in-osimertinib-resistant-nsclc-patients/) - BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients with C797S mutations, showing 88% disease control in Phase 1/2 trial.
- [Summit Therapeutics Presents Updated Overall Survival Data for Ivonescimab in EGFR-Mutated NSCLC](https://www.clinicaltrialvanguard.com/news/summit-therapeutics-presents-updated-overall-survival-data-for-ivonescimab-in-egfr-mutated-nsclc/) - Summit Therapeutics presents updated overall survival results for ivonescimab in EGFR-mutated NSCLC from the Phase III HARMONi trial.
- [Roche's Lunsumio combo meets primary endpoint in Phase III follicular lymphoma trial](https://www.clinicaltrialvanguard.com/news/roches-lunsumio-combo-meets-primary-endpoint-in-phase-iii-follicular-lymphoma-trial/) - Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide on progression-free survival.
- ["Hard to Reach" Is a Sponsor Operations Failure, Not a Population Problem](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/hard-to-reach-is-a-sponsor-operations-failure-not-a-population-problem/) - The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure with a measurable fix.
- [Benchmark Scores Don't Save Patients: Why Clinical AI Needs RCT-Grade Evidence Before It Touches a Workflow](https://www.clinicaltrialvanguard.com/opinion/benchmark-scores-dont-save-patients-why-clinical-ai-needs-rct-grade-evidence-before-it-touches-a-workflow/) - Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets a real patient at 2 a.m.
- [Mednet AI Intake Tool Automates EHR-to-EDC Data Entry in Clinical Trials](https://www.clinicaltrialvanguard.com/news/mednet-ai-intake-tool-automates-ehr-to-edc-data-entry-in-clinical-trials/) - Mednet AI intake tool automates EHR-to-EDC data entry in clinical trials, reducing manual transcription and entry errors for research coordinators.
- [Hinge Bio Uses Single Medrio Platform for Phase I Trial Operations](https://www.clinicaltrialvanguard.com/news/hinge-bio-uses-single-medrio-platform-for-phase-i-trial-operations/) - Hinge Bio runs its Phase I trial on a single Medrio platform, consolidating EDC, ePRO, and RTSM to reduce setup time and site burden.
- [Pulse Biosciences Closes PRECISE-BTN Thyroid Nodule Trial Enrollment](https://www.clinicaltrialvanguard.com/news/pulse-biosciences-closes-precise-btn-thyroid-nodule-trial-enrollment/) - Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout within
- [FDA Aligns on Rocket Pharmaceuticals RP-A501 Phase 2 Trial Design for Danon Disease](https://www.clinicaltrialvanguard.com/news/fda-aligns-on-rocket-pharmaceuticals-rp-a501-phase-2-trial-design-for-danon-disease/) - FDA aligns on RP-A501 Phase 2 trial design for Danon disease, approving a 12-patient pivotal population and 12-month endpoint structure.
- [CRB-913 Obesity Drug Shows 5% Weight Loss in Phase 1b Trial](https://www.clinicaltrialvanguard.com/news/crb-913-obesity-drug-shows-5-weight-loss-in-phase-1b-trial/) - CRB-913 obesity drug achieved 5% weight loss in Phase 1b trial, signaling potential for a peripheral CB1 mechanism without central nervous system effects.
- [TRUTAKNA Meets All Endpoints in Phase 3 IgA Nephropathy Trial Final Analysis](https://www.clinicaltrialvanguard.com/news/trutakna-meets-all-endpoints-in-phase-3-iga-nephropathy-trial-final-analysis/) - TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease progression prevention over 104 weeks.
- [When the Scan Knows Before the Spirometer Does](https://www.clinicaltrialvanguard.com/executiveinterviews/when-the-scan-knows-before-the-spirometer-does/) - Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT is rewriting the evidence playbook for fibrotic lung disease, and what it will take to make that standard of care.
- [FDA Hears 80 Speakers on Psychedelic Drug Therapy Standards](https://www.clinicaltrialvanguard.com/conference-coverage/fda-hears-80-speakers-on-psychedelic-drug-therapy-standards/) - FDA held public hearing on psychedelic drug therapy with 80 speakers. Explore debates on safety, credentialing, and equitable access.
- [Compass Pathways Just Answered the Durability Question. Now Comes the Harder Problem.](https://www.clinicaltrialvanguard.com/clinical-bellwether/compass-pathways-just-answered-the-durability-question-now-comes-the-harder-problem/) - Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without scheduling…
- [Biohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA Requires Every Sponsor to Answer](https://www.clinicaltrialvanguard.com/clinops-watchdog/biohaven-advanced-bhv-7000-to-pivotal-trials-without-answering-a-question-the-fda-requires-every-sponsor-to-answer/) - FDA's Sept. 4 partial hold on Biohaven's opakalim exposes a metabolite characterization gap that ICH M3(R2) and FDA's 2021 guidance forbid sponsors from…
- [The FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.](https://www.clinicaltrialvanguard.com/article/trend-watch/the-fda-just-handed-psychedelic-drug-sponsors-a-framework-now-the-hard-part-starts/) - FDA finalized its psychedelic drug guidance July 14, 2026. COMPASS, Usona, and MAPS now face blinding failures, DEA barriers, and "set and setting" protocol…
- [YPrime Guide: Supply Management Critical to IRT Trial Success for Biotech Sponsors](https://www.clinicaltrialvanguard.com/news/yprime-guide-supply-management-critical-to-irt-trial-success-for-biotech-sponsors/) - Supply management and vendor accountability determine IRT trial success for biotech sponsors. YPrime's guide identifies critical cost exposure points and evalua
- [Researchers Misread IRB Review Pathways, Delaying Study Startups](https://www.clinicaltrialvanguard.com/news/researchers-misread-irb-review-pathways-delaying-study-startups/) - Researchers commonly misread IRB review pathways, causing study delays. Understanding exemption categories and expedited eligibility prevents protocol cycling.
- [Definium's DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study](https://www.clinicaltrialvanguard.com/news/definiums-dt120-odt-meets-primary-endpoint-in-phase-3-gad-study/) - Definium's DT120 ODT met its primary endpoint in Phase 3 testing for generalized anxiety disorder, potentially offering an alternative to decades-old SSRI and S
- [Sionna to Test SION-451 and SION-2222 Combo in CF Phase 2a Trial](https://www.clinicaltrialvanguard.com/news/sionna-to-test-sion-451-and-sion-2222-combo-in-cf-phase-2a-trial/) - Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients.
- [Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC](https://www.clinicaltrialvanguard.com/news/ivonescimab-beats-pembrolizumab-on-survival-in-first-line-pd-l1-positive-nsclc/) - Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC, extending median OS by over eight months in Phase III trial.
- [When the CRO and Sponsor Speak the Same Language, Oversight Stops Being a Negotiation](https://www.clinicaltrialvanguard.com/executiveinterviews/when-the-cro-and-sponsor-speak-the-same-language-oversight-stops-being-a-negotiation/) - Ed Fowler, Parexel's former Vice President of Operational Excellence, on what shared CTMS infrastructure has changed — and what sponsors running manual processes are still getting wrong.
- [The Algorithm Passed Every Benchmark. The Patients Didn't Notice.](https://www.clinicaltrialvanguard.com/article/article-deep-dive/the-algorithm-passed-every-benchmark-the-patients-didnt-notice/) - A landmark Nature Medicine RCT found AI improved clinician decisions but not patient outcomes, exposing the fatal flaw in how trials validate AI tools.
- [Novartis Pays $50M Milestone as MRT-6160 Enters Phase 2 for Sjögren's Disease](https://www.clinicaltrialvanguard.com/news/novartis-pays-50m-milestone-as-mrt-6160-enters-phase-2-for-sjogrens-disease/) - Novartis triggers $50M milestone payment as MRT-6160 enters Phase 2 for Sjögren's disease, advancing VAV1 degrader development.
- [The FDA Alignment Playbook Behind Ocular Therapeutix's Single-Trial NDA](https://www.clinicaltrialvanguard.com/executiveinterviews/the-fda-alignment-playbook-behind-ocular-therapeutixs-single-trial-nda/) - How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing trials the old way.
- [AI in Clinical Trials Doesn't Have a Capability Problem. It Has a Honesty Problem.](https://www.clinicaltrialvanguard.com/clinical-bellwether/ai-in-clinical-trials-doesnt-have-a-capability-problem-it-has-a-honesty-problem/) - Six AI models picked the same "random" number. Clinical ops leaders are finally asking what that reveals about every AI-assisted trial decision underneath.
- [When the ER Is Not an Option: Milestone's CMO on Bringing AFib Rate Control Home](https://www.clinicaltrialvanguard.com/executiveinterviews/when-the-er-is-not-an-option-milestones-cmo-on-bringing-afib-rate-control-home/) - The FDA approval of etripamil for PSVT occurred in December, 2025. Investigation about a potential role of etripamil in highly symptomatic AFib, The ReVeRA-Phase 3, trial is another test: can this self-administered nasal spray put an all-too-frequent emergency department problem back in the patient'
- [FDA Grants Priority Review to Roche's Enspryng for MOGAD](https://www.clinicaltrialvanguard.com/news/fda-grants-priority-review-to-roches-enspryng-for-mogad/) - FDA grants Priority Review to Roche's Enspryng for MOGAD after Phase III trial showed 68% reduction in relapse risk versus placebo.
- [Ivonescimab Meets Overall Survival Endpoint Against Pembrolizumab in Phase III Trial](https://www.clinicaltrialvanguard.com/news/ivonescimab-meets-overall-survival-endpoint-against-pembrolizumab-in-phase-iii-trial/) - Ivonescimab meets overall survival endpoint against pembrolizumab in Phase III HARMONi-2 trial, with statistically significant results expected to influence FDA
- [What the FDA's New Psychedelic Framework Actually Means for the Clinic](https://www.clinicaltrialvanguard.com/article/psych-pulse/what-the-fdas-new-psychedelic-framework-actually-means-for-the-clinic/) - FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and MDMA therapies.
- [Insilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPF](https://www.clinicaltrialvanguard.com/news/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-ipf/) - Rentosertib becomes first AI-discovered drug in Phase III trial for IPF, testing lung-function decline over 52 weeks across 47 Chinese sites.
- [J&J Exits LAA Closure Market, Sells Laminar Program to Jaguar LAA](https://www.clinicaltrialvanguard.com/news/jj-exits-laa-closure-market-sells-laminar-program-to-jaguar-laa/) - Johnson & Johnson sells Laminar program to newly formed Jaguar LAA for left atrial appendage closure technology development and regulatory pursuit.
- [BridgeBio Shifts BBO-8520 Focus to KRAS Combinations in Second-Line NSCLC](https://www.clinicaltrialvanguard.com/news/bridgebio-shifts-bbo-8520-focus-to-kras-combinations-in-second-line-nsclc/) - BridgeBio shifts BBO-8520 focus to KRAS combinations in second-line NSCLC, building on a 63% response rate from monotherapy.
- [Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Lp(a) Trial](https://www.clinicaltrialvanguard.com/news/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lpa-trial/) - Pelacarsen fails to meet primary endpoint in Phase 3 Lp(a) trial, raising questions about biomarker-outcome relationships in cardiovascular drug development.
- [Fresenius Got a Warning Letter Six Months After the Complaints Started. That Gap Is the Real Problem.](https://www.clinicaltrialvanguard.com/clinops-watchdog/fresenius-got-a-warning-letter-six-months-after-the-complaints-started-that-gap-is-the-real-problem/) - FDA's August 2026 warning letter to Fresenius Kabi's Ogden, Utah plant exposes how sponsor oversight of CMOs fails long before regulators arrive.
- [Tarsus Pharmaceuticals Acquires Alkeus, Gildeuretinol for Stargardt Disease](https://www.clinicaltrialvanguard.com/news/tarsus-pharmaceuticals-acquires-alkeus-gildeuretinol-for-stargardt-disease/) - Tarsus Pharmaceuticals acquires gildeuretinol for Stargardt disease, an oral drug in Phase 3 development with FDA breakthrough therapy designation.
- [Inhibrx to Present INBRX-106 Phase 2 Data in Head and Neck Cancer Study](https://www.clinicaltrialvanguard.com/news/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study/) - Inhibrx releases Phase 2 primary endpoint data for INBRX-106 in head and neck cancer, testing hexavalent OX40 agonist plus pembrolizumab.
- [The Mitochondrial Switch That Makes Drugs Different From Food](https://www.clinicaltrialvanguard.com/article/psych-pulse/the-mitochondrial-switch-that-makes-drugs-different-from-food/) - New Nature Neuroscience data shows MCU inhibition blocks drug reward without touching natural reward circuits, a mechanistic breakthrough for OUD trial design.
- [Kylo-11's 97% Lp(a) Reduction from a Single Dose Rewrites the Durability Standard for siRNA Cardiovascular Trials](https://www.clinicaltrialvanguard.com/article/intel-brief/kylo-11s-97-lpa-reduction-from-a-single-dose-rewrites-the-durability-standard-for-sirna-cardiovascular-trials/) - A single 600 mg dose of Kylo-11 cut lipoprotein(a) by 97% at 48 weeks in a Phase 1 trial, setting a new efficacy benchmark for siRNA cardiovascular drug…
- [Ivonescimab Beats Pembrolizumab on Overall Survival in Phase 3 NSCLC Trial](https://www.clinicaltrialvanguard.com/news/ivonescimab-beats-pembrolizumab-on-overall-survival-in-phase-3-nsclc-trial/) - Ivonescimab beats pembrolizumab on overall survival in Phase 3 NSCLC trial, marking a significant shift from the decade-long PD-L1 standard.
- [In Vivo CAR-T for CNS Autoimmune Disease Looks Promising. The Trial Design Problem Is Hiding in Plain Sight.](https://www.clinicaltrialvanguard.com/opinion/in-vivo-car-t-for-cns-autoimmune-disease-looks-promising-the-trial-design-problem-is-hiding-in-plain-sight/) - NEJM's lentiviral in vivo CAR-T data in neurologic autoimmune disease is compelling, but the trial infrastructure to validate it at scale barely exists.
- [TScan Therapeutics cuts 75% of workforce, pauses Phase 3 ALLOHA-2 trial for TSC-101](https://www.clinicaltrialvanguard.com/news/tscan-therapeutics-cuts-75-of-workforce-pauses-phase-3-alloha-2-trial-for-tsc-101/) - TScan Therapeutics pauses Phase 3 ALLOHA-2 trial after 75% workforce cut, shifting focus to preclinical solid tumor development.
- [Inventiva Completes NATiV3 Phase 3 Trial of Lanifibranor in MASH](https://www.clinicaltrialvanguard.com/news/inventiva-completes-nativ3-phase-3-trial-of-lanifibranor-in-mash/) - Inventiva completes NATiV3 Phase 3 trial of lanifibranor in MASH with histological readout weeks away, challenging established competitors.
- [Ultragenyx's apazunersen fails Phase 3 primary endpoint in Angelman syndrome](https://www.clinicaltrialvanguard.com/news/ultragenyxs-apazunersen-fails-phase-3-primary-endpoint-in-angelman-syndrome/) - Ultragenyx's apazunersen fails Phase 3 primary endpoint in Angelman syndrome, missing both cognitive and multidomain responder measures.
- [Rybrevant's Second Act: How J&J Is Rewriting the Rules for EGFR-Mutant Lung Cancer](https://www.clinicaltrialvanguard.com/executiveinterviews/rybrevants-second-act-how-jj-is-rewriting-the-rules-for-egfr-mutant-lung-cancer/) - From exon 20 insertions to subcutaneous delivery and inclusive trial design, Joshua Bauml explains why the biology demanded a different approach, and why first-line tolerability is now an efficacy argument.
- [Another AI Clinical Data Platform Just Launched. Here's What Sponsors Actually Need to Ask Before They Sign.](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/another-ai-clinical-data-platform-just-launched-heres-what-sponsors-actually-need-to-ask-before-they-sign/) - nPhase's AI clinical data platform promises smarter trial design, but before sponsors add another vendor, the activation-cycle math deserves a hard look.
- [MRI Surveillance Alone Outperforms MRI Plus Radiation in SCLC Trial](https://www.clinicaltrialvanguard.com/news/mri-surveillance-alone-outperforms-mri-plus-radiation-in-sclc-trial/) - MRI surveillance alone reduced cognitive failure risk by 40% versus MRI plus radiation in SCLC patients, per phase III MAVERICK trial results.
- [Trastuzumab Botidotin Shows 11.1-Month PFS vs T-DM1 in Phase 3 Trial](https://www.clinicaltrialvanguard.com/news/trastuzumab-botidotin-shows-11-1-month-pfs-vs-t-dm1-in-phase-3-trial/) - Trastuzumab Botidotin Phase 3 trial shows 11.1-month PFS versus 4.4 months with T-DM1 in HER2-positive breast cancer, with manageable safety profile.
- [Tam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancer](https://www.clinicaltrialvanguard.com/news/tam-peli-extends-survival-to-13-3-months-in-relapsed-small-cell-lung-cancer/) - Tam-Peli extends median survival to 13.3 months in relapsed small-cell lung cancer, a significant improvement over topotecan in phase III trials.
- [Ivonescimab Cuts Death Risk 27% vs Pembrolizumab in NSCLC Trial](https://www.clinicaltrialvanguard.com/news/ivonescimab-cuts-death-risk-27-vs-pembrolizumab-in-nsclc-trial/) - Ivonescimab cuts death risk 27% versus pembrolizumab in Phase III NSCLC trial, with median OS of 30.8 months versus 22.6 months.
- [Amivantamab plus chemotherapy achieves 34.3-month OS in EGFR exon 20 insertion lung cancer](https://www.clinicaltrialvanguard.com/news/amivantamab-plus-chemotherapy-achieves-34-3-month-os-in-egfr-exon-20-insertion-lung-cancer/) - Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling historical survival rates.
- [Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here's What the ENERGIZE-T Data Actually Mean](https://www.clinicaltrialvanguard.com/article/article-deep-dive/mitapivat-just-rewrote-the-treatment-floor-for-transfusion-dependent-thalassaemia-heres-what-the-energize-t-data-actually-mean/) - ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design reveals about the new evidentiary…
- [CMO Location Drives Site Selection for Parkinsonian Imaging Trial](https://www.clinicaltrialvanguard.com/news/cmo-location-drives-site-selection-for-parkinsonian-imaging-trial/) - CMO location drives site selection for Parkinsonian imaging trial, requiring geographic proximity to manufacturing over patient populations.
- [Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC](https://www.clinicaltrialvanguard.com/news/iza-bren-2-5-mg-kg-dose-advances-to-phase-3-in-egfr-mutated-nsclc/) - Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC after demonstrating superior efficacy and manageable safety in global patient populations.
- [Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial](https://www.clinicaltrialvanguard.com/news/tam-peli-meets-primary-endpoint-for-relapsed-small-cell-lung-cancer-in-phase-iii-trial/) - Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial, showing OS benefit over topotecan in Chinese patients.
- [What FDA's July 2026 Psychedelic Drug Guidance Actually Says About Trial Design](https://www.clinicaltrialvanguard.com/opinion/what-fdas-july-2026-psychedelic-drug-guidance-actually-says-about-trial-design/) - FDA's finalized psychedelic guidance rewrites the rules on blinding, informed consent, and session monitoring, and the NEJM's September 2026 analysis reveals…
- [Ennov Appoints Dr. Oxana Pickeral as New Chief Executive Officer](https://www.clinicaltrialvanguard.com/news/ennov-appoints-dr-oxana-pickeral-as-new-chief-executive-officer/) - Ennov appoints Dr. Oxana Pickeral as Chief Executive Officer, succeeding 27-year founder Olivier Pâris amid accelerating regulatory compliance demand.
- [PerZeption Receives NEI SBIR Grant for AMD Photostress Recovery Test](https://www.clinicaltrialvanguard.com/news/perzeption-receives-nei-sbir-grant-for-amd-photostress-recovery-test/) - PerZeption receives NEI SBIR grant to develop a photostress recovery test for AMD on tablet hardware, aiming to detect vision loss earlier than standard testing
- [Lyell completes LYL273 manufacturing transfer, delays Phase 1/2 timeline](https://www.clinicaltrialvanguard.com/news/lyell-completes-lyl273-manufacturing-transfer-delays-phase-1-2-timeline/) - Lyell completes LYL273 manufacturing transfer to its Bothell facility, though the Phase 1/2 colorectal cancer trial now faces enrollment delays.
- [China Accepts NCX 470 NDA for Review in Glaucoma Treatment](https://www.clinicaltrialvanguard.com/news/china-accepts-ncx-470-nda-for-review-in-glaucoma-treatment/) - China's drug regulator accepts NCX 470 NDA for review, advancing Nicox's nitric oxide-donating glaucoma drop toward potential approval in a major ophthalmology
- [Headlands Research Opens Grand Rapids Site Led by Rheumatology Investigator](https://www.clinicaltrialvanguard.com/news/headlands-research-opens-grand-rapids-site-led-by-rheumatology-investigator/) - Headlands Research opens Grand Rapids site led by rheumatology investigator Eric Slavin, expanding clinical trial capacity in the Midwest.
- [Velocity Clinical, Stitch expand partnership across 70+ sites to boost screening attendance](https://www.clinicaltrialvanguard.com/news/velocity-clinical-stitch-expand-partnership-across-70-sites-to-boost-screening-attendance/) - Velocity Clinical and Stitch expand partnership across 70+ sites, achieving a 9-point reduction in no-show rates and boosting screening attendance by over 20%.
- [Phase 3 study shows aQIVc superior to comparators in older adults](https://www.clinicaltrialvanguard.com/news/phase-3-study-shows-aqivc-superior-to-comparators-in-older-adults/) - Phase 3 study shows aQIVc demonstrated superior immunogenicity against influenza strains in adults 50 and older, with responses sustained through the season.
- [FDA Clears Prelude's PRT13722 Phase 1 Trial in HR-Positive Breast Cancer](https://www.clinicaltrialvanguard.com/news/fda-clears-preludes-prt13722-phase-1-trial-in-hr-positive-breast-cancer/) - FDA clears Prelude's PRT13722 Phase 1 trial in HR-positive breast cancer, advancing the oral KAT6A degrader toward patient enrollment.
- [The Validation Accords: Clinical Trials Are About to Learn What "Validated AI" Actually Means](https://www.clinicaltrialvanguard.com/article/trend-watch/the-validation-accords-clinical-trials-are-about-to-learn-what-validated-ai-actually-means/) - Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate trial data if sponsors…
- [The Data Integrity Crisis That Built a Company: Rick Graham on Why Clinical Trials Keep Failing Before the AI Even Starts](https://www.clinicaltrialvanguard.com/executiveinterviews/the-data-integrity-crisis-that-built-a-company-rick-graham-on-why-clinical-trials-keep-failing-before-the-ai-even-starts/) - TruTechnologies co-founder Rick Graham argues that the industry's real execution problem is not a modeling problem.
- [Women's Hearts, Underserved by Design: Anteris Technologies President David St. Denis on Closing Structural Heart's Most Overlooked Gap](https://www.clinicaltrialvanguard.com/executiveinterviews/womens-hearts-underserved-by-design-anteris-technologies-president-david-st-denis-on-closing-structural-hearts-most-overlooked-gap/) - The problem isn't that fewer women get aortic stenosis. It's that the entire pipeline, from diagnosis to device, was built without them in mind.
- [PSI CRO to Present Agile Models for Emerging Biotech at OCT New England](https://www.clinicaltrialvanguard.com/news/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england/) - PSI CRO presents agile models emerging biotech sponsors can use to scale global trials while maintaining operational control at OCT New England.
- [Senn Framework Targets Protocol-Specific Content for Live Site Initiation Visits](https://www.clinicaltrialvanguard.com/news/senn-framework-targets-protocol-specific-content-for-live-site-initiation-visits/) - Live site initiation visits should focus on protocol-specific content that creates operational risk, per Christine Senn's framework for SIV training design.
- [Seismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shock](https://www.clinicaltrialvanguard.com/news/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-cardiogenic-shock/) - Seismic Pharmaceuticals enrolls first patient in Phase 3 trial of istaroxime for cardiogenic shock, the only late-stage program targeting this deadly condition.
- [Tyra Selects 60mg Dose of Dabogratinib in NMIBC Phase 2 Study](https://www.clinicaltrialvanguard.com/news/tyra-selects-60mg-dose-of-dabogratinib-in-nmibc-phase-2-study/) - Tyra Biosciences selects 60mg dose of dabogratinib in NMIBC Phase 2 Study, advancing oral FGFR3 inhibitor development for bladder cancer treatment.
- [DYNAMIKA™: The Operating System for Imaging Clinical Trials](https://www.clinicaltrialvanguard.com/opinion/dynamika-the-operating-system-for-imaging-clinical-trials/) - DYNAMIKA by IAG runs imaging trials on one platform: AI-driven analysis, central reads, and imaging biomarkers from protocol to submission-ready endpoints.
- [A 25% Sample Size Cut Sounds Like a Win, Until You See the Amendment Queue](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/a-25-sample-size-cut-sounds-like-a-win-until-you-see-the-amendment-queue/) - CONSONANCE's digitally enhanced MS endpoint cut required sample size 24.9%. Here's what that number costs in protocol amendments, IRB time, and eCOA validation…
- [Proteomic Aging Clocks Just Changed What a Phase 2a Trial Has to Prove](https://www.clinicaltrialvanguard.com/article/intel-brief/proteomic-aging-clocks-just-changed-what-a-phase-2a-trial-has-to-prove/) - A Nature Biotechnology phase 2a trial ran six proteomic aging clocks simultaneously, here's what that means for biomarker strategy and FDA submission readiness.
- [Advarra Releases IRB Reportable Events Checklist to Reduce Over-Reporting](https://www.clinicaltrialvanguard.com/news/advarra-releases-irb-reportable-events-checklist-to-reduce-over-reporting/) - Advarra releases IRB reportable events checklist to help research teams distinguish critical safety signals from minor deviations requiring prompt review.
- [Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata](https://www.clinicaltrialvanguard.com/news/nektar-to-release-24-week-off-treatment-data-for-rezpegaldesleukin-in-alopecia-areata/) - Nektar will release 24-week off-treatment data for rezpegaldesleukin in alopecia areata, testing durability after dosing ends in the Phase 2b REZOLVE-AA study.
- [JST-018 Orthopoxvirus Antibody Enters Phase 1 Trial Under $123.9M Defense Contract](https://www.clinicaltrialvanguard.com/news/jst-018-orthopoxvirus-antibody-enters-phase-1-trial-under-123-9m-defense-contract/) - JST-018 orthopoxvirus antibody enters phase 1 trial under $123.9M defense contract with Just-Evotec Biologics for warfighter protection.
- [Mosliciguat Advances to Phase 3 PHrontier Trial After PHocus Study Shows 20% PVR Reduction](https://www.clinicaltrialvanguard.com/news/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-reduction/) - Mosliciguat advances to Phase 3 PHrontier Trial after PHocus Study shows 20% pulmonary vascular resistance reduction in PH-ILD patients.
- [Clinical trial sites advised to build data infrastructure before deploying AI tools](https://www.clinicaltrialvanguard.com/news/clinical-trial-sites-advised-to-build-data-infrastructure-before-deploying-ai-tools/) - Clinical trial sites should establish data infrastructure before deploying AI tools, according to industry experts and recent guidance on sequencing implementat
- [Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026](https://www.clinicaltrialvanguard.com/news/ascendis-to-present-navepegritide-infant-trial-data-at-espe-2026/) - Ascendis will present sentinel cohort data from the reACHin Trial of navepegritide infant trial at ESPE 2026, extending the CNP therapy's tested age range to in
- [Fortrea's $45M Phase I Grab Is Your Vendor Continuity Problem Now](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/fortreas-45m-phase-i-grab-is-your-vendor-continuity-problem-now/) - Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors mid-study.
- [The 400-Member Protein Family That Neuroscience Has Almost Entirely Ignored](https://www.clinicaltrialvanguard.com/opinion/the-400-member-protein-family-that-neuroscience-has-almost-entirely-ignored/) - Nature Reviews Drug Discovery identifies SLC transporters as untapped CNS drug targets, but 97% remain undrugged, and trial designers have no FDA playbook for…
- [Tekton Research Sites Enroll 60 Participants in Phase 2 Obesity Trial, Triple Goal](https://www.clinicaltrialvanguard.com/news/tekton-research-sites-enroll-60-participants-in-phase-2-obesity-trial-triple-goal/) - Tekton Research sites enrolled 60 participants in Phase 2 obesity trial, tripling their combined enrollment goal and demonstrating strong patient access capabil
- [Myriad bioscaffolds show 0.7% deep infection rate in 411-patient soft tissue study](https://www.clinicaltrialvanguard.com/news/myriad-bioscaffolds-show-0-7-deep-infection-rate-in-411-patient-soft-tissue-study/) - Myriad bioscaffolds demonstrated a 0.7% deep infection rate in soft tissue reconstruction across 411 patients, significantly below historical benchmarks.
- [Clover's RSV-hMPV Vaccine Shows Antibody Rises in Phase 2 Trial](https://www.clinicaltrialvanguard.com/news/clovers-rsv-hmpv-vaccine-shows-antibody-rises-in-phase-2-trial/) - Clover's RSV-hMPV vaccine produced 6-to-9-fold antibody rises in Phase 2, with no immune interference and strong safety. Candidate targets previously vaccinated
- [FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models](https://www.clinicaltrialvanguard.com/news/fda-guidance-expands-cancer-trial-eligibility-reshaping-feasibility-models/) - FDA guidance expands cancer trial eligibility to include patients with ECOG PS 2, reshaping enrollment models and operational requirements for sponsors.
- [Signant Health, Lothar Medical Plan Integrated Respiratory Trial Device](https://www.clinicaltrialvanguard.com/news/signant-health-lothar-medical-plan-integrated-respiratory-trial-device/) - Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO measurement into a single platform.
- [Canada Recommends Conditional Reimbursement for Palopegteriparatide in Hypoparathyroidism](https://www.clinicaltrialvanguard.com/news/canada-recommends-conditional-reimbursement-for-palopegteriparatide-in-hypoparathyroidism/) - Canada's drug agency recommends conditional reimbursement for palopegteriparatide in hypoparathyroidism, pending price negotiation and provincial formulary deci
- [Roivant to Present Phase 2 Mosliciguat Data for PH-ILD on Tuesday](https://www.clinicaltrialvanguard.com/news/roivant-to-present-phase-2-mosliciguat-data-for-ph-ild-on-tuesday/) - Roivant presents Phase 2 mosliciguat data for PH-ILD, measuring pulmonary vascular resistance changes over 24 weeks in a 135-patient trial.
- [Early Termination No Longer Means Failure. It Means the Trial Was Working.](https://www.clinicaltrialvanguard.com/article/trend-watch/early-termination-no-longer-means-failure-it-means-the-trial-was-working/) - Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new operational playbook to…
- [AI Agents in Clinical Trials Require Human Review Before Data Commits](https://www.clinicaltrialvanguard.com/news/ai-agents-in-clinical-trials-require-human-review-before-data-commits/) - AI Agents in Clinical Trials require human review before data commits to clinical databases, balancing automation with regulatory accountability.
- [Intellia Secures $400M Credit Facility for NTLA-2002 HAE Trial](https://www.clinicaltrialvanguard.com/news/intellia-secures-400m-credit-facility-for-ntla-2002-hae-trial/) - Intellia secures $400M credit facility to fund the NTLA-2002 HAE trial through completion, avoiding shareholder dilution from equity offerings.
- [CluePoints Launches AI Tools for Clinical Data Review With Top 10 Pharma Partner](https://www.clinicaltrialvanguard.com/news/cluepoints-launches-ai-tools-for-clinical-data-review-with-top-10-pharma-partner/) - CluePoints launches AI tools for clinical data review with capabilities targeting 99% accuracy in medical coding and cutting manual effort by half.
- [Thryv Therapeutics licenses SGK1 inhibitors for Parkinson's, Alzheimer's research](https://www.clinicaltrialvanguard.com/news/thryv-therapeutics-licenses-sgk1-inhibitors-for-parkinsons-alzheimers-research/) - Thryv Therapeutics licenses SGK1 inhibitors from Spanish research institutions for Parkinson's and Alzheimer's disease development, targeting a first candidate
- [Argo's BW-20805 Achieves 96% Attack-Rate Reduction in HAE Phase II](https://www.clinicaltrialvanguard.com/news/argos-bw-20805-achieves-96-attack-rate-reduction-in-hae-phase-ii/) - Argo's BW-20805 achieved 96% attack-rate reduction in Phase II HAE study, with 75% of patients in the 300 mg every-24-weeks group remaining attack-free.
- [WCG releases checklist to speed protocol amendment implementation at clinical trial sites](https://www.clinicaltrialvanguard.com/eclinical-vendor-watch/wcg-releases-checklist-to-speed-protocol-amendment-implementation/) - Protocol amendments add three months to clinical trials on average. WCG's checklist helps sponsors streamline implementation and reduce site-level delays.
- [Fortrea's $45M Early Phase Deal Sets a 90-Day Test for Sponsors With Active Studies](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/fortreas-45m-early-phase-deal-sets-a-90-day-test-for-sponsors/) - Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division adds a 60,000 sq ft bioanalytical lab. Here's what it means for Phase I site…
- [NSABP B-59 Failed. The Real Question Is Why We Keep Designing Trials That Can't Detect the Signal.](https://www.clinicaltrialvanguard.com/article/article-deep-dive/nsabp-b-59-failed-the-real-question-is-why-we-keep-designing-trials-that-cant-detect-the-signal/) - The NSABP B-59/GeparDouze trial enrolled 1,550 TNBC patients and missed its primary endpoint. Atezolizumab's Phase 3 failure reveals a biomarker stratification…
- [PMV Pharmaceuticals Structures Warrant Offering Around Rezatapopt NDA Acceptance](https://www.clinicaltrialvanguard.com/news/pmv-pharmaceuticals-structures-warrant-offering-around-rezatapopt-nda-acceptance/) - PMV Pharmaceuticals ties warrant pricing to rezatapopt NDA acceptance, betting on FDA review of 46% response rate data in TP53 Y220C ovarian cancer.
- [Nanochon Enrolls First Patient in Chondrograft Knee Cartilage Study](https://www.clinicaltrialvanguard.com/news/nanochon-enrolls-first-patient-in-chondrograft-knee-cartilage-study/) - Nanochon enrolls first patient in Chondrograft knee cartilage study, a 3D-printed implant designed for focal chondral defects with immediate mechanical support.
- [Veeva Launches Falcon Safety AI for Adverse Event Processing Across E2B Systems](https://www.clinicaltrialvanguard.com/news/veeva-launches-falcon-safety-ai-for-adverse-event-processing-across-e2b-systems/) - Veeva Falcon Safety AI automates adverse event processing across E2B-compliant safety systems including Oracle Argus and ArisGlobal LifeSphere.
- [The EMA Just Opened a Door That Animal Testing Has Kept Closed for Decades](https://www.clinicaltrialvanguard.com/opinion/the-ema-just-opened-a-door-that-animal-testing-has-kept-closed-for-decades/) - EMA's September 2026 NAM data pilot lets sponsors share organ-chip and computational data directly with regulators, reshaping preclinical drug approval…
- [Medtronic acquires distribution rights to Cornerstone Robotics' Sentire surgical system for $700M](https://www.clinicaltrialvanguard.com/news/medtronic-acquires-distribution-rights-to-cornerstone-robotics-sentire-surgical-system-for-700m/) - Medtronic acquires distribution rights to Cornerstone Robotics' Sentire surgical system for $700M to expand robotic surgery access in non-U.S. markets.
- [Girl with Griscelli Syndrome Type II undergoes first haploidentical transplant at Miami hospital](https://www.clinicaltrialvanguard.com/news/girl-with-griscelli-syndrome-type-ii-undergoes-first-haploidentical-transplant-at-miami-hospital/) - Girl with Griscelli Syndrome Type II receives first haploidentical transplant at Miami hospital, offering new hope for ultra-rare genetic disease.
- [Elevar Presents Age-Stratified Camrelizumab-Rivoceranib Data After FDA Rejection](https://www.clinicaltrialvanguard.com/news/elevar-presents-age-stratified-camrelizumab-rivoceranib-data-after-fda-rejection/) - Elevar presents age-stratified camrelizumab-rivoceranib data from Phase 3 CARES-310 after two FDA rejections, signaling potential resubmission strategy.
- [PMV Pharma's Rezatapopt Achieves 44% Response Rate in TP53 Y220C Ovarian Cancer](https://www.clinicaltrialvanguard.com/news/pmv-pharmas-rezatapopt-achieves-44-response-rate-in-tp53-y220c-ovarian-cancer/) - PMV Pharma's rezatapopt achieves 44% response rate in TP53 Y220C ovarian cancer patients, positioning the drug for potential FDA accelerated approval discussion
- [Benchmarks Don't Fail Silently. Agentic AI Does.](https://www.clinicaltrialvanguard.com/clinical-bellwether/benchmarks-dont-fail-silently-agentic-ai-does/) - Scale AI's CliniCARE-Bench found 34.7% error rates and right-answer-wrong-process failures. The clinical trials field has no governance framework to catch…
- [SRD-002 Gene Therapy Shows Sustained HFpEF Improvement at 12 Months](https://www.clinicaltrialvanguard.com/news/srd-002-gene-therapy-shows-sustained-hfpef-improvement-at-12-months/) - SRD-002 gene therapy shows sustained HFpEF improvement at 12 months with 80% PCWP normalization from a single intracoronary dose.
- [Stop Writing 'Routine Labs.' Every Lab Line Needs Its Own Coverage Citation](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/stop-writing-routine-labs-every-lab-line-needs-its-own-coverage-citation/) - A CBC isn't covered because it's routine. It's covered because NCD 190.15 says when. Here's how citation-level MCAs survive audits.
- [Orexo's $4 Million DOJ Settlement Is Deliberately Vague — and That Vagueness Is the Story](https://www.clinicaltrialvanguard.com/clinops-watchdog/orexos-4-million-doj-settlement-is-deliberately-vague-and-that-vagueness-is-the-story/) - Orexo AB settled a 6-year DOJ opioid-marketing investigation for $4M, but the press release names no conduct, no victims, no violated statute. That silence…
- [Nature Medicine's 38,753-Patient HF Synthesis Signals a Replicable Model for RWE-Driven Label Expansion Without New RCTs](https://www.clinicaltrialvanguard.com/opinion/nature-medicines-38753-patient-hf-synthesis-signals-a-replicable-model-for-rwe-driven-label-expansion-without-new-rcts/) - A 38,753-patient cross-trial synthesis in Nature Medicine maps short-term safety of HF combination therapies—signaling how sponsors can use pooled RCT data to…
- [Astellas donates tacrolimus to U.S. API reserve, strikes pricing deal](https://www.clinicaltrialvanguard.com/news/astellas-donates-tacrolimus-to-u-s-api-reserve-strikes-pricing-deal/) - Astellas donates tacrolimus active pharmaceutical ingredient to U.S. Strategic API Reserve and strikes voluntary Medicaid pricing agreement with government.
- [Canada's Drug Agency Issues Positive Reimbursement Recommendation for Lecanemab](https://www.clinicaltrialvanguard.com/news/canadas-drug-agency-issues-positive-reimbursement-recommendation-for-lecanemab/) - Canada's drug agency issues positive reimbursement recommendation for lecanemab after reversing its February rejection, opening access for patients with mild co
- [When Early Efficacy Data Forces a Site Ramp You Weren't Budgeted For](https://www.clinicaltrialvanguard.com/clinical-trial-ops-brief/when-early-efficacy-data-forces-a-site-ramp-you-werent-budgeted-for/) - Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at the operational level.
- [When a Failed Primary Endpoint Teaches More Than a Win: What CARDIOTTRansform's Secondary Analysis Reveals About Stratification in Complex Trials](https://www.clinicaltrialvanguard.com/article/trend-watch/when-a-failed-primary-endpoint-teaches-more-than-a-win-what-cardiottransforms-secondary-analysis-reveals-about-stratification-in-complex-trials/) - CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background stabilizers is reshaping trial…
- [Ascletis Doses First Patient in ASC30 Phase III Obesity Trial](https://www.clinicaltrialvanguard.com/news/ascletis-doses-first-patient-in-asc30-phase-iii-obesity-trial/) - Ascletis doses first patient in ASC30 Phase III obesity trial, advancing oral GLP-1 agonist against established semaglutide competition through 2028.
- [Lecanemab's At-Home Start Dose Just Rewrote the Rules for Alzheimer's Trial Design](https://www.clinicaltrialvanguard.com/article/intel-brief/lecanemabs-at-home-start-dose-just-rewrote-the-rules-for-alzheimers-trial-design/) - FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS trial recruitment and safety…
- [enVast Mechanical Thrombectomy Meets Primary Endpoint in Large-Thrombus STEMI Trial](https://www.clinicaltrialvanguard.com/news/envast-mechanical-thrombectomy-meets-primary-endpoint-in-large-thrombus-stemi-trial/) - Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its primary endpoint.
- [Dubai's rWGS Scale-Up Rewrites the Diagnostic Playbook — But the Data Infrastructure Problem Stays Unsolved](https://www.clinicaltrialvanguard.com/article/article-deep-dive/dubais-rwgs-scale-up-rewrites-the-diagnostic-playbook-but-the-data-infrastructure-problem-stays-unsolved/) - Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf standard testing, but exposes a data…
- [Cumberland Seeks FDA Action on Ifetroban DMD Data Before Extension Study Complete](https://www.clinicaltrialvanguard.com/news/cumberland-seeks-fda-action-on-ifetroban-dmd-data-before-extension-study-complete/) - Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for cardiomyopathy treatment.
- [Reading the COMPARE Phase 1 Data in Nature Medicine Closely](https://www.clinicaltrialvanguard.com/opinion/reading-the-compare-phase-1-data-in-nature-medicine-closely/) - Nature Medicine's COMPARE phase 1 data on CD19 CAR T in refractory RA shows zero severe CRS in 6 patients — a stark contrast to the 18.5% rate in oncology.…
- [Akeso's ivonescimab meets OS endpoint in EGFR-TKI-resistant NSCLC Phase III](https://www.clinicaltrialvanguard.com/news/akesos-ivonescimab-meets-os-endpoint-in-egfr-tki-resistant-nsclc-phase-iii/) - Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results across Western and Chinese patient co
- [AusperBio Closes $120M Series C for AHB-137 Hepatitis B Program](https://www.clinicaltrialvanguard.com/news/ausperbio-closes-120m-series-c-for-ahb-137-hepatitis-b-program/) - AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
- [MBX Biosciences Doses First Patient in Phase 3 Canvuparatide Trial for Hypoparathyroidism](https://www.clinicaltrialvanguard.com/news/mbx-biosciences-doses-first-patient-in-phase-3-canvuparatide-trial-for-hypoparathyroidism/) - MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal study evaluating once-weekly PTH re
- [Genentech, DualityBio Partner on Next-Generation ADC Payloads](https://www.clinicaltrialvanguard.com/news/genentech-dualitybio-partner-on-next-generation-adc-payloads/) - Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in cancer patients.
- [How to Make Clinical Trials for Elderly with Disabilities More Inclusive](https://www.clinicaltrialvanguard.com/analysis/how-to-make-clinical-trials-for-elderly-with-disabilities-more-inclusive/) - An analysis of clinical trials for elderly with disabilities and how to make them more elderly patients in clinical trials inclusive.
- [Decentralized Clinical Trials: Big Pharma's New Frontier](https://www.clinicaltrialvanguard.com/conference-coverage/decentralized-clinical-trials-big-pharmas-new-frontier/) - While the promise and potential of Decentralized Clinical Trials are immense, Big Pharma faces significant challenges that must be effectively navigated.
- [DCTs: Washington's Jubilant Journey To Revolutionize Trials](https://www.clinicaltrialvanguard.com/conference-coverage/dcts-washingtons-jubilant-journey-to-revolutionize-trials/) - The 2023 DTRA Annual Meeting featured a pivotal moment in clinical trials with a government panel including FDA and NIH on Decentralized Clinical Trials (DCTs).
- [AstraZeneca's ASH 2023: Surging Hematology Innovations](https://www.clinicaltrialvanguard.com/news/astrazenecas-ash-2023-surging-hematology-innovations/) - At the upcoming 65th American Society of Hematology (ASH) Annual Meeting, AstraZeneca will present a wealth of new clinical and real-world data spanning multiple hematological disorders. This presentation will comprise a substantial 63 abstracts highlighting 14 approved and innovative medications within the company's extensive portfolio, including their group focusing on rare diseases, Alexion. Significant among
- [Gilead Great Trodelvy Focus: New Insights](https://www.clinicaltrialvanguard.com/news/gilead-great-trodelvy-focus-new-insights/) - Gilead Sciences, Inc. is set to present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023, highlighting the benefits of Trodelvy®
- [PsychoGenics Revolutionary Brain Drug Set to Combat Mental Ills](https://www.clinicaltrialvanguard.com/news/psychogenics-revolutionary-brain-drug-set-to-combat-mental-ills/) - PsychoGenics Inc., with its drug discovery platform PGI Drug Discovery LLC, has announced an exclusive license agreement with Roche for global rights: RO7117997
- [BMS Opdivo Wins FDA Fast-Track: Remarkable Cancer Hope](https://www.clinicaltrialvanguard.com/news/bms-opdivo-wins-fda-fast-track-remarkable-cancer-hope/) - Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy. This is intended as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma. The FDA has set a target
- [Merck Evobrutinib Fails in Trials: A Devastating Outcome for MS](https://www.clinicaltrialvanguard.com/news/merck-evobrutinib-fails-in-trials-a-devastating-outcome-for-ms/) - Merck evobrutinib trials did not meet their primary endpoints as the annualized relapse rates (ARR) in MS patients
- [Sanofi Venetoclax: Breakthrough NK Cell Therapy Stuns at ASH 2023](https://www.clinicaltrialvanguard.com/news/sanofi-venetoclax-breakthrough-nk-cell-therapy-stuns-at-ash-2023/) - Innate Pharma SA, in collaboration with Sanofi, shared updated efficacy and safety results from a Phase 1/2 dose-escalation study of venetoclax.
- [Merck & Moderna Blaze Trail with New Cancer Vaccine Trial](https://www.clinicaltrialvanguard.com/news/merck-moderna-blaze-trail-with-new-cancer-vaccine-trial/) - Merck, and Moderna, Inc., have launched INTerpath-002, a pivotal Phase 3 randomized clinical trial for a cancer vaccine.
- [Mooresville Locals Breathe Easy with Sanofi COPD Study](https://www.clinicaltrialvanguard.com/news/mooresville-locals-breathe-easy-with-sanofi-copd-study/) - A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary disease (COPD). Conducted by Sanofi, this study is investigating itepekimab's potential to diminish the frequency and severity of COPD exacerbations in both current and former smokers with moderate-to-severe COPD. COPD is a major health concern and
- [Miracle CAR T-Cell Hope from Gilead for Lymphoma](https://www.clinicaltrialvanguard.com/news/miracle-car-t-cell-hope-from-gilead-for-lymphoma/) - Kite, a Gilead company presented encouraging data from various studies on the CAR T-cell therapies Tecartus and Yescarta showing substantial long-term survival
- [BMS's RELATIVITY-123 Trial Fail: A Devastating End](https://www.clinicaltrialvanguard.com/news/bmss-relativity-123-trial-fail-a-devastating-end/) - Bristol Myers Squibb announced the discontinuation of the Phase 3 RELATIVITY-123 trial, which was evaluating the fixed-dose combination of nivolumab and relatlimab as a treatment for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients. This decision comes after an independent data monitoring committee determined that the trial was unlikely to meet its primary endpoints of
- [FDA Nods to Padcev-Keytruda for Bladder Cancer](https://www.clinicaltrialvanguard.com/news/fda-nods-to-padcev-keytruda-for-bladder-cancer/) - Pfizer Inc. and Astellas Pharma Inc. have announced the FDA’s approval of PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) combined with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This approval marks the first combination treatment option to offer an alternative to the standard
- [AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested](https://www.clinicaltrialvanguard.com/news/astrazeneca-daiichi-breakthrough-trial-new-breast-cancer-therapy-tested/) - Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their collaborative treatment, datopotamab deruxtecan (Dato-DXd), in combination with durvalumab, an anti-PD-L1 therapy by AstraZeneca. These trials aim to evaluate the efficacy and safety of the combination in treating two types of breast cancer. The trials, named
- [Breaking New Ground: AstraZeneca, Roche, Acadia in GCP & AI](https://www.clinicaltrialvanguard.com/conference-coverage/breaking-new-ground-astrazeneca-roche-acadia-in-gcp-ai/) - AstraZeneca, Roche, and Acadia Pharma discuss a shift in pharma toward quality-centric approaches in clinical trials drawing insights from manufacturing sectors
- [Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review](https://www.clinicaltrialvanguard.com/news/pfizer-tivdak-sla-accepted-by-fda-for-priority-cervical-cancer-review/) - Genmab A/S and Pfizer Inc. announced the FDA's acceptance of the(sBLA) to potentially convert the accelerated approval of TIVDAK®
- [Takeda's HYQVIA Wins FDA Approval for CIDP Therapy](https://www.clinicaltrialvanguard.com/news/takedas-hyqvia-wins-fda-approval-for-cidp-therapy/) - Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as a maintenance therapy to prevent relapse in adults. This approval allows HYQVIA, an FDA-approved combination of immunoglobulin (IG) and hyaluronidase, to be used in the treatment of CIDP, expanding its use beyond primary immunodeficiency (PI), for
- [Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer](https://www.clinicaltrialvanguard.com/news/arcus-gilead-quemliclustat-regimens-show-hope-in-pancreatic-cancer/) - Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The trial studies quemliclustat, an investigational CD73 inhibitor, combined with chemotherapy—with or without zimberelimab, an anti-PD-1 antibody—in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The results are scheduled to be presented at the ASCO GI
- [Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial](https://www.clinicaltrialvanguard.com/news/opdivo-cabometyx-show-4-year-benefits-in-rcc-trial/) - Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell carcinoma (RCC) versus sunitinib, including a 23% reduction in the risk of death. Bristol Myers Squibb and Exelixis, Inc. have announced four-year follow-up results from the CheckMate -9ER trial, which demonstrated superior progression-free survival (PFS) and
- [8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival](https://www.clinicaltrialvanguard.com/news/8-year-data-bms-opdivo-yervoy-outperform-in-rcc-survival/) - Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term survival benefits for previously untreated patients with advanced or metastatic renal cell carcinoma (RCC). In the Phase 3 CheckMate -214 trial, the immunotherapy duo reduced the risk of death by 28% compared to sunitinib, an eight-year
- [Gilead Evoke-01 Phase 3 Study: Critical Update Issued](https://www.clinicaltrialvanguard.com/news/gilead-evoke-01-phase-3-study-critical-update-issued/) - Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study, which evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) against docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) that had previously progressed following platinum-based and checkpoint inhibitor therapy, did not meet its primary endpoint of overall survival (OS). While the study did not achieve its primary
- [ICON Survey Stresses Combo Therapies in Obesity Care](https://www.clinicaltrialvanguard.com/news/icon-survey-stresses-combo-therapies-in-obesity-care/) - ICON plc conducted an industry survey of over 100 professionals engaged in obesity-related clinical research, revealing expectations for the future of obesity therapies and current research trends. The survey found that: 1. Most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and comorbidities such as diabetes, steatosis
- [Advancing ClinOps Excellence: The 15th Annual SCOPE Summit 2024](https://www.clinicaltrialvanguard.com/conference-coverage/advancing-clinops-excellence-the-15th-annual-scope-summit-2024/) - Join us at the 15th Annual SCOPE Summit, scheduled for February 11-14, 2024, in Orlando, Florida, at the Rosen Shingle Creek, which offers a comprehensive program focused on advancing clinical trial and ClinOps practices. This event, a pivotal gathering for clinical research and operations professionals, will feature 29 focused conferences covering a wide range of
- [AstraZeneca Grows US Cell Therapy Production Capacity](https://www.clinicaltrialvanguard.com/news/astrazeneca-grows-us-cell-therapy-production-capacity/) - AstraZeneca has announced a $300 million investment in a new state-of-the-art facility in Rockville, Maryland, aimed at advancing its cell therapy platforms for cancer research and future commercial supply in the U.S. This endeavor will create over 150 new skilled jobs focused on manufacturing T-cell therapies to facilitate both global clinical trials and potential future
- [BMS's Opdivo for Lung Cancer: US & EU Filings Accepted](https://www.clinicaltrialvanguard.com/news/bmss-opdivo-for-lung-cancer-us-eu-filings-accepted/) - Bristol Myers Squibb's Opdivo accepted by FDA and EMA for neoadjuvant treatment of resectable NSCLC
- [Takeda's TAK-861 Narcolepsy Phase 3 Trials Set for FY2024](https://www.clinicaltrialvanguard.com/news/takedas-tak-861-narcolepsy-phase-3-trials-set-for-fy2024/) - Takeda has announced promising topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, for patients with narcolepsy type 1 (NT1). The randomized, double-blind, placebo-controlled trial showed that TAK-861 led to significant and clinically meaningful improvements in wakefulness and reductions in cataplexy rates compared to placebo. The NT1 trial
- [Takeda's EoE Drug Eohilia Gets First FDA Approval in US](https://www.clinicaltrialvanguard.com/news/takedas-eoe-drug-eohilia-gets-first-fda-approval-in-us/) - Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE) in individuals aged 11 years and older. This approval makes EOHILIA the first and only FDA-approved oral therapy for EoE and is expected to be available by the end of February
- [Gilead Boosts Liver Portfolio by Acquiring CymaBay](https://www.clinicaltrialvanguard.com/news/gilead-boosts-liver-portfolio-by-acquiring-cymabay/) - Gilead Sciences, Inc. has agreed to acquire CymaBay Therapeutics, Inc. for $4.3 billion, expanding its portfolio with seladelpar, a treatment for primary biliary cholangitis (PBC), including pruritus. The transaction, valuing CymaBay's shares at $32.50 each in cash, will complement Gilead's existing liver disease portfolio and reaffirm its commitment to liver health. Seladelpar, an investigational oral
- [FDA OKs Xolair as Sole Drug for Multi-Food Allergies](https://www.clinicaltrialvanguard.com/news/fda-oks-xolair-as-sole-drug-for-multi-food-allergies/) - Genentech, a member of the Roche Group, has announced the FDA approval of Xolair® (omalizumab) for reducing allergic reactions, including anaphylaxis, linked to accidental exposure to one or more foods in adults and pediatric patients one year of age and older with IgE-mediated food allergy. To avoid the risk of severe reactions, patients on Xolair
- [Tagrisso & Chemo Combo Approved in US for EGFR Lung Cancer](https://www.clinicaltrialvanguard.com/news/tagrisso-chemo-combo-approved-in-us-for-egfr-lung-cancer/) - AstraZeneca's TAGRISSO® (osimertinib), in combination with chemotherapy, has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancersmall cell lung cancer (NSCLC). Following a Priority Review, the FDA based its approval on the results from the Phase III FLAURA2 trial,
- [Datopotamab Deruxtecan BLA Accepted for US Lung Cancer](https://www.clinicaltrialvanguard.com/news/datopotamab-deruxtecan-bla-accepted-for-us-lung-cancer/) - Daiichi Sankyo and AstraZeneca's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted by the U.S. FDA for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. As a specifically constructed TROP2-targeted DXd antibody drug conjugate (ADC), datopotamab deruxtecan shows
- [EU Nods Pfizer's Velsipity® for Ulcerative Colitis](https://www.clinicaltrialvanguard.com/news/eu-nods-pfizers-velsipity-for-ulcerative-colitis/) - Pfizer Inc. announced that the European Commission has approved VELSIPITY® (etrasimod) for the treatment of patients aged 16 and over with moderately to severely active ulcerative colitis (UC) in the European Union, including Iceland, Liechtenstein, and Norway. This approval is for those inadequate to conventional therapy or a biological agent. Leading expert Séverine Vermeire, MD,
- [Tagrisso's Phase III Success in Unresectable EGFR Lung Cancer](https://www.clinicaltrialvanguard.com/news/tagrissos-phase-iii-success-in-unresectable-egfr-lung-cancer/) - AstraZeneca's TAGRISSO® (osimertinib) has shown positive results in the LAURA Phase III trial, demonstrating a significant and clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small cell lung cancersmall cell lung cancer (NSCLC) following chemoradiotherapy (CRT), compared to placebo. While overall survival (OS) data is favoring TAGRISSO, it is
- [Silence Therapeutics Nabs $10M From AstraZeneca Phase 1 Start](https://www.clinicaltrialvanguard.com/news/silence-therapeutics-nabs-10m-from-astrazeneca-phase-1-start/) - Silence Therapeutics plc, a biotechnology company specializing in RNA interference (RNAi) therapies, has announced the initiation of a Phase 1 clinical trial by AstraZeneca for the first product candidate from their siRNA (short interfering RNA) collaboration. This marks a significant milestone for Silence Therapeutics, triggering a $10.0 million payment from AstraZeneca. Craig Tooman, President and
- [Xolair's NEJM Phase III Data: Hope for Multiple Food Allergies](https://www.clinicaltrialvanguard.com/news/xolairs-nejm-phase-iii-data-hope-for-multiple-food-allergies/) - Genentech announced key findings from Stage 1 of the NIH-sponsored Phase III OUtMATCH study, published in the New England Journal of Medicine (NEJM) and presented at the 2024 AAAAI Annual Meeting. The study demonstrated that treatment with Xolair® (omalizumab) raised the threshold amount of allergens such as peanuts, milk, egg, wheat, and tree nuts (cashew,
- [Merck's Keytruda Gets Positive CHMP Opinion for NSCLC Therapy](https://www.clinicaltrialvanguard.com/news/mercks-keytruda-gets-positive-chmp-opinion-for-nsclc-therapy/) - Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as a neoadjuvant treatment combined with platinum-containing chemotherapy, followed by KEYTRUDA as a monotherapy adjuvant treatment for resectable non-small cell lung cancer (NSCLC) at high risk of
- [Mandara III Data: Fasenra Aids EGPA Remission, NEJM Reports](https://www.clinicaltrialvanguard.com/news/mandara-iii-data-fasenra-aids-egpa-remission-nejm-reports/) - Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) have been published in the New England Journal of Medicine. As the first head-to-head trial of biologics in patients with EGPA, the MANDARA trial demonstrated that more than half of the patients achieved remission with eosinophil-targeting
- [FDA Priority Review for Epcoritamab in Refractory Lymphoma](https://www.clinicaltrialvanguard.com/news/fda-priority-review-for-epcoritamab-in-refractory-lymphoma/) - Genmab A/S and AbbVie have received Priority Review from the FDA for epcoritamab-bysp, a bispecific antibody for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This review status is granted to therapies with the potential to provide significant improvements over existing treatments for
- [SCRI & AstraZeneca Forge Alliance for Cancer Research Tech](https://www.clinicaltrialvanguard.com/news/scri-astrazeneca-forge-alliance-for-cancer-research-tech/) - Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca to advance the delivery of oncology clinical trials through innovative technology and operational synergies. The partnership focuses on expediting timelines for clinical trials, reducing site burden, and increasing U.S. enrollment. Genospace, a precision medicine platform, and
- [AbbVie, OSE Partner for Novel Anti-Inflammatory Antibody](https://www.clinicaltrialvanguard.com/news/abbvie-ose-partner-for-novel-anti-inflammatory-antibody/) - AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the pre-clinical development stage and designed to treat chronic and severe inflammation. OSE-230 is a first-in-class antibody that activates ChemR23, a G-protein-coupled receptor (GPCR), which could offer a novel approach to resolving chronic inflammation by modulating macrophages
- [Real-World Data Back Veklury for Hospitalized COVID-19 Patients](https://www.clinicaltrialvanguard.com/news/real-world-data-back-veklury-for-hospitalized-covid-19-patients/) - Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces mortality among COVID-19 patients, but also lowers the risk of long COVID symptoms. Based on HealthVerity data from over 52,000 patients, Veklury use was linked to a 10% lower risk of conditions associated with long COVID
- [EU Validates Datopotamab Apps for Lung & Breast Cancer](https://www.clinicaltrialvanguard.com/news/eu-validates-datopotamab-apps-for-lung-breast-cancer/) - The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan, a treatment for two types of cancer. The two MAAs are for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancersmall cell lung cancer (NSCLC), and for the treatment of adults
- [Viiv Healthcare Presents Promising Cabenuva Data at CROI](https://www.clinicaltrialvanguard.com/news/viiv-healthcare-presents-promising-cabenuva-data-at-croi/) - ViiV Healthcare has announced promising interim data from the LATITUDE phase III trial, presented at the CROI 2024. The data indicate that Cabenuva (cabotegravir + rilpivirine), a long-acting injectable antiretroviral treatment (ART) for HIV, shows superior efficacy in maintaining viral load suppression compared to daily oral therapy, particularly benefiting individuals facing ART adherence challenges. The
- [Merck Successfully Acquires Harpoon Therapeutics, Inc.](https://www.clinicaltrialvanguard.com/news/merck-successfully-acquires-harpoon-therapeutics-inc/) - Merck has successfully completed the acquisition of Harpoon Therapeutics, Inc., making Harpoon a wholly-owned subsidiary of Merck. As a result of this acquisition, Harpoon's common stock will no longer be listed or publicly traded on the Nasdaq Stock Market. This strategic move is part of Merck's ongoing efforts to bolster and diversify its oncology pipeline
- [Pfizer's Phase 3 Trial Shows Positive Survival in DLBCL](https://www.clinicaltrialvanguard.com/news/pfizers-phase-3-trial-shows-positive-survival-in-dlbcl/) - Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for treating relapsed/refractory diffuse large B-cell lymphomaB-cell lymphoma (DLBCL). The study demonstrated a statistically significant improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Key secondary endpoints, such as progression-free survival (PFS) and
- [FDA Approves Breyanzi® as First CAR-T Therapy for CLL/SLL](https://www.clinicaltrialvanguard.com/news/fda-approves-breyanzi-as-first-car-t-therapy-for-cll-sll/) - Bristol Myers Squibb announced the accelerated FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for treating adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior therapies, including a Bruton tyrosine kinase (BTK) inhibitor and a
- [BMS Strengthens Neuroscience Portfolio with Karuna Therapeutics Acquisition](https://www.clinicaltrialvanguard.com/news/bms-strengthens-neuroscience-portfolio-with-karuna-therapeutics-acquisition/) - Bristol Myers Squibb (BMS) has announced the completion of its acquisition of Karuna Therapeutics, Inc., marking a significant expansion of BMS's neuroscience portfolio. With this acquisition, Karuna has ceased trading on the Nasdaq Global Select Market and is now a fully integrated subsidiary of BMS. This move consolidates BMS's position in neuroscience and underscores its
- [GRAIL Unveils Innovative Risk Classification Test for Lung Cancer Study](https://www.clinicaltrialvanguard.com/news/grail-unveils-innovative-risk-classification-test-for-lung-cancer-study/) - GRAIL, LLC, a pioneering healthcare company dedicated to early cancer detection for potential curative treatment, has partnered with AstraZeneca to include Japanese patients in studies utilizing GRAIL's innovative Methylation Platform. This cutting-edge test, focused on blood-based detection, is set to classify the recurrence risk in patients newly diagnosed with Stage I lung adenocarcinoma, marking a
- [Takeda's Iclusig® Granted FDA Approval for Newly Diagnosed Ph+ ALL](https://www.clinicaltrialvanguard.com/news/takedas-iclusig-granted-fda-approval-for-newly-diagnosed-ph-all/) - Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved ICLUSIG® (ponatinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. This landmark approval makes ICLUSIG the first and only targeted therapy in the U.S. for frontline Ph+ ALL, distinguishing itself
- [JCR Pharmaceuticals Achieves Milestone with J-Brain Cargo® in Neurodegenerative Disease Research Collaboration with Alexion](https://www.clinicaltrialvanguard.com/news/jcr-pharmaceuticals-achieves-milestone-with-j-brain-cargo-in-neurodegenerative-disease-research-collaboration-with-alexion/) - JCR Pharmaceuticals Co., Ltd. (JCR), a leading specialty pharmaceutical company, has announced the achievement of a significant research milestone in its collaboration with Alexion, AstraZeneca Rare Disease (Alexion), focusing on the development of a novel therapeutic molecule for the treatment of a neurodegenerative disease. This development leverages JCR’s proprietary J-Brain Cargo® technology, designed to enhance
- [Cybin Closes $150 Million Private Placement](https://www.clinicaltrialvanguard.com/news/cybin-closes-150-million-private-placement/) - Cybin Inc., a clinical-stage biopharmaceutical company focused on creating innovative psychedelic-based treatments for mental health disorders, recently completed a significant private placement, raising U.S. $150 million. The offering, which involved issuing 348,837,210 common shares at U.S. $0.43 each, witnessed considerable interest and was oversubscribed. Key investors in this private placement included Deep Track Capital, RA
- [AstraZeneca Acquires Fusion to Advance Next-Gen Cancer Radioconjugates](https://www.clinicaltrialvanguard.com/news/astrazeneca-acquires-fusion-to-advance-next-gen-cancer-radioconjugates/) - AstraZeneca has announced a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing next-generation radioconjugates (RCs) for cancer treatment. This acquisition significantly advances AstraZeneca's goal to revolutionize cancer therapy by incorporating more precise and targeted treatment methods, moving away from traditional chemotherapy and radiotherapy approaches. Radioconjugates represent a cutting-edge treatment
- [NIH Study on Syn-One Test® as Diagnostic Tool Published in JAMA](https://www.clinicaltrialvanguard.com/news/nih-study-on-syn-one-test-as-diagnostic-tool-published-in-jama/) - CND Life SciencesLife Sciences, a leading medical technology company specializing in neurodiagnostic tests, has announced a groundbreaking publication in the Journal of the American Medical Association (JAMA) detailing the efficacy of their Syn-One Test. The test, which utilizes a simple skin biopsy procedure, has proven remarkably effective in detecting phosphorylated alpha-synuclein (P-SYN), a key biomarker
- [Tevogen Bio's Investigational T Cell Therapy Effective Against JN.1 Variant](https://www.clinicaltrialvanguard.com/news/tevogen-bios-investigational-t-cell-therapy-effective-against-jn-1-variant/) - Tevogen Bio Holdings announced the enduring efficacy of its investigational COVID-19 treatment, TVGN 489, against the latest dominant SARS-CoV-2 strains, including the highly mutated JN.1 variant. TVGN 489, a pioneering allogeneic immunotherapy, utilizes Cytotoxic CD8+ T lymphocytes (CTLs) specifically tailored to combat SARS-CoV-2 in high-risk patients and those suffering from Long COVID. Leveraging its unique
- [BMS's Checkmate-9DW Trial Shows Opdivo Plus Yervoy Efficacy in Advanced Hepatocellular Carcinoma](https://www.clinicaltrialvanguard.com/news/bmss-checkmate-9dw-trial-shows-opdivo-plus-yervoy-efficacy-in-advanced-hepatocellular-carcinoma/) - Bristol Myers Squibb (BMY) has revealed positive outcomes from the Phase 3 CheckMate -9DW clinical trial, showcasing the effectiveness of combining Opdivo (nivolumab) with Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy. This combination treatment demonstrated a statistically significant and clinically meaningful improvement
- [eGenesis Achieves Breakthrough: First Successful Transplant of Genetically Engineered Porcine Kidney](https://www.clinicaltrialvanguard.com/news/egenesis-achieves-breakthrough-first-successful-transplant-of-genetically-engineered-porcine-kidney/) - eGenesis, a pioneering biotechnology company, has announced a groundbreaking advancement in transplantation with the successful transplantation of a genetically engineered porcine kidney into a living human recipient. This historic procedure was conducted at Massachusetts General Hospital (MGH) under the leadership of Drs. Tatsuo Kawai and Nahel Elias was authorized by the U.S. Food & Drug
- [Digital Biomarkers Market 2024-2029: Virtual Research & Mental Health Applications Drive Growth](https://www.clinicaltrialvanguard.com/news/digital-biomarkers-market-2024-2029-virtual-research-mental-health-applications-drive-growth/) - The "Global Digital Biomarkers Market - Outlook & Forecast 2024-2029" report showcases the rapidly expanding digital biomarkers market, which was valued at USD 2.49 billion in 2023 and is projected to soar to $8.59 billion by 2029, growing at an impressive CAGR of 22.86%. This growth underscores the transformative role of digital biomarkers in revolutionizing
- [Gilead Sciences Successfully Acquires CymaBay](https://www.clinicaltrialvanguard.com/news/gilead-sciences-successfully-acquires-cymabay/) - Gilead Sciences, Inc. has finalized its acquisition of CymaBay Therapeutics, Inc. for an approximate total equity value of $4.3 billion. This strategic move integrates seladelpar, CymaBay's investigational product for treating primary biliary cholangitis (PBC), including symptoms like pruritus, into Gilead's robust liver disease portfolio. This acquisition aligns with Gilead's commitment to providing innovative treatments for
- [BMS Enhances Health Equity Grant Initiatives for Better Health Outcomes](https://www.clinicaltrialvanguard.com/news/bms-enhances-health-equity-grant-initiatives-for-better-health-outcomes/) - Bristol Myers Squibb (BMY) has launched a $1.8 million initiative to advance health equity by addressing the social determinants of health (SDoH) in Brazil, India, Thailand, and the United Kingdom. This initiative represents a crucial component of the company's larger commitment to invest $150 million in health equity by 2025, illustrating a significant step towards
- [Volastra Therapeutics Forms New Partnerships to Advance KIF18A Inhibitors in Cancer](https://www.clinicaltrialvanguard.com/news/volastra-therapeutics-forms-new-partnerships-to-advance-kif18a-inhibitors-in-cancer/) - Volastra Therapeutics, a clinical-stage biotechnology company at the forefront of developing cancer treatments targeting chromosomal instability (CIN), has announced strategic collaborations with Microsoft, Function Oncology, and Tailor Bio. These partnerships aim to enhance the potential of Volastra's therapeutic pipeline by identifying predictive biomarkers across various tumor types. This initiative can potentially extend the application of
- [Trisalus Life Sciences Technology Spotlighted in SIR Annual Scientific Meeting](https://www.clinicaltrialvanguard.com/news/trisalus-life-sciences-technology-spotlighted-in-sir-annual-scientific-meeting/) - TriSalus Life Sciences® Inc., an oncology company specializing in novel delivery technologies combined with immunotherapy for liver and pancreatic tumors, showcased its groundbreaking technology through two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting. The presentations highlighted the promising developments of the TriSalus Infusion System and its Pressure-Enabled Drug Delivery™ (PEDD™) method
- [Photopharmics Initiates Largest Phototherapy Trial for Parkinson's Disease](https://www.clinicaltrialvanguard.com/news/photopharmics-initiates-largest-phototherapy-trial-for-parkinsons-disease/) - PhotoPharmics, in partnership with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center (URMC), has initiated a groundbreaking pivotal trial named the "Celeste Light for PD Trial." This significant research effort aims to evaluate the efficacy of the Celeste® phototherapy device in improving both non-motor and motor functions and the
- [SecondWave Systems Secures $3M Additional Financing to Advance Ultrasound-Based Anti-Inflammatory Therapy](https://www.clinicaltrialvanguard.com/news/secondwave-systems-secures-3m-additional-financing-to-advance-ultrasound-based-anti-inflammatory-therapy/) - SecondWave Systems, Inc., an innovative company at the forefront of bio-ultrasonic medicine development, is making significant strides in creating new therapeutic options for rheumatoid arthritisarthritis (RA) and other immune-mediated inflammatory conditions. With the appointment of Professor Paul Peter Tak as the first member of its advisory board, SecondWave gains a wealth of experience from a
- [AN2 Therapeutics Resumes Phase 2/3 Trial for EBO-301](https://www.clinicaltrialvanguard.com/news/an2-therapeutics-resumes-phase-2-3-trial-for-ebo-301/) - AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to creating treatments for rare, chronic, and significant infectious diseases, announced its financial results for the fourth quarter and the full year ending December 31, 2023. The company highlighted its sturdy financial position, with cash, cash equivalents, and investments totaling $134.5 million as of the end of
- [BMS's KRYSAL-12 Trial Shows Promise for Krazati in KRASG12C-Mutated NSCLC](https://www.clinicaltrialvanguard.com/news/bmss-krysal-12-trial-shows-promise-for-krazati-in-krasg12c-mutated-nsclc/) - Bristol Myers Squibb has announced significant outcomes from its Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) in patients with pretreated, locally advanced or metastatic non-small cell lung cancersmall cell lung cancer (NSCLC) with a KRASG12C mutation. This pivotal trial met its primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response
- [European Commission Approves Keytruda® Plus Chemotherapy for Resectable NSCLC](https://www.clinicaltrialvanguard.com/news/european-commission-approves-keytruda-plus-chemotherapy-for-resectable-nsclc/) - Merck announced that the European Commission (EC) has approved KEYTRUDA, its anti-PD-1 therapy, for use in combination with platinum-containing chemotherapy as a neoadjuvant treatment, followed by KEYTRUDA as monotherapy in the adjuvant setting, for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This significant development marks the first approval
- [Gilead and Xilio Enter Exclusive License Agreement for Tumor-Activated IL-12 Program](https://www.clinicaltrialvanguard.com/news/gilead-and-xilio-enter-exclusive-license-agreement-for-tumor-activated-il-12-program/) - Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have entered into an exclusive license agreement to develop and commercialize XTX301, Xilio’s Phase 1 tumor-activated IL-12 program. This partnership leverages Xilio’s innovative technology to develop immuno-oncology therapies specifically activated within the tumor microenvironment, potentially mitigating systemic toxicities and enhancing the efficacy of treatments for a broad range
- [BMS Updates on Phase 3 Yellowstone Trial for Zeposia in Crohn's Disease](https://www.clinicaltrialvanguard.com/news/bms-updates-on-phase-3-yellowstone-trial-for-zeposia-in-crohns-disease/) - Bristol Myers Squibb (BMY) has reported that a Phase 3 study within the YELLOWSTONE clinical trial program, which was evaluating the efficacy of Zeposia (ozanimod) in adult patients with moderate to severe active Crohn's diseaseCrohn'sCrohn's disease, did not achieve its primary endpoint of clinical remission at Week 12. Despite this outcome, Zeposia's safety profile remained
- [Pyros Pharmaceuticals Launches Vigpoder™ (Vigabatrin) for Market](https://www.clinicaltrialvanguard.com/news/pyros-pharmaceuticals-launches-vigpoder-vigabatrin-for-market/) - Pyros Pharmaceuticals, Inc., a leading company in the development of specialty pharmaceuticals for rare diseases, has announced the availability of VIGPODER™ (vigabatrin) for oral solution, USP, for the treatment of appropriate patients with infantile spasms (IS). VIGPODER™ provides a therapeutically equivalent, affordable treatment option with a safety and efficacy profile anticipated to be the same
- [Zai Lab's Partner BMS Confirms KRYSAL-12 Trial Success for Krazati in KRASG12C-Mutated Cancer](https://www.clinicaltrialvanguard.com/news/zai-labs-partner-bms-confirms-krysal-12-trial-success-for-krazati-in-krasg12c-mutated-cancer/) - Zai Lab Limited, in collaboration with Bristol Myers Squibb, announced significant progress in the fight against lung cancer with the successful outcome of the KRYSTAL-12 study for KRAZATI® (adagrasib), specifically targeting NSCLC with KRASG12C mutations. The Phase 3 study achieved its primary endpoint, progression-free survival (PFS), and a key secondary endpoint, overall response rate (ORR),
- [MRD Testing Market Analysis 2024: Revolution in Cancer Management Drives Growth](https://www.clinicaltrialvanguard.com/news/mrd-testing-market-analysis-2024-revolution-in-cancer-management-drives-growth/) - The MRD (Minimal Residual Disease) testing market is experiencing substantial growth, with its value projected to increase from $1.67 billion in 2023 to $6.67 billion by 2033, at a Compound Annual Growth Rate (CAGR) of 14.81%. This surge is attributable to several factors, including expanded Medicare coverage for MRD testing and its utilization in diagnosing
- [Mirum's Livmarli Gets Positive CADTH Reimbursement Nod for Alagille Syndrome in Canada](https://www.clinicaltrialvanguard.com/news/mirums-livmarli-gets-positive-cadth-reimbursement-nod-for-alagille-syndrome-in-canada/) - The Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for the public reimbursement of LIVMARLI® (maralixibat oral solution) for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS). This follows Health Canada's authorization of LIVMARLI for this indication in 2023, marking an
- [QLS-111 by Qlaris Bio Enters Phase II Trials for IOP Reduction](https://www.clinicaltrialvanguard.com/news/qls-111-by-qlaris-bio-enters-phase-ii-trials-for-iop-reduction/) - Qlaris Bio, Inc., a biotechnology firm focusing on ophthalmic diseases, has announced the initiation of two Phase II clinical trials in the U.S. to investigate QLS‑111, a pioneering treatment for patients with ocular hypertension and glaucoma. This first-in-class product targets episcleral venous pressure (EVP) to achieve intraocular pressure (IOP) reductions beyond current possibilities. The commencement
- [US FDA Accepts Astrazeneca License Application for Datopotamab Deruxtecan in Metastatic HR+, HER2- Breast Cancer](https://www.clinicaltrialvanguard.com/news/us-fda-accepts-astrazeneca-license-application-for-datopotamab-deruxtecan-in-metastatic-hr-her2-breast-cancer/) - Biopharmaceutical companies AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted in the US, paving the way for this potential treatment for adult patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received previous systemic therapy. Datopotamab deruxtecan is a TROP2-directed DXd antibody-drug conjugate engineered by
- [D&D Pharmatech Receives Fast Track Designation from FDA for DD01 - Novel Treatment for NASH/MASH](https://www.clinicaltrialvanguard.com/news/dd-pharmatech-receives-fast-track-designation-from-fda-for-dd01-novel-treatment-for-nash-mash/) - D&D Pharmatech, a biotech company, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its DD01 drug, aimed at treating adults with non-alcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH). This designation could potentially expedite the process of the drug review to meet the unmet requirements for serious diseases.
- [EC Approves Bristol Myers' Reblozyl as First-Line Treatment for LR-MDS Anemia](https://www.clinicaltrialvanguard.com/news/ec-approves-bristol-myers-reblozyl-as-first-line-treatment-for-lr-mds-anemia/) - The European Commission (EC) has expanded approval of Reblozyl (luspatercept), a first-in-class treatment for patients with disease-related anemia, for the first-line treatment of adult patients with anemia due to very low to intermediate risk myelodysplastic syndromes (MDS). The decision is based on the Phase 3 COMMANDS study which demonstrated that Reblozyl almost doubled the percentage
- [Allurion Bridges Digital Gap, Introduces Virtual Care Suite in US](https://www.clinicaltrialvanguard.com/news/allurion-bridges-digital-gap-introduces-virtual-care-suite-in-us/) - Allurion Technologies has launched its Virtual Care Suite (VCS) in the United States. It provides a comprehensive weight loss management platform for providers offering GLP-1 medications, bariatric surgery, and other weight loss devices. The VCS combines remote patient monitoring, telehealth, and care team collaboration in one digital platform, optimizing patient outcomes and satisfaction. Its AI-powered
- [FDA Grants 510(k) Clearance to Angiodynamics' AlphaVac F1885 System for PE Treatment](https://www.clinicaltrialvanguard.com/news/fda-grants-510k-clearance-to-angiodynamics-alphavac-f1885-system-for-pe-treatment/) - AngioDynamics has received FDA clearance for the AlphaVac F1885 System to treat pulmonary embolism (PE), a life-threatening condition. PE affects a significant portion of the population and is a leading cause of cardiovascular deaths. Expanding the AlphaVac F1885 System's indication enhances its use in critical medical settings. The system offers a non-surgical option for removing
- [Merck Launches Phase 3 Trial with Combo of MK-1084 & KeytrudaⓇ for NSCLC Treatment](https://www.clinicaltrialvanguard.com/news/merck-launches-phase-3-trial-with-combo-of-mk-1084-keytrudaⓡ-for-nsclc-treatment/) - Merck has initiated a Phase 3 clinical trial (NCT06345729) to evaluate MK-1084, an oral KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of metastatic non-small cell lung cancersmall cell lung cancer (NSCLC) with KRAS G12C mutations and PD-L1 expression (TPS ≥50%). MK-1084 is a potent and specific KRAS G12C covalent inhibitor being
- [Bristol Myers Squibb & 2Seventy Abecma Expands Approval for Multiple Myeloma Treatment](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibb-2seventy-abecma-expands-approval-for-multiple-myeloma-treatment/) - Abecma, a personalized CAR T cell therapy, has received expanded approval from the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma. This new indication allows for earlier use of Abecma after two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38
- [AltPep Study in Nature Journal Affirms Potential of Blood Test for Alzheimer's Detection](https://www.clinicaltrialvanguard.com/news/altpep-study-in-nature-journal-affirms-potential-of-blood-test-for-alzheimers-detection/) - AltPep Corporation's SOBA-AD blood test has demonstrated promising accuracy in detecting Alzheimer's diseaseAlzheimer's disease (AD) in two independent studies. Published in the peer-reviewed journal Scientific Reports, the study evaluated 265 blinded plasma samples, achieving 100% sensitivity, >95% specificity, and >98% area under the curve in distinguishing AD patients from cognitively unimpaired controls. The SOBA-AD test
- [Denovo Biopharma's Revelation: Precision Treatment for Depression's Grip](https://www.clinicaltrialvanguard.com/news/denovo-biopharmas-revelation-precision-treatment-for-depressions-grip/) - Denovo Biopharma's Phase 2b ENLIGHTEN trial has demonstrated the efficacy and safety of liafensine (DB104) in treating treatment-resistant depression (TRD). Using a novel genetic biomarker, DGM4™, researchers identified patients most likely to respond to liafensine. Over 23 million Americans suffer from major depressive disorder (MDD), and 30% have TRD, which is notoriously challenging to treat.
- [Synthekine Trial Shows New Hope for Advanced Tumor Battles](https://www.clinicaltrialvanguard.com/news/synthekine-trial-shows-new-hope-for-advanced-tumor-battles/) - Synthekine Inc., a leader in engineered cytokine therapeutics, has announced promising initial findings from a Phase 1a/1b trial of their novel drug STK-012, an α/β biased IL-2 partial agonist. STK-012 is designed to stimulate specific T cells associated with tumor-fighting abilities, while avoiding the toxic effects often seen with IL-2 therapies. In the Phase 1a
- [Obsidian Therapeutics Study Finds Hope in Advanced Melanoma](https://www.clinicaltrialvanguard.com/news/obsidian-therapeutics-study-finds-hope-in-advanced-melanoma/) - Obsidian Therapeutics, a biotechnology company, unveiled promising updates on its Phase 1 study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy, at the American Association for Cancer Research (AACR) Annual Meeting. OBX-115 is being tested in patients with advanced melanoma who have not responded to immune checkpoint inhibitors (ICIs). Six patients received OBX-115 in the
- [Amra Medical's Breakthrough Fat Z-Score Biomarkers Unlock the Power of Tirzepatide Treatment](https://www.clinicaltrialvanguard.com/news/amra-medicals-breakthrough-fat-z-score-biomarkers-unlock-the-power-of-tirzepatide-treatment/) - Recent research from AMRA Medical and collaborators has highlighted the impact of tirzepatide treatment on fat distribution in patients with type 2 diabetes (T2D). Using personalized fat z-scores derived from MRI scans, the study explored changes in fat storage patterns after 52 weeks of treatment. Traditional clinical trials often rely on body weight and BMI
- [EPiENDO Reports Results for Lead Asset, EP395, in COPD](https://www.clinicaltrialvanguard.com/news/epiendo-reports-results-for-lead-asset-ep395-in-copd/) - EpiEndo Pharmaceuticals has successfully concluded its Phase 2A clinical trial evaluating EP395, a novel oral therapeutic for Chronic Obstructive Pulmonary Disease (COPD). •Safety and Tolerability: EP395 exhibited a favorable safety and tolerability profile, similar to antibiotic macrolides. •Biomarker Effects: EP395 demonstrated beneficial effects on inflammatory biomarkers, indicating its potential to reduce disease-causing inflammation. •No Antibiotic-Related
- [Boundless Bio Announces First Patient Dosed in Phase 1/2 Trial for Cancer Patients](https://www.clinicaltrialvanguard.com/news/boundless-bio-announces-first-patient-dosed-in-phase-1-2-trial-for-cancer-patients/) - Boundless Bio has initiated patient enrollment in a Phase 1/2 clinical trial (STARMAP) to investigate BBI-825, a novel therapy targeting resistance gene amplifications in cancer. BBI-825 is an oral ribonucleotide reductase (RNR) inhibitor, designed to inhibit the formation and repair of extrachromosomal DNA (ecDNA). EcDNA plays a crucial role in amplifying genes that drive cancer
- [DeepCure Closes $24M Funding Round Led by IAG Capital Partners](https://www.clinicaltrialvanguard.com/news/deepcure-closes-24m-funding-round-led-by-iag-capital-partners/) - DeepCure, a pioneer in AI-powered small molecule drug discovery, has closed a $24.6 million Series A-1 financing round led by IAG Capital Partners. This brings the total funding raised by DeepCure to over $72 million since its inception. DeepCure's innovative platform combines generative AI with physics-based engines to discover novel small-molecule therapies for complex targets.
- [CND Life Sciences' Skin Biopsy Tool: A Breakthrough for Parkinson's Diagnosis](https://www.clinicaltrialvanguard.com/news/cnd-life-sciences-skin-biopsy-tool-a-breakthrough-for-parkinsons-diagnosis/) - The Synuclein-One Study has successfully detected P-SYN in cutaneous nerve fibers of patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI). Small skin biopsies, combined with advanced laboratory techniques, offer a promising diagnostic tool for detecting misfolded protein associated with Parkinson's disease and other synucleinopathies. The Synuclein-One Study results provide crucial insights into
- [Unlock the Latest in Cancer Treatment: Sanofi and Innate Pharma's Sar443579/IPH6101 Breakthrough](https://www.clinicaltrialvanguard.com/news/unlock-the-latest-in-cancer-treatment-sanofi-and-innate-pharmas-sar443579-iph6101-breakthrough/) - Innate Pharma has announced the initiation of the Phase 2 dose expansion portion of a clinical trial sponsored by Sanofi. The trial evaluates SAR443579, an investigational trifunctional anti-CD123 NK cell engager, as a monotherapy for treating blood cancers with high unmet medical needs. These cancers include relapsed or refractory acute myeloid leukemia (R/R AML), B-cell
- [Spikimm, Satt Conectus Join Forces for Innovative BK Virus Treatment](https://www.clinicaltrialvanguard.com/news/spikimm-satt-conectus-join-forces-for-innovative-bk-virus-treatment/) - SpikImm, a biotech company established in 2021, has entered an exclusive agreement with SATT Conectus for the development of monoclonal antibodies (mAbs) against the BK virus (BKV). BKV, prevalent in early life, often persists latently. However, immunosuppressive treatments, such as those given to transplant patients, can reactivate the virus, leading to urinary tract complications. Kidney
- [Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib](https://www.clinicaltrialvanguard.com/news/volastra-therapeutics-announces-first-patient-dosed-in-phase-ib-clinical-trial-of-sovilnesib/) - Volastra Therapeutics has advanced its clinical-stage KIF18A inhibitor, sovilnesib, into Phase Ib clinical trials. The trials will evaluate the safety and efficacy of sovilnesib in treating platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC). Sovilnesib is designed to target cancers with high levels of chromosomal instability. The FDA has designated it Fast Track, recognizing its
- [Biotech Asher Secures $55 Million Funding: Phase 1B Trials on the Horizon](https://www.clinicaltrialvanguard.com/news/biotech-asher-secures-55-million-funding-phase-1b-trials-on-the-horizon/) - Asher Biotherapeutics, a leader in developing targeted immunotherapies, has secured $55 million in Series C funding led by RA Capital Management. This investment will enable the company to advance its lead program, AB248, a CD8-targeted IL-2 immunotherapy. • The financing will fund Phase 1b monotherapy expansion data and early safety and efficacy results from the
- [Calidi Biotherapeutics IPO Raises $6.1 Million](https://www.clinicaltrialvanguard.com/news/calidi-biotherapeutics-ipo-raises-6-1-million/) - Calidi Biotherapeutics, a biotechnology company focused on developing targeted immunotherapies, has priced its public offering for 15,197,500 shares of common stock or pre-funded warrants. The offering also includes Series A, B, and C Common Warrants, each comprising one share of common stock and a corresponding warrant. The combined effective price for the offering is $0.40
- [Medincell's Partnership with AbbVie: Unlocking Next-Gen Injectable Therapies](https://www.clinicaltrialvanguard.com/news/medincells-partnership-with-abbvie-unlocking-next-gen-injectable-therapies/) - Medincell has teamed up with AbbVie to develop and commercialize up to six innovative long-acting injectable (LAI) therapies. This collaboration capitalizes on Medincell's commercial-stage LAI technology and development expertise and AbbVie's clinical development and commercialization capabilities. Medincell will receive an upfront payment of $35 million and potential milestones of up to $1.9 billion based on
- [Artifa's Allonk: Unprecedented Lupus Breakthrough](https://www.clinicaltrialvanguard.com/news/artifas-allonk-unprecedented-lupus-breakthrough/) - Artiva Biotherapeutics has begun a Phase 1 trial of its AlloNK (AB-101) cell therapy in combination with monoclonal antibodies for lupus nephritis (LN). AlloNK is a cryopreserved, allogeneic NK cell therapy that enhances monoclonal antibodies' activity against B-cells. Autologous CAR-T cell studies have shown that B-cell depletion can improve LN symptoms and potentially provide long-term
- [OPM Obtains €5.6 Million for DEMOCRITE Program’s Clinical Development](https://www.clinicaltrialvanguard.com/news/opm-obtains-e5-6-million-for-democrite-programs-clinical-development/) - Oncodesign Precision Medicine (OPM) has received €5.6 million in funding for the DEMOCRITE project, aimed at demonstrating the efficacy of OPM-101 in treating Inflammatory Bowel Disease (IBD). OPM-101, derived from OPM's Nanocyclix® platform, inhibits RIPK2, a key regulator of cell death and inflammation. The project focuses on Immune-Induced Ulcerative Colitis (IIUC), a severe form of
- [Unveiling the Revolutionary ALECENSA: A Game-Changer for ALK+ Lung Cancer](https://www.clinicaltrialvanguard.com/news/unveiling-the-revolutionary-alecensa-a-game-changer-for-alk-lung-cancer/) - The U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the treatment of patients with ALK-positive non-small cell lung cancersmall cell lung cancerlung cancer (NSCLC) following surgical removal of the tumor. This approval stems from the Phase III ALINA study, which demonstrated a significant reduction in the risk of disease recurrence or death
- [Lantern Pharma's Harmonic™ Trial Expands to Japan and Taiwan](https://www.clinicaltrialvanguard.com/news/lantern-pharmas-harmonic-trial-expands-to-japan-and-taiwan/) - Lantern Pharma has received regulatory approval to expand its Phase 2 clinical trial (HarmonicTM) to evaluate the efficacy of LP-300 for non-small cell lung cancersmall cell lung cancer (NSCLC) in non-smokers in Japan and Taiwan. Approximately one-third of lung cancer cases in East Asia occur in non-smokers, a proportion that has been rising steadily. The
- [Neurogene's Revolutionary Gene Therapy for Rett Syndrome: Exciting Data Unlocks Hope](https://www.clinicaltrialvanguard.com/news/neurogenes-revolutionary-gene-therapy-for-rett-syndrome-exciting-data-unlocks-hope/) - Neurogene's NGN-401 gene therapy for Rett syndrome has exhibited promising safety results in initial clinical trials. After several months of observation, the therapy has been well-tolerated by all three patients, with no significant adverse events or signs of excessive MeCP2 protein production. NGN-401 utilizes Neurogene's EXACT transgene regulation technology to deliver a full-length MECP2 gene
- [Anktiva®: An FDA-Approved Game-Changer for Non-Muscle Invasive Bladder Cancer](https://www.clinicaltrialvanguard.com/news/anktiva-an-fda-approved-game-changer-for-non-muscle-invasive-bladder-cancer/) - The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) that has not responded to BCG therapy. This milestone marks a significant advancement in the fight against NMIBC, a form of bladder cancer that can lead to
- [Exciting New Clinical Trial Results for Duchenne Muscular Dystrophy](https://www.clinicaltrialvanguard.com/news/exciting-new-clinical-trial-results-for-duchenne-muscular-dystrophy/) - The international gene therapy trial for Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD) using GNT0004 has unveiled promising findings at the Myology 2024 conference. The trial, led by Professor Francesco Muntoni, combines phases I to III with a dose escalation stage, followed by a pivotal phase. The trial has enrolled ambulant boys aged 6 to 10
- [Incyte's Acquisition: Unlocking a Promising Pipeline of Groundbreaking Medicines](https://www.clinicaltrialvanguard.com/news/incytes-acquisition-unlocking-a-promising-pipeline-of-groundbreaking-medicines/) - Incyte, a renowned biopharmaceutical company, has acquired Escient Pharmaceuticals, a pioneer in developing small molecule therapeutics for immune disorders. This strategic move expands Incyte's portfolio with two first-in-class drugs, EP262 and EP547, targeting systemic and neuro-immune conditions. EP262, a potent antagonist of the MRGPRX2 receptor, holds promise for treating mast cell-mediated diseases such as atopic
- [Exgenesis Bio: Positive Phase 1/2 Clinical Trial Data for EXG001-307 Gene Therapy for Spinal Muscular Atrophy](https://www.clinicaltrialvanguard.com/news/exgenesis-bio-positive-phase-1-2-clinical-trial-data-for-exg001-307-gene-therapy-for-spinal-muscular-atrophy/) - Exegenesis Bio, a leading genetic medicines company, unveiled encouraging clinical efficacy and safety results for their EXG001-307 gene therapy in SMA Type 1 patients at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. EXG001-307 is a novel recombinant adeno-associated virus (rAAV) gene therapy designed to address the genetic defect responsible for SMA.
- [Landmark Nature Paper Unveils Groundbreaking Covalent Inhibitor for Rare Disease](https://www.clinicaltrialvanguard.com/news/landmark-nature-paper-unveils-groundbreaking-covalent-inhibitor-for-rare-disease/) - Vividion Therapeutics, a biopharmaceutical company, has made a significant discovery in the development of novel cancer and immune disorder treatments. Vividion's chemoproteomic platform enabled the discovery of a covalent allosteric inhibitor of WRN helicase, known as VVD-133214 (RO7589831). WRN is a promising target for cancers with microsatellite instability. The publication of the discovery in Nature
- [Taking Stock of Obesity Drug Development: Trends and Challenges Facing Today’s Researchers](https://www.clinicaltrialvanguard.com/article/taking-stock-of-obesity-drug-development-trends-and-challenges-facing-todays-researchers/) - Rising levels of obesity have become a global health issue, with an estimated 2.8 million people dying each year as a result.1 In the face of this major medical crisis, the development of effective drugs and interventions for the treatment of obesity is clearly an important undertaking. And, with recent advances in the field —
- [Merck's V116 Vaccine: A Revolutionary Breakthrough for Adult Pneumococcal Protection](https://www.clinicaltrialvanguard.com/news/mercks-v116-vaccine-a-revolutionary-breakthrough-for-adult-pneumococcal-protection/) - A Phase 3 trial (STRIDE-10) evaluated V116, a 21-valent pneumococcal conjugate vaccine, in adults over 50. The study compared V116 to a standard 23-valent pneumococcal vaccine (PPSV23) and assessed its immunogenicity, safety, and tolerability. Key findings revealed that V116 induced strong immune responses to the serotypes responsible for the majority of invasive pneumococcal disease in
- [Tivdak's Full FDA Approval: A Triumphant Victory for Metastatic Cervical Cancer Treatment](https://www.clinicaltrialvanguard.com/news/tivdaks-full-fda-approval-a-triumphant-victory-for-metastatic-cervical-cancer-treatment/) - The U.S. Food and Drug Administration (FDA) has granted full approval to TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer who have undergone prior chemotherapy. The approval is based on results from the Phase 3 innovaTV 301 trial, which demonstrated significant overall survival (OS) benefits for patients treated with
- [FDA Approves Pfizer's Gene Therapy Treatment for Hemophilia B](https://www.clinicaltrialvanguard.com/news/fda-approves-pfizers-gene-therapy-treatment-for-hemophilia-b/) - Pfizer's BEQVEZ, a one-time gene therapy, has received FDA approval for treating adults with moderate to severe hemophilia B. Patients who have life-threatening hemorrhages, repeated spontaneous bleeding episodes, or current use of factor IX (FIX) prophylaxis therapy are eligible for this treatment. Hemophilia B is a rare disorder that affects blood clotting due to a
- [c2n Diagnostics partners with Mediford for Precivity™ Alzheimer's Blood Test Expansion in Japan](https://www.clinicaltrialvanguard.com/news/c2n-diagnostics-partners-with-mediford-for-precivity-alzheimers-blood-test-expansion-in-japan/) - C2N Diagnostics has partnered with Mediford Corporation, a subsidiary of PHC Holdings, to enhance access to its clinical research services in Japan. C2N's Precivity™ blood tests provide highly accurate identification and quantification of biomarkers related to neurological diseases, including Alzheimer's disease. The tests aid in diagnosis, prognosis, and treatment monitoring. Notably, C2N's innovative MTBR-tau biomarker
- [Walmart Health Center Exit: Is It Good For Clinical Trials?](https://www.clinicaltrialvanguard.com/article/walmart-health-center-exit-is-it-good-for-clinical-trials/) - Explore Walmart Health center impact on healthcare delivery and clinical trials. Discover the history, growth, and recent closure of Walmart's healthcare initiative.
- [Trisalus Strengthens Infusion System Growth with $50M Debt Financing](https://www.clinicaltrialvanguard.com/news/trisalus-strengthens-infusion-system-growth-with-50m-debt-financing/) - TriSalus Life Sciences recently secured a $50 million debt facility from OrbiMed. This financing aims to support TriSalus' expansion plans and continued growth, enhancing its financial flexibility and allowing for further investment in its TriNav commercial and technology pipeline. To execute strategic initiatives, TriSalus borrowed $25 million initially, with an option for additional tranches up
- [Qlaris Bio Secures $24 Million Funding for Revolutionary Glaucoma Drug Development](https://www.clinicaltrialvanguard.com/news/qlaris-bio-secures-24-million-funding-for-revolutionary-glaucoma-drug-development/) - Qlaris Bio, a biotechnology company specializing in ophthalmic diseases, secured $24 million in Series B financing. The round was co-led by Canaan and New Leaf Venture Partners, with participation from abrdn Inc., Mayo Clinic Ventures, and Correlation Ventures. The proceeds will support the continued development of QLS-111, an innovative therapeutic targeting episcleral venous pressure (EVP)
- [Innovative Tech Solutions for Challenges in Clinical Research](https://www.clinicaltrialvanguard.com/executiveinterviews/innovative-tech-solutions-for-challenges-in-clinical-research/) - Dive into how technology meets the challenges in clinical research head-on. Uncover innovative solutions that are transforming trials, enhancing efficiency
- [Ultrasound Therapy Shows Promise in Relieving Rheumatoid Arthritis](https://www.clinicaltrialvanguard.com/news/ultrasound-therapy-shows-promise-in-relieving-rheumatoid-arthritis/) - SecondWave Systems has made a breakthrough in the treatment of rheumatoid arthritisarthritis (RA) with their novel ultrasonic stimulation technology. The pilot clinical study involved the noninvasive treatment of 13 participants, significantly improving disease activity. The wearable MINI™ device delivers ultrasound stimulation to the spleen, effectively reducing inflammation and symptoms. Ten out of 13 participants experienced
- [Remepy Unveils $15 Million Investment for Revolutionary Drug](https://www.clinicaltrialvanguard.com/news/remepy-unveils-15-million-investment-for-revolutionary-drug/) - Remepy, a pioneer in "hybrid drugs," has secured $15 million in funding, led by NFX and supported by several other investors. Hybrid drugs combine traditional medications with "digital molecules," therapeutic interventions that use non-invasive cognitive or behavioral techniques to trigger physiological effects. These digital molecules have been shown to enhance the effectiveness of traditional drugs
- [Unlock the Secrets of Parkinson's: Cambridge Cognition and Fox Foundation Team Up](https://www.clinicaltrialvanguard.com/news/unlock-the-secrets-of-parkinsons-cambridge-cognition-and-fox-foundation-team-up/) - Cambridge Cognition, a leader in digital brain health assessment solutions, and The Michael J. Fox Foundation for Parkinson's Disease Research are collaborating on the Parkinson's Progression Markers Initiative (PPMI). The PPMI will leverage Cambridge Cognition's CANTAB cognitive assessments to characterize the cognitive profiles of Parkinson's Disease patients. This initiative aims to unravel the mechanisms of
- [NIAID Awards $14M for Institutional Review Services to Advarra](https://www.clinicaltrialvanguard.com/news/niaid-awards-14m-for-institutional-review-services-to-advarra/) - The National Institutes of Health (NIH) has chosen Advarra as its exclusive single institutional review board (sIRB) for clinical trials. This multi-year contract is valued at over $13 million. Advarra's expertise in project management and administrative oversight for sIRBs, coupled with its robust digital platform and extensive experience, were key factors in the decision. Advarra's
- [MCL Treatment Revolution: Calquence Powers Progression-Free Life](https://www.clinicaltrialvanguard.com/news/mcl-treatment-revolution-calquence-powers-progression-free-life/) - A promising new treatment option has emerged for patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. The ECHO Phase III clinical trial demonstrated significant benefits of CALQUENCE (acalabrutinib) when combined with standard chemotherapy (bendamustine and rituximab). CALQUENCE, a Bruton tyrosine kinase (BTK) inhibitor, showed a statistically significant improvement in
- [Unlock the Doors of Health Equity: Walgreens and Boehringer Ingelheim's Partnership](https://www.clinicaltrialvanguard.com/news/unlock-the-doors-of-health-equity-walgreens-and-boehringer-ingelheims-partnership/) - Boehringer Ingelheim and Walgreens have joined forces to revolutionize clinical trials. Through this collaboration, people with obesity, overweight, and type 2 diabetes will have access to a Phase III clinical trial in a convenient setting - Walgreens pharmacies. This initiative aims to remove obstacles, promote equity, and enhance the representation of diverse communities in clinical
- [BMS Submits EMA Application for Opdivo and Yervoy for mCRC](https://www.clinicaltrialvanguard.com/news/bms-submits-ema-application-for-opdivo-and-yervoy-for-mcrc/) - Bristol Myers Squibb (BMS) recently submitted an application to the European Medicines Agency (EMA) for the use of the immunotherapy combination of Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for adult patients with MSI-H or dMMR metastatic colorectal cancer (mCRC). The EMA's acceptance of this application initiates the centralized review process. The application
- [Cybin Unveils Strategies For CYB003 & CYB004 Psychedelic Drug Development](https://www.clinicaltrialvanguard.com/news/cybin-unveils-strategies-for-cyb003-cyb004-psychedelic-drug-development/) - Cybin Inc., a biopharmaceutical company specializing in psychedelic-based mental health treatments, has secured $150 million in funding to advance its clinical-stage programs, CYB003 and CYB004. CYB003, a deuterated psilocybin analog, has received Breakthrough Therapy Designation (BTD) from the FDA for the adjunctive treatment of Major Depressive Disorder (MDD). This designation recognizes CYB003's potential to significantly
- [AI Predicts Metastasis Risk in Prostate Cancer: Revolutionary Biomarker](https://www.clinicaltrialvanguard.com/news/ai-predicts-metastasis-risk-in-prostate-cancer-revolutionary-biomarker/) - ArteraAI has announced the validation of its AI-based digital pathology biomarker for predicting metastasis risk in prostate cancer patients who have undergone radical prostatectomy and subsequently experienced biochemical recurrence (BCR). This biomarker will help clinicians determine the optimal treatment plan for these patients. After a radical prostatectomy, about 20-40% of patients develop BCR, indicating a
- [Neurogene Unveils Remarkable Trial Results in Rett Syndrome](https://www.clinicaltrialvanguard.com/news/neurogene-unveils-remarkable-trial-results-in-rett-syndrome/) - Neurogene Inc. has reported positive initial safety and tolerability data from its ongoing Phase 1/2 gene therapy trial for Rett syndrome. The treatment, NGN-401, was well-tolerated in the first three patients dosed, with follow-up periods ranging from three to nine months. NGN-401 incorporates Neurogene's EXACTTM technology, aiming to provide therapeutic levels of protein expression without
- [Lokavant Expands Team to Enhance AI-Driven Clinical Trial Feasibility Solution](https://www.clinicaltrialvanguard.com/news/lokavant-expands-team-to-enhance-ai-driven-clinical-trial-feasibility-solution/) - Lokavant, a clinical trial intelligence platform, has strengthened its team with the appointment of three new Advisory Board members and a new executive. The Advisory Board includes industry leaders like Pfizer's Head of Predictive Analytics, Jonathan Crowther, who provide insights into the data and analytics needs of clinical trial sponsors and contract research organizations (CROs).
- [PLK Targeted Therapies Market Boasts Promise in Cancer and Beyond](https://www.clinicaltrialvanguard.com/news/plk-targeted-therapies-market-boasts-promise-in-cancer-and-beyond/) - Polo-like kinases (PLKs) are key players in cellular processes like cell cycle regulation and DNA damage response. Their dysregulation in various diseases, particularly cancer, makes them promising therapeutic targets. The global PLK targeted therapies market is nascent but rapidly evolving, with several pharmaceutical companies investing in research. These therapies aim to inhibit PLKs, leading to
- [Merck's KEYNOTE-B21 Trial: Failed To Meet Primary Endpoint For Endrometrial Cancer](https://www.clinicaltrialvanguard.com/news/mercks-keynote-b21-trial-failed-to-meet-primary-endpoint-for-endrometrial-cancer/) - Merck's Phase 3 KEYNOTE-B21 trial has shown that its anti-PD-1 therapy, KEYTRUDA, in combination with chemotherapy, did not improve disease-free survival (DFS) in high-risk endometrial cancer patients after surgery. An interim analysis revealed that KEYTRUDA plus chemotherapy, with or without radiotherapy, did not meet the study's criteria for DFS compared to placebo plus chemotherapy. Therefore,
- [Kite and Arcellx Advance Multiple Myeloma Program with Anti-BCMA CAR-T Momentum](https://www.clinicaltrialvanguard.com/news/kite-and-arcellx-advance-multiple-myeloma-program-with-anti-bcma-car-t-momentum/) - Arcellx and Kite have partnered on the development of anitocabtagene autoleucel (anito-cel), a BCMA CAR T cell therapy for multiple myeloma. The companies have designed a global Phase 3 trial, iMMagine-3, to evaluate the efficacy and safety of anito-cel in patients who have received prior treatment with an immunomodulatory drug and an anti-CD38 monoclonal antibody.
- [AC Immune and Takeda: A Remarkable Agreement for Alzheimer's Therapy](https://www.clinicaltrialvanguard.com/news/ac-immune-and-takeda-a-remarkable-agreement-for-alzheimers-therapy/) - Takeda Pharmaceutical Company and AC Immune have entered into an exclusive global option and licensing agreement for AC Immune's active immunotherapies, including ACI-24.060, which targets Alzheimer's diseaseAlzheimer's disease. ACI-24.060 is designed to trigger an immune response against toxic amyloid beta (Abeta) forms, which are linked to plaque formation and Alzheimer's progression. By clearing plaques and
- [Merck Terminates Investigational Melanoma Treatment Arm](https://www.clinicaltrialvanguard.com/news/merck-terminates-investigational-melanoma-treatment-arm/) - Merck has terminated a clinical trial arm combining vibostolimab and pembrolizumab for treating resected high-risk melanoma. The decision was made after an analysis revealed a higher discontinuation rate for the coformulation arm due to immune-related events, diminishing the likelihood of a significant improvement in the primary endpoint of recurrence-free survival (RFS). The independent Data Monitoring
- [Can-Fite BioPharma Proceeds with Phase 3 Liver Cancer Trial](https://www.clinicaltrialvanguard.com/news/can-fite-biopharma-proceeds-with-phase-3-liver-cancer-trial/) - Can-Fite BioPharma has secured approval from the FDA and EMA for a pivotal Phase 3 clinical trial for the treatment of advanced liver cancer. The trial is now underway in Israel, Europe, and the US and aims to enroll patients who have not responded to other approved therapies. The drug being evaluated in the trial,
- [Medidata: Enhancing Trials, Transforming Patient Care Worldwide](https://www.clinicaltrialvanguard.com/news/medidata-enhancing-trials-transforming-patient-care-worldwide/) - Medidata, a leading clinical trial solutions provider, has partnered with Worldwide Clinical Trials (Worldwide) to leverage Medidata AI. This collaboration aims to enhance trial planning and facilitate data-driven decision-making across Worldwide's operations. By utilizing Medidata AI's capabilities, Worldwide can systematically plan, design, and execute research. This enables them to reduce trial timelines and improve site
- [Alto Neuroscience's Astonishing Financial Results and Breakthrough Highlights](https://www.clinicaltrialvanguard.com/news/alto-neurosciences-astonishing-financial-results-and-breakthrough-highlights/) - Alto Neuroscience has initiated a Phase 2 study of ALTO-203, a PDE4 inhibitor targeted at patients with major depressive disorder (MDD) and anhedonia. This follows positive Phase 1 data for the transdermal formulation of ALTO-101. The improved drug delivery system significantly increased exposure while reducing tolerability issues compared to oral administration. Phase 2b studies for
- [Moffitt Cancer Center and Fulgent Pharma Unite to Unveil Nanotherapeutics Cancer Therapies](https://www.clinicaltrialvanguard.com/news/moffitt-cancer-center-and-fulgent-pharma-unite-to-unveil-nanotherapeutics-cancer-therapies/) - Moffitt Cancer Center and Fulgent Pharma have formed a partnership to accelerate the development of personalized cancer therapies. • Moffitt provides Fulgent access to clinical expertise and resources, prioritizing Fulgent's clinical pipeline. • Fulgent contributes its nanotherapeutics and genomics platforms. • Co-development of personalized treatment options based on Moffitt's scientific and immunology expertise, as well
- [Breyanzi FDA Approved: A Remarkable New Hope for Follicular Lymphoma Patients](https://www.clinicaltrialvanguard.com/news/breyanzi-fda-approved-a-remarkable-new-hope-for-follicular-lymphoma-patients/) - Bristol Myers Squibb's Breyanzi has received accelerated FDA approval for adult patients with relapsed or refractory follicular lymphoma who have undergone at least two prior therapies. Breyanzi is a personalized therapy that uses chimeric antigen receptor (CAR) T cells to target CD19, a protein found in lymphoma cells. The treatment involves a single infusion of
- [Alpha Cognition: Surprising Results Unlock New Opportunities](https://www.clinicaltrialvanguard.com/news/alpha-cognition-surprising-results-unlock-new-opportunities/) - Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative disorders, has shared its financial results and updated it for the first quarter of 2024. The company's lead drug, ALPHA-1062, is undergoing review by the FDA for mild-to-moderate Alzheimer's diseaseAlzheimer's disease. Alpha Cognition is actively planning for its commercialization and manufacturing, anticipating a PDUFA date of
- [Sotyktu's Power: Long-Lasting Relief in Plaque Psoriasis](https://www.clinicaltrialvanguard.com/news/sotyktus-power-long-lasting-relief-in-plaque-psoriasis/) - New data revealed that after four years of continuous treatment, over 70% of patients with psoriasis achieved a 75% reduction in disease severity, known as PASI 75, in a long-term extension trial of Sotyktu. Similarly, around 57% achieved clear or almost clear skin, based on the static Physician's Global Assessment (sPGA). The safety profile of
- [AI-Powered Cell Simulations Soar in Biopharma with Accenture's Latest Investment](https://www.clinicaltrialvanguard.com/news/ai-powered-cell-simulations-soar-in-biopharma-with-accentures-latest-investment/) - Accenture Ventures, the venture capital arm of Accenture, has invested in Turbine, a predictive simulation company developing a platform for understanding human biology. This strategic investment aims to enhance Turbine's capabilities for global biopharma companies. Turbine's central technology, the Simulated Cell™ platform, leverages machine learning to decipher decision-making processes in human cells. It models molecular
- [Tezspire's Potential Role in Chronic Obstructive Pulmonary Disease: Latest ATS Findings Revealed](https://www.clinicaltrialvanguard.com/news/tezspires-potential-role-in-chronic-obstructive-pulmonary-disease-latest-ats-findings-revealed/) - A Phase IIa trial, known as COURSE, has assessed the effectiveness of TEZSPIRE (tezepelumab) in reducing COPD exacerbations in patients with varying eosinophil counts. TEZSPIRE showed a notable reduction in exacerbations among patients with higher eosinophil counts. Overall, TEZSPIRE led to a 17% numerical decrease in exacerbations compared to placebo, although it was not statistically
- [Terran Biosciences Unveils Remarkable Breakthrough: TERXT for Schizophrenia](https://www.clinicaltrialvanguard.com/news/terran-biosciences-unveils-remarkable-breakthrough-terxt-for-schizophrenia/) - Terran Biosciences has developed TerXT, a combination of novel prodrugs of xanomeline and trospium, for treating schizophrenia. The prodrug approach aims to overcome the limitations of xanomeline and trospium, enabling fixed-dose combinations for once-daily oral administration and long-acting intramuscular injections. Terran's team of experts designed over 10,000 prodrugs using medicinal chemistry and PK modeling to
- [Pathai's AISight Breaks Barriers, Empowering Pathologists with Next-Gen Image Management](https://www.clinicaltrialvanguard.com/news/pathais-aisight-breaks-barriers-empowering-pathologists-with-next-gen-image-management/) - PathAI, a leader in AI-powered pathology, launches an Early Access Program (EAP) for its AISight Image Management System (IMS) in Europe. This program provides labs access to advanced digital pathology solutions and AI capabilities. AISight is a cloud-based platform that streamlines end-to-end digital pathology workflows. It enhances case management, viewing, collaboration, and integration with laboratory
- [Foundation Medicine Launches Groundbreaking RNA Sequencing Test, FoundationOne®RNA, in the U.S.](https://www.clinicaltrialvanguard.com/news/foundation-medicine-launches-groundbreaking-rna-sequencing-test-foundationonerna-in-the-u-s/) - Foundation Medicine has launched FoundationOne®RNA, an RNA sequencing test that complements its DNA-based FoundationOne®CDx. This combination provides enhanced fusion detection in cancer, particularly in non-small cell lung cancersmall cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors. RNA sequencing detects fusions in 318 genes, expanding the company's portfolio of genomic profiling tests. By offering
- [Unlock the Extraordinary: AngioDynamics' AlphaVac F18⁸⁵ Revolutionizes Vascular Health](https://www.clinicaltrialvanguard.com/news/unlock-the-extraordinary-angiodynamics-alphavac-f18⁸⁵-revolutionizes-vascular-health/) - AngioDynamics, Inc. has obtained CE Mark approval in Europe for its AlphaVac F1885 System, enabling the non-surgical removal of blood clots from pulmonary arteries and the treatment of pulmonary embolism (PE). This approval marks a significant advancement in patient care and safety for endovascular therapies within the European Union, which experiences a higher prevalence of
- [Gilead: Insights for Liver Disease at EASL 2024](https://www.clinicaltrialvanguard.com/news/gilead-insights-for-liver-disease-at-easl-2024/) - Gilead Sciences announced significant research findings to be presented at the European Association for the Study of the Liver (EASL) Congress in 2024. Primary Biliary Cholangitis (PBC) • Long-term data from the Phase 3 ASSURE study will demonstrate the sustained effectiveness and safety of seladelpar for treating PBC. • The study includes individuals who received
- [Middle East Clinical Trial Regulatory Update: Pioneering Frameworks](https://www.clinicaltrialvanguard.com/conference-coverage/middle-east-clinical-trial-regulatory-update-pioneering-frameworks/) - The Middle East Town Hall at DIA Europe 2024 showcased significant Middle East clinical trial regulatory advancements across the region, with representatives from Saudi Arabia, Egypt, Jordan, and Qatar detailing their strategies to enhance healthcare outcomes. Each country highlighted its unique approaches to aligning with international standards, leveraging reliance practices, and implementing digital solutions to
- [Fulgent Announces Clinical Data Presentation for Lead Oncology Candidate at ASCO 2024](https://www.clinicaltrialvanguard.com/news/fulgent-announces-clinical-data-presentation-for-lead-oncology-candidate-at-asco-2024/) - Fulgent Pharma, a subsidiary of Fulgent Genetics, will present Phase 1 clinical data on FID-007, its lead therapeutic candidate for head and neck cancer, at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2024. FID-007 is a nanoparticle formulation of paclitaxel designed to improve drug delivery and tolerability. The
- [SpyBiotech and Oxford Team Up to Conquer Epstein-Barr Virus](https://www.clinicaltrialvanguard.com/news/spybiotech-and-oxford-team-up-to-conquer-epstein-barr-virus/) - SpyBiotech and The University of Oxford have entered a research agreement to develop a vaccine against Epstein-Barr virus (EBV). EBV is a widespread virus that can cause various health conditions, including infectious mononucleosis, and is associated with certain cancers and multiple sclerosis. The collaboration will leverage Oxford's academic research expertise and SpyBiotech's proprietary SPYVLP vaccine
- [Devoted to Amyloidosis: AstraZeneca's Heartfelt Commitment at ISA 2024](https://www.clinicaltrialvanguard.com/news/devoted-to-amyloidosis-astrazenecas-heartfelt-commitment-at-isa-2024/) - AstraZeneca and Alexion will present at the International Symposium on Amyloidosis (ISA) 2024, showcasing studies on their amyloidosis treatment pipeline. Key findings include subgroup analyses from the NEURO-TTRansform study of WAINUATM (eplontersen), which the FDA approved for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis. Clinical data will also be presented on ALXN2220 and anselamimab, undergoing
- [Merck: Phase 3 Trial Success for TNBC Patients](https://www.clinicaltrialvanguard.com/news/merck-phase-3-trial-success-for-tnbc-patients/) - KEYTRUDA (pembrolizumab) has demonstrated promising results in the treatment of high-risk early-stage triple-negative breast cancer (TNBC) in the Phase 3 KEYNOTE-522 trial. KEYTRUDA, in combination with chemotherapy as pre-operative treatment followed by single-agent use after surgery, significantly improved overall survival (OS) compared to pre-operative chemotherapy alone. This landmark achievement marks the first immunotherapy-based regimen to
- [AI Validation in Massive Bio Clinical Trial: A Revolutionary Breakthrough](https://www.clinicaltrialvanguard.com/news/ai-validation-in-massive-bio-clinical-trial-a-revolutionary-breakthrough/) - The Precision Cancer Consortium (PCC) and Massive Bio have conducted a comprehensive study on the efficacy of Massive Bio's artificial intelligence (AI) system for clinical trial matching. The study evaluated the system's ability to refine the matching process using real-world clinical and genomic data for a multi-study oncology platform. Typically, screening patients for cancer trials
- [ViVani Medical Unveils Groundbreaking Weight Loss Solution for Pets with OKV-119: A Life-Changing Innovation](https://www.clinicaltrialvanguard.com/news/vivani-medical-unveils-groundbreaking-weight-loss-solution-for-pets-with-okv-119-a-life-changing-innovation/) - A study published in BMC Veterinary Research demonstrates the effectiveness of OKV-119, a miniature drug implant containing exenatide, in reducing weight in obese cats. This implant leverages Vivani Medical's patented NanoPortal technology, allowing long-term medication delivery through a subdermal implant. The exenatide drug is known for regulating blood sugar levels and promoting weight loss. The
- [Revolutionary FDA Clearance Paves Way for Game-Changing Hemophilia B Therapy](https://www.clinicaltrialvanguard.com/news/revolutionary-fda-clearance-paves-way-for-game-changing-hemophilia-b-therapy/) - Be Biopharma, Inc., a pioneer in developing Engineered B Cell Medicines (BCMs), has received IND clearance from the FDA for BE-101, a revolutionary treatment for hemophilia B. This Phase 1/2 clinical trial, BeCoMe-9, will evaluate BE-101's safety and efficacy in adults with hemophilia B. The trial is expected to begin in late 2024. BE-101 is
- [Pfizer's Lorbrena® CROWN Study: Remarkable Milestone for Lung Cancer Patients](https://www.clinicaltrialvanguard.com/news/pfizers-lorbrena-crown-study-remarkable-milestone-for-lung-cancer-patients/) - A recent Phase 3 CROWN trial has demonstrated the long-term effectiveness of LORBRENA in treating ALK-positive advanced non-small cell lung cancersmall cell lung cancerlung cancer (NSCLC). After five years of follow-up, patients treated with LORBRENA experienced a remarkable 81% reduction in disease progression or death compared to those receiving XALKORI. Significantly, 60% of LORBRENA recipients
- [Study Results in Metastatic NSCLC Presented at ASCO 2024: Astonishing Breakthrough](https://www.clinicaltrialvanguard.com/news/study-results-in-metastatic-nsclc-presented-at-asco-2024-astonishing-breakthrough/) - The EVOKE-01 study investigated Trodelvy against docetaxel in patients with advanced non-small cell lung cancersmall cell lung cancer (NSCLC) that had progressed after standard treatments. The study revealed a 16% reduction in mortality risk for patients treated with Trodelvy compared to docetaxel (median overall survival: 11.1 vs. 9.8 months). This improvement was observed across all
- [Calidi Biotherapeutics $2.1 Million Warrant Exercise](https://www.clinicaltrialvanguard.com/news/calidi-biotherapeutics-2-1-million-warrant-exercise/) - Calidi Biotherapeutics, a biotechnology company focusing on targeted immunotherapies, announced the exercise of warrants for purchasing over 10.6 million shares of its common stock at a reduced price of $0.20. The warrants were initially issued in April 2024 and had terms of 12 months and four months, respectively. The company anticipates approximately $2.1 million in
- [Artera Unveils Extraordinary AI Cancer Platform, Unveiling the Future of Cancer Treatment](https://www.clinicaltrialvanguard.com/news/artera-unveils-extraordinary-ai-cancer-platform-unveiling-the-future-of-cancer-treatment/) - Artera's multimodal artificial intelligence (MMAI) platform has demonstrated notable prognostic value in prostate and early-stage breast cancer. Studies presented at ASCO 2024 highlighted the platform's ability to provide personalized therapy recommendations based on image analysis of hematoxylin and eosin (H&E)-stained pathology slides. Traditionally, personalized cancer treatment plans required multiple tests, which can be costly and
- [FDA Approves BMS's Revolutionary CAR-T Therapy for Cancer](https://www.clinicaltrialvanguard.com/news/fda-approves-bmss-revolutionary-car-t-therapy-for-cancer/) - Bristol Myers Squibb has garnered FDA approval for Breyanzi, a CAR-T cell therapy for relapsed or refractory mantle cell lymphoma (MCL). This marks the fourth subtype of non-Hodgkin lymphoma treatable with Breyanzi, making it the most widely applicable CAR T cell therapy for B-cell malignancies. Breyanzi requires only one infusion of CAR-positive viable T cells
- [Unlock the Power of AI for Life Science: Paige's Revolutionary Approach](https://www.clinicaltrialvanguard.com/news/unlock-the-power-of-ai-for-life-science-paiges-revolutionary-approach/) - Paige, a digital pathology and AI leader, has introduced a service line powered by its Foundation Models. These models include the world's largest multi-modal AI model for pathology and oncology. AI developers, organizations building computational pathology products, and life sciences companies can license and utilize these models to create their AI models for various purposes.
- [Incyte Acquires Escient Pharmaceuticals for Uncommon Progress](https://www.clinicaltrialvanguard.com/news/incyte-acquires-escient-pharmaceuticals-for-uncommon-progress/) - Incyte has strengthened its Inflammation and Autoimmunity pipeline by acquiring Escient Pharmaceuticals. The acquisition brings EP262 and EP547, two oral MRGPR antagonists, into Incyte's portfolio. EP262 targets MRGPRX2, a receptor found on mast cells. By blocking its activation, EP262 aims to treat mast cell-mediated diseases such as chronic inducible urticaria, chronic spontaneous urticaria, and atopic
- [Thermo Fisher Unveils New Facility Enriching Advanced Therapies Progress in EU](https://www.clinicaltrialvanguard.com/news/thermo-fisher-unveils-new-facility-enriching-advanced-therapies-progress-in-eu/) - Thermo Fisher Scientific's new facility in Bleiswijk, Netherlands, offers comprehensive cold and ultra-cold storage services for clinical trials and biorepository storage. This cGMP-compliant facility caters to the growing demand for cell and gene therapies, biologics, antibodies, and vaccines. The facility provides a full range of services, including ambient to cryogenic storage, clinical packaging, labeling, distribution,
- [Summit Therapeutics $200M Raise: Exclusive Licenses Expand Ivoscimab Territories](https://www.clinicaltrialvanguard.com/news/summit-therapeutics-200m-raise-exclusive-licenses-expand-ivoscimab-territories/) - Summit Therapeutics raised $200 million through an institutional investment, with shares sold at a premium to the previous closing price. The proceeds will fund the clinical development of ivonescimab, an anti-cancer therapy. In a separate transaction, Summit expanded the license territories for ivonescimab. Akeso, Inc. amended their collaboration agreement to include Latin America, the Middle
- [Takeda's TAK-861 Phase 2B Data: A Breakthrough for Narcolepsy Type 1](https://www.clinicaltrialvanguard.com/news/takedas-tak-861-phase-2b-data-a-breakthrough-for-narcolepsy-type-1/) - A Phase 2b trial has demonstrated significant improvements for TAK-861, an investigational treatment for narcolepsy type 1 (NT1). The trial involved 112 patients and evaluated the efficacy and safety of TAK-861 over 8 weeks. NT1 is a chronic neurological disorder caused by the loss of orexin neurons. This results in low levels of orexin neuropeptides,
- [Calidi Presents Phase 1 Update and Preclinical Data on Cld-101 at ASCO 2024](https://www.clinicaltrialvanguard.com/news/calidi-presents-phase-1-update-and-preclinical-data-on-cld-101-at-asco-2024/) - Calidi Biotherapeutics presented its latest developments in antitumor virotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting. NeuroNova (CLD-101): • Phase 1 study for recurrent high-grade gliomas has progressed, demonstrating safety and feasibility. • Four weekly doses of CLD-101 are being administered, and no adverse events have been reported in cohorts 2 and
- [FDA Selects Neurogene's NGN-401 for Innovative Rett Syndrome Therapy Pilot Program](https://www.clinicaltrialvanguard.com/news/fda-selects-neurogenes-ngn-401-for-innovative-rett-syndrome-therapy-pilot-program/) - Neurogene Inc.'s NGN-401 gene therapy for Rett syndrome has been selected for the FDA's Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. This program provides enhanced communication between sponsors and the FDA to expedite the development of therapies for rare diseases. NGN-401 was chosen for its potential clinical benefits and the maturity
- [Fulgent Data: Uncovering Fid-007 in Head and Neck Cance](https://www.clinicaltrialvanguard.com/news/fulgent-data-uncovering-fid-007-in-head-and-neck-cance/) - Fulgent Pharma, a subsidiary of Fulgent Genetics, presented data at ASCO 2024 showing promising results for their therapeutic candidate, FID-007, in treating head and neck cancer. Phase 1 clinical trials evaluated FID-007 in 11 head and neck squamous cell carcinoma patients. Of these, 45% experienced a partial response, and 27% achieved stable disease. Notably, the
- [Obsidian's OBX-115 Data Unveiled at ASCO 2024: Safety, Efficacy, and Surprises](https://www.clinicaltrialvanguard.com/news/obsidians-obx-115-data-unveiled-at-asco-2024-safety-efficacy-and-surprises/) - Obsidian Therapeutics presented updated data from the Phase 1 study of OBX-115, an engineered tumor-derived autologous T-cell immunotherapy, at the 2024 American Society of Clinical Oncology Annual Meeting. OBX-115 exhibited a differentiated safety profile compared to IL2-dependent non-engineered TIL cell therapies. The therapy demonstrated a consistent efficacy profile in heavily pre-treated patients with resistant/refractory disease.
- [Bristol Myers Squibb Unveils Remarkable Analyses on Opdivo's Efficacy in Non-Small Cell Lung Cancer](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibb-unveils-remarkable-analyses-on-opdivos-efficacy-in-non-small-cell-lung-cancer/) - Bristol Myers Squibb's ongoing research in non-small cell lung cancer (NSCLC) has yielded promising results in various stages of the disease. Perioperative Opdivo in Early-Stage NSCLC Updated data from the CheckMate -77T study demonstrate the effectiveness of perioperative Opdivo in improving event-free survival in resectable stage III NSCLC patients, regardless of the number of lymph
- [Visugromab/Nivolumab Combo Triumphs in Advanced Cancer Battle](https://www.clinicaltrialvanguard.com/news/visugromab-nivolumab-combo-triumphs-in-advanced-cancer-battle/) - Positive Results from CatalYm's GDFATHER Trial CatalYm's "GDFATHER" Phase 1/2a trial has shown promising results for its lead candidate, visugromab, in combination with nivolumab, an anti-PD-1 antibody. The trial included cohorts of patients with non-small cell lung cancersmall cell lung cancer (NSCLC), urothelial cancer (UC), hepatocellular carcinoma (HCC), and an additional biomarker cohort. Mechanism of
- [Legend Biotech shares data on CARVYKTI® in the treatment of multiple myeloma](https://www.clinicaltrialvanguard.com/news/legend-biotech-shares-data-on-carvykti-in-the-treatment-of-multiple-myeloma/) - Legend Biotech Corporation, a leader in cell therapy, announced positive results from its Phase 2 CARTITUDE-2 Cohort D study, demonstrating the efficacy of CARVYKTI in treating multiple myeloma patients. CARVYKTI, approved for relapsed/refractory multiple myeloma, showed promising results in patients with less than a complete response after autologous stem cell transplant (ASCT). The study enrolled
- [Breyanzi: Remarkable Outcomes in B-Cell Malignancies Revealed](https://www.clinicaltrialvanguard.com/news/breyanzi-remarkable-outcomes-in-b-cell-malignancies-revealed/) - Long-term follow-up data from the TRANSFORM trial reveals that Breyanzi, a chimeric antigen receptor T-cell (CAR T) therapy, continues to provide event-free survival and durable responses in patients with relapsed or refractory large B-cell lymphomaB-cell lymphoma (LBCL) who received treatment in the second line. Subgroup analysis from the TRANSCEND NHL 001 trial demonstrates Breyanzi's consistent
- [Be Bio: FDA Grants New Designation for Novel Medicine - Hemophilia B Breakthrough](https://www.clinicaltrialvanguard.com/news/be-bio-fda-grants-new-designation-for-novel-medicine-hemophilia-b-breakthrough/) - Be Biopharma (Be Bio) announced that the FDA has granted Orphan Drug Designation to BE-101, an engineered B Cell Medicine (BCM) for Hemophilia B. The designation provides exclusive marketing rights, user fee exemption, and clinical trial tax credits. BE-101 is designed to provide sustained therapeutic FIX activity with a single infusion, potentially eliminating the frequent
- [AstraZeneca's Investment Powers Nucleus Radiopharma's Series A Extension](https://www.clinicaltrialvanguard.com/news/astrazenecas-investment-powers-nucleus-radiopharmas-series-a-extension/) - Nucleus RadioPharma has expanded its capabilities with a Series A investment extension and the appointment of Dr. Tyrell Rivers to its Board of Directors. This funding, led by AstraZeneca, will advance targeted radiotherapies and theranostics, offering new hope for patients battling metastatic cancers. Theranostics seamlessly integrates diagnostics and therapeutics, employing radiotracers to precisely target cancer
- [FDA Grants Tagrisso® Priority Review for Unresectable Stage III EGFR-Mutated Lung Cancer](https://www.clinicaltrialvanguard.com/news/fda-grants-tagrisso-priority-review-for-unresectable-stage-iii-egfr-mutated-lung-cancer/) - AstraZeneca has filed and received Priority Review status in the United States for TAGRISSO® (osimertinib) for treating adult patients with unresectable, Stage III non-small cell lung cancersmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations following chemoradiotherapy (CRT). The FDA has also granted Breakthrough Therapy Designation for TAGRISSO in this setting. The
- [Unveiling Calidi's Breakthrough Virotherapy: Revolutionizing Cancer Treatment](https://www.clinicaltrialvanguard.com/news/unveiling-calidis-breakthrough-virotherapy-revolutionizing-cancer-treatment/) - Calidi Biotherapeutics, a biotechnology company focused on developing anti-tumor virotherapies, has forged a partnership with SIGA Technologies to advance its RTNova platform. This platform utilizes an enveloped vaccinia virus (RTNova) engineered to target and eliminate tumor cells. The RTNova platform holds potential as a universal treatment for various cancer types, primarily focusing on lung cancer
- [FDA Approves GSK's AREXVY RSV Vaccine for At-Risk Seniors over 50](https://www.clinicaltrialvanguard.com/news/fda-approves-gsks-rsv-vaccine-for-at-risk-seniors-over-50/) - The US Food and Drug Administration (FDA) has given its approval to AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) for preventing lower respiratory tract disease (LRTD) caused by RSV in high-risk adults between the ages of 50 and 59. RSV is a prevalent respiratory virus that can cause severe illness, particularly in adults with chronic underlying
- [First Patient Enrolled in Monotherapy Study Evaluating Camonsertib in Non-Small Cell Lung Cancer](https://www.clinicaltrialvanguard.com/news/first-patient-enrolled-in-monotherapy-study-evaluating-camonsertib-in-non-small-cell-lung-cancer/) - Repare Therapeutics, a precision oncology company, has initiated patient dosing in the expanded phase of its TRESR clinical trial, which evaluates camonsertib monotherapy in non-small cell lung cancersmall cell lung cancer (NSCLC) with ATM mutations. Camonsertib has shown promising anti-tumor activity in ongoing trials involving patients with ATM-mutated NSCLC. The rapid expansion of the TRESR
- [Viridian Therapeutics Launches Two Phase 3 Trials: TED](https://www.clinicaltrialvanguard.com/news/viridian-therapeutics-launches-two-phase-3-trials-ted/) - Viridian Therapeutics plans to initiate two phase 3 clinical trials (REVEAL-1 and REVEAL-2) for VRDN-003, an anti-IGF-1R antibody, in August 2024. The trials will evaluate VRDN-003 for treating moderate-to-severe thyroid eye disease (TED). VRDN-003 is designed to be administered subcutaneously as infrequently as every eight weeks. The company believes this convenience factor could enhance patient
- [Vector Labs and Absolute Biotech Merge](https://www.clinicaltrialvanguard.com/news/vector-labs-and-absolute-biotech-merge/) - The union of Vector Laboratories and Absolute Biotech, facilitated by Thompson Street Capital Partners, is a strategic move that strengthens both companies' positions in the industry. This merger enhances their combined capabilities as manufacturers of critical components and expands their joint commercial presence in key markets. Vector Laboratories, known for its reagents and components for
- [Medable's Digital Health Solution Recognized with Prestigious Award](https://www.clinicaltrialvanguard.com/news/medables-digital-health-solution-recognized-with-prestigious-award/) - Medable, a leading provider of clinical trial technology, has once again secured the "Best Digital Health Solution" award at the Prix Galien UK Forum. This is the second consecutive year the company has received this recognition for its innovative platform, PALO ALTO. Medable's platform has gained widespread trust among major pharmaceutical companies and CROs, including
- [Brenus Pharma's Revolutionary Colorectal  Cancer Vaccine Launches in Human Trial](https://www.clinicaltrialvanguard.com/news/brenus-pharmas-revolutionary-colorectal-cancer-vaccine-launches-in-human-trial/) - Lyon, France-based biotech company Brenus Pharma has announced the study design of "BreAK-CRC," a first-in-human trial of its lead candidate, STC-1010, for colorectal cancer. The trial will evaluate the safety and efficacy of STC-1010, an immunotherapeutic approach based on a cancer vaccine mechanism. STC-1010 has shown promising preclinical results, and the Phase I/IIA BreAK-CRC trial
- [CyanVac Receives Barda-Funded Award to Evaluate Intranasal COVID-19 Vaccine Candidate in Phase 2b Study](https://www.clinicaltrialvanguard.com/news/cyanvac-receives-barda-funded-award-to-evaluate-intranasal-covid-19-vaccine-candidate-in-phase-2b-study/) - CyanVac LLC, a biotechnology company, received federal funding to conduct a comparative Phase 2b study of CVXGA, its PIV5-based intranasal vaccine candidate for COVID-19. This funding is part of the Project NextGen initiative, aimed at developing innovative vaccines for COVID-19. Through BARDA's Clinical Studies Network, the study will compare CVXGA to an FDA-approved mRNA-based COVID-19
- [Ensem Therapeutics Partners With Beigene as Novel CDK2 Inhibitor Enters Clinical Trials for Solid Tumors](https://www.clinicaltrialvanguard.com/news/ensem-therapeutics-partners-with-beigene-as-novel-cdk2-inhibitor-enters-clinical-trials-for-solid-tumors/) - Ensem Therapeutics has partnered with BeiGene to advance ETX-197, now known as BG-68501, into clinical trials. BG-68501 is a potent inhibitor of the cyclin-dependent kinase 2 (CDK2), an enzyme involved in the uncontrolled growth of solid tumors. This achievement is a testament to the power of Ensem's Kinetic Ensemble® platform, which leverages artificial intelligence (AI)
- [Calquence® Plus Chemoimmunotherapy: Remarkable Breakthrough in Mantle Cell Lymphoma Treatment](https://www.clinicaltrialvanguard.com/news/calquence-plus-chemoimmunotherapy-remarkable-breakthrough-in-mantle-cell-lymphoma-treatment/) - AstraZeneca's CALQUENCE (acalabrutinib), combined with bendamustine and rituximab, has demonstrated significant benefits for patients with mantle cell lymphoma (MCL). In the Phase III ECHO trial, the CALQUENCE regimen improved progression-free survival (PFS) by 27% compared to standard chemoimmunotherapy, with a median PFS of 66.4 months versus 49.6 months. Additionally, the CALQUENCE combination showed a favorable
- [Empatica's New Integration Enhances Clinical Mobility Solutions](https://www.clinicaltrialvanguard.com/news/empaticas-new-integration-enhances-clinical-mobility-solutions/) - Empatica, a leader in digital biomarker development, has partnered with Mobilise-D, an initiative funded by the Innovative Medicines Initiative. This collaboration aims to integrate Mobilise-D's Digital Mobility Outcomes (DMOs) into Empatica's Health Monitoring Platform. DMOs are validated digital measures that assess mobility using wearable sensors. By integrating these outcomes into its platform, Empatica provides researchers
- [Unveiling the Promising Advancements in Blood Cancer Treatment: Innate Pharma's Groundbreaking Trial Findings](https://www.clinicaltrialvanguard.com/news/unveiling-the-promising-advancements-in-blood-cancer-treatment-innate-pharmas-groundbreaking-trial-findings/) - At the European Hematology Association Congress, Innate Pharma and Sanofi presented promising results from their Phase 1/2 study of SAR'579, a Natural Killer Cell Engager (NKCE). SAR'579, targeting CD123, showed significant clinical efficacy in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The study assessed SAR'579 as monotherapy for blood cancers, including AML,
- [Pyros Pharmaceuticals' FDA-Approved Vigafyde™: The Only Ready-to-Use Vigabatrin Oral Solution](https://www.clinicaltrialvanguard.com/news/pyros-pharmaceuticals-fda-approved-vigafyde-the-only-ready-to-use-vigabatrin-oral-solution/) - Pyros Pharmaceuticals has received FDA approval for VIGAFYDE™, an oral vigabatrin solution for treating infantile spasms (IS) in pediatric patients aged 1 month to 2 years. IS is a rare and severe form of epilepsy with lasting effects. VIGAFYDE™ is a monotherapy indicated where the benefits outweigh the potential risk of vision loss. The approval
- [Aribio and KCTL Partner to Revolutionize Alzheimer's Testing with Uncommon Innovation](https://www.clinicaltrialvanguard.com/news/aribio-and-kctl-partner-to-revolutionize-alzheimers-testing-with-uncommon-innovation/) - AriBio Co., Ltd. has partnered with Kentucky Clinical Trial Laboratory (KCTL) to enhance Alzheimer's diseaseAlzheimer's disease testing. This collaboration will improve access to accurate and efficient testing of cerebral spinal fluid (CSF) using the Lumipulse® system from FujireBio. Samples from AriBio's Phase 3 POLARIS-AD trial, investigating the efficacy of AR1001 in early Alzheimer's patients, will
- [Bristol Myers Squibb Introduces FDA-Approved Krazati® for Metastatic Colorectal Cancer](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibb-introduces-fda-approved-krazati-for-metastatic-colorectal-cancer/) - The FDA has approved KRAZATI (adagrasib) in combination with cetuximab as a treatment for locally advanced or metastatic colorectal cancer (CRC) in adult patients with a KRASG12C mutation. This approval is based on the Phase 1/2 KRYSTAL-1 study, which showed a 34% objective response rate in pretreated patients with KRASG12C-mutated CRC. KRAZATI is the first
- [EMA Validates Bristol Myers Squibb's Subcutaneous Nivolumab Filing](https://www.clinicaltrialvanguard.com/news/ema-validates-bristol-myers-squibbs-subcutaneous-nivolumab-filing/) - Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has accepted an extension application for a new subcutaneous Opdivo (nivolumab) formulation. This formulation includes a new solution for injection and a strength of 600 mg/vial. The application seeks approval for the subcutaneous use of Opdivo to treat multiple solid tumors in adults. This
- [Precision Biosciences Enhances Hepatitis Scientific Advisory Board with Renowned Investigators](https://www.clinicaltrialvanguard.com/news/precision-biosciences-enhances-hepatitis-scientific-advisory-board-with-renowned-investigators/) - Precision BioSciences, a gene editing company, has appointed Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific Advisory Board (SAB). Drs. Sulkowski and Feld bring extensive experience in hepatitis clinical trials. Dr. Sulkowski is a renowned expert at Johns Hopkins University School of Medicine, while Dr. Feld holds leadership roles at Toronto General
- [Lenacapavir: Revolutionary Injection Beats Truvada for HIV Prevention](https://www.clinicaltrialvanguard.com/news/lenacapavir-revolutionary-injection-beats-truvada-for-hiv-prevention/) - A phase 3 clinical trial known as PURPOSE 1 has yielded breakthrough results in HIV prevention. The trial studied the efficacy of lenacapavir, an injectable HIV-1 capsid inhibitor. Among cisgender women, twice-yearly lenacapavir demonstrated 100% efficacy in preventing HIV infections. This result is superior to the currently approved once-daily oral PrEP (pre-exposure prophylaxis) regimen, Truvada.
- [Groundbreaking Treatment: Elevidys Expands Access for Duchenne Patients](https://www.clinicaltrialvanguard.com/news/groundbreaking-treatment-elevidys-expands-access-for-duchenne-patients/) - The U.S. Food and Drug Administration (FDA) has granted traditional approval to ELEVIDYS for ambulatory Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) patients and accelerated approval for non-ambulatory patients. ELEVIDYS is now indicated for individuals with DMD who are at least 4 years old and have a confirmed DMD gene mutation. The label expansion includes both
- [Scholar Rock Unveils Remarkable SRK-439 Findings: Preserving Lean Mass, Curbing Fat Gain](https://www.clinicaltrialvanguard.com/news/scholar-rock-unveils-remarkable-srk-439-findings-preserving-lean-mass-curbing-fat-gain/) - Scholar Rock, a biotechnology company, has initiated the Phase 2 EMBRAZE trial to evaluate apitegromab, a myostatin inhibitor, for preserving muscle mass in obese individuals receiving GLP-1 receptor agonist (GLP-1 RA) therapy. The trial will also assess apitegromab's impact on weight loss maintenance after GLP-1 RA discontinuation. Preclinical studies have demonstrated that SRK-439, a selective
- [Cybin's Triumph: Set For Novel Psychiatric Research](https://www.clinicaltrialvanguard.com/news/cybins-triumph-set-for-novel-psychiatric-research/) - Cybin Inc., a biopharmaceutical company focused on developing treatments for mental health disorders, has achieved significant milestones in its research programs. CYB003 for Major Depressive Disorder (MDD) • Received FDA Breakthrough Therapy Designation (BTD) for CYB003, a deuterated psilocybin analog. • BTD accelerates the development process and provides increased FDA guidance on trial design. •
- [DM199 (Rinvecalinase Alfa) Program Expanded by Diamedica Therapeutics into Preeclampsia](https://www.clinicaltrialvanguard.com/news/dm199-rinvecalinase-alfa-program-expanded-by-diamedica-therapeutics-into-preeclampsia/) - DiaMedica Therapeutics, a biotechnology company, is expanding its clinical development program for DM199 into preeclampsia. Preeclampsia is a severe pregnancy-related condition characterized by high blood pressure and protein in the urine, posing risks to both the mother and the baby. DM199 is a protein therapeutic that improves blood vessel function. It is believed to lower
- [VIR Biotechnology Receives FDA Clearance and Fast Track Designation: Chronic Hepatitis Delta Treatment](https://www.clinicaltrialvanguard.com/news/vir-biotechnology-receives-fda-clearance-and-fast-track-designation-chronic-hepatitis-delta-treatment/) - The U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application and granted Fast Track designation to the combination of tobevibart and elebsiran for chronic hepatitis delta treatment. Tobevibart, a monoclonal antibody, and elebsiran, a small interfering ribonucleic acid, have shown promising Phase 2 preliminary results. They have demonstrated high rates
- [QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy](https://www.clinicaltrialvanguard.com/news/qps-announces-new-laboratory-services-for-clinical-trials-and-cell-therapy/) - QPS, a prominent global contract research organization, has introduced enhanced laboratory services at its Springfield, Missouri unit. This expansion complements the company's existing bioanalysis, translational medicine, and peripheral blood mononuclear cell (PBMC) laboratories, extending its comprehensive services. The newly expanded clinical trials unit now offers clinical trial sample analysis and leukopak cell therapy products. Additionally,
- [COVID-19: Pfizer-BioNTech's New Omicron Vaccine Receives EU Approval](https://www.clinicaltrialvanguard.com/news/covid-19-pfizer-biontechs-new-omicron-vaccine-receives-eu-approval/) - Pfizer and BioNTech's Omicron JN.1-adapted COVID-19 vaccine (COMIRNATY® JN.1) has received a positive recommendation for marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The vaccine is intended for active immunization against COVID-19 caused by SARS-CoV-2 in individuals six months and older. The vaccine adaptation aligns with recommendations from
- [Thermo Fisher's Lab Expansion: A Boon for Kentucky's Health Research](https://www.clinicaltrialvanguard.com/news/thermo-fishers-lab-expansion-a-boon-for-kentuckys-health-research/) - Thermo Fisher Scientific's PPD clinical research arm is significantly expanding its presence in Kentucky. The expansion entails a 65,000-square-foot facility in Covington, increasing the company's laboratory footprint. This investment of $47.8 million will generate over 250 new positions in the region over the next eight years. PPD has maintained a central laboratory operation in Highland
- [Breakthrough Med: Epcoritamab Revolutionizes Follicular Lymphoma Treatment](https://www.clinicaltrialvanguard.com/news/breakthrough-med-epcoritamab-revolutionizes-follicular-lymphoma-treatment/) - The European Medicines Agency (EMA) has recommended granting marketing authorization for epcoritamab, a monoclonal antibody for treating relapsed or refractory follicular lymphoma (FL). This recommendation is based on positive Phase 1/2 EPCORE NHL-1 clinical trial results. Epcoritamab is administered subcutaneously and demonstrated significant efficacy in patients with FL who had previously undergone multiple lines of
- [TAURx Submits Extraordinary Application for HMTM as Alzheimer's Disease Breakthrough](https://www.clinicaltrialvanguard.com/news/taurx-submits-extraordinary-application-for-hmtm-as-alzheimers-disease-breakthrough/) - TauRx Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) in the UK for hydromethylthionine mesylate (HMTM), a potential treatment for Alzheimer's diseaseAlzheimer's disease (AD). HMTM targets the accumulation of tau proteins, a hallmark of AD. The application is supported by data from Phase 3 trials, including the LUCIDITY trial, which demonstrated benefits in cognitive function
- [Merck and Orion Exclusive Rights to Opevesostat for Metastatic Prostate Cancer](https://www.clinicaltrialvanguard.com/news/merck-and-orion-exclusive-rights-to-opevesostat-for-metastatic-prostate-cancer/) - Merck and Orion Corporation have converted their co-development and co-commercialization agreement for opevesostat into an exclusive global license for Merck. Opevesostat is an investigational CYP11A1 inhibitor being evaluated in Phase 3 trials for metastatic castration-resistant prostate cancer. Merck's President of Research Laboratories, Dr. Dean Y. Li, highlighted the progress made in the collaboration, including the
- [Acticor Biotech: Disclosure of Voting Rights, Shares May 2024](https://www.clinicaltrialvanguard.com/news/acticor-biotech-disclosure-of-voting-rights-shares-may-2024/) - ACTICOR BIOTECH, a clinical-stage pharmaceutical company, reports its voting rights and shares as of May 31, 2024. The company focuses on developing glenzocimab, a drug for treating cardiovascular emergencies, particularly ischemic stroke. Glenzocimab has shown promising results in Phase 1b/2a (ACTIMIS) and Phase 2/3 (ACTISAVE) clinical trials. ACTIMIS demonstrated glenzocimab's safety profile and reduced mortality
- [Announcing Calidi's Stock Split](https://www.clinicaltrialvanguard.com/news/announcing-calidis-stock-split/) - Calidi Biotherapeutics has authorized a one-for-ten reverse stock split, effective July 15, 2024. The split will be applied to all outstanding common stock, reducing the total number of shares by a factor of ten. Under the revised structure, Calidi's common stock will continue trading under the ticker "CLDI" on the NYSE American. The CUSIP number
- [Genexine and EPD Bio Announce Merger, Paving the Way for Revolutionized Drug Development](https://www.clinicaltrialvanguard.com/news/genexine-and-epd-bio-announce-merger-paving-the-way-for-revolutionized-drug-development/) - Genexine, a Korean biopharmaceutical company, has merged with EPD Biotherapeutics, specializing in targeted protein degradation (TPD) technology. This merger aims to bolster Genexine's research capabilities and drug pipeline. EPD Bio's bioPROTAC platform, EPDegTM, offers several advantages over traditional small molecule-based PROTAC technology. It utilizes mRNA-LNP delivery to overcome tissue-specific limitations of E3 ligase expression, enabling
- [Genentech Unveils Second Chance for Susvimo to Combat AMD](https://www.clinicaltrialvanguard.com/news/genentech-unveils-second-chance-for-susvimo-to-combat-amd/) - The Food and Drug Administration (FDA) has approved updates to Susvimo, an eye implant treatment for wet age-related macular degeneration (AMD). Susvimo provides an alternative to regular eye injections, the current standard of care. Wet AMD affects approximately 1.5 million Americans and 20 million people worldwide. If left untreated, it can lead to blindness. Susvimo
- [Antidote Strengthens Clinical Trial Enrollment Collaboration](https://www.clinicaltrialvanguard.com/news/antidote-strengthens-clinical-trial-enrollment-collaboration/) - Find Samantha Veeck at Antidote Technologies, including phone, fax, and details on their clinical trial enrollment collaboration services.
- [Obsidian's OBX-115 T-Cell Therapy For Melanoma Receives FDA Fast Track](https://www.clinicaltrialvanguard.com/news/obsidians-obx-115-t-cell-therapy-for-melanoma-receives-fda-fast-track/) - Obsidian Therapeutics has secured Fast Track Designation from the FDA for OBX-115, an engineered T-cell therapy targeting metastatic or locally advanced melanoma resistant to PD-1/PD-L1 inhibitors. OBX-115, based on patient-derived tumor-infiltrating lymphocytes (TILs), is enhanced with membrane-bound interleukin-15 (mbIL15), enabling pharmacological regulation. This potentially addresses the unmet need for effective treatments for melanoma patients who
- [Pluristyx and Humacyte Announce Partnership](https://www.clinicaltrialvanguard.com/news/pluristyx-and-humacyte-announce-partnership/) - Pluristyx, a renowned cellular therapy developer, has partnered with Humacyte, a biotechnology company specializing in bioengineered human tissue. This collaboration will leverage Pluristyx's advanced stem cell technology to create insulin-producing cells for Humacyte's BioVascular Pancreas (BVP) therapy. Pluristyx's PluriBank™ stem cell line, renowned for its clinical-grade purity, genetic integrity, and safety features, will serve as
- [Pfizer: New Formulation of Oral GLP-1 Agonist Advances to Development Stage](https://www.clinicaltrialvanguard.com/news/pfizer-new-formulation-of-oral-glp-1-agonist-advances-to-development-stage/) - Pfizer has selected a once-daily formulation of danuglipron, an oral GLP-1 receptor agonist, based on encouraging results from an ongoing pharmacokinetic study. The company aims to optimize dosing through studies in the second half of 2024 before initiating registration-enabling trials. Pfizer emphasizes the importance of obesity as a therapeutic focus, with danuglipron being the most
- [City of Hope and Mount Sinai Unlock New Treatment for Diabetes](https://www.clinicaltrialvanguard.com/news/city-of-hope-and-mount-sinai-unlock-new-treatment-for-diabetes/) - Recent research published in Science Translational Medicine offers promising advancements in developing regenerative therapies for diabetes. A team of scientists from City of Hope and Mount Sinai Health System has discovered a therapeutic combination that stimulates the regeneration of human beta cells, the insulin-producing cells critical for blood sugar regulation. The research involved transplanting a
- [Ebglyss Receives NICE Recommendation for Moderate to Severe Atopic Dermatitis](https://www.clinicaltrialvanguard.com/news/ebglyss-receives-nice-recommendation-for-moderate-to-severe-atopic-dermatitis/) - The National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) as an additional treatment option for moderate to severe Atopic Dermatitis in England. Lebrikizumab is indicated for adults and adolescents (12 years and older) with moderate-to-severe Atopic Dermatitis who are candidates for systemic therapy. The recommendation is significant as it provides eligible
- [OPM Records Unprecedented Success in Phase 1 of OPM-101 Human Trials](https://www.clinicaltrialvanguard.com/news/opm-records-unprecedented-success-in-phase-1-of-opm-101-human-trials/) - Oncodesign Precision Medicine (OPM) has announced positive results from a Phase 1 trial evaluating OPM-101, a selective small molecule inhibitor targeting the RIPK2 kinase. The trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of OPM-101 in healthy volunteers. The randomized, double-blind, placebo-controlled study (EudraCT: 2022-003122-50) enrolled 104 volunteers, 78 treated with OPM-101, and 26 received
- [Samantree Medical Secures $14 Million to Revolutionize Surgical Care Globally](https://www.clinicaltrialvanguard.com/news/samantree-medical-secures-14-million-to-revolutionize-surgical-care-globally/) - SamanTree Medical, a leading medical technology company specializing in surgical advancements, has secured $14 million in a Series B financing round. The funds will be allocated to advance and market their groundbreaking Histolog® Scanner, boost their presence in Europe and the US and enhance their digital offerings. The Histolog Scanner, a CE-marked device, offers real-time
- [Elixia: A Revolution in Clinical Research](https://www.clinicaltrialvanguard.com/news/elixia-a-revolution-in-clinical-research/) - American Clinical Research Services, now known as Elixia, has rebranded to reflect its expanded clinical research and patient recruitment capabilities. This change represents the company's mission to accelerate drug development and improve patient outcomes. Elixia combines the expertise of premier clinical research sites with a patient recruitment engine. This allows it to conduct clinical trials
- [Phesi Data Emerging Clinical Trial Shift to Diabetes](https://www.clinicaltrialvanguard.com/news/phesi-data-emerging-clinical-trial-shift-to-diabetes/) - Recent data from Phesi, a clinical development analytics company, reveals a significant shift in medical research priorities. Type 2 diabetes has emerged as one of the top five most studied diseases globally in the first half of 2024, surpassing COVID-19. Breast cancer, solid tumors, stroke, and prostate cancer are the top five. This change coincides
- [Orum and Vertex Partner to Conquer Disease](https://www.clinicaltrialvanguard.com/news/orum-and-vertex-partner-to-conquer-disease/) - Orum Therapeutics and Vertex Pharmaceuticals have agreed to develop novel targeted conditioning agents for gene editing using Orum's Dual-Precision Targeted Protein Degradation (TPD²) technology. Vertex can exclusively license and commercialize DACs developed with Orum's TPD² technology for up to three targets. In return, Orum will receive an upfront payment of $15 million and potential option
- [Predicta Biosciences Secures $5.2 Million Seed Funding for Non-Invasive Multiple Myeloma Diagnostics](https://www.clinicaltrialvanguard.com/news/predicta-biosciences-secures-5-2-million-seed-funding-for-non-invasive-multiple-myeloma-diagnostics/) - Predicta Biosciences, a company focused on precision oncology, has secured an oversubscribed seed round of $5.2 million. The round was led by The Engine Ventures, with Illumina Ventures, Time Boost Capital, American Cancer Society Bright Edge, and the Oetgen family as participating investors. Founded by leading cancer genomics researchers and clinicians, Predicta is developing a
- [Scorpion Therapeutics Secure $150M for Cancer-Fighting Pipeline](https://www.clinicaltrialvanguard.com/news/scorpion-therapeutics-secure-150m-for-cancer-fighting-pipeline/) - Scorpion Therapeutics, a leading oncology company, announced a successful $150 million Series C financing round to advance its precision oncology pipeline. Frazier Life Sciences and Lightspeed Venture Partners co-led the financing, with significant participation from new and existing investors. Scorpion's small molecule discovery engine has generated a robust pipeline, including the promising STX-478, a mutant-selective
- [Bayer's Nubeqa Triumph: A Milestone in Prostate Cancer Treatment](https://www.clinicaltrialvanguard.com/news/bayers-nubeqa-triumph-a-milestone-in-prostate-cancer-treatment/) - The Phase III ARANOTE trial has demonstrated significant benefits for NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study met its primary endpoint of extended radiological progression-free survival (rPFS) compared to placebo plus ADT. NUBEQA, an androgen receptor inhibitor, has shown a clinically meaningful increase
- [Crescita Therapeutics Partners with NanoPass to Enhance Medical Aesthetics Portfolio](https://www.clinicaltrialvanguard.com/news/crescita-therapeutics-partners-with-nanopass-to-enhance-medical-aesthetics-portfolio/) - Crescita Therapeutics and NanoPass have entered an exclusive distribution agreement to introduce MicronJetTM600, an advanced intradermal delivery device, to the Canadian market. MicronJet's innovative design leverages MEMS technology to provide a consistent, effective, and painless delivery of aesthetic products and therapeutic substances. Featuring three 0.6mm silicon pyramids, MicronJet enables precise administration to delicate areas such
- [NIH, FDA Effort Unveils Revolutionary Parkinson's Diagnosis Advancements](https://www.clinicaltrialvanguard.com/news/nih-fda-effort-unveils-revolutionary-parkinsons-diagnosis-advancements/) - A new partnership aims to improve diagnosis and outcomes for Parkinson's disease and related disorders. The Accelerating Medicines Partnership in Parkinson's Disease and Related Disorders (AMP PDRD) brings together expertise from the National Institutes of Health, Food and Drug Administration, The Michael J. Fox Foundation, and private stakeholders. With a commitment of $21 million, the
- [Leo Pharma Reveals Groundbreaking Phase 3 Success for Hand Eczema](https://www.clinicaltrialvanguard.com/news/leo-pharma-reveals-groundbreaking-phase-3-success-for-hand-eczema/) - LEO Pharma, a leader in dermatology, has announced the publication of its DELTA 1 and DELTA 2 phase 3 trial findings for delgocitinib cream in The Lancet, a renowned peer-reviewed medical journal. This publication marks a significant advancement in understanding and treating chronic hand eczema (CHE). The DELTA 1 and DELTA 2 trials evaluated the
- [Data Unveils Susvimo's Enduring Power in Treating Diabetic Eye Diseases](https://www.clinicaltrialvanguard.com/news/data-unveils-susvimos-enduring-power-in-treating-diabetic-eye-diseases/) - Susvimo, an innovative refillable eye implant, has shown promising results in Phase III clinical trials for treating DME and DR, vision-threatening conditions related to diabetes. Over two years, Susvimo demonstrated sustained effectiveness in maintaining visual acuity in DME patients and improving DRSS scores in DR patients. Its safety profile remained consistent with previous findings. The
- [Parker Institute Pledges $125M for Cancer Cure Quest](https://www.clinicaltrialvanguard.com/news/parker-institute-pledges-125m-for-cancer-cure-quest/) - The Parker Institute for Cancer Immunotherapy (PICI) has announced a significant $125 million investment to bolster its research and accelerate the creation of groundbreaking cancer immunotherapies. This funding represents PICI's largest commitment since its establishment in 2016. The investment will fuel PICI's collaborative research model, establishing seven research centers at leading academic institutions, including Gladstone
- [Bristol Myers Squibb's Validation for Breakthrough Cancer Treatment](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibbs-validation-for-breakthrough-cancer-treatment/) - Bristol Myers Squibb's immunotherapy combination therapy, Opdivo plus Yervoy, has received validation from the European Medicines Agency (EMA) for its application as a first-line treatment for unresectable or advanced hepatocellular carcinoma (HCC) in adults who have not received prior systemic therapy. The application is supported by positive results from the Phase 3 CheckMate -9DW trial,
- [JCR Pharmaceuticals' Innovative Gene Therapy Research Unveiled at Lysosomal Forum](https://www.clinicaltrialvanguard.com/news/jcr-pharmaceuticals-innovative-gene-therapy-research-unveiled-at-lysosomal-forum/) - JCR Pharmaceuticals unveiled significant advancements in gene therapy research at the International Forum of Lysosomal Disorders. The company's proprietary J-Brain Cargo® technology, modified to enhance drug delivery to the central nervous system, showed promising results in non-clinical trials. The modified adeno-associated virus (AAV) vector successfully delivered therapeutic genes to the brains of mice and monkeys.
- [NuView Liquid Biopsy: High Tech, High Impact, High Reliability](https://www.clinicaltrialvanguard.com/executiveinterviews/nuview-liquid-biopsy-high-tech-high-impact-high-reliability/) - Discover the innovative NV-VPAC1 liquid biopsy technology in an exclusive interview with NuView CEO. Learn more about the upcoming Phase 2 Clinical Trial.
- [Virocell Biologics Secures Master Agreement with NCI Cancer Center for Transformative Therapy](https://www.clinicaltrialvanguard.com/news/virocell-biologics-secures-master-agreement-with-nci-cancer-center-for-transformative-therapy/) - A five-year Master Services Agreement (MSA) has been signed between ViroCell Biologics and a prominent U.S. NCI-designated cancer center. This agreement provides the cancer center access to ViroCell's comprehensive viral vector manufacturing services for preclinical and clinical applications. ViroCell's services include viral vector design, small-scale manufacturing, process development, and global plasmid sourcing. Clinical services encompass
- [Azitra Strengthens Patent Portfolio with Latest Grants for Atopic Dermatitis](https://www.clinicaltrialvanguard.com/news/azitra-strengthens-patent-portfolio-with-latest-grants-for-atopic-dermatitis/) - Azitra, Inc., a biopharmaceutical company specializing in dermatology, has secured a U.S. patent (No. 12,036,248) for its potential treatment of atopic dermatitis, a common skin condition affecting approximately 16.5 million individuals in the United States. The patent covers therapeutic applications of recombinant skin microorganisms. In addition, Azitra has received allowances for three patents in the
- [BeiGene Expands Presence in New Jersey with $800 Million Investment](https://www.clinicaltrialvanguard.com/news/beigene-expands-presence-in-new-jersey-with-800-million-investment/) - BeiGene, a global oncology company, has established its flagship U.S. facility in Hopewell, New Jersey, aiming to bolster its manufacturing and clinical development capabilities. The investment, totaling $800 million, has resulted in a state-of-the-art facility contributing to BeiGene's innovative oncology model. The 42-acre campus houses advanced biologics manufacturing capabilities, enabling the flexible production of BeiGene's
- [Psychedelics Make Mind-Blowing Progress in Poland](https://www.clinicaltrialvanguard.com/news/psychedelics-make-mind-blowing-progress-in-poland/) - A groundbreaking alliance between Worldwide Clinical Trials (Worldwide), Centrum Badan Klinicznych PI-House, and the Polish Psychedelic Society (PTP) aims to establish Poland as a leading center for psychedelic research. This collaboration stems from Poland's first industry-sponsored psychedelic study supported by Worldwide. The partnership was unveiled at the "Nauka Psychodeliczna" conference, where over 500 experts gathered
- [Pfizer Uncovers Exciting Advance in Hemophilia A Gene Therapy](https://www.clinicaltrialvanguard.com/news/pfizer-uncovers-exciting-advance-in-hemophilia-a-gene-therapy/) - The AFFINE study evaluating giroctocogene fitelparvovec, a gene therapy for moderate to severe hemophilia A, has achieved significant results. The study's primary objective of non-inferiority and superiority in total annualized bleeding rate (ABR) compared to routine Factor VIII (FVIII) prophylaxis treatment was met. After a single infusion, giroctocogene fitelparvovec significantly reduced mean total ABR by
- [LEO Pharma Receives Positive CHMP Opinion for Anzupgo® for Moderate to Severe Chronic Hand Eczema](https://www.clinicaltrialvanguard.com/news/leo-pharma-receives-positive-chmp-opinion-for-anzupgo-for-moderate-to-severe-chronic-hand-eczema/) - LEO Pharma, a leading dermatology company, announced a positive opinion from the European Medicines Agency (EMA) for Anzupgo® (delgocitinib cream). This topical treatment is intended for adults with moderate to severe chronic hand eczema (CHE), with limited approved treatment options. Delgocitinib cream is a novel JAK inhibitor that targets the JAK-STAT signaling pathway, which plays
- [Merck's Keytruda and Padcev Combo Receives EU Recommendation for Unresectable Urothelial Carcinoma](https://www.clinicaltrialvanguard.com/news/mercks-keytruda-and-padcev-combo-receives-eu-recommendation-for-unresectable-urothelial-carcinoma/) - The European Medicines Agency (EMA) has recommended approval of Merck's KEYTRUDA and Padcev combination for the first-line treatment of unresectable or metastatic urothelial carcinoma. This recommendation follows positive results from the Phase 3 KEYNOTE-A39 trial. The combination therapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy. The risk of death
- [Viridian Therapeutics Announces: Thrive-2 Enrollment Complete for Ted Patients](https://www.clinicaltrialvanguard.com/news/viridian-therapeutics-announces-thrive-2-enrollment-complete-for-ted-patients/) - Viridian Therapeutics announced the completion of enrollment in its phase 3 clinical trials, THRIVE and THRIVE-2, targeting patients with thyroid eye disease (TED). THRIVE-2, focused on chronic TED, surpassed its target of 159 patients, enrolling 188 participants—approximately 40% of these patients enrolled from US sites. Topline data for THRIVE-2 is expected by the end of
- [Seqster's Digital Health Technology: Unveiling a Revolutionary Alzheimer's Screening Breakthrough](https://www.clinicaltrialvanguard.com/news/seqsters-digital-health-technology-unveiling-a-revolutionary-alzheimers-screening-breakthrough/) - SEQSTER PDM Inc. and Boston University researchers, led by Dr. Rhoda Au, have partnered to develop an innovative early Alzheimer's screening tool. Dr. Au, a leading expert in digital health, will use SEQSTER's 1-Click Records platform to collect longitudinal health data that will inform the development of a risk-assessment AI tool. SEQSTER's platform simplifies data
- [Venetoclax and Fixed-Duration Calquence® Significantly Improve Leukemia Survival](https://www.clinicaltrialvanguard.com/news/venetoclax-and-fixed-duration-calquence-significantly-improve-leukemia-survival/) - An interim analysis of the AMPLIFY Phase III trial has revealed encouraging results in the treatment of chronic lymphocytic leukemia (CLL) with AstraZeneca's CALQUENCE® (acalabrutinib). The combination of CALQUENCE with venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) compared to standard chemotherapy in previously untreated patients. Although the data for overall survival (OS)
- [BioAge Announces Groundbreaking Obesity Treatment Trial](https://www.clinicaltrialvanguard.com/news/bioage-announces-groundbreaking-obesity-treatment-trial/) - BioAge Labs has initiated a Phase 2 clinical trial, STRIDES, to assess the efficacy of azelaprag, a small molecule that mimics the effects of exercise in combination with tirzepatide for treating obesity in individuals aged 55 and above. Azelaprag, an apelin receptor agonist, is designed to activate signaling pathways that promote metabolic benefits similar to
- [New Study: Alzheimer's Progression Explored with Revolutionary Cell Platform](https://www.clinicaltrialvanguard.com/news/new-study-alzheimers-progression-explored-with-revolutionary-cell-platform/) - Groundbreaking research has led to a novel model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to understand Alzheimer's diseaseAlzheimer's disease (AD). This model accurately reproduces key aspects of aging in a microphysiological system, offering a valuable tool for drug discovery and disease study. AD affects millions, and current treatments provide limited relief. The
- [Unlearn's AI-Powered Clinical Trials with AbbVie and Johnson & Johnson](https://www.clinicaltrialvanguard.com/news/unlearns-ai-powered-clinical-trials-with-abbvie-and-johnson-johnson/) - Unlearn, an AI company, showcased the impact of its technology in two poster sessions at the Alzheimer's Association International Conference. Their Digital Twin Generators create personalized forecasts of clinical outcomes for participants, enhancing the efficiency of clinical trials. Unlearn's Digital Twin Generators have demonstrated significant benefits in Phase III clinical trials for mild-to-moderate Alzheimer's Disease
- [COYA Therapeutics' Novel Patent Filing: Expanding Pipeline in Alzheimer's Disease](https://www.clinicaltrialvanguard.com/news/coya-therapeutics-novel-patent-filing-expanding-pipeline-in-alzheimers-disease/) - COYA 301, a recombinant human low-dose interleukin-2 (LD IL-2), and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) have demonstrated potential for synergistic anti-inflammatory effects. This combination targets multiple cell types, including enhancing regulatory T cell (Treg) function, suppressing pro-inflammatory myeloid and T cells, and promoting their conversion to anti-inflammatory phenotypes. The combination of COYA 301 and
- [Lantern Pharma's Remarkable Phase 2 Trial Update in Advanced Lung Cancer](https://www.clinicaltrialvanguard.com/news/lantern-pharmas-remarkable-phase-2-trial-update-in-advanced-lung-cancer/) - Lantern Pharma's ongoing HARMONIC™ clinical trial has yielded promising early results. The trial examines the efficacy of LP-300, a novel drug candidate, combined with chemotherapy in non-smokers with advanced non-small cell lung cancersmall cell lung cancer (NSCLC). HARMONIC™'s initial patient cohort showed encouraging safety and efficacy outcomes. LP-300 did not produce any unexpected adverse events,
- [Artera Announces Prostate Test Expansion in Prostate Cancer Patients](https://www.clinicaltrialvanguard.com/news/artera-announces-prostate-test-expansion-in-prostate-cancer-patients/) - Artera has improved its ArteraAI Prostate Test to support clinicians in determining the suitability of active surveillance for prostate cancer patients. This advancement enables more informed decisions regarding patient care. The ArteraAI Prostate Test, powered by MMAI technology, evaluates a patient's cancer progression risk and predicts treatment benefits. Its prognostic performance has been validated across
- [Sangamo Inks Capsid Delivery Deal With Genetech for Neurodegenerative Diseases](https://www.clinicaltrialvanguard.com/news/sangamo-inks-capsid-delivery-deal-with-genetech-for-neurodegenerative-diseases/) - Sangamo Therapeutics and Genentech, a Roche Group member, have joined forces to develop intravenous genomic treatments for neurodegenerative diseases. Sangamo has granted Genentech exclusive rights to its zinc finger repressors targeting the tau gene, which plays a role in Alzheimer's and tauopathies. Additionally, Genentech will have access to Sangamo's neurotropic adeno-associated virus (AAV) capsid, STAC-BBB,
- [eClinical Solutions' Protocol Deviations Boost Clinical Trial Success](https://www.clinicaltrialvanguard.com/news/eclinical-solutions-protocol-deviations-boost-clinical-trial-success/) - eClinical Solutions has introduced enhancements and AI-powered functionalities to its Elluminate Clinical Data Cloud platform. These updates aim to streamline clinical trial oversight and reduce manual workload, ensuring data integrity and patient safety. eClinical Solutions has added the Protocol Deviations feature, which improves trial oversight. It allows users to standardize and manage protocol deviation data
- [Neurogene's NG-401 Gets RMAT Designation for Rett Syndrome Treatment](https://www.clinicaltrialvanguard.com/news/neurogenes-ng-401-gets-rmat-designation-for-rett-syndrome-treatment/) - Neurogene's NGN-401, a gene therapy, has obtained Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating Rett syndrome. This designation stems from promising clinical evidence in an ongoing trial, suggesting NGN-401's potential to fulfill unmet medical needs in this disorder. RMAT designation grants NGN-401 eligibility for an Accelerated Approval pathway under the 21st
- [C2N Diagnostics and Unilabs Forge Unprecedented Alliance to Advance Brain Health](https://www.clinicaltrialvanguard.com/news/c2n-diagnostics-and-unilabs-forge-unprecedented-alliance-to-advance-brain-health/) - In a groundbreaking partnership, Unilabs and C2N Diagnostics are collaborating to enhance brain health diagnostics and research in Europe and globally. This multi-year agreement grants Unilabs exclusive access to C2N's Precivity portfolio of blood tests in Europe, including Norway, Switzerland, the United Kingdom, Peru, Saudi Arabia, and the United Arab Emirates. C2N's Precivity blood tests
- [Merck to Secure Novel B-Cell Therapy CN201 in Deal with Curon Bio](https://www.clinicaltrialvanguard.com/news/merck-to-secure-novel-b-cell-therapy-cn201-in-deal-with-curon-bio/) - Merck (MSD outside the US and Canada) has acquired CN201, a novel bispecific antibody, from Curon Biopharmaceutical. CN201 targets CD3 and CD19 receptors on T cells and B cells, respectively. This acquisition expands Merck's pipeline with a promising treatment for B-cell malignancies and autoimmune diseases. CN201 has shown early clinical success in targeting and eliminating
- [Neurogene's Triumphant Progress in NGN-401 Gene Therapy](https://www.clinicaltrialvanguard.com/news/neurogenes-triumphant-progress-in-ngn-401-gene-therapy/) - Neurogene Inc. has made significant progress in its clinical-stage development of NGN-401 gene therapy for Rett syndrome. The therapy has received RMAT designation from the FDA, recognizing its potential to address unmet medical needs. Additionally, NGN-401 has been selected for the FDA's START Program, which aims to accelerate its development. Interim efficacy data from Cohort
- [Merck Unveils Groundbreaking ESCC Trial Results: Unlocking New Hope for Patients](https://www.clinicaltrialvanguard.com/news/merck-unveils-groundbreaking-escc-trial-results-unlocking-new-hope-for-patients/) - Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The decision followed a recommendation from an independent Data Monitoring Committee. Analysis revealed that the primary endpoint of overall survival did not meet the pre-specified criteria for
- [Cybin Unveils Record Q1 Financials and Key Milestones](https://www.clinicaltrialvanguard.com/news/cybin-unveils-record-q1-financials-and-key-milestones/) - Cybin Inc., a clinical-stage neuropsychiatry company, reported its financial results for the first quarter ended June 30, 2024, and provided an update on its business operations. Cybin's lead product candidate, CYB003, a deuterated psilocybin analog, is in development for the treatment of Major Depressive Disorder (MDD) and has received Breakthrough Therapy Designation from the U.S.
- [DeepCure's Groundbreaking AI-Generated Drug DC-9476](https://www.clinicaltrialvanguard.com/news/deepcures-groundbreaking-ai-generated-drug-dc-9476/) - DeepCure, a biotechnology company leveraging AI for drug discovery, has unveiled its first development candidate, DC-9476. This third-generation BRD inhibitor targets the BD2 domain of Brd4, a key regulator of cytokine pathways implicated in autoimmune diseases. DC-9476 exhibits promising efficacy in preclinical models of autoimmune diseases, including rheumatoid arthritisarthritis, surpassing standard therapies and enhancing the
- [Tempus AI's Precision Oncology Study Unveils Validated Hla-Loh Assay](https://www.clinicaltrialvanguard.com/news/tempus-ais-precision-oncology-study-unveils-validated-hla-loh-assay/) - Tempus AI, a leading company in applying AI to precision medicine, has published a study validating its investigational human leukocyte antigen (HLA) loss of heterozygosity (LOH) assay in the journal npj Precision Oncology. This test identifies patients with solid tumors who may benefit from targeted therapies based on specific HLA-LOH events. The study confirmed the
- [AN2 Therapeutics Fails Phase 2 Lung Trial](https://www.clinicaltrialvanguard.com/news/an2-therapeutics-fails-phase-2-lung-trial/) - After releasing unfavorable results from the Phase 2 portion of the EBO-301 study, AN2 Therapeutics has decided to cease the trial. This study examined the efficacy of epetraborole in conjunction with an optimized background regimen (OBR) for treating treatment-refractory Mycobacterium avium complex (MAC) lung disease. Despite achieving its primary objective of validating a patient-reported outcome
- [Blue Earth Therapeutics and Seibersdorf Expand Horizons](https://www.clinicaltrialvanguard.com/news/blue-earth-therapeutics-and-seibersdorf-expand-horizons/) - Blue Earth Therapeutics Expands Manufacturing Collaboration with Seibersdorf Labor Blue Earth Therapeutics, a subsidiary of Bracco, has expanded its manufacturing partnership with Seibersdorf Labor GmbH to include the production of its investigational (225Ac) rhPSMA-10.1 radioligand therapy. This expansion complements existing agreements for the manufacture of (177Lu) rhPSMA-10.1. (225Ac) rhPSMA-10.1 is a radiohybrid therapeutic radiopharmaceutical that
- [Summit Therapeutics HARMONI-2: A Ivonescimab Achieves Clinically Significant Benefits in NSCLC](https://www.clinicaltrialvanguard.com/news/summit-therapeutics-harmoni-2-a-ivonescimab-achieves-clinically-significant-benefits-in-nsclc/) - Summit Therapeutics' investigational bispecific antibody, Ivonescimab, has achieved clinically significant benefits in a Phase III trial (HARMONi-2) compared to the current standard of care, Pembrolizumab, in patients with locally advanced or metastatic non-small cell lung cancersmall cell lung cancer (NSCLC). HARMONi-2 evaluated Ivonescimab monotherapy against Pembrolizumab monotherapy in patients with PD-L1-positive tumors. The trial showed
- [Alzamend Neuro Partners with MGH for Phase 2 MDD Study](https://www.clinicaltrialvanguard.com/news/alzamend-neuro-partners-with-mgh-for-phase-2-mdd-study/) - Alzamend Neuro partners with Massachusetts General Hospital, a renowned Harvard Medical School research facility, to conduct a groundbreaking Phase II clinical study of AL001 for treating Major Depressive Disorder (MDD). Lithium, the first FDA-approved mood stabilizer, has been used off-label for MDD augmentation. Alzamend aims to demonstrate the potential of AL001 as an enhanced lithium
- [Report Predicts $11.9B Surge in eClinical Solutions Market Driven by Clinical Trial and EHR Adoption](https://www.clinicaltrialvanguard.com/news/__trashed-50/) - The global market for eClinical solutions, which streamline clinical trials, is projected to expand rapidly, reaching $21.9 billion by 2030, growing at an 11.8% annual rate from 2023. Several factors drive this growth: •Increased Clinical Trials: The growing number of clinical trials is fueling demand for eClinical solutions. •Data Quality Focus: These solutions enhance data
- [NorthStar and Convergent Expand Collaboration on Conv01-α](https://www.clinicaltrialvanguard.com/news/northstar-and-convergent-expand-collaboration-on-conv01-α/) - NorthStar Medical Radioisotopes and Convergent Therapeutics have inked a contract for manufacturing services, collaborating on CONV01-α, targeted radiotherapy for prostate cancer. CONV01-α, spearheaded by Convergent, employs a monoclonal antibody linked to the radionuclide Ac-225, targeting the PSMA receptor prevalent in prostate cancer cells. Upon regulatory approval, NorthStar's expertise will encompass manufacturing, quality control, and potential
- [Cybin's Breakthrough Therapy for Major Depressive Disorder: A Game-Changer in Mental Health](https://www.clinicaltrialvanguard.com/news/cybins-breakthrough-therapy-for-major-depressive-disorder-a-game-changer-in-mental-health/) - Cybin, a neuropsychiatry company, recently held a successful meeting with the FDA regarding its Type B Breakthrough Therapy for their drug CYB003. The drug targets the treatment of Major Depressive Disorder (MDD). Cybin's Phase 3 pivotal trial will commence in late summer 2024. The study will involve 30 clinical sites throughout the United States and
- [Anti-TIGIT Antibody: The Revolutionary Cancer Treatment You Must Know About](https://www.clinicaltrialvanguard.com/news/anti-tigit-antibody-the-revolutionary-cancer-treatment-you-must-know-about/) - Anti-TIGIT antibodies are revolutionizing cancer treatment by targeting the immune inhibitory receptor TIGIT, expressed on T cells and NK cells. By binding to TIGIT, these antibodies remove immune suppression and reinvigorate the immune response against cancer cells. Over 50 anti-TIGIT antibodies are in clinical development, with several in advanced phase 3 trials. Key players include
- [Incyte Reveals Promise in Cancer Treatment with Revolutionary Drug](https://www.clinicaltrialvanguard.com/news/incyte-reveals-promise-in-cancer-treatment-with-revolutionary-drug/) - A pivotal Phase 3 trial (inMIND) has demonstrated the efficacy of tafasitamab in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma (FL). The primary endpoint of progression-free survival (PFS) was met, as were crucial secondary endpoints. Tafasitamab, a monoclonal antibody targeting CD19, displayed no new safety concerns when added to the
- [Pfizer and BioNTech Announce Results From New Combo Vaccine for Influenza and COVID-19](https://www.clinicaltrialvanguard.com/news/pfizer-and-biontech-announce-results-from-new-combo-vaccine-for-influenza-and-covid-19/) - Pfizer and BioNTech have released preliminary findings from a Phase 3 clinical trial evaluating their mRNA vaccine candidate that combines protection against influenza and COVID-19. The trial enrolled over 8,000 participants between the ages of 18 and 64. The vaccine candidate, which combines Pfizer's influenza vaccine with BioNTech's COVID-19 vaccine, demonstrated robust immune responses against
- [Bristol Myers Squibb's Revolutionary CAR T Cell Therapy for Lymphoma Gains EMA Validation](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibbs-revolutionary-car-t-cell-therapy-for-lymphoma-gains-ema-validation/) - The European Medicines Agency (EMA) has validated an application to expand the indication of Breyanzi for treating relapsed or refractory follicular lymphoma (FL) in adults who have received two or more prior systemic therapies. Data from the Phase 2 TRANSCEND FL trial, the largest study of CAR T cell therapy in FL, supports the application.
- [Walgreens, BARDA Team Up to Empower Decentralized Clinical Trials](https://www.clinicaltrialvanguard.com/news/walgreens-barda-team-up-to-empower-decentralized-clinical-trials/) - Walgreens and the Biomedical Advanced Research and Development Authority (BARDA) have joined forces to enhance decentralized clinical trials through the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program. This initiative aims to address challenges in accessing clinical trials and streamline research efforts over five years with a potential investment of up to $100 million.
- [IGC Pharma: AI Advances Therapeutic Potential for Metabolic and Neurological Diseases](https://www.clinicaltrialvanguard.com/news/igc-pharma-ai-advances-therapeutic-potential-for-metabolic-and-neurological-diseases/) - The discovery of IGC-1A's potential as a GLP-1 agonist, resulting from IGC Pharma's advanced Artificial Intelligence (AI) modeling, has revealed significant therapeutic opportunities for metabolic and neurological disorders. GLP-1, a hormone regulating blood sugar and weight, has shown promise in treating type 2 diabetes and aiding weight loss. IGC-1A's potential role as a GLP-1 agonist
- [Novartis New Mobility Digital Biomarker in Clinical Trials](https://www.clinicaltrialvanguard.com/conference-coverage/novartis-new-mobility-digital-biomarker-in-clinical-trials/) - The 7th Annual Digital Biomarkers in Clinical Trials conference featured a compelling presentation by Tilo Hache, Director of Strategy and Planning at Novartis Biomedical Research. Hache shared valuable insights and learnings from the Innovative Medicines Initiative (IMI) Mobilise-D project, a public-private partnership to address the challenges of integrating mobility as a vital sign in clinical
- [Bristol Myers Squibb Achieves FDA Acceptance for Treatment Option in Hepatocellular Carcinoma](https://www.clinicaltrialvanguard.com/news/bristol-myers-squibb-achieves-fda-acceptance-for-treatment-option-in-hepatocellular-carcinoma/) - Bristol Myers Squibb has announced the acceptance by the U.S. Food and Drug Administration (FDA) of its application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a possible first-line treatment for unresectable hepatocellular carcinoma (HCC). This acceptance is based on promising results from the Phase 3 CheckMate -9DW trial. The FDA has set a goal date
- [Uncommonly Funded Cancer Research Gains Momentum with Accolades](https://www.clinicaltrialvanguard.com/news/uncommonly-funded-cancer-research-gains-momentum-with-accolades/) - Curebound, a philanthropic organization that funds groundbreaking cancer research, announces significant updates for its grant recipients. The 2021 recipient of Curebound's oncofertility Discovery Grant has secured $4.1 million in follow-on funding to expand clinical trials investigating fertility restoration in cancer patients. Additionally, one of the 2023 Cure Prize recipients has received $1.2 million to support
- [FDA Approves Pfizer BioNTech COVID KP.2 Omicron Vaccine: A Health Milestone](https://www.clinicaltrialvanguard.com/news/fda-approves-pfizer-biontech-covid-kp-2-omicron-vaccine-a-health-milestone/) - The U.S. Food and Drug Administration (FDA) has approved Pfizer and BioNTech's Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine for individuals 12 years and older. It has also granted emergency use authorization for children aged 6 months to 11 years. This season's vaccine will be a single dose for those 5 years and older. Immunocompromised individuals
- [Rafael Holdings and Cyclo Therapeutics Seal Definitive Merger Pact](https://www.clinicaltrialvanguard.com/news/rafael-holdings-and-cyclo-therapeutics-seal-definitive-merger-pact/) - Rafael Holdings and Cyclo Therapeutics announce their merger to advance the development of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. This rare and fatal genetic disease has no approved treatment options. Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ has completed enrollment. Interim analysis results are anticipated in mid-2025. Rafael Holdings will
- [Care Access Enters into New Partnership with BARDA to Sharpen Pandemic Preparedness](https://www.clinicaltrialvanguard.com/news/care-access-enters-into-new-partnership-with-barda-to-sharpen-pandemic-preparedness/) - Care Access, a global health research company, has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to enhance vaccine and treatment accessibility for underserved and hard-to-reach communities during public health emergencies. Care Access's decentralized clinical trial network will be employed to establish a nationally representative network of community-based clinicians, foster partnerships with organizations
- [Merck's Bomedemstat Begins Phase 3 Trial for Essential Thrombocythemia](https://www.clinicaltrialvanguard.com/news/mercks-bomedemstat-begins-phase-3-trial-for-essential-thrombocythemia/) - Merck has launched Shorespan-007, a Phase 3 clinical trial evaluating bomedemstat for treating patients with essential thrombocythemia (ET) who haven't received cytoreductive therapy. Essential thrombocythemia, a chronic rare blood disorder, is the most common myeloproliferative neoplasm. The standard of care hasn't changed significantly in decades, leaving patients needing new options for disease control and improved
- [ESC Congress 2024: Bayer Presents Phase III Kerendia® (Finerenone) Data](https://www.clinicaltrialvanguard.com/news/esc-congress-2024-bayer-presents-phase-iii-kerendia-finerenone-data/) - During the 2024 European Society of Cardiology (ESC) Congress, Bayer will unveil late-breaking results from the Phase III FINEARTS-HF trial evaluating finereneone's efficacy in patients with HF and left ventricular ejection fraction (LVEF) of 40% or higher. Finerenone, marketed as KERENDIA®, is currently approved for reducing cardiovascular risks in patients with chronic kidney disease (CKD)
- [Merck Discontinues Two Phase 3 Trials](https://www.clinicaltrialvanguard.com/news/merck-discontinues-two-phase-3-trials/) - Merck has discontinued two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. The KEYNOTE-867 trial evaluated the combination of KEYTRUDA (pembrolizumab) and stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer (NSCLC) patients ineligible for surgery. However, an interim analysis showed no improvement in event-free or overall survival compared to placebo and SBRT,
- [Median's Revolutionary Lung Cancer Diagnostic Earns Pivotal Validation](https://www.clinicaltrialvanguard.com/news/medians-revolutionary-lung-cancer-diagnostic-earns-pivotal-validation/) - Median Technologies' eyonis™ LCS, an AI-powered SaMD for lung cancer screening, has demonstrated strong performance in its REALITY pivotal study. The technology excels in detecting and characterizing cancerous nodules, increasing the accuracy of low-dose computed tomography (LDCT) scans. By improving the precision of LDCT, eyonis™ LCS has the potential to significantly enhance early detection and
- [Pyros Pharma's Vigafyde: The Breakthrough Oral Solution for Infantile Spasm](https://www.clinicaltrialvanguard.com/news/pyros-pharmas-vigafyde-the-breakthrough-oral-solution-for-infantile-spasm/) - Pyros Pharmaceuticals introduces VIGAFYDE™, an oral solution containing vigabatrin for treating infantile spasms (IS) in children aged 1 month to 2 years. This premeasured solution simplifies dosing and improves accuracy, addressing the challenges associated with administering medication to infants with this severe seizure disorder. As the first ready-to-use vigabatrin oral solution, VIGAFYDE™ offers several advantages.
- [Merck Keytruda and Padcev Advance Urothelial Carcinoma Treatment: An Uncommon Breakthrough](https://www.clinicaltrialvanguard.com/news/merck-keytruda-and-padcev-advance-urothelial-carcinoma-treatment-an-uncommon-breakthrough/) - The European Commission (EC) has granted approval to the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin) as a first-line treatment for unresectable or metastatic urothelial carcinoma in adults. This approval aligns with recent guidelines recommending the combination as the preferred initial treatment approach. The approval is based on findings from the KEYNOTE-A39 trial, which
- [MedinCell Unveils Remarkable Progress in Product and R&D Pipeline with Abbvie](https://www.clinicaltrialvanguard.com/news/medincell-unveils-remarkable-progress-in-product-and-rd-pipeline-with-abbvie/) - Medincell has partnered with AbbVie to develop and commercialize up to six innovative therapies using Medincell's long-acting injectable platform. Medincell will conduct formulation and preclinical studies, including Chemistry, Manufacturing, and Controls (CMC) work, to advance a first candidate into clinical development. AbbVie will finance and lead clinical trials, regulatory approvals, manufacturing, and commercialization. Medincell will
- [AngioDynamics Auryon System Now Available in Europe](https://www.clinicaltrialvanguard.com/news/angiodynamics-auryon-system-now-available-in-europe/) - AngioDynamics has secured CE Mark approval for its innovative Auryon Atherectomy System, a groundbreaking technology for treating Peripheral Artery Disease (PAD). This approval marks a significant milestone for the company and offers new treatment options for PAD patients in Europe. The Auryon System utilizes groundbreaking solid-state laser technology to remove plaque and blockages in arteries,
- [Foundation Medicine and Syndax Pharma Unveil Companion Diagnostic in Hematology](https://www.clinicaltrialvanguard.com/news/foundation-medicine-and-syndax-pharma-unveil-companion-diagnostic-in-hematology/) - Foundation Medicine and Syndax Pharmaceuticals have initiated a partnership to develop a tool to identify acute myeloid leukemia (AML) patients with NPM1 mutations. NPM1 mutations are common in AML, affecting around 30% of newly diagnosed patients. However, there are currently no approved targeted treatments for these patients, with an overall survival rate of approximately 50%
- [Arsenal Biosciences Unlocks $325M to Drive Programmable Cell Therapies to Clinical Triumph](https://www.clinicaltrialvanguard.com/news/arsenal-biosciences-unlocks-325m-to-drive-programmable-cell-therapies-to-clinical-triumph/) - Arsenal Biosciences, a leading cell therapy company specializing in solid tumor treatment, has secured $325 million in Series C funding. The oversubscribed round attracted new investors like ARCH Venture Partners and Milky Way Investments Group. Existing investors, including the Parker Institute for Cancer Immunotherapy and SoftBank Vision Fund 2, also participated. ArsenalBio's proprietary T-cell engineering
- [Kincell Bio Expands Its Dominance in the Biotech Industry Through Groundbreaking Partnership](https://www.clinicaltrialvanguard.com/news/kincell-bio-expands-its-dominance-in-the-biotech-industry-through-groundbreaking-partnership/) - Kincell Bio, a cell therapy CDMO, has forged a new partnership to produce early-phase clinical material for an allogeneic cell therapy product. The deal extends Kincell Bio's manufacturing capabilities following the acquisition of a GMP-ready facility in 2024. The partnership reflects Kincell Bio's expertise in allogeneic cell therapy production, a key focus for the company.
- [FDA Letter Supports Amprion's Revolutionary α-Synuclein Test](https://www.clinicaltrialvanguard.com/news/fda-letter-supports-amprions-revolutionary-α-synuclein-test/) - The U.S. Food & Drug Administration (FDA) recently issued a Letter of Support (LoS) endorsing the use of the alpha-synuclein (α-syn) seed amplification assay (synSAA) in research and clinical trials. This assay has demonstrated exceptional specificity and sensitivity in detecting misfolded α-syn in cerebrospinal fluid (CSF). It is a valuable diagnostic tool for neurodegenerative disorders
- [Summit Therapeutics's Remarkable Cancer Breakthrough: New Treatment Reduces Disease Progression by 49%](https://www.clinicaltrialvanguard.com/news/summit-therapeuticss-remarkable-cancer-breakthrough-new-treatment-reduces-disease-progression-by-49/) - Summit Therapeutics and Akeso announced positive results from the Phase III HARMONi-2 trial, evaluating ivonescimab, an investigational bispecific antibody, as a first-line treatment for advanced non-small cell lung cancersmall cell lung cancer (NSCLC) with PD-L1 positive expression. Ivonescimab demonstrated a statistically significant improvement in progression-free survival (PFS) compared to pembrolizumab, a current standard of care.
- [AstraZeneca TROP2 Biomarker Predicts Lung Cancer Treatment Outcomes](https://www.clinicaltrialvanguard.com/news/astrazeneca-trop2-biomarker-predicts-lung-cancer-treatment-outcomes/) - An exploratory analysis of the TROPION-Lung01 phase 3 trial revealed TROP2 expression, measured using AstraZeneca's computational pathology platform, as a predictor of clinical outcomes in advanced non-small cell lung cancersmall cell lung cancer (NSCLC) patients treated with datopotamab deruxtecan (Dato-DXd). In patients whose tumors showed high TROP2-QCS biomarker levels, Dato-DXd significantly improved efficacy compared to
- [Innate Pharma's Monalizumab NeoCOAST-2 Phase 2 Trial Reports Encouraging Outcomes in Early-Stage Lung Cancer](https://www.clinicaltrialvanguard.com/news/innate-pharmas-monalizumab-neocoast-2-phase-2-trial-reports-encouraging-outcomes-in-early-stage-lung-cancer/) - The NeoCOAST-2 trial evaluated the efficacy and safety of treatments in patients with early-stage non-small cell lung cancersmall cell lung cancer (NSCLC). Interim results from three treatment arms were presented at the World Conference on Lung Cancer. One arm, combining monalizumab, durvalumab, and chemotherapy, showed promising results. This combination achieved a 26.7% pathological complete response
- [Silexion Therapeutics Unveils Pioneering RNAi Technology from Silexion Therapeutics for Revolutionizing the Fight Against KRAS-Driven Cancers](https://www.clinicaltrialvanguard.com/news/silexion-therapeutics-unveils-pioneering-rnai-technology-from-silexion-therapeutics-for-revolutionizing-the-fight-against-kras-driven-cancers/) - Silexion's proprietary LODER™ platform enables targeted oncogene silencing, using siRNA to block the production of oncogenic proteins. This approach differs from small molecule KRAS inhibitors targeting already-produced oncogenic proteins. The localized delivery system bypasses tumor barriers, ensuring higher treatment concentrations within the tumor while minimizing systemic side effects. SIL-204, Silexion's improved siRNA formulation, targets a
- [AiCure H.code Patient Engagement Platform Unveiled at dpharm 2024](https://www.clinicaltrialvanguard.com/news/aicure-h-code-patient-engagement-platform-unveiled-at-dpharm-2024/) - AiCure, a pioneer in clinical trial monitoring and patient engagement, will debut its innovative H.Code platform at the DPHARM conference. This technology combines computer vision, communication tools, and analytics to enhance site teams' understanding of participant behavior. H.Code extends beyond adherence monitoring, enabling the development of digital assessments that connect behavior to disease and treatment
- [New Clinical Trial Technology Innovations at Veeva R&D And Quality Summit](https://www.clinicaltrialvanguard.com/conference-coverage/new-clinical-trial-technology-innovations-at-veeva-rd-and-quality-summit/) - The 2024 Veeva R&D and Quality Summit brought together industry leaders and professionals to discuss the latest clinical trial technologies, life sciences advancements, and strategies shaping the industry. The event featured keynotes and sessions from industry leaders, including Peter Gassner, Founder and CEO of Veeva Systems, along with other keynote speakers like Seb Moity, Head
- [Sanofi, Radiomedix, and OranoMed Sign Revolutionary Licensing Agreement for Next-Gen Radioligand Medicine](https://www.clinicaltrialvanguard.com/news/sanofi-radiomedix-and-oranomed-sign-revolutionary-licensing-agreement-for-next-gen-radioligand-medicine/) - Sanofi, RadioMedix, and Orano Med have partnered to advance AlphaMedixTM, a treatment for a rare cancer known as neuroendocrine tumors (NETs). AlphaMedixTM, a radiopharmaceutical, employs a unique peptide to target somatostatin receptors on NETs. This peptide is combined with lead-212 (212Pb), which releases alpha particles to destroy cancerous cells. AlphaMedixTM has shown promising results in
- [Unveiling Mavenclad's Remarkable Benefits: Sustained Efficacy in MS](https://www.clinicaltrialvanguard.com/news/unveiling-mavenclads-remarkable-benefits-sustained-efficacy-in-ms/) - EMD Serono presented data at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, showcasing the sustained efficacy and safety of MAVENCLAD (cladribine) tablets in treating relapsing multiple sclerosis (RMS). Studies have consistently demonstrated the efficacy of MAVENCLAD in reducing relapse rates and disease activity. Additional analyses now reveal its impact on
- [AI-Enhanced Gene Therapy Vector: A Revolutionary Advance for Muscle Disease Treatment](https://www.clinicaltrialvanguard.com/news/ai-enhanced-gene-therapy-vector-a-revolutionary-advance-for-muscle-disease-treatment/) - Genethon, a leading gene therapy research facility, has significantly progressed in developing a new generation of adeno-associated virus (AAV) capsids using artificial intelligence (AI). These capsids enhance gene therapies for muscle diseases by targeting muscles more effectively and avoiding the liver. This breakthrough, published in Nature Communications, utilizes AI to design capsids that selectively bind
- [Unveiling the Power of Targeted Radionuclide Pharmaceuticals](https://www.clinicaltrialvanguard.com/news/unveiling-the-power-of-targeted-radionuclide-pharmaceuticals/) - Molecular Targeting Technologies (MTTI) and Brookline Capital Markets are collaborating at the 2nd Targeted Radionuclide Pharmaceuticals (TRPs) Supply Chain & Manufacturing Summit, held in Boston from September 24-26, 2024. MTTI will present a workshop titled "Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential," focusing on the emerging radiopharmaceutical market and its investment
- [FDA Authorizes Ocrevus Zunovo™: The Revolutionary MS Treatment](https://www.clinicaltrialvanguard.com/news/fda-authorizes-ocrevus-zunovo-the-revolutionary-ms-treatment/) - The U.S. Food and Drug Administration (FDA) has authorized Ocrevus Zunovo, a new subcutaneous injection, to treat relapsing and primary progressive multiple sclerosis (MS). This approval expands treatment options for MS patients, providing greater flexibility and accessibility. Ocrevus Zunovo is a twice-a-year subcutaneous injection administered by a healthcare professional, offering an alternative to the existing
- [AstraZeneca and Moffitt Cancer Center: Oncology Cell Therapy Collaboration](https://www.clinicaltrialvanguard.com/news/astrazeneca-and-moffitt-cancer-center-oncology-cell-therapy-collaboration/) - Moffitt Cancer Center and AstraZeneca have forged a strategic partnership to advance the development of cell therapies, particularly CAR-T and TCR-T treatments. This collaboration leverages Moffitt's clinical expertise and extensive network of cancer centers to accelerate AstraZeneca's pipeline of cell therapies. AstraZeneca accesses Moffitt's leading clinical environment and physician-scientist connections, facilitating the swift investigation of
- [Why Innovation in Big Pharma Is So Slow: Insights from BMS](https://www.clinicaltrialvanguard.com/conference-coverage/why-innovation-in-big-pharma-is-so-slow-insights-from-bms/) - At the 2023 DPHARM conference, Hassan Kadhim from Bristol-Myers Squibb offered an insightful look into the challenges driving innovation in Big Pharma. His presentation, “Addressing the Innovation Gap,” shed light on the slow adoption of new technologies in clinical trials and the internal processes pharmaceutical companies use to navigate their complex, highly regulated landscape. Kadhim’s
- [Where Parexel Stands on The Future of Clinical Trials](https://www.clinicaltrialvanguard.com/executiveinterviews/where-parexel-stands-on-the-future-of-clinical-trials/) - At the 2024 DPHARM Conference, we had the chance to interview Peyton Howell, CEO of Parexel, and she shared industry trends, challenges, and future strategies. Moe Alsumidaie: Can you share your transition to CEO at Parexel and your priorities for the coming year? Peyton Howell: I'm about 100 days into my role as the new
- [FDA Approves Keytruda® Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma](https://www.clinicaltrialvanguard.com/news/fda-approves-keytruda-plus-pemetrexed-and-platinum-chemotherapy-for-malignant-pleural-mesothelioma/) - The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, as a first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval is based on the Phase 3 CCTG IND.227/KEYNOTE-483 trial. In this trial, KEYTRUDA plus chemotherapy showed a statistically significant improvement in overall survival
- [New Zeposia Data Reveal Durable Efficacy and Unwavering Safety in Relapsing MS](https://www.clinicaltrialvanguard.com/news/new-zeposia-data-reveal-durable-efficacy-and-unwavering-safety-in-relapsing-ms/) - According to new data, a Phase 3 extension study of Zeposia for multiple sclerosis (MS) found a sustained decrease in brain volume loss over five years. The open-label extension of the DAYBREAK trial showed that patients treated with Zeposia experienced low and stable rates of brain volume loss. The annualized rate of loss for whole
- [Fasenra: A Breakthrough in Treating Eosinophilic Granulomatosis with Polyangiitis](https://www.clinicaltrialvanguard.com/news/fasenra-a-breakthrough-in-treating-eosinophilic-granulomatosis-with-polyangiitis/) - AstraZeneca's FASENRA (benralizumab) has received FDA approval for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune vasculitis that affects various organs and can be life-threatening if left untreated. The approval stems from the positive results of the MANDARA Phase III trial, where FASENRA demonstrated comparable efficacy to mepolizumab, the only previously approved
- [Tivic Health Study Ready for Enrollment With Non-Invasive Vagus Nerve Stimulation Technology](https://www.clinicaltrialvanguard.com/news/tivic-health-study-ready-for-enrollment-with-non-invasive-vagus-nerve-stimulation-technology/) - Tivic Health has received approval for the next phase of clinical research on its non-invasive cervical vagus nerve stimulation (ncVNS) approach. This collaboration with Feinstein Institutes aims to refine the stimulation parameters of the ncVNS technology. Physiological measurements will guide device performance enhancements, including electrode positioning and waveform optimizations. The data will inform clinical trial
- [CD137 Antibodies: A Promising Cancer Immunotherapy Target](https://www.clinicaltrialvanguard.com/news/cd137-antibodies-a-promising-cancer-immunotherapy-target/) - CD137 (4-1BB) is a promising target for cancer immunotherapy. Its ability to stimulate T cells and enhance tumor cell killing has drawn attention from researchers and pharmaceutical companies. Despite the absence of approved CD137-targeted therapies, numerous candidates are under clinical development. Major companies like BioNTech and Shanghai Henlius Biotech are actively involved. CD137 antibodies, particularly
- [DeepCure: Unveiling the Potential of BD2 Inhibitor DC-9476 in Macrophage Activation Syndrome](https://www.clinicaltrialvanguard.com/news/deepcure-unveiling-the-potential-of-bd2-inhibitor-dc-9476-in-macrophage-activation-syndrome/) - DeepCure, a company employing AI for drug discovery, will present preclinical data on their BRD4 Inhibitor, DC-9476, at the EMBO 2024 Conference. DC-9476 targets macrophage activation syndrome (MAS), a life-threatening condition often accompanying juvenile and adult-onset Still's disease. The current standard treatment, glucocorticoids, has limitations, creating a need for effective alternatives. Studies reveal that DC-9476
- [Exelixis Announces Phase 3 CABINET Study Results Unveiled at ESMO 2024](https://www.clinicaltrialvanguard.com/news/exelixis-announces-phase-3-cabinet-study-results-unveiled-at-esmo-2024/) - The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this trial showed significant improvement in progression-free survival (PFS) with cabozantinib in both pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) cohorts. In the pNET cohort, cabozantinib led to a median PFS of 13.8 months compared to
- [Massive Bio Inroduces Global Platform Launches to Enhance Patient Access to Clinical Trials](https://www.clinicaltrialvanguard.com/news/massive-bio-inroduces-global-platform-launches-to-enhance-patient-access-to-clinical-trials/) - Massive Bio, an industry leader in AI-powered clinical trial enrollment, has introduced Patient Connect, an innovative portal designed to enhance cancer patients' access to clinical trials worldwide. Patient Connect empowers patients by providing: • Access to their medical records to enable in-depth AI analysis • Identification of optimal clinical trial options based on their medical
- [Cybin Completes Announced Share Consolidation](https://www.clinicaltrialvanguard.com/news/cybin-completes-announced-share-consolidation/) - Toronto-based Cybin Inc., a clinical-stage neuropsychiatry company focused on developing novel treatments for mental health conditions, has consolidated its common shares. Effective immediately, this adjustment combines every 38 existing shares into one new one. The consolidation has reduced the number of outstanding common shares from 759,692,495 to approximately 19,991,907. While each shareholder's proportionate ownership and
- [Cybin Announces Groundbreaking Clinical Progress, Unveiling Transformative Therapies for Mental Health](https://www.clinicaltrialvanguard.com/news/cybin-announces-groundbreaking-clinical-progress-unveiling-transformative-therapies-for-mental-health/) - Cybin Inc., a clinical-stage biotech company, is advancing its clinical programs for neuropsychiatric disorders. The company's lead programs, CYB003 and CYB004, are entering late-stage development. CYB003, a proprietary deuterated psilocin, is being developed for MDD. It received FDA Breakthrough Therapy Designation based on promising preliminary results. A Phase 3 study in MDD will commence shortly,
- [Unveiling the Transformative Power of Takeda's Narcolepsy Treatment: Clinical Trial Triumphs at Sleep Europe 2024](https://www.clinicaltrialvanguard.com/news/unveiling-the-transformative-power-of-takedas-narcolepsy-treatment-clinical-trial-triumphs-at-sleep-europe-2024/) - Takeda will showcase data from its Phase 2b trials and long-term extension study of TAK-861, an investigational orexin receptor 2 agonist, for narcolepsy type 1 (NT1) at Sleep Europe 2024. TAK-861 aims to address the orexin deficiency in NT1 by stimulating the orexin receptor 2. Promising Phase 2b results have led to initiating the FirstLight
- [AngioDynamics Initiates Landmark Trial for Pulmonary Embolism Treatment](https://www.clinicaltrialvanguard.com/news/angiodynamics-initiates-landmark-trial-for-pulmonary-embolism-treatment/) - AngioDynamics has initiated a comprehensive study to evaluate the efficacy and safety of the AlphaVac Mechanical Aspiration Thrombectomy System for treating acute, intermediate-risk pulmonary embolism (PE) in Europe. The RECOVER-AV trial will recruit patients at multiple European hospital sites and assess the system's ability to reduce the ratio of right ventricular (RV) to left ventricular
- [Introducing Ultherapy PRIME: Revolutionizing Non-Surgical Skin Lifting](https://www.clinicaltrialvanguard.com/news/introducing-ultherapy-prime-revolutionizing-non-surgical-skin-lifting/) - Ultherapy PRIME, a groundbreaking ultrasound technology, significantly advances noninvasive skin treatments. With real-time imaging, it delivers personalized and long-lasting lifts, targeting precise tissue layers where collagen and elastin reside. Ultherapy PRIME builds upon the legacy of Ultherapy, recognized as the gold standard for skin tightening and lifting. Clinical studies and over 56 clinical trials have
- [MedinCell Partner Teva Delivers Unprecedented Antipsychotic Data](https://www.clinicaltrialvanguard.com/news/medincell-partner-teva-delivers-unprecedented-antipsychotic-data/) - A positive efficacy, safety, and tolerability profile has emerged from Medincell and Teva's Phase 3 SOLARIS trial evaluating Olanzapine LAI in patients with schizophrenia. Key Findings • Efficacy results at 8 weeks in Period 1 demonstrated significant patient improvements across multiple parameters. • Systemic safety data aligned with other olanzapine formulations; no new safety signals
- [FDA Accepts LEO Pharma's NDA for Delgocitinib Cream for Chronic Hand Eczema](https://www.clinicaltrialvanguard.com/news/fda-accepts-leo-pharmas-nda-for-delgocitinib-cream-for-chronic-hand-eczema/) - LEO Pharma has announced the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for delgocitinib cream 20 mg/g for adults with moderate to severe Chronic Hand Eczema (CHE). This submission marks a significant milestone in LEO Pharma's efforts to bring this innovative treatment to patients in the United
- [Trisalus: Improved Tumor Delivery with PEDD™ Method](https://www.clinicaltrialvanguard.com/news/trisalus-improved-tumor-delivery-with-pedd-method/) - TriSalus Life Sciences' Pressure Enabled Drug Delivery (PEDD) method enhances the delivery of glass microspheres into liver tumors in a porcine model. Published in the Journal of Vascular and Interventional Radiology, the study demonstrates that PEDD significantly improves penetration of glass microspheres into tumors using the TriNav Infusion System. Compared to conventional microcatheters, the PEDD
- [Merck's Keytruda® Wins Japan Approval for Advanced Lung and Bladder Cancers](https://www.clinicaltrialvanguard.com/news/mercks-keytruda-wins-japan-approval-for-advanced-lung-and-bladder-cancers/) - Japan's Ministry of Health has approved new indications for KEYTRUDA (pembrolizumab) in treating certain lung and urothelial cancers. KEYTRUDA, combined with chemotherapy, has been approved for preoperative (neoadjuvant) and follow-up (adjuvant) treatment of NSCLC patients. This approval is based on the KEYNOTE-671 trial, which demonstrated improved overall and event-free survival in patients receiving the KEYTRUDA
- [Investigational Favezelimab and Pembrolizumab Combo Shows Promise in Colorectal Cancer](https://www.clinicaltrialvanguard.com/news/investigational-favezelimab-and-pembrolizumab-combo-shows-promise-in-colorectal-cancer/) - Merck's Phase 3 KEYFORM-007 trial tested the efficacy of a fixed-dose combination of favezelimab and pembrolizumab in treating PD-L1-positive microsatellite-stable metastatic colorectal cancer (mCRC). The trial failed to meet its primary endpoint of improved overall survival (OS) compared to the standard of care (regorafenib or TAS-102). The safety profile of the combination was consistent with
- [Pfizer Recalls Worldwide Supplies of Sickle Cell Disease Treatment](https://www.clinicaltrialvanguard.com/news/pfizer-recalls-worldwide-supplies-of-sickle-cell-disease-treatment/) - Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events observed in clinical data. The company is also discontinuing clinical trials and expanded access programs for the drug worldwide. According to Pfizer, the overall benefit of OXBRYTA no longer outweighs the risk in the approved patient
- [Genialis Unveils RNA- and ML-Powered Biomarker for Cancer Treatment Selection](https://www.clinicaltrialvanguard.com/news/genialis-unveils-rna-and-ml-powered-biomarker-for-cancer-treatment-selection/) - Genialis, a leader in RNA biomarker development, has announced the launch of Genialis krasID, a groundbreaking biomarker capable of predicting patient response and benefits from KRAS inhibitors (KRASi). This biomarker algorithm is universally applicable across tissue types and KRAS mutation statuses. Genialis krasID harnesses machine learning to analyze gene expression patterns in patient tumors, revealing
- [City of Hope's Horizon: City of Hope Gets $20M for Pancreatic Disease Breakthroughs](https://www.clinicaltrialvanguard.com/news/city-of-hopes-horizon-city-of-hope-gets-20m-for-pancreatic-disease-breakthroughs/) - City of Hope, a leading cancer research and treatment institution, has received a $20 million donation from philanthropists Norman and Melinda Payson. This significant gift will establish a dedicated pancreas center to accelerate groundbreaking research and treatments for pancreatic cancer and diabetes. Inspired by the personal impact of pancreatic cancer on his mother, Norman Payson,
- [LEO Pharma Unveils Remarkable Results of ANZUPGO® Cream in Chronic Hand Eczema](https://www.clinicaltrialvanguard.com/news/leo-pharma-unveils-remarkable-results-of-anzupgo-cream-in-chronic-hand-eczema/) - LEO Pharma presented data at the 33rd European Academy of Dermatology and Venereology (EADV) Congress on the effectiveness and safety of delgocitinib cream for moderate to severe chronic hand eczema (CHE). The DELTA FORCE trial, a 12-week phase 3 study, compared delgocitinib cream to oral alitretinoin capsules. Delgocitinib cream showed superior efficacy, with a greater
- [Metsera Announces Positive Phase 1 Results for MET-097, an Ultra-Long-Acting GLP-1 Agonist](https://www.clinicaltrialvanguard.com/news/metsera-announces-positive-phase-1-results-for-met-097-an-ultra-long-acting-glp-1-agonist/) - In a Phase 1 clinical trial, Metsera's MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing. The 125 participants in the trial received various doses of MET-097. Key Findings: • MET-097 demonstrated significant and sustained weight loss, achieving a 7.5% reduction in body weight. • The weight loss was maintained for at
- [Revolutionary Peripulse System Approved for Nerve Regeneration](https://www.clinicaltrialvanguard.com/news/revolutionary-peripulse-system-approved-for-nerve-regeneration/) - Epineuron has achieved a significant milestone with the approval of its PeriPulse™ system by Health Canada. This innovative nerve regeneration solution represents a breakthrough in nerve care, offering patients with severe injuries and chronic conditions a promising path toward recovery. PeriPulse™ is the first therapeutic solution specifically designed to promote nerve regeneration. Its advanced electrode
- [Curebound Grants $2 Million to Cancer Research Innovations](https://www.clinicaltrialvanguard.com/news/curebound-grants-2-million-to-cancer-research-innovations/) - Curebound, a philanthropic organization dedicated to cancer research, has awarded eight grants totaling $2 million to innovative oncology-based projects. These grants support pre-series A life science companies conducting groundbreaking research with commercialization potential. They provide up to $250,000 to projects that aim to develop transformative products, therapies, or services for cancer treatment. Awarded recipients include:
- [OHRP's 7th Exploratory Workshop: Navigating AI in Clinical Trials](https://www.clinicaltrialvanguard.com/conference-coverage/ohrps-7th-exploratory-workshop-navigating-ai-in-clinical-trials/) - Explore the ethical, legal, and practical implications of AI in clinical trials with insights from the OHRP workshop.
- [Innovating FDA Approval for Novel Schizophrenia Treatment](https://www.clinicaltrialvanguard.com/news/innovating-fda-approval-for-novel-schizophrenia-treatment/) - Bristol Myers Squibb's COBENFY has received FDA approval for treating adult schizophrenia. As a first-of-its-kind medication, COBENFY adopts a novel pharmacological approach by targeting brain receptors M1 and M4, breaking away from the current therapeutic paradigm. COBENFY's approval stems from the EMERGENT clinical program, which yielded positive results. In two Phase 3 trials (EMERGENT-2 and
- [Enterprise Therapeutics' ETD001 Receives Rare Pediatric Disease Designation for Cystic Fibrosis](https://www.clinicaltrialvanguard.com/news/enterprise-therapeutics-etd001-receives-rare-pediatric-disease-designation-for-cystic-fibrosis/) - Enterprise Therapeutics, a biotechnology company specializing in respiratory disease therapies, has earned the "rare pediatric disease designation" (RPD) for its investigational cystic fibrosis (CF) treatment, ETD001, from the US Food and Drug Administration (FDA). This designation recognizes the severity and limited treatment options available for CF, a life-threatening genetic disorder primarily affecting children. ETD001, a
- [New Hope for Hormone-Sensitive Prostate Cancer: Nubeqa® Expansion Application Submitted](https://www.clinicaltrialvanguard.com/news/new-hope-for-hormone-sensitive-prostate-cancer-nubeqa-expansion-application-submitted/) - Bayer submitted a supplemental application to the FDA for NUBEQA, an oral androgen receptor inhibitor combined with androgen deprivation therapy. This application aims to expand the use of NUBEQA in treating metastatic hormone-sensitive prostate cancer (mHSPC) patients, irrespective of chemotherapy use. The submission is supported by positive results from the ARANOTE trial, presented at ESMO
- [TAGRISSO Approved for Unresectable Stage III EGFR-Mutated Lung Cancer](https://www.clinicaltrialvanguard.com/news/tagrisso-approved-for-unresectable-stage-iii-egfr-mutated-lung-cancer/) - AstraZeneca's TAGRISSO (osimertinib) has received US approval for treating adults with unresectable, Stage III EGFR-mutated non-small cell lung cancersmall cell lung cancer (NSCLC). The approval stems from the LAURA Phase III trial, revealing that TAGRISSO significantly extended progression-free survival (PFS) by 39.1 months compared to 5.6 months with a placebo. The trial demonstrated an 84%
- [Viviani's GLP-1 Implant Cleared for Human Trials in Australia: A Revolutionary Approach to Fighting Obesity and Overweight](https://www.clinicaltrialvanguard.com/news/vivianis-glp-1-implant-cleared-for-human-trials-in-australia-a-revolutionary-approach-to-fighting-obesity-and-overweight/) - Vivani Medical announces the approval of its clinical trial for a miniature GLP-1 implant, designed to offer comparable effectiveness to semaglutide, found in Ozempic® and Wegovy®. This implant aims to provide treatment with twice-yearly administration, a significant advantage over existing products. The clinical trial, LIBERATE-1™, will evaluate the safety, tolerance, and pharmacological effects of the
- [BioAlberta, AxialBridge Team Up to Empower Alberta Life Sciences Companies](https://www.clinicaltrialvanguard.com/news/bioalberta-axialbridge-team-up-to-empower-alberta-life-sciences-companies/) - BioAlberta has partnered with AxialBridge to support Alberta biotech and MedTech companies in expanding their clinical trials and R&D endeavors into the United Kingdom. This partnership aims to bridge the gap between Canadian and UK life science sectors. AxialBridge, with its extensive experience in the UK healthcare market, will guide BioAlberta members through the regulatory
- [Precision's Exciting HBV Trial: A Breakthrough for Hepatitis B Patients](https://www.clinicaltrialvanguard.com/news/precisions-exciting-hbv-trial-a-breakthrough-for-hepatitis-b-patients/) - Precision BioSciences has submitted Clinical Trial Applications (CTAs) to initiate a Phase 1 study for its in vivo gene editing therapy, PBGENE-HBV. This therapy aims to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the primary source of viral replication. Additionally, it inactivates integrated HBV DNA in hepatocytes. PBGENE-HBV is unique in its
- [InCarda Phase 3 Trial Prematurely Terminated](https://www.clinicaltrialvanguard.com/news/incarda-phase-3-trial-prematurely-terminated/) - InCarda Therapeutics has demonstrated promising results in developing FlecIH-103, an inhaled solution for converting paroxysmal atrial fibrillation (PAF) to sinus rhythm. Though prematurely terminated, the Phase 3 RESTORE-1 trial showed that inhaled flecainide achieved a statistically significant cardioversion rate of 31% in PAF patients compared to placebo. The median time to restore normal sinus rhythm
- [Biosimilar Otuli™ Receives FDA Approval: Encouraging News for Arthritis Patients](https://www.clinicaltrialvanguard.com/news/biosimilar-otuli-receives-fda-approval-encouraging-news-for-arthritis-patients/) - Fresenius Kabi, a subsidiary of Fresenius, and Formycon AG, a leading biosimilars developer, have received FDA approval for Otulfi™ (ustekinumab-aauz). This biosimilar targets Crohn's diseaseCrohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Otulfi™ was developed through a comprehensive evaluation of data, demonstrating its biosimilarity to Stelara® in efficacy, safety, and pharmacokinetics. It offers a
- [ENHERTU® Granted Priority Review in the U.S. for Patients Battling Metastatic Breast Cancer](https://www.clinicaltrialvanguard.com/news/enhertu-granted-priority-review-in-the-u-s-for-patients-battling-metastatic-breast-cancer/) - Daiichi Sankyo and AstraZeneca's application for ENHERTU has been accepted for Priority Review by the US Food and Drug Administration (FDA). This treatment targets adult patients with HER2 low or ultralow unresectable or metastatic breast cancer who have undergone prior endocrine therapy. ENHERTU, an antibody-drug conjugate, was jointly developed by Daiichi Sankyo and AstraZeneca. The
- [Merck Acquires Novel B-Cell Depletion Therapy From Curon](https://www.clinicaltrialvanguard.com/news/merck-acquires-novel-b-cell-depletion-therapy-from-curon/) - Merck has acquired CN201, a bispecific antibody, from Curon Biopharmaceutical. This acquisition strengthens Merck's pipeline for treating B-cell malignancies and autoimmune diseases. CN201 targets and eliminates B cells, offering potential applications in various B-cell-related conditions. Preliminary clinical trials indicate that CN201 is well-tolerated and effectively reduces B-cell populations in patients with relapsed or refractory B-cell
- [Maze Therapeutics Pioneers Revolutionary Kidney Disease Treatment](https://www.clinicaltrialvanguard.com/news/maze-therapeutics-pioneers-revolutionary-kidney-disease-treatment/) - Maze Therapeutics, a biopharmaceutical company, has commenced its Phase 1 clinical trial for MZE782, an oral small molecule therapy. MZE782 targets SLC6A19, a solute transporter, potentially benefiting approximately 5 million chronic kidney disease (CKD) patients in the United States who have limited responses to existing treatments. Harold Bernstein, president and chief medical officer of Maze,
- [Advanced Prostate Cancer Breakthrough: Posluma Unlocks Hope and Extends Lives](https://www.clinicaltrialvanguard.com/news/advanced-prostate-cancer-breakthrough-posluma-unlocks-hope-and-extends-lives/) - Blue Earth Diagnostics, a renowned company in PET radiopharmaceutical development, announced the results of a post-hoc analysis from the Phase 3 SPOTLIGHT trial. The study evaluated the use of POSLUMA injection for detecting prostate cancer recurrence in patients who had undergone radical prostatectomy and had low PSA levels. The analysis revealed high detection rates for
- [Owkin and AstraZeneca Team Up to Triumph Over Breast Cancer](https://www.clinicaltrialvanguard.com/news/owkin-and-astrazeneca-team-up-to-triumph-over-breast-cancer/) - Owkin and AstraZeneca are collaborating on an AI-powered tool that will pre-screen for harmful mutations in breast cancer genes (gBRCAm) using digital pathology slides. The tool aims to enhance accessibility and streamline testing for these mutations. BRCA testing identifies mutations in BRCA1 and BRCA2 genes and is crucial in determining cancer risk and guiding treatment
- [How Causal Machine Learning is Transforming Clinical Trials](https://www.clinicaltrialvanguard.com/executiveinterviews/how-causal-machine-learning-is-transforming-clinical-trials/) - Welcome to an insightful discussion on the future of clinical trials and the role of causal machine learning in drug development. In this interview at DPHARM 2024, we speak with Raviv Pryluk, CEO and Co-founder of PhaseV, to explore how this technology is reshaping the landscape, addressing challenges, and enhancing the precision of medical treatments.
- [Calquence (Acalabrutinib) Receives Priority Review in the US for Untreated Mantle Cell Lymphoma Patients](https://www.clinicaltrialvanguard.com/news/calquence-acalabrutinib-receives-priority-review-in-the-us-for-untreated-mantle-cell-lymphoma-patients/) - AstraZeneca's CALQUENCE (acalabrutinib) has received Priority Review designation from the FDA for treating untreated adult patients with mantle cell lymphoma (MCL). This review status is reserved for drugs that offer substantial improvements over existing therapies. MCL is an aggressive form of non-Hodgkin lymphoma that affects over 27,500 people worldwide. It is often diagnosed in advanced
- [DeepCure Presents Breakthrough Data: DC-9476 Triumphs over Etanercept in Rheumatoid Arthritis Battle](https://www.clinicaltrialvanguard.com/news/deepcure-presents-breakthrough-data-dc-9476-triumphs-over-etanercept-in-rheumatoid-arthritis-battle/) - DeepCure, a biotechnology company, has unveiled promising data on its selective BRD4 (BD2) inhibitor, DC-9476. Preclinical studies indicate its superiority to existing anti-TNF-α treatments in a rheumatoid arthritisarthritis (RA) mouse model. Activated macrophages play a crucial role in RA. They release inflammatory cytokines such as TNF-α, IL-1β, and IL-6, leading to joint damage and symptoms.
- [Allele-Selective Therapies for Rare Genetic Disorders: Regulatory Challenges and Solutions](https://www.clinicaltrialvanguard.com/news/allele-selective-therapies-for-rare-genetic-disorders-regulatory-challenges-and-solutions/) - Recent advances in genetic sequencing have identified an increasing number of rare heterozygous toxic gain-of-function (TGOF) mutations. These mutations pose significant challenges in developing therapies due to the need for allele-selective approaches that target only the mutant allele. Antisense oligonucleotide (ASO) technology offers a promising solution for allele-selective targeting. However, clinical trials for TGOF patients
- [Humanetics Corp. Wows at 2024 DoD Scientific Meeting: A Testimony to Enduring Innovation](https://www.clinicaltrialvanguard.com/news/humanetics-corp-wows-at-2024-dod-scientific-meeting-a-testimony-to-enduring-innovation/) - Humanetics Corporation presented updates on the progress of BIO 300, an orally administered drug designed to prevent radiation toxicity in military personnel. The presentation was made at the 2024 Military Health System Research Symposium. BIO 300 was initially developed as a radioprotectant by the Armed Forces Radiobiology Research Institute. Humanetics holds an exclusive license for
- [U.S. FDA Approves Opdivo® for Resectable Non-Small Cell Lung Cancer](https://www.clinicaltrialvanguard.com/news/u-s-fda-approves-opdivo-for-resectable-non-small-cell-lung-cancer/) - The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for treating adults with resectable non-small cell lung cancersmall cell lung cancer (NSCLC). The regimen combines neoadjuvant therapy with platinum-doublet chemotherapy followed by adjuvant Opdivo treatment after surgery. The approval stems from the CheckMate-77T trial, where the Opdivo-based regimen significantly extended event-free survival compared
- [ACTICOR Biotech Secures Receivership Extension for Glenzocimab Development](https://www.clinicaltrialvanguard.com/news/acticor-biotech-secures-receivership-extension-for-glenzocimab-development/) - The Paris Commercial Court has granted an extension of receivership proceedings for ACTICOR Biotech, a biopharmaceutical company focused on cardiovascular emergencies. The receivership aims to facilitate the company's efforts to secure financing, seek partners, and continue the development of its drug, glenzocimab. This extension provides ACTICOR with financial support to operate until January 2025. Glenzocimab
- [Summit Therapeutics: Remarkable Results in Phase III HARMONI Trial for Lung Cancer](https://www.clinicaltrialvanguard.com/news/summit-therapeutics-remarkable-results-in-phase-iii-harmoni-trial-for-lung-cancer/) - Summit Therapeutics has completed enrollment in the multi-regional Phase III HARMONi trial, evaluating ivonescimab in combination with chemotherapy for patients with EGFR-mutated, locally advanced, or metastatic non-small cell lung cancersmall cell lung cancer (NSCLC). This patient population has historically shown poor response to PD-1 antibodies. The U.S. Food and Drug Administration (FDA) has granted Fast
- [New HPV Vaccine Trial Gives Hope to Cancer Patients](https://www.clinicaltrialvanguard.com/news/new-hpv-vaccine-trial-gives-hope-to-cancer-patients/) - TheraVectys, a biotechnology company specializing in lentiviral vector-based vaccines and immunotherapies, has begun enrolling patients in a Phase I/IIa clinical trial to evaluate the efficacy and safety of Lenti-HPV-07, a therapeutic vaccine targeting human papillomavirus (HPV)-induced cancers. The trial employs a dose-escalation protocol and will involve 36 patients with HPV-16 or HPV-18-induced oropharyngeal or cervical
- [Airsupra Reduces Severe Asthma Attacks: A Game-Changer for Patients](https://www.clinicaltrialvanguard.com/news/airsupra-reduces-severe-asthma-attacks-a-game-changer-for-patients/) - A clinical trial (BATURA) has shown the efficacy of AstraZenaca's AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. AIRSUPRA, an inhaled anti-inflammatory rescue medication, was tested against albuterol alone in patients with intermittent or mild persistent asthma, including those taking maintenance therapy. The trial met its primary endpoint, demonstrating a statistically significant reduction
- [Verastem Presents Positive Updated Data for Atutometinib](https://www.clinicaltrialvanguard.com/news/verastem-presents-positive-updated-data-for-atutometinib/) - Verastem Oncology, a company dedicated to developing cancer treatments, has released promising data from its Phase 2 RAMP 201 clinical trial. This trial examines the effectiveness of combining avutometinib (a RAF/MEK clamp) and defactinib (a FAK inhibitor) in patients with recurrent low-grade serous ovarian cancer (LGSOC). The trial demonstrated a 31% overall response rate in
- [Resposne Pharmaceuticals Initates RDX-002 Phase 2 Study Weight management](https://www.clinicaltrialvanguard.com/news/resposne-pharmaceuticals-initates-rdx-002-phase-2-study-weight-management/) - Response Pharmaceuticals, a clinical-stage company specializing in weight management and metabolic health, has begun enrolling participants in a Phase 2 trial. This trial will evaluate their drug candidate, RDX-002, for its effectiveness in addressing weight rebound experienced by individuals after discontinuing GLP-1 agonist treatment for obesity. RDX-002 operates by inhibiting intestinal microsomal triglyceride transfer protein
- [Gilead and Merck Announce Phase 2 Islatravir and Lenacapavir Data](https://www.clinicaltrialvanguard.com/news/gilead-and-merck-announce-phase-2-islatravir-and-lenacapavir-data/) - Gilead Sciences and Merck have announced positive results from a Phase 2 clinical trial investigating a novel combination therapy for HIV. The trial evaluated the effectiveness of weekly oral doses of islatravir, an experimental nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. The study involved 104 adults with suppressed HIV who
- [Oncoprism® Earns Medicare Coverage: Predicting Immunotherapy Response](https://www.clinicaltrialvanguard.com/news/oncoprism-earns-medicare-coverage-predicting-immunotherapy-response/) - Cofactor Genomics, a clinical-stage company focused on RNA analysis for precision medicine, has received national coverage from Medicare contractor Palmetto GBA for its OncoPrism test. This predictive diagnostic tool analyzes a patient's tumor immune profile using high-dimensional RNA-based Health Expression Models (HEMs). It predicts a patient's response to immune checkpoint inhibitor (ICI) immunotherapy, leading to
- [ArteraAI Prostate Test Now Accessible in CA](https://www.clinicaltrialvanguard.com/news/arteraai-prostate-test-now-accessible-in-ca/) - Artera, a company specializing in AI-powered cancer tests, has received a license from the California Department of Public Health, allowing them to offer their ArteraAI Prostate Test in California. This makes the test accessible in one of the biggest healthcare markets in the United States. The ArteraAI Prostate Test is unique in its ability to
- [New Study Links Antidepressant Use to Muscle Health and Cardiometabolic Risk](https://www.clinicaltrialvanguard.com/news/new-study-links-antidepressant-use-to-muscle-health-and-cardiometabolic-risk/) - A recent study from AMRA Medical and the University of Oslo sheds light on the impact of antidepressants, specifically SSRIs and TCAs, on muscle health and cardiometabolic risk. This research is particularly relevant given the rising global use of antidepressants and their potential adverse effects. The study, conducted as part of the CoMorMent project, analyzed
- [Gilead Unveils Latest Liver Disease Research at AASLD 2024](https://www.clinicaltrialvanguard.com/news/gilead-unveils-latest-liver-disease-research-at-aasld-2024/) - Gilead Sciences is set to present over 40 research abstracts at The Liver Meeting® 2024, highlighting its commitment to advancing liver disease research. A significant portion of these presentations will focus on new data for primary biliary cholangitis (PBC), including findings from the RESPONSE trial showcasing the efficacy and safety of Livdelzi® (seladelpar) in patients
- [FDA Approves Pfizer's Abrysvo RSV Vaccine for Adults](https://www.clinicaltrialvanguard.com/news/fda-approves-pfizers-abrysvo-rsv-vaccine-for-adults/) - Pfizer recently received approval from the U.S. Food and Drug Administration (FDA) for ABRYSVO®, its respiratory syncytial virus (RSV) vaccine. This approval expands the vaccine's use to individuals between 18 and 59 years old with an elevated risk of RSV-related lower respiratory tract disease (LRTD). ABRYSVO is now the most broadly applicable RSV vaccine for
- [OPM-101 RIPK2 Inhibitor Shows Strong Safety, No Cardiac Toxicity in Phase 1 Study](https://www.clinicaltrialvanguard.com/news/opm-101-ripk2-inhibitor-shows-strong-safety-no-cardiac-toxicity-in-phase-1-study/) - Oncodesign Precision Medicine (OPM) has announced the successful completion of its Phase 1 clinical trial for OPM-101, an orally administered RIPK2 inhibitor. The trial began in February 2023 and concluded in October 2024 and involved 104 healthy volunteers. The study was divided into two parts: single ascending dose (SAD) and multiple ascending dose (MAD). In
- [Nanoknife® System's Long-Term Effects Studied in New Trial](https://www.clinicaltrialvanguard.com/news/nanoknife-systems-long-term-effects-studied-in-new-trial/) - AngioDynamics, a medical technology company specializing in vascular health and cancer treatment, has initiated a global registry study to assess the long-term effectiveness of the NanoKnife System in treating men with intermediate-risk prostate cancer. This study is being conducted in collaboration with University College London Hospital (UCLH), a leading institution in robotic prostate surgery and
- [Predicting First-Line Incontinence Treatment Success in Women](https://www.clinicaltrialvanguard.com/news/predicting-first-line-incontinence-treatment-success-in-women/) - Researchers have developed a potential machine learning model that could personalize treatments for female pelvic floor disorders, specifically urinary incontinence. Based on an analysis of over 600 patients, this model utilizes data such as demographics, initial symptoms, and information gathered from the Leva® Pelvic Health System within the first 14 days of use. The researchers
- [Precision Biosciences Announces First-in-Human Study for Chronic Hepatitis B Treatment](https://www.clinicaltrialvanguard.com/news/precision-biosciences-announces-first-in-human-study-for-chronic-hepatitis-b-treatment/) - Precision BioSciences, a clinical-stage gene editing company, has announced a significant advancement in its quest to cure chronic hepatitis B. The company has received Clinical Trial Application (CTA) approval in Moldova for its lead candidate, PBGENE-HBV, marking a pivotal step towards a potential cure for the nearly 300 million individuals globally affected by this chronic
- [Dermavant Unveils VTAMA Cream Data for Atopic Dermatitis](https://www.clinicaltrialvanguard.com/news/dermavant-unveils-vtama-cream-data-for-atopic-dermatitis/) - Dermavant Sciences has released promising data from their ADORING 3 study, highlighting the effectiveness of VTAMA cream, 1% in treating atopic dermatitis (AD), also known as eczema. The open-label, long-term extension study involved adults and children as young as two years old. Results demonstrated high rates of complete skin clearance and significant treatment-free intervals. Over
- [Leo Pharma Presents Long-Term Adbry® Trial Results at Fall Clinical 2024](https://www.clinicaltrialvanguard.com/news/leo-pharma-presents-long-term-adbry-trial-results-at-fall-clinical-2024/) - LEO Pharma Inc., a leader in medical dermatology, announced the final results of ECZTEND, a five-year study on Adbry® (tralokinumab-ldrm). The study, presented at the Fall Clinical Dermatology Conference in Las Vegas, demonstrated the long-term safety and efficacy of Adbry® in treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents. ECZTEND, a Phase 3, open-label,
- [Unpacking FDA Guidance on Digital Health Technologies in Clinical Trials](https://www.clinicaltrialvanguard.com/article/unpacking-fda-guidance-on-digital-health-technologies-in-clinical-trials/) - Digital Health Technologies (DHTs) use in clinical research is no longer a futuristic concept—it’s quickly becoming the norm. Recognizing this shift, the FDA issued comprehensive guidance in 2023 on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. This guidance sets critical standards for validating, deploying, and monitoring these tools in clinical trials. The
- [How to Alleviate Clinical Trial Burden at Study Sites](https://www.clinicaltrialvanguard.com/executiveinterviews/how-to-alleviate-clinical-trial-burden-at-study-sites/) - Addressing recruitment challenges for underrepresented populations: proofpilot eases connectivity and educates patients prior to consent.
- [Boomi, Base Life Science Partner to Boost Digital Transformation](https://www.clinicaltrialvanguard.com/news/boomi-base-life-science-partner-to-boost-digital-transformation/) - Boomi, a leader in intelligent integration and automation, has partnered with BASE Life Science, an Infosys company specializing in cloud-based solutions for the life sciences industry. This partnership expands on Boomi’s existing relationship with Infosys and strengthens integration capabilities for organizations transitioning from outdated technologies to the Veeva Vault Platform. This collaboration aligns with Boomi's
- [Organon Completes Acquisition of Dermavant](https://www.clinicaltrialvanguard.com/news/organon-completes-acquisition-of-dermavant/) - Organon, a global healthcare company focused on women's health, has finalized its acquisition of Dermavant Sciences Ltd. from Roivant. This strategic move bolsters Organon's dermatology offerings with the addition of VTAMA® (tapinarof) cream, 1%, a novel topical treatment for plaque psoriasis in adults. VTAMA, a non-biologic, non-steroidal therapy, stands out for its favorable safety profile,
- [Lucent Diagnostics' New Blood Test for Early Alzheimer's Diagnosis](https://www.clinicaltrialvanguard.com/news/lucent-diagnostics-new-blood-test-for-early-alzheimers-diagnosis/) - Lucent Diagnostics has launched LucentAD Complete, a novel multi-marker blood test designed to enhance the detection of Alzheimer’s Disease (AD). This test addresses limitations of existing diagnostic methods, particularly the uncertainty associated with the “intermediate zone” in single-marker tests like plasma p-Tau 217. LucentAD Complete analyzes five AD-related biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP) using
- [Synedgen Gets $2.2M for Radiation Countermeasure](https://www.clinicaltrialvanguard.com/news/synedgen-gets-2-2m-for-radiation-countermeasure/) - Synedgen, Inc., a biotechnology company specializing in gastrointestinal disease treatment, has secured a $2.2 million contract from the Joint Warfighter Medical Research Program (JWMRP). The funding will support the development of MIIST305, a promising therapeutic, as a preventative measure against radiation exposure. This builds upon previous research and development of MIIST305 for radiation mitigation and
- [Verastem Oncology NDAs Avutometinib for Ovarian Cancer](https://www.clinicaltrialvanguard.com/news/verastem-oncology-ndas-avutometinib-for-ovarian-cancer/) - Verastem Oncology has completed its New Drug Application (NDA) to the U.S. FDA for a combination therapy targeting recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). This investigational treatment combines avutometinib, an oral RAF/MEK clamp, and defactinib, an oral selective FAK inhibitor, and is intended for adults who have undergone at least one prior systemic
- [Koru Medical Systems Data at PODD Conference: Nursing Preference for FreedomEdge® Infusion System](https://www.clinicaltrialvanguard.com/news/koru-medical-systems-data-at-podd-conference-nursing-preference-for-freedomedge-infusion-system/) - KORU Medical Systems presented data at the 2024 PODD Conference showcasing nurse preference for the KORU FreedomEdge® Infusion System in administering subcutaneous oncology infusions. The study, conducted across six Danish hospitals, involved 33 nurses administering over 3,000 infusions of an oncology drug exceeding 10mL in volume, with an average administration time of around 10 minutes.
- [Cobenfy™ Long-Term Schizophrenia Data Presented at Psych Congress 2024](https://www.clinicaltrialvanguard.com/news/cobenfy-long-term-schizophrenia-data-presented-at-psych-congress-2024/) - Bristol Myers Squibb recently unveiled positive topline results from two Phase 3 open-label trials, EMERGENT-4 and EMERGENT-5. These trials assessed the long-term efficacy, safety, and tolerability of COBENFY (xanomeline and trospium chloride) in adults with schizophrenia over a 52-week treatment period. The data were presented at the 2024 Psych Congress in Boston. EMERGENT-4, a 52-week
- [Scholar Rock to Present New Data from Phase 1 DRAGON Trial at SITC](https://www.clinicaltrialvanguard.com/news/scholar-rock-to-present-new-data-from-phase-1-dragon-trial-at-sitc/) - Scholar Rock, a late-stage biopharmaceutical company specializing in treatments for serious diseases like spinal muscular atrophy (SMA), cardiometabolic disorders, and cancer, will present data from its Phase 1 DRAGON trial of SRK-181 at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation, scheduled for November 9th, 2024, will focus on updated safety,
- [Sunbird Bio's Blood Test Accurately Diagnoses Parkinson's](https://www.clinicaltrialvanguard.com/news/sunbird-bios-blood-test-accurately-diagnoses-parkinsons/) - Sunbird Bio, a biotechnology company focused on neurological disorders and early-stage cancer diagnostics, has unveiled promising data regarding its blood-based alpha-synuclein (α-synuclein) test. This test accurately detects aggregated α-synuclein in the brain through a simple blood draw, potentially offering a groundbreaking diagnostic tool for Parkinson’s disease and other neurodegenerative conditions. These findings were presented at
- [Mood Bloom™ Delivers ROI in New Economic Study](https://www.clinicaltrialvanguard.com/news/mood-bloom-delivers-roi-in-new-economic-study/) - Hedonia, a mobile mental health solutions provider, has released promising findings from a recent economic model. The study, conducted in collaboration with Arbital Health, indicates a potential 5:1 return on investment (ROI) for employers, payers, and healthcare providers utilizing Hedonia's digital therapeutic app, Mood Bloom. Designed to treat depression and anxiety, Mood Bloom leverages a
- [CINFINA Pharma Unveils Promising Phase 1 Obesity Drug Data at ObesityWeek® 2024](https://www.clinicaltrialvanguard.com/news/cinfina-pharma-unveils-promising-phase-1-obesity-drug-data-at-obesityweek-2024/) - CinFina Pharma, a CinRx portfolio company focused on obesity treatments, has released promising interim data from a Phase 1 single ascending dose (SAD) study of CIN-110 and final data from a multiple ascending dose (MAD) study of CIN-109. Both treatments demonstrated tolerability and significant weight loss. CIN-110, a long-acting PYY3-36 analog, is designed to minimize
- [MedinCell & Teva: Olanzapine LAI Phase 3 Positive, Uzedy Real-World Data](https://www.clinicaltrialvanguard.com/news/medincell-teva-olanzapine-lai-phase-3-positive-uzedy-real-world-data/) - Medincell's long-acting injectable technology, BEPO®, has achieved commercial success with its first product, UZEDY® (risperidone LAI), for treating schizophrenia in adults. Approved by the FDA in April 2023 and launched by Teva the following month, UZEDY demonstrates high adherence rates, particularly among patients with unmet social needs, according to real-world data analysis. This analysis examined
- [Scholar Rock Announces Preclinical Data for SRK-439](https://www.clinicaltrialvanguard.com/news/scholar-rock-announces-preclinical-data-for-srk-439/) - Scholar Rock, a late-stage biopharmaceutical company, has released promising preclinical data for SRK-439, an investigational anti-myostatin antibody. The data suggest SRK-439 can increase lean mass and decrease fat mass gain when combined with metformin. These findings were presented at the ObesityWeek conference in San Antonio, Texas. The preclinical study utilized a diet-induced obesity mouse model.
- [Allurion's Obesity Data from 19,428 Patients Revealed](https://www.clinicaltrialvanguard.com/news/allurions-obesity-data-from-19428-patients-revealed/) - Allurion Technologies, a company focused on combating obesity, presented two abstracts at Obesity Week 2024. The first abstract showcased real-world data from their largest cohort to date. Data collected from 19,428 patients across 72 countries between 2018 and 2023, utilizing the Allurion Program and tracked via the Allurion Virtual Care Suite, demonstrated an average total
- [Vertex Reports Strong Q3 2024 Financial Results](https://www.clinicaltrialvanguard.com/news/vertex-reports-strong-q3-2024-financial-results/) - Vertex Pharmaceuticals reported strong third-quarter 2024 financial results and raised its full-year product revenue guidance. The company anticipates continued growth driven by existing products and upcoming launches. Third-quarter product revenue reached $2.77 billion, a 12% increase compared to the same period in 2023. This growth was primarily fueled by the consistent performance of TRIKAFTA/KAFTRIO. U.S.
- [Enveric Biosciences: Broad Range of Patents Issued](https://www.clinicaltrialvanguard.com/news/enveric-biosciences-broad-range-of-patents-issued/) - Enveric Biosciences, a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, has significantly expanded its patent protection. Five new US patents have been issued, and three more applications have been allowed by the United States Patent and Trademark Office, bolstering the intellectual property surrounding the company's EVM301 portfolio. This portfolio comprises a wide
- [Immunis Studies Canine Muscle Atrophy](https://www.clinicaltrialvanguard.com/news/immunis-studies-canine-muscle-atrophy/) - Immunis, a clinical-stage biotech company, has launched non-terminal safety studies for canine muscle atrophy in partnership with VetBio Partners. This STEM-K9 program builds upon preclinical success observed in aged mouse models using Immunis' investigational secretome (IMM01-STEM) and complements ongoing human clinical trials for STEM-MYO and STEM-META programs. The company aims to improve mobility and quality
- [How Johnson & Johnson is Innovating its Organizational Infrastructure](https://www.clinicaltrialvanguard.com/conference-coverage/how-johnson-johnson-is-innovating-its-organizational-infrastructure/) - At DPHARM 2024, Johnson & Johnson's representatives, Gordon Gregory III, and Laszlo Vasko, unveiled their transformative "Team of Teams" approach to clinical development. This innovative strategy, supported by advanced automation and integrated workflows, aims to revolutionize the development of oncology compounds. By addressing the inefficiencies of traditional communication methods, Johnson & Johnson seeks to enhance
- [Exact Sciences Q3 2024 Results: Surprising Growth](https://www.clinicaltrialvanguard.com/news/exact-sciences-q3-2024-results-surprising-growth/) - Exact Sciences Corp. (Nasdaq: EXAS), a prominent cancer screening and diagnostics company, reported third-quarter 2024 revenue of $709 million, a 13% increase compared to $628 million in the same quarter of 2023. This growth was driven by increased test volume, reaching more patients than in any previous quarter. However, the company acknowledged that third-quarter performance
- [Acadia Sells Rare Pediatric Disease Voucher for $150M](https://www.clinicaltrialvanguard.com/news/acadia-sells-rare-pediatric-disease-voucher-for-150m/) - Acadia Pharmaceuticals has finalized an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The sale is expected to close after fulfilling standard closing conditions, including the waiting period mandated by the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Acadia received this PRV in March 2023 following FDA approval of DAYBUE™
- [Alzheimer's Drugs Market to Hit $9.2B by 2030: Global Overview & CAGR](https://www.clinicaltrialvanguard.com/news/alzheimers-drugs-market-to-hit-9-2b-by-2030-global-overview-cagr/) - The global market for Alzheimer's drugs is poised for significant growth, projected to reach $9.2 billion by 2030, reflecting a robust 9.9% compound annual growth rate (CAGR) from its 2024 value of $5.2 billion. This expansion is primarily driven by the increasing prevalence of Alzheimer's disease, a consequence of the aging global population and extended
- [Viridian Therapeutics Grants Inducement Awards](https://www.clinicaltrialvanguard.com/news/viridian-therapeutics-grants-inducement-awards/) - Viridian Therapeutics, a Nasdaq-listed biopharmaceutical company (VRDN), granted stock options to six new employees on November 1, 2024. These options, totaling 150,600 shares of common stock, are considered inducement grants designed to attract these individuals to Viridian. While outside the company's standard equity incentive plan, the grants adhere to its terms and conditions and comply
- [DPHARM Follow the Money: Investor Insights on Technology Investment in Clinical Trials](https://www.clinicaltrialvanguard.com/conference-coverage/dpharm-follow-the-money-investor-insights-on-technology-investment-in-clinical-trials/) - Explore the challenges and growth opportunities in the clinical trial industry, highlighted by key panelists at the DPHARM conference.
- [Gilead Sciences Announces Strong Q3 2024 Results](https://www.clinicaltrialvanguard.com/news/gilead-sciences-announces-strong-q3-2024-results/) - Gilead Sciences reported third-quarter solid 2024 financial results, with a 7% year-over-year increase in total product sales, reaching $7.5 billion. Excluding Veklury, product sales grew by 7%, totaling $6.8 billion. This growth was primarily attributed to increased sales in HIV, Oncology, and Liver Disease. HIV product sales reached $5.1 billion, a 9% increase in the
- [Janux Therapeutics Q3 2024 Financial Results & Highlights](https://www.clinicaltrialvanguard.com/news/janux-therapeutics-q3-2024-financial-results-highlights/) - Janux Therapeutics, a clinical-stage biopharmaceutical company, recently announced its third-quarter 2024 financial results and provided a business update. The company focuses on developing novel immunotherapies using its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. The company's primary focus is enrolling participants in clinical trials for its two lead candidates:
- [Sarepta Q3 2024: Financial Results & Developments](https://www.clinicaltrialvanguard.com/news/sarepta-q3-2024-financial-results-developments/) - Sarepta Therapeutics reported strong third-quarter 2024 financial results, marked by a significant revenue increase and positive net income. Net product revenue reached $429.8 million, a 39% year-over-year surge. This growth is largely attributed to the successful launch and expanded label of ELEVIDYS, their gene therapy for Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD). ELEVIDYS alone generated
- [How High Interest Rates Are Impacting Clinical Trial Investment](https://www.clinicaltrialvanguard.com/conference-coverage/how-high-interest-rates-are-impacting-clinical-trial-investment/) - The DPHARM 2024 conference recently convened a panel of industry leaders to discuss the alignment of innovations to address the significant challenges in clinical trials, particularly within a resource-constrained environment. The panel, moderated by Nick Slack, Chairman and CEO of The START Center, included representatives from major pharmaceutical companies, CROs, and investment firms. They provided
- [Alzheimer’s Trials and Others See More Diversity When Technology and Humans Work Together](https://www.clinicaltrialvanguard.com/article/alzheimers-trials-and-others-see-more-diversity-when-technology-and-humans-work-together/) - Clinical trial sponsors are facing mounting pressure to secure trial participants that more closely reflect the diverse populations affected by their treatments, but are still struggling to do so. This isn’t an issue that only affects some pharmaceutical companies or that’s only present when trialing some health conditions. At the very highest level, trials simply
- [Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial](https://www.clinicaltrialvanguard.com/news/tezspire-meets-co-primary-endpoints-in-phase-3-waypoint-trial/) - A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The randomized, double-blind trial demonstrated that TEZSPIRE significantly reduced nasal polyp size and nasal congestion compared to a placebo in adults with severe CRSwNP. Participants were symptomatic despite receiving standard intranasal corticosteroid
- [Neurogene Reports Positive Interim Data from NGN-401 Gene Therapy Clinical Trial for Rett Syndrome](https://www.clinicaltrialvanguard.com/news/neurogene-reports-positive-interim-data-from-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome/) - Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett syndrome in female pediatric patients. The low-dose cohort demonstrated a favorable safety profile and meaningful skills and developmental milestones improvements. These improvements were consistent across multiple assessment scales and exceeded expectations based on the natural progression
- [GenSight Submits Lumevoq® Dossier to ANSM for Early Access Program Restart](https://www.clinicaltrialvanguard.com/news/gensight-submits-lumevoq-dossier-to-ansm-for-early-access-program-restart/) - GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French medicines safety agency (ANSM). This submission paves the way for the restart of the early access program in France. The company successfully manufactured LUMEVOQ®, blending two GMP drug substance batches to maximize available clinical vials and pass all necessary
- [Diamedica Doses First Patient in DM199 Preeclampsia Trial](https://www.clinicaltrialvanguard.com/news/diamedica-doses-first-patient-in-dm199-preeclampsia-trial/) - DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has initiated its Phase 2 investigator-sponsored trial for DM199, a potential preeclampsia (PE) treatment. The company anticipates initial results in the first half of 2025. This part of the study aims to establish DM199's safety profile and ability to reduce blood pressure. For patients experiencing early-onset PE, researchers
- [Tae Life Sciences & Stella Pharma Announce BPA Strategic Agreement](https://www.clinicaltrialvanguard.com/news/tae-life-sciences-stella-pharma-announce-bpa-strategic-agreement/) - TAE Life Sciences (TLS), a prominent developer of boron neutron capture therapy (BNCT) technology and related boron target drugs, and Stella Pharma, the developer of the boronophenylalanine (BPA) drug Steboronine® for BNCT, have announced a strategic collaboration. This partnership focuses on developing, commercializing, and expanding BNCT using BPA within the United States and European markets.
- [Omeros Corp. Q3 2024 Financial Results](https://www.clinicaltrialvanguard.com/news/omeros-corp-q3-2024-financial-results/) - Omeros Corporation recently announced its third-quarter 2024 financial results and provided updates on its clinical development programs. The company anticipates resubmitting its Biologics License Application (BLA) for narsoplimab in Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (TA-TMA) following a productive pre-submission meeting with the FDA in September. Minor revisions to the analysis plan, requested by the
- [Quince Therapeutics Q3 2024 Results & Business Update](https://www.clinicaltrialvanguard.com/news/quince-therapeutics-q3-2024-results-business-update/) - Quince Therapeutics, a late-stage biotechnology company focused on treating rare diseases, provided a pipeline update and financial results for the third quarter of 2024. The company highlighted progress in its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T). As of the announcement date, 32 patients with A-T were enrolled across U.S., U.K., and EU
- [Koru Medical Systems Announces Q3 2024 Financial Results, Raises Guidance](https://www.clinicaltrialvanguard.com/news/koru-medical-systems-announces-q3-2024-financial-results-raises-guidance/) - KORU Medical Systems, Inc. reported strong third-quarter 2024 financial results and raised its full-year 2024 guidance for revenue, gross margin, and year-end cash. The company achieved $8.2 million in revenue, marking the third consecutive quarter of double-digit growth. This growth was accompanied by improved gross margin and operating leverage. The company attributes its success to
- [Global Healthy Living Foundation Brings Innovative Research to ACR 2024](https://www.clinicaltrialvanguard.com/news/global-healthy-living-foundation-brings-innovative-research-to-acr-2024/) - The Global Healthy Living Foundation (GHLF) presented groundbreaking research at the 2024 American College of Rheumatology (ACR) Convergence in Washington DC, marking their ninth consecutive year and coinciding with PatientSpot's 10th anniversary. This patient-powered research registry, formerly known as ArthritisPower, underscores GHLF's commitment to improving care for individuals with chronic inflammatory diseases. This year's presentations
- [Cancer Patient Rights: Expanding Lifesaving Care in Illinois](https://www.clinicaltrialvanguard.com/news/cancer-patient-rights-expanding-lifesaving-care-in-illinois/) - A coalition of prominent cancer organizations, alongside Illinois lawmakers, is advocating for the Illinois Cancer Patients Bill of Rights. This resolution asserts that all Illinois residents diagnosed with cancer deserve access to innovative treatments, advanced care centers, and comprehensive support, regardless of their socioeconomic status. The Cancer Care is Different Coalition, spearheaded by City of
- [Lineage Cell Therapeutics Q3 2024 Results & Update](https://www.clinicaltrialvanguard.com/news/lineage-cell-therapeutics-q3-2024-results-update/) - Lineage Cell Therapeutics announced its third quarter 2024 financial and operating results, highlighting progress in its allogeneic cell therapy programs. A key achievement was the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for OpRegen, a retinal pigment epithelial cell therapy being developed in collaboration with Roche and Genentech for geographic atrophy secondary to age-related macular
- [Zura Bio Submits Scleroderma Drug Protocol for FDA Phase 2 Study](https://www.clinicaltrialvanguard.com/news/zura-bio-submits-scleroderma-drug-protocol-for-fda-phase-2-study/) - Zura Bio, a clinical-stage immunology company, has submitted a Phase 2 study protocol to the FDA for tibulizumab. This drug is a novel dual-action antibody designed to treat systemic sclerosis (SSc) in adults by neutralizing both IL-17A and BAFF. The company believes this dual-pathway approach can address both immune system dysfunction and fibrosis, two key
- [CHMP Positive on Opdivo + Yervoy for MSI-H/dMMR mCRC](https://www.clinicaltrialvanguard.com/news/chmp-positive-on-opdivo-yervoy-for-msi-h-dmmr-mcrc/) - Bristol Myers Squibb (BMS) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Opdivo (nivolumab) combined with Yervoy (ipilimumab) as a first-line treatment. This treatment targets adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC). The CheckMate
- [VIR Biotech HBV Combination Therapy Shows Promise in March Study](https://www.clinicaltrialvanguard.com/news/vir-biotech-hbv-combination-therapy-shows-promise-in-march-study/) - Vir Biotechnology announced positive end-of-treatment results from Part B of its MARCH Phase 2 clinical study. This study is evaluating combinations of tobevibart and elebsiran, with and without pegylated interferon alfa (PEG-IFNα), for chronic hepatitis B. The study showed promising hepatitis B surface antigen (HBsAg) loss (seroclearance) rates in participants with low baseline HBsAg (
- [Boston Pharmaceuticals Positive Phase 2 NASH Data at AASLD 2024](https://www.clinicaltrialvanguard.com/news/boston-pharmaceuticals-positive-phase-2-nash-data-at-aasld-2024/) - Boston Pharmaceuticals announced positive Phase 2 study results for efimosfermin alfa, a long-acting FGF21 analogue, in patients with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). The once-monthly treatment showed significant fibrosis improvement without worsening MASH, and MASH resolution without worsening fibrosis over 24 weeks, alongside a favorable tolerability profile. These findings will be
- [Innate Pharma's Next-Gen ANKET® IPH6501 Highlighted in Science Immunology](https://www.clinicaltrialvanguard.com/news/innate-pharmas-next-gen-anket-iph6501-highlighted-in-science-immunology/) - Innate Pharma announced preclinical data demonstrating the potential of IPH6501, its proprietary NK cell engager, for B-cell non-Hodgkin lymphoma (B-NHL). In a Phase 1/2 clinical trial, IPH6501, also known as CD20-NKCE-IL2v, enhances NK cell proliferation and cytotoxicity. It has shown activity against various B-NHL cell lines, even those with low CD20 density. In vivo studies
- [Silence Therapeutics Unveils Groundbreaking Zerlasiran Phase 2 Data at AHA 2024](https://www.clinicaltrialvanguard.com/news/silence-therapeutics-unveils-groundbreaking-zerlasiran-phase-2-data-at-aha-2024/) - Silence Therapeutics recently unveiled end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, an siRNA therapy, in individuals with atherosclerotic cardiovascular disease (ASCVD) and high lipoprotein(a) [Lp(a)] levels. The findings were presented at the American Heart Association Scientific Sessions 2024 and concurrently published in JAMA. The study explored the efficacy of various zerlasiran dosages
- [ADICET Opens ADI-270 Phase 1 Trial Enrollment for Metastatic Renal Cell Carcinoma](https://www.clinicaltrialvanguard.com/news/adicet-opens-adi-270-phase-1-trial-enrollment-for-metastatic-renal-cell-carcinoma/) - Adicet Bio has initiated a Phase 1 clinical trial for ADI-270, a novel cancer therapy. This trial focuses on patients with advanced clear cell renal cell carcinoma (ccRCC), a prevalent and aggressive kidney cancer subtype. Solid tumors, like ccRCC, have yet to experience the same therapeutic advancements as blood cancers treated with CAR T cell
- [EMA Grants Orphan Drug Designation to Tobevibart and Elebsiran for Chronic Hepatitis Delta](https://www.clinicaltrialvanguard.com/news/ema-grants-orphan-drug-designation-to-tobevibart-and-elebsiran-for-chronic-hepatitis-delta/) - Vir Biotechnology announced a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) regarding orphan drug designation for tobevibart and elebsiran. These medications are intended for the treatment of chronic hepatitis delta (CHD). This positive opinion stems from promising preliminary Phase 2 SOLSTICE trial data. Twenty-four-week data from this trial
- [Otsuka Provides Sibeprenlimab Update for IgA Nephropathy](https://www.clinicaltrialvanguard.com/news/otsuka-provides-sibeprenlimab-update-for-iga-nephropathy/) - Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical Co., Ltd. plan to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sibeprenlimab in the first half of 2025. This investigational drug aims to treat immunoglobulin A nephropathy (IgA nephropathy) in adults. This decision follows a positive interim
- [AgelessRx Enters Sleep Health Market](https://www.clinicaltrialvanguard.com/news/agelessrx-enters-sleep-health-market/) - AgelessRx, a leading telehealth platform specializing in longevity, has expanded its services to include sleep health. Recognizing the crucial role of sleep in overall well-being and longevity, the company now offers personalized sleep treatment plans incorporating lifestyle recommendations, prescription medication, and over-the-counter supplements. This expansion builds upon AgelessRx's commitment to proactive healthcare and redefining aging.
- [Asimov, Revopsis Sign Licensing Deal for Multispecific-Expressing Cell Line](https://www.clinicaltrialvanguard.com/news/asimov-revopsis-sign-licensing-deal-for-multispecific-expressing-cell-line/) - Asimov, a synthetic biology company focused on therapeutic design and manufacturing, has entered into a licensing agreement with RevOpsis Therapeutics. RevOpsis specializes in developing next-generation multispecific biologics for ophthalmic therapies. This partnership stems from a successful cell line development campaign using Asimov's CHO Edge System for RevOpsis’s lead asset, RO-104. The agreement grants RevOpsis the
- [Immunis Achieves Breakthrough in Muscle Atrophy Trial](https://www.clinicaltrialvanguard.com/news/immunis-achieves-breakthrough-in-muscle-atrophy-trial/) - Immunis, Inc., a clinical-stage biotechnology company, has successfully completed a Phase 1/2a clinical trial of IMM01-STEM, a novel multi-active biologic designed to address age and disease-related immune dysregulation. The trial focused on the safety, tolerability, and preliminary efficacy of IMM01-STEM in reversing muscle atrophy in older adults with knee osteoarthritis. Initial data suggest positive outcomes
- [Pfizer Appoints New Chief Scientific Officer](https://www.clinicaltrialvanguard.com/news/pfizer-appoints-new-chief-scientific-officer/) - Pfizer has appointed Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Dr. Boshoff, currently Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten. In this new role, Dr. Boshoff will report to Chairman and CEO Albert Bourla, overseeing all research
- [Real-World Data Addresses Cancer Care Gaps in Older Adults](https://www.clinicaltrialvanguard.com/news/real-world-data-addresses-cancer-care-gaps-in-older-adults/) - COTA, Inc., a real-world data (RWD) and analytics company specializing in oncology, and Memorial Sloan Kettering Cancer Center (MSK) will present data from two Diffuse Large B-Cell LymphomaB-Cell Lymphoma (DLBCL) studies at the 66th American Society of Hematology Annual Meeting (ASH) in December 2024. The studies focus on older DLBCL patients, aiming to improve cancer
- [Alisertib in HR+, HER2- Metastatic Breast Cancer: Phase II Trial Launch](https://www.clinicaltrialvanguard.com/news/alisertib-in-hr-her2-metastatic-breast-cancer-phase-ii-trial-launch/) - Puma Biotechnology initiated its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285). This trial investigates alisertib combined with endocrine therapy for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) recurrent or metastatic breast cancer. The study targets patients previously treated with CDK 4/6 inhibitors and at least two prior lines of endocrine
- [Forte Biosciences Raises $53M to Advance Autoimmune Treatment](https://www.clinicaltrialvanguard.com/news/forte-biosciences-raises-53m-to-advance-autoimmune-treatment/) - Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and related diseases, has raised $53 million in an oversubscribed equity financing. This substantial investment will fuel the continued clinical development of FB-102, a promising anti-CD122 monoclonal antibody therapeutic candidate. The financing attracted significant interest from new and existing investors, including prominent firms like OrbiMed,
- [Laekna and Lilly Partner to Develop Novel Obesity Treatment](https://www.clinicaltrialvanguard.com/news/laekna-and-lilly-partner-to-develop-novel-obesity-treatment/) - Laekna, a global biotechnology company specializing in metabolic and cancer drug development, has partnered with Eli Lilly and Company to expedite the development of LAE102. This novel Activin Receptor Type 2A (ActRIIA) antagonistic monoclonal antibody (mAb) targets muscle-preserving weight loss in individuals with obesity. This collaboration aims to address the global obesity epidemic and improve
- [Northstar & Cellectar Sign Actinium-225 Supply Deal](https://www.clinicaltrialvanguard.com/news/northstar-cellectar-sign-actinium-225-supply-deal/) - NorthStar Medical Radioisotopes and Cellectar Biosciences forged a strategic partnership which centers around the supply of non-carrier-added (n.c.a.) Actinium-225 (Ac-225). NorthStar, a leader in radiopharmaceutical development and production, will provide Cellectar, a clinical-stage biopharmaceutical company focused on cancer treatments, with a secure supply of this crucial radioisotope. Cellectar will integrate the Ac-225 into its Phospholipid
- [Amprion's Landmark Lancet Neurology Study](https://www.clinicaltrialvanguard.com/news/amprions-landmark-lancet-neurology-study/) - A groundbreaking study published in The Lancet Neurology demonstrates the ability of a novel synuclein seed amplification assay (synSAA) to differentiate between Type 1 and Type 2 synuclein seeds. This differentiation allows for significantly improved diagnostic accuracy for multiple system atrophy (MSA), a fatal neurodegenerative disease often misdiagnosed as Parkinson's disease (PD), dementia with Lewy
- [Omeros Corp. BLA Resubmission Update](https://www.clinicaltrialvanguard.com/news/omeros-corp-bla-resubmission-update/) - Narsoplimab, a first-in-class antibody targeting MASP-2, the effector enzyme of the complement lectin pathway, is under development for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Omeros has received feedback from the U.S. Food and Drug Administration (FDA) on its revised statistical analysis plan (SAP) for the biologics license application (BLA) resubmission. No further presubmission information
- [eClinical Solutions: Top Leader in Everest Group's Life Sciences D&A Assessment](https://www.clinicaltrialvanguard.com/news/eclinical-solutions-top-leader-in-everest-groups-life-sciences-da-assessment/) - Everest Group has positioned eClinical Solutions as a Leader in Life Sciences Clinical Data and Analytics Platforms in their 2024 PEAK Matrix® Assessment. The assessment evaluated 18 providers based on market impact, vision, and capability, highlighting eClinical Solutions’ platform, elluminate, for its ability to streamline clinical data management and accelerate drug development. eClinical Solutions achieved
- [Unleashing Patient Insights: Transforming Clinical Trials with Patient Perspectives](https://www.clinicaltrialvanguard.com/conference-coverage/unleashing-patient-insights-transforming-clinical-trials-with-patient-perspectives/) - Integrating patient insights to enhance patient-centric clinical research: challenges, solutions, and innovative approaches discussed by Chiesi at SCOPE Europe 2024
- [Advancing Immunotherapy: Insights from Ymmunobio CEO](https://www.clinicaltrialvanguard.com/executiveinterviews/advancing-immunotherapy-insights-from-ymmunebio-ceo/) - Discover how Ymmunobio revolutionizes targeted therapy for solid tumors at a molecular level.
- [Exelixis Cabozantinib Update for Advanced Neuroendocrine Tumors](https://www.clinicaltrialvanguard.com/news/exelixis-cabozantinib-update-for-advanced-neuroendocrine-tumors/) - Exelixis announced that the FDA will discuss its supplemental New Drug Application for cabozantinib, intended to treat advanced pancreatic and extra-pancreatic neuroendocrine tumors (pNET and epNET), at an Oncologic Drugs Advisory Committee meeting in March 2025. This sNDA is based on the positive results of the Phase 3 CABINET trial, which showed significant improvement in
- [Lantern Pharma & Starlight Therapeutics Present LP-184 Phase 1b Trial Design & Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality](https://www.clinicaltrialvanguard.com/news/lantern-pharma-starlight-therapeutics-present-lp-184-phase-1b-trial-design-preclinical-data-in-glioblastoma-at-society-for-neuro-oncology-sno-2024-highlighting-novel-synthetic-lethality/) - Lantern Pharma, through its subsidiary Starlight Therapeutics, revealed preclinical data and Phase 1b trial designs for LP-184 (STAR-001 for CNS indications) at the 2024 Society for Neuro-Oncology meeting. The drug is being explored for its potential in treating glioblastoma, a challenging brain cancer. The new data highlights the drug's mechanism, ability to penetrate the brain,
- [Lung Cancer Therapy Market 2023-2029: $70.39 Billion Analysis & Growth](https://www.clinicaltrialvanguard.com/news/lung-cancer-therapy-market-2023-2029-70-39-billion-analysis-growth/) - The global lung cancer therapy market, valued at $32.50 billion in 2023, is projected to reach $70.39 billion by 2029, exhibiting a 14% compound annual growth rate. This expansion is driven by the increasing prevalence of lung cancer, advancements in treatment modalities like targeted therapies and immunotherapies, and a growing emphasis on early detection. The
- [Eyoni LCS: AI Lung Cancer Diagnostics at RSNA 2024](https://www.clinicaltrialvanguard.com/news/eyoni-lcs-ai-lung-cancer-diagnostics-at-rsna-2024/) - Median Technologies, a developer of AI-powered medical imaging software, will present its latest advancements at the 2024 Radiological Society of North America (RSNA) annual meeting. The company will showcase its eyonis™ Lung Cancer Screening (LCS) software and its AI-driven imaging services for oncology drug developers. This presentation follows the successful completion of the REALITY clinical
- [Claudin 18.2 Targeted Therapy Market Forecast 2024-2029](https://www.clinicaltrialvanguard.com/news/claudin-18-2-targeted-therapy-market-forecast-2024-2029/) - Claudin 18.2, a protein typically found in tight junctions, has emerged as a promising therapeutic target for various cancers, particularly gastric and gastroesophageal junction (G/GEJ) adenocarcinomas. Its overexpression in cancerous tissues but limited presence in healthy tissues makes it an ideal candidate for targeted therapies. The recent approval of Zolbetuximab (Vyloy) and the robust pipeline
- [EU Approves Tevimbra for Esophageal and Gastric Cancer](https://www.clinicaltrialvanguard.com/news/eu-approves-tevimbra-for-esophageal-and-gastric-cancer/) - The European Commission approved BeiGene's tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. This approval is based on positive Phase 3 trial results showing statistically significant overall survival benefits in patients with these cancers whose tumors express PD-L1 with a specific threshold. This expanded
- [Addressing Clinical Trial Diversity: Challenges, Opportunities, and Critical Capabilities](https://www.clinicaltrialvanguard.com/conference-coverage/addressing-clinical-trial-diversity-challenges-opportunities-and-critical-capabilities/) - Enhancing clinical trial diversity: Key Insights from SCOPE Europe 2024 conference on the critical need for diversity and equity in research.
- [Sudo Biosciences Doses First Participants in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor Sudo-550](https://www.clinicaltrialvanguard.com/news/sudo-biosciences-doses-first-participants-in-phase-1-trial-of-brain-penetrant-allosteric-tyk2-inhibitor-sudo-550/) - Sudo Biosciences, a company focused on developing precision TYK2 inhibitors, has initiated a Phase 1 clinical trial for SUDO-550. This novel drug is an orally administered, brain-penetrant, allosteric TYK2 inhibitor designed to treat neuroinflammatory diseases. This marks the second allosteric TYK2 inhibitor from Sudo Biosciences to enter clinical trials this year, following SUDO-286, a topical
- [Zorevunersen Data for Dravet Syndrome at AES 2024](https://www.clinicaltrialvanguard.com/news/zorevunersen-data-for-dravet-syndrome-at-aes-2024/) - Stoke Therapeutics, a biotechnology company focused on RNA medicine, will present data at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, from December 6th to 10th. A virtual event for investors and research analysts will also be held on December 9th at 8:30 am EST, featuring discussions led by clinicians and
- [Daiichi Sankyo Oncology Progress at ESMO Asia, SABCS & ASH](https://www.clinicaltrialvanguard.com/news/daiichi-sankyo-oncology-progress-at-esmo-asia-sabcs-ash/) - Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO Asia Congress, San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH) Annual Meeting. These presentations will precede the company's Science & Technology Day and demonstrate advancements toward establishing new cancer care standards. Three
- [Rallybio Confirmatory Study Launch in Q2 2025](https://www.clinicaltrialvanguard.com/news/rallybio-confirmatory-study-launch-in-q2-2025/) - Rallybio Corporation announced new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous C5 inhibitor for complement-mediated diseases. These findings suggest RLYB116 achieved greater complement inhibition in a Phase 1 study than originally reported, potentially positioning it as a best-in-class therapy. A confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study is planned for the second
- [Omeros Reveals ASH Presentations](https://www.clinicaltrialvanguard.com/news/omeros-reveals-ash-presentations/) - Omeros Corporation announced two upcoming presentations on their investigational MASP-3 inhibitor, zaltenibart (OMS906), at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego this December. The presentations will focus on zaltenibart's potential in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder. Phase 3 clinical trials for zaltenibart
- [Ajax Presents Phase 1 Trial Results of JAK2 Inhibitor for Myelofibrosis](https://www.clinicaltrialvanguard.com/news/ajax-presents-phase-1-trial-results-of-jak2-inhibitor-for-myelofibrosis/) - Ajax Therapeutics announced the presentation of its ongoing first-in-human study of AJ1-11095, a next-generation Type II JAK2 inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego on December 8, 2024. The Phase 1 study, led by principal investigator Dr. John Mascarenhas, focuses on AJ1-11095 as an oral monotherapy for patients
- [Janux Expands Phase 1b Trials for JANX007 in mCRPC](https://www.clinicaltrialvanguard.com/news/janux-expands-phase-1b-trials-for-janx007-in-mcrpc/) - Janux Therapeutics, a clinical-stage biopharmaceutical company, announced positive interim clinical data for its JANX007 program, a Tumor Activated T Cell Engager (TRACTr) therapy for metastatic castration-resistant prostate cancer (mCRPC). The company highlighted the substantial activity observed in heavily pre-treated patients, paving the way for expansion trials in earlier treatment lines. The Phase 1a clinical trial
- [MammaPrint Predicts Benefit of Extended Endocrine Therapy](https://www.clinicaltrialvanguard.com/news/mammaprint-phase-3-trial-data-identifies-ideal-patients-who-benefit-from-endocrine-therapy/) - A secondary analysis of the IDEAL phase 3 randomized clinical trial, published in JAMA Network Open, confirms that the MammaPrint genomic test can predict the benefit of extended endocrine therapy (EET) in postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. This reinforces previous findings from the NSABP B-42 trial, demonstrating MammaPrint's ability to identify
- [Kairos Pharma and City of Hope Team Up For Phase 2 Trial](https://www.clinicaltrialvanguard.com/news/kairos-pharma-and-city-of-hope-team-up-for-phase-2-trial/) - Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a novel cancer drug resistance therapy, by adding City of Hope Cancer Center as a trial site. This expansion aims to broaden the patient population for ENV105, a treatment for castrate-resistant prostate cancer, and identify biomarkers that predict patient response. The
- [Trio Pharmaceuticals Secures $3.1M to Advance Cancer Therapeutics](https://www.clinicaltrialvanguard.com/news/trio-pharmaceuticals-secures-3-1m-to-advance-cancer-therapeutics/) - TRIO Pharmaceuticals, a biotechnology company developing bispecific antibodies for cancer treatment, secured $3.1 million in pre-Series A funding. This funding round, led by Friedman Bioventure Fund with significant contributions from the Myeloma Investment Fund and others, will fuel the expansion of preclinical activities and advancement of TRIO’s programs toward clinical trials. The investment highlights the
- [Anzupgo® (Delgocitinib) Cream Approved in Great Britain](https://www.clinicaltrialvanguard.com/news/anzupgo-delgocitinib-cream-approved-in-great-britain/) - The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved delgocitinib cream, a topical Janus kinase (JAK) inhibitor, for treating moderate to severe Chronic Hand Eczema (CHE) in adults. This approval offers a new treatment option for those for whom topical corticosteroids are ineffective or unsuitable. CHE is a persistent inflammatory skin disease causing
- [Daiichi Sankyo's Oncology Breakthroughs at ESMO Asia, SABCS & ASH](https://www.clinicaltrialvanguard.com/news/daiichi-sankyos-oncology-breakthroughs-at-esmo-asia-sabcs-ash/) - Daiichi Sankyo will present over 45 abstracts showcasing new clinical research in various cancers at the 2024 ESMO Asia Congress, San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH) Annual Meeting, leading up to its Science & Technology Day. These presentations will highlight the company's progress in establishing new standards of cancer
- [PIF Partners Small Molecule SJIA Drug Granted FDA Rare Pediatric Disease Designation](https://www.clinicaltrialvanguard.com/news/pif-partners-small-molecule-sjia-drug-granted-fda-rare-pediatric-disease-designation/) - PIF Partners' investigational therapeutic, 101-PGC-005 (‘005), has received Rare Pediatric Disease Designation (RPDD) from the FDA for treating systemic juvenile idiopathic arthritis (sJIA) flares. This prodrug of dexamethasone targets CD206+ macrophages and is currently in Phase 3 clinical trials in India for ARDS induced by COVID-19. The RPDD designation underscores the potential of ‘005 to
- [Rallybio to Initiate RLYB116 Clinical PK/PD Study in 2025](https://www.clinicaltrialvanguard.com/news/rallybio-to-initiate-rlyb116-clinical-pk-pd-study-in-2025/) - Rallybio Corporation announced positive findings from new biomarker analyses and manufacturing process enhancements for RLYB116, its investigational once-weekly, subcutaneous C5 inhibitor. These advancements support the potential of RLYB116 as a best-in-class treatment for complement-mediated diseases, leading to plans for a confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study in the second quarter of 2025. Following the completion of
- [Ajax Presents Phase 1 Trial Results for Myelofibrosis Treatment](https://www.clinicaltrialvanguard.com/news/ajax-presents-phase-1-trial-results-for-myelofibrosis-treatment/) - Ajax Therapeutics, a biopharmaceutical company focused on developing advanced JAK inhibitors for myeloproliferative neoplasms (MPNs), will present data from its first-in-human study of AJ1-11095 at the 66th American Society of Hematology (ASH) Annual Meeting. The poster presentation, scheduled for December 8, 2024, in San Diego, will detail the ongoing Phase 1 clinical trial of AJ1-11095,
- [Omniscience and Inmune Bio Partner to Accelerate Alzheimer's Drug Trial](https://www.clinicaltrialvanguard.com/news/omniscience-and-inmune-bio-partner-to-accelerate-alzheimers-drug-trial/) - OmniScience and INmune Bio have partnered to utilize OmniScience's AI-powered platform, Vivo, in INmune Bio's Phase 2 Alzheimer's diseaseAlzheimer's disease clinical trial (AD02). Vivo will centralize and analyze the trial's extensive data in real time, offering immediate insights to improve decision-making and expedite the typically lengthy trial management process. This partnership aims to revolutionize clinical
- [Maat Pharma Announces First US Patient Treated Under Expanded Access for Graft-Versus-Host Disease](https://www.clinicaltrialvanguard.com/news/maat-pharma-announces-first-us-patient-treated-under-expanded-access-for-graft-versus-host-disease/) - MaaT Pharma has administered its investigational microbiome therapeutic, MaaT013, to the first patient in the United States under the FDA's compassionate use program. This treatment is for a patient with acute Graft-versus-Host Disease (aGvHD) who has exhausted other treatment options, including steroids and ruxolitinib, and highlights the unmet medical need for effective aGvHD therapies. The
- [Envision Trial Shows UGN-102's Potential for LG-IR-NMIBC Treatment](https://www.clinicaltrialvanguard.com/news/envision-trial-shows-ugn-102s-potential-for-lg-ir-nmibc-treatment/) - UroGen Pharma announced positive Phase 3 ENVISION trial results for UGN-102, a mitomycin-based intravesical solution for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The study demonstrated a high complete response rate and durable efficacy in patients, marking a significant step toward a potential new treatment option for this challenging condition. The findings were presented at
- [Veracyte Decipher Prostate Test Recommended in NCCN Guidelines](https://www.clinicaltrialvanguard.com/news/decipher-prostate-test-recommended-in-nccn-guidelines/) - Veracyte's Decipher Prostate Genomic Classifier is the only gene expression test included in the 2025 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for prostate cancer. This inclusion solidifies Decipher Prostate's position as a leading diagnostic tool for assessing the risk of metastatic prostate cancer, enabling clinicians to personalize treatment strategies. The test's
- [Datopotamab Deruxtecan Shows Promising Activity in EGFR-Mutated NSCLC](https://www.clinicaltrialvanguard.com/news/datopotamab-deruxtecan-shows-promising-activity-in-egfr-mutated-nsclc/) - Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate, showed promising results in a pooled analysis of two clinical trials for patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancersmall cell lung cancer (NSCLC). The analysis demonstrated a confirmed objective response rate of 42.7% and a median overall survival of 15.6 months. This
- [Exploring the Future of Membrane Protein Modulation in Clinical Trials with Rectify Pharmaceuticals](https://www.clinicaltrialvanguard.com/executiveinterviews/exploring-the-future-of-membrane-protein-modulation-in-clinical-trials-with-rectify-pharmaceuticals/) - Learn about the critical role of membrane-bound proteins, particularly ABC transporters, in disease pathophysiology in this insightful interview.
- [Innate Pharma & IFLI Announce $7.9M Investment for IPH6501 in Follicular Lymphoma](https://www.clinicaltrialvanguard.com/news/innate-pharma-ifli-announce-7-9m-investment-for-iph6501-in-follicular-lymphoma/) - Innate Pharma and the Institute for Follicular Lymphoma (IFLI) have partnered to explore the potential of IPH6501, Innate's anti-CD20 ANKET® therapy, in treating follicular lymphoma (FL). This partnership involves IFLI investing initially $3 million in Innate Pharma, with the potential for an additional $4.9 million based on milestone achievements. This investment will support the inclusion
- [Bluebird Bio Lyfgenia Gene Therapy Shows Positive Long-Term Sickle Cell Disease Data](https://www.clinicaltrialvanguard.com/news/bluebird-bio-lyfgenia-gene-therapy-shows-positive-long-term-sickle-cell-disease-data/) - Bluebird bio announced updated data from its LYFGENIA gene therapy for sickle cellsickle cell disease (SCD) patients with a history of vaso-occlusive events (VOEs). The data, presented at the American Society of Hematology (ASH) Annual Meeting, showed sustained benefits and explored outcomes in patients with a history of stroke, a population not studied in other
- [Kite Pharma Yescarta Curative Potential in Relapsed Lymphoma](https://www.clinicaltrialvanguard.com/news/kite-pharma-yescarta-curative-potential-in-relapsed-lymphoma/) - Kite, a Gilead Company, presented three analyses of Yescarta (axicabtagene ciloleucel) at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing improved outcomes for patients with relapsed or refractory large B-cell lymphomaB-cell lymphoma (R/R LBCL). The largest real-world evidence analysis to date confirmed high overall survival (OS) rates consistent with the ZUMA-7 trial, while
- [Vertex Pharma Casgevy Exagamglogene Autotemcel: Positive Long-Term Data](https://www.clinicaltrialvanguard.com/news/vertex-pharma-casgevy-exagamglogene-autotemcel-positive-long-term-data/) - Vertex Pharmaceuticals announced long-term data from global clinical trials of CASGEVY, a CRISPR/Cas9 gene-edited therapy, for severe sickle cellsickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The data, presented at the American Society of Hematology (ASH) Annual Meeting, showcased the therapy's sustained clinical benefits, with follow-up periods extending beyond five years for some patients. The
- [Orca Bio Shows Promising 3-Year Survival in Hematological Malignancies](https://www.clinicaltrialvanguard.com/news/orca-bio-shows-promising-3-year-survival-in-hematological-malignancies/) - Orca Bio presented positive three-year follow-up data for its allogeneic T-cell immunotherapy, Orca-T, at the 66th American Society of Hematology (ASH) Annual Meeting. The therapy showed an 86% overall survival rate in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and high-risk myelodysplastic syndrome (MDS), compared to 67% in a historical control group
- [Merck Zilovertamab Shows 100% Remission in DLBCL Trial](https://www.clinicaltrialvanguard.com/news/merck-zilovertamab-shows-100-remission-in-dlbcl-trial/) - Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with standard chemotherapy (R-CHP) for previously untreated diffuse large B-cell lymphomaB-cell lymphoma (DLBCL). The combination achieved a 100% complete response rate in patients treated with a 1.75 mg/kg dose of zilovertamab vedotin, leading to the establishment of
- [Indapta and Sanofi Collaborate on Myeloma Study](https://www.clinicaltrialvanguard.com/news/indapta-and-sanofi-collaborate-on-myeloma-study/) - Indapta Therapeutics and Sanofi are collaborating to investigate the combined efficacy and safety of Indapta's allogeneic g-NK cell therapy, IDP-023, and Sanofi's monoclonal antibody, Sarclisa, in patients with relapsed/refractory multiple myeloma. This partnership aims to enhance the treatment options for this challenging blood cancer by combining a novel cell therapy with an established targeted therapy.
- [Arcellx Announces Positive Data for Relapsed Multiple Myeloma from IMAGINE-1 Study at ASH Meeting](https://www.clinicaltrialvanguard.com/news/arcellx-announces-positive-data-for-relapsed-multiple-myeloma-from-imagine-1-study-at-ash-meeting/) - Arcellx, a biotechnology company, announced positive Phase 2 iMMagine-1 study data for anitocabtagene autoleucel (anito-cel), a CAR T-cell therapycell therapy for relapsed or refractory multiple myeloma (RRMM). The study, with a median follow-up of 9.5 months, showed a 97% overall response rate (ORR) and a 62% complete response/stringent complete response (CR/sCR) rate in 86 efficacy-evaluable
- [PureTech Presents Lyt-200 Data for Relapsed/Refractory AML/MDS](https://www.clinicaltrialvanguard.com/news/puretech-presents-lyt-200-data-for-relapsed-refractory-aml-mds/) - PureTech Health presented positive Phase 1b trial data for LYT-200, a novel anti-galectin-9 monoclonal antibody, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial evaluated LYT-200 as a monotherapy and in combination with standard-of-care venetoclax and hypomethylating agents (HMAs). Early results indicate a favorable safety profile and promising
- [Stoke Therapeutics Zorevunersen Shows Promise in Dravet Syndrome Treatment](https://www.clinicaltrialvanguard.com/news/stoke-therapeutics-zorevunersen-shows-promise-in-dravet-syndrome-treatment/) - Stoke Therapeutics announced positive data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen, a drug candidate for Dravet syndrome. The studies showed substantial and durable reductions in convulsive seizure frequency in patients given 70mg followed by 45mg maintenance doses of zorevunersen, alongside existing anti-seizure medications. Furthermore, patients demonstrated continuous improvements in cognitive and
- [Bayer Transforms Clinical Trials with Digital Protocols](https://www.clinicaltrialvanguard.com/conference-coverage/bayer-transforms-clinical-trials-with-digital-protocols/) - Bayer AG's initiative with TransCelerate BioPharma Inc. aims to accelerate clinical research through a shift from document-centric to data-centric approach.
- [Advancing Diversity in Aesthetic Clinical Trials: Insights from Allergan Aesthetics](https://www.clinicaltrialvanguard.com/executiveinterviews/advancing-diversity-in-aesthetic-clinical-trials-insights-from-allergan-aesthetics/) - Explore Allergan Aesthetics' initiatives to enhance diversity in clinical trials with Dr. Stephanie Manson Brown, Head of Clinical Development.
- [Star Therapeutics Presents Interim Clinical Data for VGA039 in VWD Patients at ASH 2024](https://www.clinicaltrialvanguard.com/news/star-therapeutics-presents-interim-clinical-data-for-vga039-in-vwd-patients-at-ash-2024/) - Star Therapeutics announced interim Phase 1 clinical trial data for VGA039, a novel subcutaneous monoclonal antibody for Von Willebrand Disease (VWD). The therapy targets Protein S to rebalance blood clotting, potentially offering the first subcutaneous treatment option for all VWD types. Early data from three patients with high bleeding rates showed significant reductions in annualized
- [Belantamab Mafodotin Shows 42% OS Benefit in Relapsed Multiple Myeloma](https://www.clinicaltrialvanguard.com/news/belantamab-mafodotin-shows-42-os-benefit-in-relapsed-multiple-myeloma/) - The DREAMM-7 trial interim analysis revealed that belantamab mafodotin combined with bortezomib and dexamethasone (BVd) significantly improved overall survival (OS) in relapsed or refractory multiple myeloma patients compared to the daratumumab, bortezomib, and dexamethasone (DVd) combination. This positive OS data reinforces earlier findings from DREAMM-7 and DREAMM-8, which demonstrated improved progression-free survival (PFS) with belantamab
- [Kite's Tecartus Car T-Cell Therapy Shows Durable Efficacy and Survival](https://www.clinicaltrialvanguard.com/news/kites-tecartus-car-t-cell-therapy-shows-durable-efficacy-and-survival/) - Kite, a Gilead Company, presented promising data on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma (R/R MCL) and B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) at the American Society of Hematology meeting. The ZUMA-2 trial showed high overall and complete response rates in BTKi-naïve R/R MCL patients, while five-year follow-up data revealed prolonged overall
- [Yescarta® Shows Durable Response & Long-Term Survival in NHL Patients](https://www.clinicaltrialvanguard.com/news/yescarta-shows-durable-response-long-term-survival-in-nhl-patients/) - A five-year follow-up analysis of the ZUMA-5 Phase 2 study shows promising results for Yescarta (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL), specifically follicular lymphoma (FL) and marginal zone lymphoma (MZL). The analysis reveals durable responses and long-term survival after Yescarta treatment, with a median overall response rate of 90% and a complete
- [BMS Showcases Cell Therapy Portfolio at ASH 2024](https://www.clinicaltrialvanguard.com/news/bms-showcases-cell-therapy-portfolio-at-ash-2024/) - Bristol Myers Squibb (BMS) presented 18 analyses at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the efficacy, durability, and safety of their current cell therapies for blood cancers, along with promising pipeline data for future indications, including autoimmune diseases. The presented data highlighted advancements in blood cancers and beyond, reaffirming BMS's commitment
- [BeiGene Brukinsa Impact on CLL: 2024 ASH Hematology Data & New Advances](https://www.clinicaltrialvanguard.com/news/beigene-brukinsa-impact-on-cll-2024-ash-hematology-data-new-advances/) - BeiGene, soon to be BeOne Medicines, presented positive clinical data for BRUKINSA (zanubrutinib) and other pipeline assets in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at the 66th American Society of Hematology (ASH) Annual Meeting. Long-term data from the SEQUOIA study showed BRUKINSA significantly improved progression-free survival compared to bendamustine-rituximab, particularly in high-risk patients. Further data
- [How The Trump Administration Will Impact The Future of Clinical Trials and Biopharma](https://www.clinicaltrialvanguard.com/article/how-the-trump-administration-will-impact-the-future-of-clinical-trials-and-biopharma/) - The re-election of Donald Trump in 2024 sparks a healthcare and biopharmaceutical transformation amidst global tensions and rising conflict with China.
- [Acticor Biotech Liquidation Proceedings Announced](https://www.clinicaltrialvanguard.com/news/acticor-biotech-liquidation-proceedings-announced/) - Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has requested the conversion of its receivership proceedings. The Paris Commercial Court will address this request on December 19, 2024. This situation arises after glenzocimab failed to demonstrate significant neurological improvement in stroke patients during three international clinical
- [Tafasitamab Improves PFS in Follicular Lymphoma](https://www.clinicaltrialvanguard.com/news/tafasitamab-improves-pfs-in-follicular-lymphoma/) - The Phase 3 inMIND trial showed positive results for tafasitamab combined with lenalidomide and rituximab in treating relapsed or refractory follicular lymphoma (FL). The combination therapy significantly improved progression-free survival (PFS) compared to the control group, reducing the risk of disease progression, relapse, or death by 57%. This improvement was observed across all patient subgroups,
- [Incyte Tafasitamab Improves PFS in Relapsed/Refractory Follicular Lymphoma](https://www.clinicaltrialvanguard.com/news/incyte-tafasitamab-improves-pfs-in-relapsed-refractory-follicular-lymphoma/) - Incyte announced positive Phase 3 inMIND trial results for tafasitamab combined with lenalidomide and rituximab in relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint, showing a statistically significant improvement in progression-free survival (PFS) compared to the control group. This combination therapy reduced the risk of disease progression, relapse, or death by
- [City of Hope ASH Conference: Novel Cancer Therapies](https://www.clinicaltrialvanguard.com/news/city-of-hope-ash-conference-novel-cancer-therapies/) - City of Hope researchers presented groundbreaking studies at the 2024 ASH conference, focusing on innovative treatments for various blood cancers, including rare subtypes and graft-versus-host disease. These studies explored novel therapies such as CAR T-cell therapycell therapy, monoclonal antibodies, and targeted inhibitors, while also emphasizing supportive care and improved risk assessment for transplant patients. The
- [Visugromab Reverses Checkpoint Inhibitor Resistance](https://www.clinicaltrialvanguard.com/news/visugromab-reverses-checkpoint-inhibitor-resistance/) - CatalYm's lead drug candidate, visugromab, a monoclonal antibody targeting the immunosuppressant GDF-15, has shown promising results in a Phase 1/2a trial for various solid tumors. The study, published in •Nature•, revealed visugromab's ability to induce significant and durable cancer remission, especially when combined with the PD-1 inhibitor nivolumab, in patients with late-stage cancers resistant to
- [Stemline Therapeutics: New Therapeutic Strategy for Advanced Breast Cancer](https://www.clinicaltrialvanguard.com/news/stemline-therapeutics-new-therapeutic-strategy-for-advanced-breast-cancer/) - Menarini Group, along with its subsidiary Stemline Therapeutics and research partner MEDSIR, presented research at the San Antonio Breast Cancer Symposium 2024 (SABCS) on the ADELA clinical trial. This phase III trial is investigating a combination therapy of elacestrant and everolimus for advanced ER+/HER2- breast cancer patients with ESR1 mutations who have progressed after first-line
- [Atropos Evidence Network Automates Healthcare AI Model Training](https://www.clinicaltrialvanguard.com/news/atropos-evidence-network-automates-healthcare-ai-model-training/) - Atropos Health launched AI model training on its Atropos Evidence Network, a federated healthcare data network containing over 300 million patient records. This allows members to use de-identified real-world data (RWD) to train AI models and deploy them through partners like pharmaceutical companies and health systems. The aim is to improve the safety and efficacy
- [Tobevibart & Elebsiran Get Breakthrough & PRIME for Chronic Hep D](https://www.clinicaltrialvanguard.com/news/tobevibart-elebsiran-get-breakthrough-prime-for-chronic-hep-d/) - Tobevibart and elebsiran, developed by Vir Biotechnology for chronic hepatitis delta (CHD), have received Breakthrough Therapy designation from the U.S. FDA and Priority Medicines (PRIME) designation from the EMA. These designations are based on positive safety and efficacy data from the Phase 2 SOLSTICE trial, showing the drug combination’s potential to significantly suppress the hepatitis
- [Corcept Catalyst Trial Shows Positive Results in Cushing's Syndrome & Diabetes Treatment](https://www.clinicaltrialvanguard.com/news/corcept-catalyst-trial-shows-positive-results-in-cushings-syndrome-diabetes-treatment/) - Corcept Therapeutics' Phase 4 CATALYST study demonstrated that Korlym® significantly improved blood sugar control in patients with both Cushing's syndrome and difficult-to-control type 2 diabetes. The study also revealed a higher-than-expected prevalence of Cushing's syndrome in this patient population, with nearly one in four qualifying patients exhibiting the condition. This research underscores the potential of
- [Positive Results for Lunresertib & Camonsertib Combo in Gynecologic Trial](https://www.clinicaltrialvanguard.com/news/positive-results-for-lunresertib-camonsertib-combo-in-gynecologic-trial/) - Repare Therapeutics announced positive data from its Phase 1 MYTHIC trial combining lunresertib and camonsertib (Lunre+Camo) in patients with endometrial and platinum-resistant ovarian cancers. The combination therapy showed promising overall response rates (ORR) of 25.9% and 37.5% respectively, with nearly half the patients experiencing progression-free survival at 24 weeks. These findings stem from 51 evaluable
- [Zelenectide Pevedotin Program Updates & Nectin-4 Gene Amplification Strategy](https://www.clinicaltrialvanguard.com/news/zelenectide-pevedotin-program-updates-nectin-4-gene-amplification-strategy/) - Bicycle Therapeutics presented data at the 2024 San Antonio Breast Conference Symposium (SABCS) highlighting the enhanced anti-tumor activity of their drug, zelenectide pevedotin, in breast cancer patients with NECTIN4 gene amplification. They also announced topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer (mUC) patients, along with updates on the Duravelo-2
- [Beigene's Global MAT2A Inhibitor Licensing Deal](https://www.clinicaltrialvanguard.com/news/beigenes-global-mat2a-inhibitor-licensing-deal/) - BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC. This drug targets the MTAP gene deletion, a mutation present in roughly 15% of all cancers, including prevalent types like glioblastoma, pancreatic cancer, and non-small cell lung cancersmall cell lung cancer. The deal involves an upfront
- [How Sangamo is Navigating the Future of Gene Therapy for Rare Diseases](https://www.clinicaltrialvanguard.com/executiveinterviews/how-sangamo-is-navigating-the-future-of-gene-therapy-for-rare-diseases/) - In this interview, we speak with Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo Therapeutics, about the FDA's accelerated approval pathway and its impact on rare disease treatments, focusing on Fabry disease. We discussed the benefits and challenges of surrogate endpoints, post-approval trials, and ethical considerations for patient access. Moe Alsumidaie: How does the FDA's accelerated
- [Contineum PIPE-791 Phase 1b PET Trial Begins Patient Dosing](https://www.clinicaltrialvanguard.com/news/contineum-pipe-791-phase-1b-pet-trial-begins-patient-dosing/) - Contineum Therapeutics has initiated a Phase 1b positron emission tomography (PET) trial for PIPE-791, a novel brain-penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R). This open-label, single-center trial aims to correlate pharmacokinetics with receptor occupancy in healthy volunteers, as well as patients with idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS),
- [Lerodalcibep Biologic License Application Submitted to FDA](https://www.clinicaltrialvanguard.com/news/lerodalcibep-biologic-license-application-submitted-to-fda/) - LIB Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for Lerodalcibep, a novel PCSK9 inhibitor designed to lower LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD, and primary hyperlipidemia, including familial hypercholesterolemia. Lerodalcibep is administered as a once-monthly, self-administered subcutaneous injection with long ambient stability,
- [Naropa University and Center for Psychedelic Studies Separate](https://www.clinicaltrialvanguard.com/news/naropa-university-and-center-for-psychedelic-studies-separate/) - Naropa University's Center for Psychedelic Studies has become an independent entity, the Memoru Center for Visionary Healing Arts, in collaboration with therapists and researchers Marcela Ot’alora, Bruce Poulter, and Sara Gael Beauregard. This new center will focus on clinical care, training, and research related to psychedelic therapies, with plans to open clinics and expand training
- [Strategic Navigation for Clinical Trials in Mid-Size Biopharma: Insights from Almirall](https://www.clinicaltrialvanguard.com/conference-coverage/strategic-navigation-for-clinical-trials-in-mid-size-biopharma-insights-from-almirall/) - Gain insights on navigating clinical trial complexities in mid-size biopharma companies with Estrella García's strategic guidance.
- [Trodelvy Gets Breakthrough Therapy for Lung Cancer](https://www.clinicaltrialvanguard.com/news/trodelvy-gets-breakthrough-therapy-for-lung-cancer/) - The FDA has granted Breakthrough Therapy Designation to Gilead Sciences' Trodelvy for treating extensive-stage small cell lung cancerlung cancer (ES-SCLC) in adults who have progressed on or after platinum-based chemotherapy. This designation stems from the positive results of the Phase 2 TROPiCS-03 study, where Trodelvy showed encouraging antitumor activity and a manageable safety profile in
- [Silexion's Precision Oncology Collaboration: Targeting KRAS](https://www.clinicaltrialvanguard.com/news/silexions-precision-oncology-collaboration-targeting-kras/) - Silexion Therapeutics is developing SIL-204, a next-generation siRNA therapy targeting a broad range of KRAS mutations prevalent in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. The company's collaboration with Evonik has yielded a promising long-acting PLGA microparticle formulation for SIL-204, showing efficacy in preclinical studies by shrinking tumors in KRAS-mutated pancreatic cancer models. This
- [eClinical Solutions and Snowflake Partner for Life Sciences](https://www.clinicaltrialvanguard.com/news/eclinical-solutions-and-snowflake-partner-for-life-sciences/) - eClinical Solutions and Snowflake have partnered to integrate eClinical's elluminate Clinical Data Cloud with the Snowflake AI Data Cloud. This integration aims to address the growing data challenges faced by life sciences organizations by providing a modern, efficient, and scalable data architecture. The collaboration seeks to streamline data access and empower the development of next-generation
- [Protein Helps Cancer Evade CAR T-Cell Therapy](https://www.clinicaltrialvanguard.com/news/protein-helps-cancer-evade-car-t-cell-therapy/) - Scientists at City of Hope have identified a protein, YTHDF2, that helps blood cancer cells evade CAR T cell therapy, a treatment that uses the immune system to attack tumors. They also developed a compound, CCI-38, which targets and suppresses YTHDF2, thereby reducing cancer growth and improving treatment outcomes. This discovery stems from research published
- [Colorado's Life Sciences Raised $2.15B in 2024](https://www.clinicaltrialvanguard.com/news/colorados-life-sciences-raised-2-15b-in-2024/) - Colorado's life sciences ecosystem flourished in 2024, raising $2.15 billion, a 46% increase from 2023, marking the second time in four years funding has surpassed $2 billion. This impressive sum adds to the nearly $12 billion raised over the past eight years, solidifying Colorado's position as a leading hub for life sciences innovation. The surge
- [Tolerance Bio, Inc. Launches $20.2M Seed Round for Thymus-Based Therapies](https://www.clinicaltrialvanguard.com/news/tolerance-bio-inc-launches-20-2m-seed-round-for-thymus-based-therapies/) - Tolerance Bio, Inc., a biopharmaceutical company, has formed a Scientific Advisory Board and completed a $20.2 million seed financing round. The company is developing an allogeneic iPSC-based thymus cell therapy platform and pharmacological thymus therapies to address immune-mediated diseases like cancer, autoimmunity, and transplant rejection. The oversubscribed funding round, including Pacific 8 Ventures, will support
- [Tiximed Secures $2.65M Investment for Novel Oral Therapy Trials](https://www.clinicaltrialvanguard.com/news/tiximed-secures-2-65m-investment-for-novel-oral-therapy-trials/) - TIXiMED, a clinical-stage pharmaceutical company, has secured a $2.65 million loan from the Helmsley Charitable Trust to advance its oral drug candidate, TIX100, into a first-in-human clinical trial starting in January. This funding will support the single ascending dose (SAD) study, a crucial step in evaluating the safety and dosage of TIX100 in humans. The
- [SCOPE 2025 Participant Engagement Awards Finalists Announced](https://www.clinicaltrialvanguard.com/news/scope-2025-participant-engagement-awards-finalists-announced/) - Discover the six finalists for the 2025 Participant Engagement Awards at SCOPE Summit, recognizing innovation in clinical trials.
- [Ellipses Launches Pioneering Clinical Trial in Middle East](https://www.clinicaltrialvanguard.com/news/ellipses-launches-pioneering-clinical-trial-in-middle-east/) - Ellipses Pharma has launched its first large-scale Phase 1/2 oncology clinical trial in the United Arab Emirates (UAE) for its selective RET inhibitor (SRI), EP0031/A400. This trial, focusing on RET-altered tumors prevalent in non-small cell lung cancersmall cell lung cancer and thyroid cancer, is supported by Abu Dhabi investors and will initially be conducted at
- [Mirailab Launches NMN Supplements in Singapore](https://www.clinicaltrialvanguard.com/news/mirailab-launches-nmn-supplements-in-singapore/) - MIRAILAB BIOSCIENCE Inc., a Tokyo-based company specializing in NMN supplements, has partnered with Global Ocean Distribution Pte Ltd to launch its "MIRAI LAB" brand on Shopee, a major Singaporean e-commerce platform. This expansion marks a significant step in making their β-Nicotinamide Mononucleotide (β-NMN) supplements more accessible to consumers in Singapore. The company highlights NMN's potential
- [Oncodesign Reacquires Rights to OPM-201 After Positive Phase 1 Trial](https://www.clinicaltrialvanguard.com/news/oncodesign-reacquires-rights-to-opm-201-after-positive-phase-1-trial/) - Oncodesign Precision Medicine (OPM) has regained full rights to its Parkinson's disease treatment program, OPM-201, after Servier Laboratories shifted its neurological focus to rare diseases. A Phase 1 study on healthy volunteers recently concluded, confirming OPM-201's safety, with final results anticipated in Q2 2025. OPM plans to continue developing the program internally until a new
- [JCR's JR-142 Phase III Trial Launched in Japan](https://www.clinicaltrialvanguard.com/news/jcrs-jr-142-phase-iii-trial-launched-in-japan/) - JCR Pharmaceuticals has initiated a Phase III clinical trial in Japan for JR-142 (redalsomatropin alfa), a long-acting growth hormone therapy for pediatric growth hormone deficiency. This trial marks a crucial step in developing a more convenient treatment option for young patients. The study will evaluate 54 children over a year, comparing JR-142's efficacy against JCR's
- [FDA Approves Braftovi for BRAF V600E Metastatic Colorectal Cancer](https://www.clinicaltrialvanguard.com/news/fda-approves-braftovi-for-braf-v600e-metastatic-colorectal-cancer/) - The FDA granted accelerated approval to Pfizer's BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for treating metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. This approval, based on positive results from the Phase 3 BREAKWATER trial, offers a new first-line treatment option for these patients, showing significant improvement in response rate and durability
- [FDA Approves Trikafta for Additional Cystic Fibrosis Variants](https://www.clinicaltrialvanguard.com/news/fda-approves-trikafta-for-additional-cystic-fibrosis-variants/) - The FDA has expanded the approval of Vertex Pharmaceuticals' TRIKAFTA, a cystic fibrosis (CF) treatment, to include individuals aged two and older with at least one F508del mutation or a responsive mutation in the CFTR gene. This expansion adds 94 non-F508del CFTR mutations to the approved list and makes approximately 300 more people in the
- [Exicure & GPCR Therapeutics Partner to Fuel Biotech Growth](https://www.clinicaltrialvanguard.com/news/exicure-gpcr-therapeutics-partner-to-fuel-biotech-growth/) - Exicure, Inc. signed a Memorandum of Understanding with GPCR Therapeutics to acquire GPCR USA, a subsidiary specializing in G Protein-Coupled Receptor (GPCR) drug development. This acquisition includes the transfer of technology and collaborative research on GPCR Therapeutics' ongoing drug pipelines, most notably a CXCR4 inhibitor currently in Phase 2 clinical trials for multiple myeloma, a
- [Daiichi and AstraZeneca Datopotamab Deruxtecan Application Withdrawn from EU](https://www.clinicaltrialvanguard.com/news/daiichi-and-astrazeneca-datopotamab-deruxtecan-application-withdrawn-from-eu/) - Daiichi Sankyo and AstraZeneca have withdrawn their EU marketing authorization application for datopotamab deruxtecan (Dato-DXd) in locally advanced or metastatic non-squamous non-small cell lung cancersmall cell lung cancer (NSCLC). This decision follows feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and is based on data from the TROPION-Lung01 phase
- [Therapeutic Blood Thinners Reduce COVID-19 Mortality](https://www.clinicaltrialvanguard.com/news/therapeutic-blood-thinners-reduce-covid-19-mortality/) - A new international study, analyzing 22 clinical trials and 11,000 patients across 21 countries, found that therapeutic doses of heparin can significantly improve the survival rate of hospitalized COVID-19 patients. This World Health Organization-coordinated research, published in the •Annals of Internal Medicine•, aimed to clarify conflicting findings from previous studies on blood thinner dosages for
- [Axena Health Starts UI Treatment Patient Enrollment at Two Nigerian Sites](https://www.clinicaltrialvanguard.com/news/axena-health-starts-ui-treatment-patient-enrollment-at-two-nigerian-sites/) - Axena Health has launched a feasibility study in Nigeria to explore a new treatment for female incontinence, combining the Leva® Pelvic Health System with a digital home-based program. The study, funded by ArcHealth Foundation and supported by Helium Health, is enrolling 60 women across two teaching hospitals in Abuja and Ikeja. This research builds upon
- [PainReform Delivers Phase 3 Trial Update on PRF-110](https://www.clinicaltrialvanguard.com/news/painreform-delivers-phase-3-trial-update-on-prf-110/) - PainReform Ltd. (Nasdaq: PRFX), a clinical-stage pharmaceutical company specializing in reformulating existing therapies, has provided an update on its Phase 3 clinical trial for PRF-110. This trial evaluated the drug's efficacy in managing post-surgical pain for patients undergoing bunionectomies. While the company previously reported statistically significant pain reduction compared to a placebo during the initial
- [Ikena Oncology and Inmagene Merger Announcement](https://www.clinicaltrialvanguard.com/news/ikena-oncology-and-inmagene-merger-announcement/) - Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. The combined company will focus on developing IMG-007, Inmagene’s lead asset, a monoclonal antibody targeting OX40 for atopic dermatitis treatment. The new entity plans to operate as “ImageneBio, Inc.” and trade on NASDAQ under the ticker symbol “IMA.” Concurrently with the merger, Ikena
- [Vor Bio Announces $55.6M Private Placement](https://www.clinicaltrialvanguard.com/news/vor-bio-announces-55-6m-private-placement/) - Vor Bio, a clinical-stage cell and genome engineering company, has secured approximately $55.6 million in gross proceeds through a private investment in public equity financing (PIPE). This financing involves issuing over 55.8 million shares of common stock and warrants to purchase nearly 70 million additional shares at a combined price of $0.99425 per share and
- [Psyence Biomed Closes $2M Private Placement](https://www.clinicaltrialvanguard.com/news/psyence-biomed-closes-2m-private-placement/) - Psyence Biomedical Ltd., a Nasdaq-listed biotechnology company (Nasdaq: PBM), recently finalized a private placement, raising approximately $2 million before expenses. The offering involved 1,000,000 common shares (or pre-funded warrants), along with series A and short-term series B common warrants, each allowing the purchase of up to 1,000,000 common shares. The purchase price was $2.00 per
- [Takeda Hyqvia 10% Injection Approved in Japan for Immunodeficiency](https://www.clinicaltrialvanguard.com/news/takeda-hyqvia-10-injection-approved-in-japan-for-immunodeficiency/) - Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare for HYQVIA, a facilitated subcutaneous immunoglobulin (fSCIG) therapy, for patients with agammaglobulinemia or hypogammaglobulinemia. These conditions, characterized by low antibody levels, increase the risk of serious recurring infections stemming from primary or secondary immunodeficiencies. This approval marks the first fSCIG treatment option
- [Beigene Tevibra Approved in US for Gastric Cancer Treatment](https://www.clinicaltrialvanguard.com/news/beigene-tevibra-approved-in-us-for-gastric-cancer-treatment/) - The FDA approved BeiGene's TEVIMBRA (tislelizumab-jsgr), combined with chemotherapy, for first-line treatment of advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults with PD-L1-positive tumors. This approval is based on the positive results from the RATIONALE-305 Phase 3 trial, which showed a significant overall survival benefit for patients receiving TEVIMBRA plus chemotherapy compared to
- [Telix Pharma: Noble Registry Update: TLX599-CDX PSMA SPECT Imaging](https://www.clinicaltrialvanguard.com/news/telix-pharma-noble-registry-update-tlx599-cdx-psma-spect-imaging/) - Telix Pharmaceuticals and the Oncidium foundation announced positive initial results from the NOBLE Registry, a real-world evidence study of TLX599-CDx for prostate cancer imaging. The study, published in the •European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports•, demonstrated a management change in 42.5% of the 40 patients across six countries who received TLX599-CDx
- [Kala Bio's $10.75M Private Placement: A Promising Opportunity?](https://www.clinicaltrialvanguard.com/news/kala-bios-10-75m-private-placement-a-promising-opportunity/) - Kala Bio, a clinical-stage biopharmaceutical company focused on eye diseases, secured approximately $10.75 million in a private placement involving both new and existing investors. The funding will primarily support the clinical development of KPI-012, a treatment for persistent corneal epithelial defect (PCED), and general corporate operations. The Phase 2b CHASE trial for KPI-012 is currently
- [Delcath Systems Secures $16.3M in Funding](https://www.clinicaltrialvanguard.com/news/delcath-systems-secures-16-3m-in-funding/) - Delcath Systems, Inc. secured $16.3 million in funding through the exercise of Series E and E1 warrants, with a small percentage exercised through cashless provisions. These warrants, originally issued in 2019 as part of a private placement, had a $10.00 exercise price and were set to expire in 2024. This influx of capital bolsters Delcath's
- [Sangamo Regains Full Rights to Hemophilia A Gene Therapy](https://www.clinicaltrialvanguard.com/news/sangamo-regains-full-rights-to-hemophilia-a-gene-therapy/) - Sangamo Therapeutics will regain control of giroctocogene fitelparvovec, a hemophilia A gene therapy candidate, after Pfizer terminated their collaboration and licensing agreement. Pfizer cited its decision not to pursue a Biologics License Application or commercialization, despite positive Phase 3 trial results. Sangamo plans to explore all options for the program, including finding a new partner.
- [RenovoRx's IP Portfolio Grows, Drug-Delivery Platform Expands](https://www.clinicaltrialvanguard.com/news/renovorxs-ip-portfolio-grows-drug-delivery-platform-expands/) - RenovoRx (Nasdaq: RNXT) is bolstering its intellectual property (IP) portfolio with a new international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, adding to its existing 18 issued and 13 pending patents. The new application details methods and tools for targeted drug delivery using micro-vessels surrounding larger arteries, aiming to improve treatment efficacy and
- [Verastem Oncology: Avutometinib/defactinib NDA for Low-Grade Serous Ovarian Cancer Gets Priority Review](https://www.clinicaltrialvanguard.com/news/verastem-oncology-avatometinib-defactinib-nda-for-low-grade-serous-ovarian-cancer-gets-priority-review/) - Verastem Oncology's New Drug Application (NDA) for a combination therapy of avutometinib and defactinib, designed to treat recurrent low-grade serous ovarian cancer (LGSOC) with a KRAS mutation, has been accepted for Priority Review by the FDA. The FDA has set a target action date of June 30, 2025, and if approved, this would be the
- [Hutchmed Divests Non-Core Joint Venture for US$608 Million](https://www.clinicaltrialvanguard.com/news/hutchmed-divests-non-core-joint-venture-for-us608-million/) - Hutchmed is divesting its 45% stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately US$608 million to GP Health Service Capital and Shanghai Pharma. This move allows HUTCHMED to concentrate on its core oncology and immunology business, particularly its next-generation antibody-targeted therapy conjugate (ATTC) programs. The divestiture aligns with HUTCHMED’s 2022 strategy to prioritize its
- [Firefly Neuroscience Secures $12.4M Financing](https://www.clinicaltrialvanguard.com/news/firefly-neuroscience-secures-12-4m-financing/) - Firefly Neuroscience (NASDAQ: AIFF) secured up to $12.4 million in financing, consisting of $2.4 million in convertible notes and a $10 million equity line of credit. The funding will support the growth and commercialization of Firefly’s FDA-cleared Brain Network Analytics (BNA™) technology, along with general working capital needs. The company aims to partner with pharmaceutical
- [Cancer Immunotherapy Market 2025-2029: Emerging Trends & Growth](https://www.clinicaltrialvanguard.com/news/cancer-immunotherapy-market-2025-2029-emerging-trends-growth/) - A new report from ResearchAndMarkets.com analyzes the burgeoning cancer immunotherapy market, projecting its growth through 2029. The report examines various immunotherapies, including CAR-T cell therapy, checkpoint inhibitors, and cytokines, across different cancer types and customer segments. It offers strategic insights for executives, investors, and consultants, providing data on market size, trends, key players, and recent
- [Cellenkos and the Future of T-Regulatory Cell Therapy: A Conversation with Simrit Parmar](https://www.clinicaltrialvanguard.com/executiveinterviews/cellenkos-and-the-future-of-t-regulatory-cell-therapy-a-conversation-with-simrit-parmar/) - Discover the groundbreaking work of Cellenkos in T-regulatory cell therapies, focusing on the potential of CK0804 in treating myelofibrosis.
- [Navigating Clinical Trials: Insights from Scitech Development](https://www.clinicaltrialvanguard.com/executiveinterviews/navigating-clinical-trials-insights-from-scitech-development/) - Discover the progress of SciTech Development's Phase 1 trial for ST-001 nanoFenretinide and their future plans for nanoparticle delivery.
- [Exploring New Frontiers in Immunology with Revolo](https://www.clinicaltrialvanguard.com/executiveinterviews/exploring-new-frontiers-in-immunology-with-revolo/) - ‘1104 shows promise in treating chronic conditions like EoE and atopic dermatitis, offering a safer and effective treatment approach.
- [Neumora Therapeutics Reports Positive Navacaprant Data in MDD](https://www.clinicaltrialvanguard.com/news/neumora-therapeutics-reports-positive-navacaprant-data-in-mdd/) - Neumora Therapeutics announced Phase 3 trial results for its major depressive disorder (MDD) drug, navacaprant. The KOASTAL-1 study, the first of three in the pivotal KOASTAL program, did not meet its primary endpoint of a statistically significant reduction in depressive symptoms, measured by the MADRS total score, compared to placebo. However, a potential efficacy signal
- [Capricor Submits Deramiocel BLA to FDA for Duchenne Muscular Dystrophy](https://www.clinicaltrialvanguard.com/news/capricor-submits-deramiocel-bla-to-fda-for-duchenne-muscular-dystrophy/) - Capricor Therapeutics has submitted a Biologics License Application (BLA) to the U.S. FDA for deramiocel, a cell therapy designed to treat Duchenne muscular dystrophy (DMD) cardiomyopathy. This submission triggered a $10 million milestone payment from Nippon Shinyaku, Capricor’s distribution partner. If approved, deramiocel would be the first therapy specifically targeting DMD-related heart disease. This BLA
- [Pain Treatment Market 2024-2029: Medtronic, Abbott, GSK, Pfizer, J&J](https://www.clinicaltrialvanguard.com/news/pain-treatment-market-2024-2029-medtronic-abbott-gsk-pfizer-jj/) - The global conventional and alternative pain treatment market, valued at $96.2 billion in 2024, is projected to reach $144.2 billion by 2029, growing at a CAGR of 8.40%. This growth is driven by increasing demand for pain management solutions, including pharmaceuticals, devices like TENS units and spine stimulators, and alternative therapies like medical cannabis. The
- [Advancing Leukemia Care with Sellas: GPS & SLS009 Insights](https://www.clinicaltrialvanguard.com/executiveinterviews/advancing-leukemia-care-with-sellas-gps-sls009-insights/) - Enhance leukemia treatment with Sellas' innovative assets GPS and SLS009, targeting improved survival and quality of life for patients.
- [Grove Secures $4.9M for Agentic AI Clinical Trials](https://www.clinicaltrialvanguard.com/news/grove-secures-4-9m-for-agentic-ai-clinical-trials/) - Grove AI, a clinical trial management company, secured $4.9 million in seed funding led by A•, with participation from other venture capital firms and industry angels. The funding will support team and product expansion as Grove aims to revolutionize clinical trial operations. The company's goal is to transform trials from siloed processes into participant-centric ecosystems
- [Biomea Fusion Reveals Promising Preclinical Data on Icovamenib Combination](https://www.clinicaltrialvanguard.com/news/biomea-fusion-reveals-promising-preclinical-data-on-icovamenib-combination/) - Biomea Fusion announced positive preclinical data for icovamenib combined with semaglutide, a GLP-1 receptor agonist, in treating type 2 diabetes. The combination therapy showed significant improvements in several metabolic parameters compared to semaglutide alone, including enhanced glucose control, reduced insulin resistance, and increased lean muscle mass. These findings were observed in a preclinical study using
- [Sight Sciences Study Shows OMNI's Effectiveness in Glaucoma Management](https://www.clinicaltrialvanguard.com/news/sight-sciences-study-shows-omnis-effectiveness-in-glaucoma-management/) - A 36-month study using data from the American Academy of Ophthalmology IRIS® Registry demonstrated that Sight Sciences' OMNI® Surgical System significantly reduced intraocular pressure (IOP) and medication dependence in patients with primary open-angle glaucoma (POAG). This research is notable because it analyzes standalone OMNI use, independent of cataract surgery, providing crucial real-world data on its
- [Sana Biotechnology Shows Positive Results in Type 1 Diabetes Study](https://www.clinicaltrialvanguard.com/news/sana-biotechnology-shows-positive-results-in-type-1-diabetes-study/) - Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study, conducted in partnership with Uppsala University Hospital, transplanted allogeneic pancreatic islet cells engineered with Sana’s hypoimmune (HIP) technology, UP421, without requiring immunosuppression. Four weeks post-transplant, the patient exhibited detectable C-peptide levels, indicating insulin production by the
- [Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia](https://www.clinicaltrialvanguard.com/news/solid-biosciences-announces-fda-ind-clearance-for-first-in-industry-dual-route-of-administration-gene-therapy-to-treat-both-neurologic-and-cardiac-manifestations-of-friedreichs-ataxia/) - Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed to treat Friedreich’s ataxia (FA). SGT-212 is unique because it uses a dual route of administration – intravenous infusion and direct infusion into the cerebellum – to deliver a full-length frataxin gene. This approach aims to
- [Asher Biotherapeutics AB248 & Rilvegostomig in NSCLC: Phase 1b/2 Study Announced](https://www.clinicaltrialvanguard.com/news/asher-biotherapeutics-ab248-rilvegostomig-in-nsclc-phase-1b-2-study-announced/) - Asher Biotherapeutics and AstraZeneca have partnered to evaluate etakafusp alfa (AB248), Asher Bio’s CD8+ T cell-targeted IL-2 immunotherapy, in combination with AstraZeneca’s PD-1/TIGIT bispecific antibody, rilvegostomig. This combination therapy will be investigated as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a global study sponsored by AstraZeneca. Asher
- [Cassava Sciences Slashes Workforce by 33%](https://www.clinicaltrialvanguard.com/news/cassava-sciences-slashes-workforce-by-33/) - Cassava Sciences announced a 33% workforce reduction, cost-cutting measures, and anticipated topline data release from its Phase 3 REFOCUS-ALZ study of simufilam for Alzheimer's diseaseAlzheimer's disease in late Q1/early Q2 2025. This follows the failure of its Phase 3 RETHINK-ALZ study to meet primary endpoints in November 2024. The company held $128.6 million in cash
- [Bitterroot Bio Announces Positive Phase 1 Data for BRB-002](https://www.clinicaltrialvanguard.com/news/bitterroot-bio-announces-positive-phase-1-data-for-brb-002/) - Bitterroot Bio announced positive Phase 1 results for BRB-002, a first-in-class immune-modulating protein therapy targeting CD47 for atherosclerotic cardiovascular disease. The study in healthy volunteers showed BRB-002 was safe at all tested doses, with no serious adverse events, and demonstrated dose-dependent target engagement. A Phase 2 proof-of-concept study in patients with established atherosclerosis is anticipated
- [Aerwave's Ultrasound Therapy Shows Promise for COPD & Asthma](https://www.clinicaltrialvanguard.com/news/aerwaves-ultrasound-therapy-shows-promise-for-copd-asthma/) - AerWave Medical completed its first-in-human feasibility study of a novel ultrasound lung denervation therapy for chronic obstructive pulmonary disease (COPD) and asthma. The study, involving five patients, confirmed the feasibility and efficiency of AerWave’s ultrasound platform, which simplifies lung denervation by eliminating the need for fluoroscopic guidance, esophageal marker balloons, and multiple catheter exchanges. The
- [Quanta FDA Clearance for QTX3544 KRAS Inhibitor & Pipeline Updates](https://www.clinicaltrialvanguard.com/news/quanta-fda-clearance-for-qtx3544-kras-inhibitor-pipeline-updates/) - Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor, allowing for a Phase 1 clinical trial. The company also initiated the combination phase of its ongoing Phase 1 trial evaluating QTX3046, a G12D-selective KRAS inhibitor, with cetuximab, an EGFR inhibitor. A separate Phase 1 trial
- [Molecular Switches in Cell Signaling: Drug Development](https://www.clinicaltrialvanguard.com/news/molecular-switches-in-cell-signaling-drug-development/) - The sales of the top 20 drugs targeting molecular switches have exceeded $30 billion, highlighting the growing importance of these biological mechanisms in medicine and drug development. These switches play a crucial role in cell signaling, controlling various cellular processes and offering valuable therapeutic targets for a range of diseases. The research focuses on the
- [Maia and BeiGene Partner for Phase 2 Cancer Trials](https://www.clinicaltrialvanguard.com/news/maia-and-beigene-partner-for-phase-2-cancer-trials/) - MAIA Biotechnology will collaborate with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer drug, in combination with BeiGene's immune checkpoint inhibitor tislelizumab. The Phase 2 trials will focus on hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and colorectal cancer (CRC), three prevalent and deadly cancer types. This collaboration leverages BeiGene’s established CPI and MAIA’s promising
- [Sana Biotechnology Announces Positive Clinical Trial Results](https://www.clinicaltrialvanguard.com/news/sana-biotechnology-announces-positive-clinical-trial-results/) - Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study, conducted in partnership with Uppsala University Hospital, transplanted allogeneic pancreatic islet cells engineered with Sana’s hypoimmune (HIP) technology without immunosuppression. The transplanted cells survived, functioned, and evaded immune detection, evidenced by C-peptide production, increased C-peptide levels
- [Acumen Pharmaceutics Alzheimer's Prevention Study in Journal](https://www.clinicaltrialvanguard.com/news/acumen-pharmaceutics-alzheimers-prevention-study-in-journal/) - Acumen Pharmaceuticals announced positive Phase 1 clinical trial results for sabirnetug (ACU193), a potential Alzheimer's diseaseAlzheimer's disease treatment targeting amyloid beta oligomers (AβOs). Published in the •Journal of Prevention of Alzheimer’s Disease•, the INTERCEPT-AD trial data showed sabirnetug was well-tolerated, effectively engaged AβOs, and reduced amyloid plaques in higher dose groups. A Phase 2 trial,
- [IO Biotech's Cancer Vaccine Trial Enrolls Patients with Melanoma and Head/Neck Cancer](https://www.clinicaltrialvanguard.com/news/io-biotechs-cancer-vaccine-trial-enrolls-patients-with-melanoma-and-head-neck-cancer/) - IO Biotech has completed enrollment in its Phase 2 basket trial, IOB-032/PN-E40, ahead of schedule. The trial evaluates the company's lead cancer vaccine candidate, IO102-IO103, combined with Merck's Keytruda (pembrolizumab), in patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN). Initial data from this trial is anticipated in 2025. This
- [MRNA Cancer Vaccine Clinical Trials & Research](https://www.clinicaltrialvanguard.com/news/mrna-cancer-vaccine-clinical-trials-research/) - Over 60 mRNA cancer vaccine candidates are currently in clinical trials, with two reaching Phase III. BioNTech's BNT111, a promising mRNA vaccine for advanced melanoma, showed positive Phase II results when combined with the anti-PD-1 antibody cemiplimab. Kuick Research projects the first commercial approval of an mRNA cancer vaccine by 2029. This burgeoning field of
- [Rapport Therapeutics Announces Promising Phase 1 Data for CNS Disorders](https://www.clinicaltrialvanguard.com/news/rapport-therapeutics-announces-promising-phase-1-data-for-cns-disorders/) - Rapport Therapeutics (Nasdaq: RAPP) announced positive Phase 1 results for RAP-219, a drug candidate for central nervous system disorders. The trials demonstrated that RAP-219 achieved target receptor occupancy within five days and showed a favorable tolerability profile. The company also announced the resignation of their chief medical officer, Bradley Galer. These results are important because
- [EMA Discusses European Clinical Trial Decline at DTRA](https://www.clinicaltrialvanguard.com/conference-coverage/ema-discusses-european-clinical-trial-decline-at-dtra/) - Addressing the decline in clinical trials within Europe and the EMA's new regulation to streamline the approval process for multinational trials.
- [Pioneering the First Lab and Theranostic Platform: A Conversation with NuView CEO, Paul Crowe](https://www.clinicaltrialvanguard.com/executiveinterviews/pioneering-the-first-lab-and-theranostic-platform-a-conversation-with-nuview-ceo-paul-crowe/) - Learn how NuView's NV-VPAC1 platform is reshaping cancer care with advanced diagnostics and personalized therapy.
- [Ashvattha Therapeutics Secures $50M, Unveils Promising Ophthalmology Trial Results](https://www.clinicaltrialvanguard.com/news/ashvattha-therapeutics-secures-50m-unveils-promising-ophthalmology-trial-results/) - Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital with continued support from existing investors led by Natural Capital. This funding will propel Ashvattha's ongoing Phase 2 ophthalmology and Phase 1/2 neuroinflammation trials for its hydroxyl dendrimer therapeutic (HDT) platform. The company's lead candidate, migaldendranib (MGB), a subcutaneous
- [ORIC-944 Phase 1b Data, 2024 Highlights, Milestones](https://www.clinicaltrialvanguard.com/news/oric-944-phase-1b-data-2024-highlights-milestones/) - ORIC Pharmaceuticals announced encouraging early safety and efficacy data from a Phase 1b trial of ORIC-944 combined with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The company also highlighted operational achievements in 2024, including collaborations with Johnson & Johnson and Bayer, and provided anticipated milestones for the next 18 months. ORIC expects its
- [NeuroSigma ADHD Trial of Monarch eTNS System Completes Enrollment](https://www.clinicaltrialvanguard.com/news/neurosigma-adhd-trial-of-monarch-etns-system-completes-enrollment/) - NeuroSigma, Inc. announced the completion of enrollment for the ATTENS trial, a multicenter, double-blind, placebo-controlled study evaluating the effectiveness of its Monarch® eTNS System for treating ADHD in children and adolescents. The trial, funded by the UK's National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC), enrolled 150 participants aged
- [Artelo Biosciences Announces Successful Completion of First Cohort in Phase 1 Study of ART26.12](https://www.clinicaltrialvanguard.com/news/artelo-biosciences-announces-successful-completion-of-first-cohort-in-phase-1-study-of-art26-12/) - Artelo Biosciences has initiated a Phase 1 clinical trial of ART26.12, its lead FABP5 inhibitor, marking the first time a selective FABP5 inhibitor has been administered to humans. The company expects initial safety and pharmacokinetic data in the first half of 2025. This trial focuses on evaluating ART26.12 as a non-opioid treatment for various pain
- [Ashvattha Therapeutics Secures $50M, Unveils Promising Phase 2 Ophthalmology Results](https://www.clinicaltrialvanguard.com/news/ashvattha-therapeutics-secures-50m-unveils-promising-phase-2-ophthalmology-results/) - Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital and existing investors led by Natural Capital. This funding supports the continued development of migaldendranib (MGB), a novel subcutaneous treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), currently in Phase 2 trials. Interim results
- [Sage Therapeutics Unveils 2025 Strategic Focus at JPM Healthcare Conference](https://www.clinicaltrialvanguard.com/news/sage-therapeutics-unveils-2025-strategic-focus-at-jpm-healthcare-conference/) - Sage Therapeutics announced its 2025 strategic focus, centering on the growth of ZURZUVAE (zuranolone) for postpartum depression (PPD) and a recalibrated R&D approach focused on neurodevelopmental disorders and neuropsychiatry. The company expects substantial decreases in R&D and G&A expenses in 2025, extending their cash runway to mid-2027. This strategic shift follows the successful launch of
- [Immunis Secures $25M in Series A-1 Funding](https://www.clinicaltrialvanguard.com/news/immunis-secures-25m-in-series-a-1-funding/) - Immunis, Inc., a clinical-stage biotech company, secured $25 million in Series A-1 funding to advance two Phase 2 clinical trials for its multi-active biologic targeting age and disease-related immune dysregulation. Existing investors, including Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners, participated in the round, alongside new investors like LifeSpan Vision Ventures and JLS
- [HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder](https://www.clinicaltrialvanguard.com/news/hmnc-brain-health-completes-patient-randomization-for-phase-2b-olive-trial-for-major-depressive-disorder/) - HMNC Brain Health has completed patient randomization for its Phase 2b OLIVE trial, investigating the efficacy and safety of BH-200, a vasopressin V1b receptor antagonist, combined with a predictive companion diagnostic for Major Depressive Disorder (MDD). The trial focuses on patients with HPA-axis dysfunction, representing roughly 30% of all MDD cases, and is the largest
- [First Participants Randomized in AskBio Phase II Gene Therapy Trial for Parkinson's Disease](https://www.clinicaltrialvanguard.com/news/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinsons-disease/) - AskBio, a Bayer subsidiary, has initiated a Phase II clinical trial, REGENERATE-PD, for its Parkinson’s disease gene therapy, AB-1005 (AAV2-GDNF). The trial will evaluate the safety and efficacy of AB-1005 in adults with moderate-stage Parkinson’s disease across clinical sites in the United States, Germany, Poland, and the United Kingdom. Positive 36-month Phase Ib data showcased
- [Pasithea Opens EU Clinical Trial Sites & Completes Cohort 4 Dosing](https://www.clinicaltrialvanguard.com/news/pasithea-opens-eu-clinical-trial-sites-completes-cohort-4-dosing/) - Pasithea Therapeutics, a clinical-stage biotechnology company, has expanded its Phase 1 clinical trial of PAS-004, a next-generation MEK inhibitor, by opening three new sites in Eastern Europe. These new sites, located in Romania and Bulgaria, join four existing sites in the United States and are actively recruiting patients for the study, which is investigating PAS-004
- [Positive Clinical Data from Netherton Syndrome Study](https://www.clinicaltrialvanguard.com/news/positive-clinical-data-from-netherton-syndrome-study/) - Quoin Pharmaceuticals (QNRX) announced positive interim data from its ongoing pediatric Netherton Syndrome clinical study of QRX003, a topical treatment. The treatment showed significant skin improvement, prompting an expansion from a 20% body surface area application to whole-body application in the pediatric subject. Notably, no adverse events or safety concerns were reported, consistent with other
- [Eterna Therapeutics ERNA-101 Shows Promise in Preclinical Ovarian Cancer Study](https://www.clinicaltrialvanguard.com/news/eterna-therapeutics-erna-101-shows-promise-in-preclinical-ovarian-cancer-study/) - Eterna Therapeutics announced positive preclinical results for its lead cell therapy product, ERNA-101, in treating ovarian cancer. The study showed increased T cell infiltration into the tumor, reduced tumor size, and improved survival rates in mice after a single dose of ERNA-101. The therapy successfully transitioned the tumor microenvironment from "cold" (low immune activity) to
- [Context Therapeutics CTIM-76 Dosed in First Patient of Phase 1 Trial](https://www.clinicaltrialvanguard.com/news/context-therapeutics-ctim-76-dosed-in-first-patient-of-phase-1-trial/) - Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CTIM-76, a T cell engager bispecific antibody targeting Claudin 6 (CLDN6)-positive gynecologic and testicular cancers. The trial is designed to evaluate the safety and efficacy of CTIM-76, with initial data expected in the first half of 2026. This trial marks a
- [Bayer's Pharma Growth Strategy Advances Pipeline](https://www.clinicaltrialvanguard.com/news/bayers-pharma-growth-strategy-advances-pipeline/) - Bayer AG announced progress in its pharmaceutical growth strategy at the 43rd J.P. Morgan Healthcare Conference, highlighting regulatory submissions for darolutamide, finerenone, and elinzanetant. These submissions represent key growth drivers for the company, strengthening its position in oncology, cardiology, and women's health. The company also highlighted advancements in its cell and gene therapy platform and
- [Umoja Biopharma Gets $100M Series C for In Vivo CAR T-cell Pipeline](https://www.clinicaltrialvanguard.com/news/umoja-biopharma-gets-100m-series-c-for-in-vivo-car-t-cell-pipeline/) - Umoja Biopharma, a clinical-stage company developing •in vivo• cell therapies, secured $100 million in Series C funding. The round was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors. This funding will support the clinical development of Umoja’s •in vivo• CAR T cell therapy pipeline, particularly its lead program,
- [Glaukos iDose Shows Positive Clinical Results](https://www.clinicaltrialvanguard.com/news/glaukos-idose-shows-positive-clinical-results/) - Glaukos Corporation announced positive clinical updates for its iDose® sustained-release drug delivery platform for glaucoma and ocular hypertension. The iDose platform offers a minimally invasive implant that delivers consistent medication within the eye, addressing patient non-adherence and side effects associated with traditional topical drops. The company is actively investing in expanding its pharmaceutical development capabilities
- [FDA Update on ICH E6, E8, QbD and RBM in Clinical Trials](https://www.clinicaltrialvanguard.com/article/fda-update-on-ich-e6-e8-qbd-and-rbm-in-clinical-trials/) - The recent FDA workshop, "Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches," brought together industry leaders, regulators, and stakeholders to discuss the integration of QbD and RBM in clinical trials. This event, co-convened by the Duke Margolis Center for Health Policy, emphasized the
- [SIL-204 Shows Synergy with Chemotherapies in Preclinical Pancreatic Cancer Study](https://www.clinicaltrialvanguard.com/news/sil-204-shows-synergy-with-chemotherapies-in-preclinical-pancreatic-cancer-study/) - Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data show SIL-204 acts synergistically with standard chemotherapy agents like 5-fluorouracil, irinotecan, and gemcitabine, significantly reducing cancer cell confluence in KRAS G12D mutated pancreatic cancer cell lines. This builds on earlier successes with Silexion's first-generation product, LODER™,
- [Solid Biosciences: Advancing Neuromuscular and Cardiac Gene Therapy](https://www.clinicaltrialvanguard.com/news/solid-biosciences-advancing-neuromuscular-and-cardiac-gene-therapy/) - Solid Biosciences provided a corporate update highlighting its expanded clinical pipeline and 2025 objectives, focusing on genetic medicines for neuromuscular and cardiac diseases. The company announced progress in its Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) programs, and confirmed a strong cash position. This progress marks Solid Biosciences' transition
- [ImmunityBio's 2025 FDA Submissions After Agency Meeting](https://www.clinicaltrialvanguard.com/news/immunitybios-2025-fda-submissions-after-agency-meeting/) - ImmunityBio announced progress in discussions with the FDA concerning its non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancersmall cell lung cancer (NSCLC) treatments. The company anticipates submitting applications for an alternative BCG source, expanding ANKTIVA's use in NMIBC, and using ANKTIVA in combination with checkpoint inhibitors for NSCLC. These advancements aim to address
- [Scaling Cell & Gene Therapies Globally: CGT & Cellex Partnership](https://www.clinicaltrialvanguard.com/news/scaling-cell-gene-therapies-globally-cgt-cellex-partnership/) - CGT Global, a US-based cell collection and expansion company, and Cellex Cell Professionals, a German cell therapy manufacturer, have partnered to improve scalability and patient access to cell and gene therapies (CGT). This collaboration leverages CGT Global’s US clinic and laboratory network and Cellex’s expertise in cell product manufacturing, particularly CAR-T therapies. The partnership aims
- [Complete 12-Week Results of NORSE Eight Trial for Outlook Therapeutics®](https://www.clinicaltrialvanguard.com/news/complete-12-week-results-of-norse-eight-trial-for-outlook-therapeutics/) - Outlook Therapeutics announced positive 12-week results from its NORSE EIGHT trial for ONS-5010, an ophthalmic bevacizumab formulation for wet age-related macular degeneration (wet AMD). The treatment demonstrated non-inferiority to ranibizumab (Lucentis) at 12 weeks, paving the way for a Biologics License Application (BLA) resubmission in Q1 2025. The company also secured funding of up to
- [Micron Biomedical Secures $33M for Needle-Free Delivery](https://www.clinicaltrialvanguard.com/news/micron-biomedical-secures-33m-for-needle-free-delivery/) - Micron Biomedical secured $16 million in a Series A3 funding round, bringing the total Series A investment to over $33 million. This funding, led by J2 Ventures and the Global Health Investment Corporation (GHIC), will expand the commercial manufacturing of Micron's needle-free drug and vaccine delivery technology based on dissolvable microarrays. The company recently received
- [Omeros Announces Narsoplimab Trial Endpoint Update](https://www.clinicaltrialvanguard.com/news/omeros-announces-narsoplimab-trial-endpoint-update/) - Omeros Corporation announced positive sensitivity analysis results for narsoplimab, its monoclonal antibody targeting the lectin pathway of complement, in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). An independent statistical group conducted the analyses, confirming the robustness of previously reported primary endpoint data showing narsoplimab's survival benefit in TA-TMA patients. The sensitivity analyses consistently demonstrated
- [Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496](https://www.clinicaltrialvanguard.com/news/rubedo-life-sciences-announces-clinical-development-plans-for-lead-candidate-rls-1496/) - Rubedo Life Sciences announced clinical development plans for RLS-1496, a first-in-class GPX4 modulator targeting aging cells, at the 12th Annual Dermatology Summit. The company also initiated its Series B financing round and highlighted the potential of the longevity market, estimated at $600 billion. Phase 1 clinical trials for RLS-1496 are slated to begin in Spring
- [Silexion's SIL-204 Shows Synergy Against KRAS-Driven Cancers](https://www.clinicaltrialvanguard.com/news/silexions-sil-204-shows-synergy-against-kras-driven-cancers/) - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company, has released promising preclinical data for SIL-204, its next-generation RNA interference (RNAi) therapy targeting KRAS-driven cancers, including pancreatic cancer. The data demonstrates SIL-204 synergizes with standard chemotherapy agents, significantly enhancing their efficacy against KRAS-mutated tumor cells. This advancement builds upon the success of Silexion's first-generation LODER™ platform,
- [Shionogi's S-892216: Breakthrough COVID-19 Antiviral for At-Risk Groups](https://www.clinicaltrialvanguard.com/news/shionogis-s-892216-breakthrough-covid-19-antiviral-for-at-risk-groups/) - Shionogi Inc. secured a $375 million agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop S-892216, a long-acting injectable 3CL protease inhibitor for COVID-19 pre-exposure prophylaxis. This funding, awarded through the Rapid Response Partnership Vehicle (RRPV), aims to address the need for preventative treatments that offer sustained protection against severe COVID-19. Shionogi
- [Abbott's Roadmap to Diversifying Clinical Trials](https://www.clinicaltrialvanguard.com/executiveinterviews/abbotts-roadmap-to-diversifying-clinical-trials/) - Learn about Abbott's initiatives to diversify clinical trials and address systemic barriers in research, ensuring transparency and inclusivity.
- [Enigma Biomedical & Neuraly Announce Research & Commercialization Deal](https://www.clinicaltrialvanguard.com/news/enigma-biomedical-neuraly-announce-research-commercialization-deal/) - Neuraly Inc., a subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. signed a research license and commercialization option agreement for PMI04, a PET imaging biomarker of neuroinflammation. The agreement grants Enigma an exclusive research license for PMI04 with the option to negotiate commercialization rights. PMI04 targets activated microglia, offering a potentially more specific
- [Acalabrutinib Plus Chemoimmunotherapy Approved for Mantle Cell Lymphoma](https://www.clinicaltrialvanguard.com/news/acalabrutinib-plus-chemoimmunotherapy-approved-for-mantle-cell-lymphoma/) - The FDA has granted full approval to AstraZeneca's CALQUENCE (acalabrutinib) combined with bendamustine and rituximab for first-line treatment of adult mantle cell lymphoma (MCL) patients ineligible for autologous hematopoietic stem cell transplantation. This approval, based on the ECHO Phase III trial, follows a Priority Review and converts CALQUENCE’s prior accelerated approval for relapsed/refractory MCL into
- [Zai Lab's KarXT for Schizophrenia Treatment Accepted by FDA](https://www.clinicaltrialvanguard.com/news/zai-labs-karxt-for-schizophrenia-treatment-accepted-by-fda/) - Zai Lab's New Drug Application (NDA) for KarXT, a schizophrenia treatment for adults, has been accepted by China’s National Medical Products Administration (NMPA). This submission follows successful Phase 3 trials in China and globally, where KarXT significantly reduced schizophrenia symptoms with a tolerable safety profile. The NDA acceptance is based on positive results from a
- [FDA Accepts Arrowhead's New Drug Application for Plozasiran Treatment](https://www.clinicaltrialvanguard.com/news/fda-accepts-arrowheads-new-drug-application-for-plozasiran-treatment/) - Arrowhead Pharmaceuticals announced that the FDA accepted its New Drug Application (NDA) for plozasiran, a treatment for the rare genetic disorder familial chylomicronemia syndrome (FCS). The FDA set a target action date of November 18, 2025, and currently does not plan to convene an advisory committee meeting. Arrowhead plans to submit applications for plozasiran to
- [Datroway® Approved for Metastatic Breast Cancer](https://www.clinicaltrialvanguard.com/news/datroway-approved-for-metastatic-breast-cancer/) - Datopotamab deruxtecan (DATROWAY), a TROP2-directed antibody-drug conjugate (ADC), has received US approval for treating adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. Developed jointly by Daiichi Sankyo and AstraZeneca, DATROWAY is indicated for patients who have undergone prior endocrine-based therapy and chemotherapy. This approval follows positive results from the TROPION-Breast01 phase 3
- [Navigating Digital Health and Clinical Trials in Saudi Arabia](https://www.clinicaltrialvanguard.com/executiveinterviews/navigating-digital-health-and-clinical-trials-in-saudi-arabia/) - Learn how Saudi Arabia's collaborative ecosystem attracts Big Pharma funding for clinical trials.
- [AI in Oncology to Hit $11.52B by 2030, with 29.4% CAGR](https://www.clinicaltrialvanguard.com/news/ai-in-oncology-to-hit-11-52b-by-2030-with-29-4-cagr/) - The global AI in oncology market, valued at US$1.92 billion in 2023, is projected to reach US$11.52 billion by 2030, driven by increased healthcare spending, advanced infrastructure adoption, and a growing prevalence of cancers. This growth is further fueled by regulatory approvals for AI-based software and its integration with radiographic imaging, exemplified by Google Health's
- [Mainz Biomed starts a next-generation clinical trial for adenoma detection](https://www.clinicaltrialvanguard.com/news/mainz-biomed-starts-a-next-generation-clinical-trial-for-adenoma-detection/) - Mainz Biomed NV launched eAArly DETECT 2, a U.S. feasibility study for its next-generation colorectal cancer (CRC) screening test. The study, involving approximately 2,000 average-risk patients, aims to validate earlier promising results and pave the way for a larger pivotal study, ReconAAsense, planned for 2026. The new test integrates mRNA biomarkers, an AI-driven algorithm, and
- [RS Biotherapeutics Sees Positive Effects of Lead Compound on Human Lung Tissue](https://www.clinicaltrialvanguard.com/news/rs-biotherapeutics-sees-positive-effects-of-lead-compound-on-human-lung-tissue/) - RS BioTherapeutics announced positive results from a human lung tissue study of its lead compound, RSBT-001. The study showed RSBT-001 significantly reduced inflammatory biomarkers and mediators of fibrosis, confirming prior animal study results and expanding the compound's potential therapeutic applications. This first-in-class, steroid-free compound is being developed for deadly lung diseases like COPD and IPF.
- [Xilio Announces Phase 2 Data for Vilastobart in Metastatic Colorectal Cancer](https://www.clinicaltrialvanguard.com/news/xilio-announces-phase-2-data-for-vilastobart-in-metastatic-colorectal-cancer/) - Xilio Therapeutics announced initial positive Phase 2 data for vilastobart (XTX101), a tumor-activated anti-CTLA-4 antibody, combined with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The combination showed a 27% objective response rate in heavily pre-treated patients without liver metastases, accompanied by biomarker and symptom improvements. Data also suggested a favorable
- [Nikang's NKT2152 Dosed in First HCC Patient: Phase 1b/2 Trial Begins](https://www.clinicaltrialvanguard.com/news/nikangs-nkt2152-dosed-in-first-hcc-patient-phase-1b-2-trial-begins/) - NiKang Therapeutics has initiated a global Phase 1b/2 clinical trial evaluating NKT2152, an oral HIF2α inhibitor, in combination with atezolizumab and bevacizumab for first-line treatment of advanced or metastatic hepatocellular carcinoma (HCC). This trial, part of Roche's MORPHEUS-liver platform, will compare the combination therapy to the standard atezolizumab and bevacizumab regimen. Preclinical data suggests NKT2152
- [Kiromic Biopharma Sees Tumor Volume Decrease in Two Deltacel-01 Patients](https://www.clinicaltrialvanguard.com/news/kiromic-biopharma-sees-tumor-volume-decrease-in-two-deltacel-01-patients/) - Kiromic BioPharma announced positive efficacy results from its Deltacel-01 Phase 1 clinical trial of Deltacel™, an allogeneic, off-the-shelf Gamma Delta T-cell therapy for late-stage non-small cell lung cancersmall cell lung cancer (NSCLC). Two patients showed significant tumor reduction: the first enrolled patient experienced a 33.33% reduction at the 12-month follow-up, and the seventh patient showed
- [Allurion Gets New US Patent for Next-Gen Weight Loss Device](https://www.clinicaltrialvanguard.com/news/allurion-gets-new-us-patent-for-next-gen-weight-loss-device/) - Allurion Technologies received a patent for its enhanced, next-generation gastric balloon technology, specifically for its improved valve system. This new patent adds to Allurion's existing intellectual property, totaling 20 patents in the U.S. and 59 globally. The patented technology focuses on the precision of the balloon's valve system, a critical component of the Allurion Program,
- [Emervax's Circular RNA: A New Frontier in Vaccine Development](https://www.clinicaltrialvanguard.com/executiveinterviews/emervaxs-circular-rna-a-new-frontier-in-vaccine-development/) - Learn how Emervax's emxRNATM platform enhances vaccine stability and efficacy, offering a promising alternative to mRNA vaccines.
- [Exploring Innovations in Muscle Wasting Disease Treatment](https://www.clinicaltrialvanguard.com/executiveinterviews/exploring-innovations-in-muscle-wasting-disease-treatment/) - In this interview, we engage with David Craig from Sarcomatrix Therapeutics to discuss the development of S-969, a novel oral small molecule targeting the Hippo-YAP pathway. Our conversation covers regulatory challenges, clinical trial design, manufacturing scale-up, intellectual property protection, and strategic partnerships, offering insights into Sarcomatrix's approach to addressing muscle wasting diseases. Moe: What regulatory
- [Coherus' Final Phase 2 Combination Data for Metastatic HCC at ASCO-GI 2025](https://www.clinicaltrialvanguard.com/news/coherus-final-phase-2-combination-data-for-metastatic-hcc-at-asco-gi-2025/) - Coherus BioSciences announced final data from its Phase 2 trial of casdozokitug (casdozo), an IL-27-targeting antibody, combined with atezolizumab and bevacizumab in patients with advanced liver cancer (HCC). The final data shows a higher overall response rate (ORR) of 38% and a complete response rate of 17.2%, significantly improved from earlier reported figures. The positive
- [Helius Pons Therapy Shows Positive Gait Improvement in MS Patients](https://www.clinicaltrialvanguard.com/news/helius-pons-therapy-shows-positive-gait-improvement-in-ms-patients/) - Helius Medical Technologies announced positive results from their PoNSTEP study, demonstrating the long-term benefits of PoNS Therapy for gait deficits in multiple sclerosis (MS) patients. The study showed a significant improvement in gait, measured by the Dynamic Gait Index (DGI), and a correlation between adherence to the therapy and the degree of improvement. This is
- [Certepetide Shows Promise in Metastatic Pancreatic Cancer Trial](https://www.clinicaltrialvanguard.com/news/certepetide-shows-promise-in-metastatic-pancreatic-cancer-trial/) - Lisata Therapeutics announced preliminary data from Cohort A of its Phase 2 ASCEND trial evaluating certepetide, combined with standard chemotherapy, for metastatic pancreatic ductal adenocarcinoma (mPDAC). The data showed a positive trend in overall survival (mOS) for the certepetide group (12.68 months) compared to the placebo group (9.72 months), and four complete responses were observed
- [Discovery of New Immune Biomarkers in MS Patients Treated with Nasal Foralumab](https://www.clinicaltrialvanguard.com/news/discovery-of-new-immune-biomarkers-in-ms-patients-treated-with-nasal-foralumab/) - Tiziana Life SciencesLife Sciences has discovered new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with their lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The biomarkers, identified through single-cell RNA sequencing, indicate modulation of T regulatory cells, central memory T cells, monocytes, and B cells – pathways associated
- [Novel Factor XI Inhibitor Reduces Bleeding in Atrial Fibrillation](https://www.clinicaltrialvanguard.com/news/novel-factor-xi-inhibitor-reduces-bleeding-in-atrial-fibrillation/) - Anthos Therapeutics announced the publication of positive results from its AZALEA-TIMI 71 study in the •New England Journal of Medicine•. The study evaluated abelacimab, a Factor XI inhibitor, against rivaroxaban (a standard direct oral anticoagulant or DOAC) in atrial fibrillation patients at moderate-to-high stroke risk. Abelacimab demonstrated a significant reduction in bleeding events across all
- [LB-102 LB Pharma Segal Trial Shows Promising Phase 2 Schizophrenia Results](https://www.clinicaltrialvanguard.com/news/lb-102-lb-pharma-segal-trial-shows-promising-phase-2-schizophrenia-results/) - Segal Trials, a clinical research network specializing in psychiatric disorders, significantly contributed to the successful Phase 2 trial of LB-102, a novel antipsychotic for acute schizophrenia. The trial, sponsored by LB Pharmaceuticals, met its primary endpoint, demonstrating the drug’s efficacy, safety, and tolerability. Two Segal Trials investigators enrolled 18% of the total study participants, exceeding
- [Exicure and GPCR Therapeutics Announce Acquisition](https://www.clinicaltrialvanguard.com/news/exicure-and-gpcr-therapeutics-announce-acquisition/) - Exicure, Inc. acquired GPCR Therapeutics USA Inc. and entered into a licensing and collaboration agreement with GPCR Therapeutics Inc. to develop and commercialize GPCR’s intellectual property and patents related to G-Protein Coupled Receptors. The acquisition centers around GPCR USA’s ongoing Phase 2 clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). Exicure will make
- [Quoin Pharma QRX003 Shows Promising Netherton Syndrome Results](https://www.clinicaltrialvanguard.com/news/quoin-pharma-qrx003-shows-promising-netherton-syndrome-results/) - Quoin Pharmaceuticals announced further clinical evidence supporting the efficacy of QRX003, its topical treatment for Netherton Syndrome. Data from an open-label study showed a complete reversal of positive clinical improvements after treatment discontinuation, highlighting the need for chronic QRX003 application. This reversal reinforces the treatment's mechanism of action as a competitive broad-spectrum serine protease inhibitor,
- [Ampligen Clinical Trial Results Published for Post-COVID Conditions](https://www.clinicaltrialvanguard.com/news/ampligen-clinical-trial-results-published-for-post-covid-conditions/) - AIM ImmunoTech Inc. announced final clinical study results (AMP-518) for Ampligen in treating post-COVID conditions, specifically fatigue. The study, posted on ClinicalTrials.gov, reinforces the company's belief in Ampligen's potential for this indication. A new analysis from the NIH's RECOVER initiative linking Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) underscores the urgency of this research.
- [Outlook Therapeutics ON5-5010 Wet AMD Trial Results: Efficacy & Safety Unveiled](https://www.clinicaltrialvanguard.com/news/outlook-therapeutics-on5-5010-wet-amd-trial-results-efficacy-safety-unveiled/) - Outlook Therapeutics presented 12-week data from its NORSE EIGHT clinical trial of ONS-5010 (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD) at the Hawaiian Eye and Retina 2025 Meeting. The results showed ONS-5010 provided early and sustained anatomical improvements comparable to ranibizumab, with steady gains in best corrected visual acuity (BCVA) and a consistent safety
- [MiNK Therapeutics Allo-INKTs + BOT/BAL for Advanced Gastroesophageal Cancers](https://www.clinicaltrialvanguard.com/news/mink-therapeutics-allo-inkts-bot-bal-for-advanced-gastroesophageal-cancers/) - MiNK Therapeutics announced a presentation at the ASCO GI Symposium detailing a Phase 2 trial of its iNKT cell therapy, agenT-797, combined with Agenus’ botensilimab/balstilimab, ramucirumab, and paclitaxel in patients with previously treated gastroesophageal cancers. The trial builds on earlier Phase 1 data showing promising responses and tolerability in various cancers, particularly gastric cancer. This
- [Tiziana Life Sciences' Nasal Spray Shows Promise in Spinal Cord Injury Treatment](https://www.clinicaltrialvanguard.com/news/tiziana-life-sciences-nasal-spray-shows-promise-in-spinal-cord-injury-treatment/) - Tiziana Life Sciences announced positive preclinical results for their intranasal anti-CD3 monoclonal antibody, foralumab, in treating traumatic spinal cord injury (SCI). The treatment showed significant improvement in motor function in preclinical models after SCI, primarily by modulating microglial inflammation, a key driver of SCI pathogenesis. The company believes this nasal delivery method offers advantages in
- [Astria Therapeutics Initiates STAR-0310 Atopic Dermatitis Trial](https://www.clinicaltrialvanguard.com/news/astria-therapeutics-initiates-star-0310-atopic-dermatitis-trial/) - Astria Therapeutics has launched a Phase 1a clinical trial for STAR-0310, a monoclonal antibody designed to treat atopic dermatitis (AD). The trial will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adults. Astria anticipates preliminary results in Q3 2025. This trial initiation is a critical step in validating STAR-0310's potential as a
- [Medidata & Tigermed Renew Partnership to Accelerate Global Trials](https://www.clinicaltrialvanguard.com/news/medidata-tigermed-renew-partnership-to-accelerate-global-trials/) - Medidata, a Dassault Systèmes company, and Tigermed, a global clinical research provider, extended their 13-year partnership. This renewed collaboration focuses on utilizing the Medidata Platform to enhance clinical trial efficiency, from early phases through post-market surveillance, and speed up the delivery of new therapies globally. The partnership aims to optimize study workflows, ensure regulatory compliance,
- [Allurion and GLP-1: Optimizing Muscle During Weight Loss Therapy](https://www.clinicaltrialvanguard.com/news/allurion-and-glp-1-optimizing-muscle-during-weight-loss-therapy/) - Allurion Technologies plans to launch a clinical study combining its weight-loss program with GLP-1 agonists to address muscle loss, a common side effect of GLP-1 therapy. Existing research indicates that GLP-1 treatments can lead to a 40% reduction in lean mass as part of overall weight loss, while the Allurion Balloon, combined with its virtual
- [Transforming Clinical Trials: ActiGraph's Strategic Acquisition](https://www.clinicaltrialvanguard.com/executiveinterviews/transforming-clinical-trials-actigraphs-strategic-acquisition/) - ActiGraph's acquisition of Biofourmis Connect aligns with patient centricity, offering convenient remote monitoring solutions for trial participants.
- [Exelixis' Zanzalintinib Shows Promise in Metastatic Colorectal Cancer Trial](https://www.clinicaltrialvanguard.com/news/exelixis-zanzalintinib-shows-promise-in-metastatic-colorectal-cancer-trial/) - Exelixis announced results from the STELLAR-001 trial, a Phase 1b/2 study evaluating zanzalintinib, alone or combined with atezolizumab, in patients with previously treated metastatic colorectal cancer (CRC). The combination therapy showed numerically improved progression-free survival (PFS) and overall survival (OS) compared to zanzalintinib alone. This is particularly notable in a subgroup of patients without liver
- [Opdivo + Yervoy vs Opdivo: CheckMate - 8HW Results](https://www.clinicaltrialvanguard.com/news/opdivo-yervoy-vs-opdivo-checkmate-816-results/) - A Phase 3 CheckMate-8HW trial analysis revealed that Opdivo plus Yervoy significantly improved progression-free survival (PFS) compared to Opdivo alone in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). At a median 47-month follow-up, the combination therapy showed a 38% reduction in the risk of disease progression or death. This builds upon prior
- [Firefly Neuroscience Publishes EEG Analytics in Drug Development](https://www.clinicaltrialvanguard.com/news/firefly-neuroscience-publishes-eeg-analytics-in-drug-development/) - Firefly Neuroscience highlighted two studies demonstrating the potential of its FDA-cleared Brain Network Analytics (BNA™) platform in drug development and neuropsychiatric care. The studies utilized advanced resting EEG and cognitive EEG (ERP) data analytics to objectively measure treatment efficacy and cognitive change. The research focused on the impact of Novartis’ MIJ821 and vortioxetine on brain
- [Axiom, Brain Health Platform Foundation Partner for Alzheimer's Research](https://www.clinicaltrialvanguard.com/news/axiom-brain-health-platform-foundation-partner-for-alzheimers-research/) - Axiom Brain Health, in partnership with the Global Alzheimer’s Platform Foundation (GAP), launched its newly renovated research facility in Tampa, Florida. The expansion aims to address the growing need for research on neurodegenerative diseases like Alzheimer's, Multiple Sclerosis, and Parkinson's. The event highlighted the importance of volunteers, or “citizen scientists,” in advancing this research. This
- [Elevated Therapeutics Post-Hoc Analysis of Etiology Impact on HCC Survival](https://www.clinicaltrialvanguard.com/news/elevated-therapeutics-post-hoc-analysis-of-etiology-impact-on-hcc-survival/) - Elevar Therapeutics announced positive results from a post-hoc analysis of the CARES-310 study, showing that camrelizumab plus rivoceranib provides a clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit for patients with unresectable hepatocellular carcinoma (uHCC), regardless of whether the underlying cause is viral (hepatitis B or C) or non-viral. These findings were presented
- [Eyonis™ AI Lung Cancer Diagnostic Secures €47.5M Funding](https://www.clinicaltrialvanguard.com/news/eyonis-ai-lung-cancer-diagnostic-secures-e47-5m-funding/) - Median Technologies secured a non-binding term sheet with the European Investment Bank (EIB) for a loan of up to €37.5 million and signed a €10 million equity line with IRIS Capital Investment. The funding will support eyonis™ Lung Cancer Screening (LCS) software’s FDA approval, CE marking, and commercialization partnerships in the U.S. The initial €4
- [Exelixis Announces Results from CABINET Subgroup Analysis at ASCO GI 2025](https://www.clinicaltrialvanguard.com/news/exelixis-announces-results-from-cabinet-subgroup-analysis-at-asco-gi-2025/) - Exelixis announced positive results from a subgroup analysis of the phase 3 CABINET study, showing cabozantinib improved progression-free survival (PFS) compared to placebo in patients with advanced gastrointestinal (GI) neuroendocrine tumors (NET). This subgroup, comprising 116 of the 203 extra-pancreatic NET patients, represents a common and challenging-to-treat form of NET with limited treatment options after
- [Allurion Raises $7.4M in At-the-Market Offering](https://www.clinicaltrialvanguard.com/news/allurion-raises-7-4m-in-at-the-market-offering/) - Allurion Technologies, a company focused on obesity treatment, announced a registered direct offering of 1,240,000 shares of common stock at $6.00 per share, raising approximately $7.4 million before expenses. Concurrent with the offering, Allurion will issue warrants for an equal number of shares at the same exercise price, subject to shareholder approval for repricing existing
- [Ocugen's OCU500 Inhaled COVID-19 Vaccine Enters Phase 1 Trial](https://www.clinicaltrialvanguard.com/news/ocugens-ocu500-inhaled-covid-19-vaccine-enters-phase-1-trial/) - Ocugen has received FDA approval to begin a Phase 1 clinical trial for OCU500, an inhaled and nasal spray vaccine for COVID-19. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), will assess the vaccine's safety, tolerability, and immunogenicity in 80 adult participants. This development leverages a novel chimpanzee adenovirus-vectored (ChAd36)
- [Adagene Announces Updated Data From Phase 1b/2 Study of Muza in Colorectal Cancer at ASCO GI](https://www.clinicaltrialvanguard.com/news/adagene-announces-updated-data-from-phase-1b-2-study-of-muza-in-colorectal-cancer-at-asco-gi/) - Adagene Inc. announced positive updated clinical data for ADG126 (muzastotug), an anti-CTLA-4 SAFEbody® drug, combined with pembrolizumab in a Phase 1b/2 trial for microsatellite stable colorectal cancer (MSS CRC). The combination therapy demonstrated a 33% overall response rate in twelve patients receiving a 20 mg/kg loading dose followed by 10 mg/kg every three weeks, with
- [FDA Grants Cartesian Special Protocol for Phase 3 Trial in Myasthenia Gravis](https://www.clinicaltrialvanguard.com/news/fda-grants-cartesian-special-protocol-for-phase-3-trial-in-myasthenia-gravis/) - Cartesian Therapeutics (NASDAQ: RNAC) received FDA approval under the Special Protocol Assessment (SPA) process for the Phase 3 AURORA trial design of Descartes-08, its mRNA cell therapy candidate for myasthenia gravis (MG). The SPA agreement confirms the trial design is suitable for a future Biologics License Application, pending trial results. The Phase 3 trial is
- [RenovoRx ASCO GI 2025: Promising Pharmacokinetic Data](https://www.clinicaltrialvanguard.com/news/renovorx-asco-gi-2025-promising-pharmacokinetic-data/) - RenovoRx announced promising pharmacokinetic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial, investigating its Trans-Arterial Micro-Perfusion (TAMP) therapy platform for locally advanced pancreatic cancer (LAPC). The sub-study compared intra-arterial gemcitabine (IAG) delivered via the RenovoCath system with the current standard of care, intravenous gemcitabine. Results indicate that IAG via TAMP reduces
- [Lerodalcibep Shows Promise in HoFH Phase 3 Study](https://www.clinicaltrialvanguard.com/news/lerodalcibep-shows-promise-in-hofh-phase-3-study/) - LIB Therapeutics' Phase 3 LIBerate-HoFH study results for lerodalcibep, a novel PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia (HoFH) were published in Lancet Diabetes & Endocrinology. The study, a randomized, crossover trial, compared lerodalcibep to evolocumab in a diverse global population of HoFH patients aged 10 and older. The primary endpoint was the percent
- [Eisai's Innovative Bayesian Approach Accelerates Alzheimer's Drug Approval](https://www.clinicaltrialvanguard.com/conference-coverage/eisais-innovative-bayesian-approach-accelerates-alzheimers-drug-approval/) - Explore the evolution of Bayesian clinical trial design and its impact on drug development, as showcased by Eisai.
- [Advancing Cancer Treatment with Nektar Therapeutics: Insights into NKTR-255](https://www.clinicaltrialvanguard.com/executiveinterviews/advancing-cancer-treatment-with-nektar-therapeutics-insights-into-nktr-255/) - Learn how NKTR-255 is revolutionizing cancer therapy by enhancing NK and CD8 cells in patients with solid tumors and hematological cancers.
- [Positive Topline Results in 5-MeO-DMT Study for Alcohol Use Disorder](https://www.clinicaltrialvanguard.com/news/positive-topline-results-in-5-meo-dmt-study-for-alcohol-use-disorder/) - Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation, for alcohol use disorder (AUD). The open-label study in 12 patients showed that a single dose of BPL-003, combined with relapse prevention therapy, led to significant and sustained reductions in alcohol consumption over 12 weeks. The
- [SAB Bio Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142](https://www.clinicaltrialvanguard.com/news/sab-bio-announces-positive-topline-phase-1-clinical-results-with-potentially-disease-modifying-t1d-therapy-sab-142/) - SAB Bio announced positive topline data from a Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin being developed to delay or prevent type 1 diabetes (T1D). The study in healthy volunteers met its primary safety and pharmacodynamic objectives, paving the way for Phase 2b development. The results confirm that SAB-142 does not cause serum
- [March Biosciences Gets FDA Orphan Drug for Lymphoma](https://www.clinicaltrialvanguard.com/news/march-biosciences-gets-fda-orphan-drug-for-lymphoma/) - March Biosciences received FDA orphan drug designation for MB-105, its CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma. The company is preparing to advance MB-105 to a Phase 2 clinical trial in early 2025, following a recently closed Series A financing round of $28.4 million. This designation acknowledges the unmet need for new treatments
- [Silexion Shows Strong Tumor Reduction in Pancreatic Cancer Models](https://www.clinicaltrialvanguard.com/news/silexion-shows-strong-tumor-reduction-in-pancreatic-cancer-models/) - Silexion Therapeutics announced positive preclinical data for SIL-204, its RNAi therapeutic candidate targeting KRAS-driven cancers. The data validates systemic administration of the drug, showing significant tumor reduction in orthotopic pancreatic cancer models. Further research will investigate SIL-204’s impact on metastasis. This preclinical success is a crucial step for Silexion and potentially for patients battling KRAS-driven
- [Tevogen Bio Secures $10M Grant Funding](https://www.clinicaltrialvanguard.com/news/tevogen-bio-secures-10m-grant-funding/) - Tevogen Bio (Nasdaq: TVGN), a clinical-stage immunotherapy biotech company, has secured up to $10 million in non-dilutive grant funding from KRHP LLC, an affiliate of an existing Tevogen investor. The initial contribution is $2 million, with the potential for an additional $8 million based on KRHP’s review of Tevogen’s progress. This funding will support the
- [First Canadian Clinic Offers C2N's PrecivityAD2 Blood Test for Alzheimer's](https://www.clinicaltrialvanguard.com/news/first-canadian-clinic-offers-c2ns-precivityad2-blood-test-for-alzheimers/) - The Toronto Memory Program (TMP) is the first clinic in Canada to offer C2N Diagnostics' PrecivityAD2 blood test for Alzheimer's diseaseAlzheimer's disease. This non-invasive test detects amyloid pathology, a hallmark of Alzheimer's, and addresses the diagnostic challenges posed by limited access to specialists and infrastructure like PET scanners. The test is designed for individuals aged
- [Transforming Clinical Trials: Gen Li's Vision for the Future](https://www.clinicaltrialvanguard.com/executiveinterviews/transforming-clinical-trials-gen-lis-vision-for-the-future/) - Explore Gen Li's insights on the challenges and innovations in clinical trials post-pandemic, and the role of AI and data analytics in mitigating risks.
- [Targeted Alpha Therapy Clinical Trials: An Overview](https://www.clinicaltrialvanguard.com/news/targeted-alpha-therapy-clinical-trials-an-overview/) - Over 20 alpha therapies are currently in clinical trials, marking a significant advancement in targeted cancer treatment. These therapies utilize alpha-emitting isotopes to deliver highly localized radiation to tumor cells, minimizing damage to surrounding healthy tissues. This approach is particularly effective against challenging cancers, including those with low cell counts or bone metastases. The increasing
- [Gamma Delta T Cell Cancer Therapy Clinical Trials Overview](https://www.clinicaltrialvanguard.com/news/gamma-delta-t-cell-cancer-therapy-clinical-trials-overview/) - The global gamma delta T cell therapy market is experiencing rapid growth, driven by over 30 therapies currently in clinical trials, primarily concentrated in the US and China. These therapies leverage the unique properties of gamma delta T cells, which can recognize a broad range of antigens without MHC presentation, offering advantages over conventional T
- [Cardiovascular Devices Market to Hit $110B by 2029](https://www.clinicaltrialvanguard.com/news/cardiovascular-devices-market-to-hit-110b-by-2029/) - The global cardiovascular devices market, valued at US$72.83 billion in 2023, is projected to reach US$110.39 billion by 2029, growing at a CAGR of 7.3%. This growth is driven by the rising prevalence of cardiovascular disease (CVD), an aging global population, and increasing risk factors such as diabetes, hypertension, and obesity. Advancements in technology, including
- [4DMT to Review 52-Week Interim Phase 2b Results](https://www.clinicaltrialvanguard.com/news/4dmt-to-review-52-week-interim-phase-2b-results/) - 4D Molecular Therapeutics will present 52-week interim data from the Phase 2b portion of its PRISM clinical trial evaluating 4D-150 for wet age-related macular degeneration (wet AMD). Dr. Dante Pieramici, a principal investigator in the trial, will present the findings at the Angiogenesis, Exudation, and Degeneration 2025 conference on February 8, 2025. A follow-up webcast
- [DPTX3496: New Drug Candidate for Colorectal, Breast, and Lung Cancers](https://www.clinicaltrialvanguard.com/news/dptx3496-new-drug-candidate-for-colorectal-breast-and-lung-cancers/) - Dewpoint Therapeutics has nominated DPTX3496, its second drug development candidate. DPTX3496 is an oral small molecule designed to treat Wnt-driven cancers like colorectal, breast, and lung cancers by modulating condensates within cells. The drug is currently in IND-enabling studies, with an IND filing anticipated for the second half of 2025. This development represents a potentially
- [Lasofoxifene vs. Fulvestrant Effects on Urogenital Symptoms in ER+/HER2- Breast Cancer](https://www.clinicaltrialvanguard.com/news/lasofoxifene-vs-fulvestrant-effects-on-urogenital-symptoms-in-er-her2-breast-cancer/) - Sermonix Pharmaceuticals announced published results from a secondary endpoint analysis of its Phase 2 ELAINE-1 study of lasofoxifene in patients with •ESR1•-mutant, ER+/HER2- metastatic breast cancer. The analysis, published in •Clinical Breast Cancer•, revealed that lasofoxifene improved vaginal and vulvar symptoms like dryness and pain, while fulvestrant, the comparator drug, did not show the same
- [Regulatory Review Update on Lecanemab for Early Alzheimer's Disease in the EU](https://www.clinicaltrialvanguard.com/news/regulatory-review-update-on-lecanemab-for-early-alzheimers-disease-in-the-eu/) - Eisai and Biogen provided an update on the European Union's regulatory review of lecanemab, a treatment for early-stage Alzheimer's diseaseAlzheimer's disease. The European Commission requested the Committee for Medicinal Products for Human Use (CHMP) to review recently available safety information on lecanemab and clarify risk mitigation measures. This review will occur at the CHMP's February
- [Cervomed Neflamapimod DLB Program Update at Lewy Body Dementia Conference](https://www.clinicaltrialvanguard.com/news/cervomed-neflamapimod-dlb-program-update-at-lewy-body-dementia-conference/) - CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The blinded portion of the trial showed no significant difference between neflamapimod and placebo, likely due to lower-than-expected drug concentrations potentially linked to the age of the drug batch used. However, subsequent analyses and a food-effect study
- [Datopotamab Deruxtecan Recommended for Approval in the EU](https://www.clinicaltrialvanguard.com/news/datopotamab-deruxtecan-recommended-for-approval-in-the-eu/) - Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval in the European Union for treating advanced hormone receptor-positive, HER2-negative breast cancer in adults who have received prior endocrine therapy and chemotherapy. The positive opinion from the CHMP is based on the TROPION-Breast01 phase 3 trial,
- [Eli Lilly's Omvoh gets FDA approval for Crohn's disease but faces challenges](https://www.clinicaltrialvanguard.com/news/eli-lillys-omvoh-gets-fda-approval-for-crohns-disease-but-faces-challenges/) - Eli Lilly's Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn'sCrohn's disease. Despite physician familiarity with Omvoh, gastroenterologists surveyed by Spherix Global Insights prefer Johnson & Johnson's Tremfya (currently awaiting approval) for Crohn’s disease treatment. This preference stems from a perception of Tremfya as a more significant advancement over
- [PrecivityAD2™ Blood Test Improves Alzheimer's Disease Evaluation](https://www.clinicaltrialvanguard.com/news/precivityad2-blood-test-improves-alzheimers-disease-evaluation/) - Researchers found that C2N Diagnostics' PrecivityAD2 blood test improved healthcare providers' ability to assess the likelihood of Alzheimer's diseaseAlzheimer's disease in their patients. This improved accuracy led to more informed decisions regarding treatment, including changes in Alzheimer's medication plans and further brain amyloid testing. The study involved diverse patient demographics, including underrepresented minorities, and took
- [Eyonis™ Lung Cancer Screening Meets Primary Endpoint in RELIVE Trial](https://www.clinicaltrialvanguard.com/news/eyonis-lung-cancer-screening-meets-primary-endpoint-in-relive-trial/) - Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software. The study met its primary endpoint, demonstrating that eyonis™ LCS significantly improves diagnostic accuracy when used in conjunction with radiologists compared to radiologists alone. This achievement follows the successful completion of the REALITY study and paves
- [Invivyd Announces Positive Phase 1/2 Data for VYD2311 for COVID-19](https://www.clinicaltrialvanguard.com/news/invivyd-announces-positive-phase-1-2-data-for-vyd2311-for-covid-19/) - Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection against COVID-19 compared to existing vaccines. The trial, involving 40 subjects, evaluated intravenous, intramuscular, and subcutaneous administration, demonstrating positive safety and pharmacokinetic results, supported by strong antiviral activity. VYD2311 offers a potential alternative to frequent booster
- [Seclidemstat and Azacitidine Trial for Hematologic Cancers Patient Enrollment Resumes](https://www.clinicaltrialvanguard.com/news/seclidemstat-and-azacitidine-trial-for-hematologic-cancers-patient-enrollment-resumes/) - Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial at MD Anderson Cancer Center (MDACC). The trial is investigating seclidemstat, an oral LSD1 inhibitor, in combination with azacitidine for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The FDA previously placed a partial clinical hold on
- [Tenaya Therapeutics Gets $8M Grant for Heart Failure Research](https://www.clinicaltrialvanguard.com/news/tenaya-therapeutics-gets-8m-grant-for-heart-failure-research/) - Tenaya Therapeutics received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its Phase 1b RIDGE-1 clinical trial of TN-401 gene therapy. TN-401 is designed to treat arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the •PKP2• gene, a condition affecting an estimated 70,000 people in the U.S. The
- [Nexalin's Breakthrough DIFS™ Device Reduces Blood Pressure, Improves Mental Health](https://www.clinicaltrialvanguard.com/news/nexalins-breakthrough-difs-device-reduces-blood-pressure-improves-mental-health/) - Nexalin Technology, Inc. announced positive results from a clinical study published in the Journal of Affective Disorders, showing its Deep Intracranial Frequency Stimulation (DIFS) technology significantly reduced blood pressure in patients with major depressive disorder (MDD). The study highlighted that patients with higher baseline blood pressure experienced the most significant improvements, and the treatment was
- [FLT201 Gene Therapy Shows Promise in Gaucher Disease Trial](https://www.clinicaltrialvanguard.com/news/flt201-gene-therapy-shows-promise-in-gaucher-disease-trial/) - Spur Therapeutics released positive Phase 1/2 trial data for FLT201, a gene therapy for Gaucher disease type 1. The therapy showed significant improvements in lyso-Gb1, a key disease marker, and maintained or improved blood counts, organ volume, and bone marrow burden after a single infusion. FLT201 also demonstrated a favorable safety profile. This advancement is
- [Auron Therapeutics Announces FDA Clearance and Series B Financing](https://www.clinicaltrialvanguard.com/news/auron-therapeutics-announces-fda-clearance-and-series-b-financing/) - Auron Therapeutics, a clinical-stage biotech company, announced progress on its lead KAT2A/B program and candidate AUTX-703, along with a successful $27 million Series B funding round. The FDA cleared Auron’s Investigational New Drug application, paving the way for clinical trials of AUTX-703, a novel oral KAT2A/B degrader, in patients with hematological malignancies. Preclinical data presented
- [FDA Approves Susvimo for Diabetic Blindness](https://www.clinicaltrialvanguard.com/news/fda-approves-susvimo-for-diabetic-blindness/) - The FDA approved Susvimo (ranibizumab injection) for diabetic macular edema (DME), a leading cause of vision loss. This marks the second indication for Susvimo, following its 2021 approval for wet age-related macular degeneration (AMD). The approval is based on the Phase III Pagoda study, which demonstrated Susvimo’s ability to maintain vision improvements in DME patients
- [GlucoTrack Announces Successful Human Clinical Trial of CGM](https://www.clinicaltrialvanguard.com/news/glucotrack-announces-successful-human-clinical-trial-of-cgm/) - Glucotrack, Inc. has successfully completed its first human clinical study of a continuous blood glucose monitor (CBGM) implanted in the subclavian vein. The study focused on the safety of the device's placement, usage, and removal in six participants with diabetes requiring intensive insulin therapy. No procedure or device-related serious adverse events were reported. This successful
- [Annovis' Buntanetap Enters Phase 3 Alzheimer's Study](https://www.clinicaltrialvanguard.com/news/annovis-buntanetap-enters-phase-3-alzheimers-study/) - Annovis Bio has initiated its pivotal Phase 3 trial for buntanetap, an oral drug candidate for early-stage Alzheimer's diseaseAlzheimer's disease. The trial will assess both the symptomatic and disease-modifying potential of the drug over 18 months in over 750 participants. This follows promising results from a Phase 2/3 study showing cognitive improvement in early AD
- [Study Shows ux111 Gene Therapy Improves Clinical Function in Children with Sanfilippo Syndrome Type A](https://www.clinicaltrialvanguard.com/news/study-shows-ux111-gene-therapy-improves-clinical-function-in-children-with-sanfilippo-syndrome-type-a/) - Ultragenyx Pharmaceutical announced positive data from its pivotal and long-term follow-up studies of UX111 (ABO-102), a gene therapy for Sanfilippo syndrome type A (MPS IIIA). The therapy showed statistically significant improvements in cognitive, receptive communication, and expressive communication scores compared to natural history data, correlating with substantial reductions in heparan sulfate (HS) in cerebrospinal fluid
- [Arbor Biotechnologies' ABO-101 Gets FDA Orphan Drug, Rare Pediatric Disease Designations](https://www.clinicaltrialvanguard.com/news/arbor-biotechnologies-abo-101-gets-fda-orphan-drug-rare-pediatric-disease-designations/) - Arbor Biotechnologies received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for ABO-101, a gene editing therapy for primary hyperoxaluria type 1 (PH1). This follows the FDA's acceptance of the Investigational New Drug application, paving the way for a Phase 1/2 trial in the first half of 2025. Preclinical data and the
- [Ziftomenib Shows Promise in AML Monotherapy & Combination Trials](https://www.clinicaltrialvanguard.com/news/ziftomenib-shows-promise-in-aml-monotherapy-combination-trials/) - Kura Oncology and Kyowa Kirin announced positive topline results from the KOMET-001 Phase 2 trial of ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The trial met its primary endpoint of complete remission (CR) plus CR with partial hematological recovery (CRh), with a statistically significant result and an encouraging
- [Zenocutuzumab Efficacy in NRG1+ Cancer: Groundbreaking Results](https://www.clinicaltrialvanguard.com/news/zenocutuzumab-efficacy-in-nrg1-cancer-groundbreaking-results/) - Merus N.V. announced that the New England Journal of Medicine (NEJM) published positive results from the phase 2 eNRGy trial of Bizengri (zenocutuzumab) for treating advanced NRG1 fusion-positive pancreatic adenocarcinoma and non-small cell lung cancersmall cell lung cancer (NSCLC). This marks the first approved therapy specifically targeting this rare genetic alteration, addressing an unmet medical
- [BioXcel: Business & Clinical Update](https://www.clinicaltrialvanguard.com/news/bioxcel-business-clinical-update/) - BioXcel Therapeutics provided an update on its late-stage clinical trials for BXCL501, a drug for acute agitation, and highlighted recent corporate developments. The company is advancing the SERENITY at-home trial for agitation related to bipolar disorders or schizophrenia and planning the TRANQUILITY in-care trial for agitation in Alzheimer's dementia. BioXcel also improved its financial position
- [Enveda's First-in-Class ENV-294 for Asthma: A Breakthrough](https://www.clinicaltrialvanguard.com/news/envedas-first-in-class-env-294-for-asthma-a-breakthrough/) - Enveda Biosciences is testing its lead drug candidate, ENV-294, for asthma, marking its second clinical application after atopic dermatitis. The drug is a small molecule designed to address shared inflammatory pathways through a novel mechanism, offering a potential non-steroidal, oral treatment option. The company has formed an advisory board of asthma experts to guide development.
- [AgelessRx Launches Oral GLP-1 Drops for Metabolic Health](https://www.clinicaltrialvanguard.com/news/agelessrx-launches-oral-glp-1-drops-for-metabolic-health/) - AgelessRx has launched oral sublingual drops for the GLP-1 receptor agonists Semaglutide and Tirzepatide, offering a non-injectable alternative for metabolic health management. This move aims to broaden access to therapies that may combat age-related decline and promote longevity. The company believes GLP-1s are crucial for overall health and healthspan due to their potential impact on
- [Vaxxas Appoints Global Vaccine Experts for Needle-Free Trials](https://www.clinicaltrialvanguard.com/news/vaxxas-appoints-global-vaccine-experts-for-needle-free-trials/) - Vaxxas, a clinical-stage biotech company, has appointed three prominent vaccine experts as advisors to guide product development and strategy. These additions aim to support the company’s progress toward later-stage clinical trials and commercialization of its high-density microarray patch (HD-MAP) vaccine technology. The company is focused on advancing its COVID-19, influenza, and RSV vaccine candidates delivered
- [Trinity Biotech CGM Trial Shows Landmark First-Day Accuracy Gains](https://www.clinicaltrialvanguard.com/news/trinity-biotech-cgm-trial-shows-landmark-first-day-accuracy-gains/) - Trinity Biotech announced positive findings from a pre-pivotal trial of its next-generation continuous glucose monitoring (CGM) system, demonstrating significant improvements in first-day accuracy. The redesigned sensor showed a 35% improvement in Mean Absolute Relative Difference (MARD) and a greater than 50% improvement in Mean Absolute Difference (MAD) compared to the previous Waveform product. This trial
- [Tonix CD40L MAb Shows Promise in Kidney Transplant Rejection](https://www.clinicaltrialvanguard.com/news/tonix-cd40l-mab-shows-promise-in-kidney-transplant-rejection/) - Tonix Pharmaceuticals announced positive topline results from its Phase 1 single ascending dose trial of TNX-1500, an anti-CD40L monoclonal antibody, in healthy participants. The trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 to inform dosing for a planned Phase 2 trial in kidney transplant recipients. The results support the continuation of TNX-1500
- [Wave Life Sciences Initiates Phase 1 Inlight Trial of WVE-007 in Obesity](https://www.clinicaltrialvanguard.com/news/wave-life-sciences-initiates-phase-1-inlight-trial-of-wve-007-in-obesity/) - Wave Life Sciences has initiated a Phase 1 clinical trial, INLIGHT, for WVE-007, a novel RNA interference (RNAi) therapy targeting obesity. WVE-007, administered as a long-acting GalNAc-siRNA, targets INHBE mRNA, which encodes a protein that inhibits fat burning. The company anticipates releasing proof-of-concept data from the trial in 2025. This development is potentially groundbreaking for
- [CytoDyn Shows Statistically Significant Fibrosis Reversal](https://www.clinicaltrialvanguard.com/news/cytodyn-shows-statistically-significant-fibrosis-reversal/) - CytoDyn Inc. announced positive preclinical results for leronlimab, demonstrating a statistically significant reversal of liver fibrosis in three separate studies conducted with SMC Laboratories. These studies utilized different models of liver fibrosis, including a high-fat diet and a fibrosis-inducing agent, and all showed leronlimab monotherapy significantly outperformed the control group. The company believes this is
- [Daring Denali Therapeutics MPS II Study Delivers!](https://www.clinicaltrialvanguard.com/news/daring-denali-therapeutics-mps-ii-study-delivers/) - Denali Therapeutics announced primary analysis results from a Phase 1/2 study of tividenofusp alfa (DNL310) in 47 participants with Hunter syndrome (MPS II). Long-term data show sustained biomarker reductions, improvements in hearing, cognition, and adaptive behavior, and a generally well-tolerated safety profile over a median follow-up of two years and up to four years. Denali
- [Eylea HD: 3-Year Results Show Durable Vision Gains in Wet AMD](https://www.clinicaltrialvanguard.com/news/eylea-hd-3-year-results-show-durable-vision-gains-in-wet-amd/) - Regeneron announced positive three-year results from an extension study of the Phase 3 PULSAR trial for EYLEA HD (aflibercept 8 mg) in patients with wet age-related macular degeneration (wAMD). The study showed that the majority of patients maintained visual and anatomical improvements with extended dosing intervals, some as long as six months. Data also revealed
- [Ampligen® & Flumist®: AIM Immunotech's Innovative Avian Flu Trial](https://www.clinicaltrialvanguard.com/news/ampligen-flumist-aim-immunotechs-innovative-avian-flu-trial/) - AIM ImmunoTech Inc. is initiating a plan to further develop Ampligen as a vaccine adjuvant for avian influenza. The company has engaged Amarex Clinical Research to manage an Investigational New Drug (IND) application for a combination therapy study involving Ampligen and AstraZeneca’s FluMist. AIM is actively pursuing grants to support the study's costs. This development
- [Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025](https://www.clinicaltrialvanguard.com/news/positive-phase-2-data-for-subcutaneous-migaldendranib-at-angiogenesis-2025/) - Ashvattha Therapeutics announced positive Phase 2 trial data for its subcutaneously administered nanomedicine, Migaldendranib (MGB), designed to treat retinal diseases like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The therapy aims to reduce the need for frequent intravitreal (IVT) injections by targeting and reducing fluid production in the retina of both
- [Achieve Life Sciences Positive Orca-OL Trial Results](https://www.clinicaltrialvanguard.com/news/achieve-life-sciences-positive-orca-ol-trial-results/) - Achieve Life Sciences announced positive safety results from the second review of their ongoing ORCA-OL trial for cytisinicline, a smoking cessation treatment. The Data Safety Monitoring Committee (DSMC) found no unexpected adverse events and noted excellent participant adherence to the medication. Achieve remains on track to submit a New Drug Application (NDA) in Q2 2025.
- [Padcev® Plus Keytruda® Shows Long-Term Efficacy in Urothelial Cancer](https://www.clinicaltrialvanguard.com/news/padcev-plus-keytruda-shows-long-term-efficacy-in-urothelial-cancer/) - Pfizer and Astellas announced updated results from the Phase 3 EV-302 trial, showing sustained overall survival (OS) and progression-free survival (PFS) benefits with enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer (la/mUC). After a median follow-up of 29.1 months, the combination therapy continued to demonstrate a significant reduction in the
- [Voyager Provides Update on SOD1 ALS Gene Therapy Program](https://www.clinicaltrialvanguard.com/news/voyager-provides-update-on-sod1-als-gene-therapy-program/) - Voyager Therapeutics is halting development of its SOD1 ALS gene therapy, VY9323, after three-month primate data revealed an off-target effect and a narrow therapeutic window. The company will explore alternative payloads for the treatment, while retaining its novel TRACER capsid, which performed well in other preclinical studies. This decision extends Voyager’s cash runway into mid-2027,
- [Corbus Pharmaceuticals Announces Clinical Data for CRB-701](https://www.clinicaltrialvanguard.com/news/corbus-pharmaceuticals-announces-clinical-data-for-crb-701/) - Corbus Pharmaceuticals announced that an abstract for its first-in-human dose-escalation clinical study of CRB-701 (SYS6002) for advanced solid tumors has been released. The study, conducted in the US and Europe, evaluates the safety, pharmacokinetics, and efficacy of CRB-701 in patients with high Nectin-4 expression. Updated data from 38 patients will be presented at the 2025
- [Positive INB-100 Phase 1 Leukemia Trial Results Reported by in8bio](https://www.clinicaltrialvanguard.com/news/positive-inb-100-phase-1-leukemia-trial-results-reported-by-in8bio/) - IN8bio's Phase 1 trial of INB-100, a gamma-delta T cell therapy for complex leukemias like AML, has shown promising results. All AML patients in the trial remain in complete remission with a median follow-up of 20.1 months, exceeding one-year progression-free survival and overall survival rates compared to historical control groups. The persistence of gamma-delta T
- [Allostem™ Shows Positive One-Year Results for Type 2 Diabetes](https://www.clinicaltrialvanguard.com/news/allostem-shows-positive-one-year-results-for-type-2-diabetes/) - Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStem™) in late-stage Type 2 Diabetes patients. The off-the-shelf, allogeneic cell therapy demonstrated an 80% efficacy rate in reducing insulin dependence and stabilizing hemoglobin A1c levels, with no serious adverse effects observed. The study, involving 20 patients, confirmed
- [Kairos Pharma and Huntsman Cancer Institute for ENV105 Phase 2 Trial](https://www.clinicaltrialvanguard.com/news/kairos-pharma-and-huntsman-cancer-institute-for-env105-phase-2-trial/) - Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate cancer, to include Huntsman Cancer Institute. The trial, which is partly funded by the National Cancer Institute, is investigating ENV105 in combination with apalutamide, an existing prostate cancer treatment. This expansion aims to broaden the patient
- [Ati-2138: Potent, Selective Inhibitor of ITK and JAK3](https://www.clinicaltrialvanguard.com/news/ati-2138-potent-selective-inhibitor-of-itk-and-jak3/) - Aclaris Therapeutics announced the publication of research on ATI-2138, a novel dual inhibitor of ITK and JAK3, currently in development for autoimmune and inflammatory diseases. Preclinical and early clinical data suggest ATI-2138 effectively inhibits key T cell activity implicated in conditions like atopic dermatitis, alopecia areata, and vitiligo. The research underscores the drug's unique mechanism
- [Aptose's Triple Drug AML Therapy Shows Promise in Phase 1/2 Trial](https://www.clinicaltrialvanguard.com/news/aptoses-triple-drug-aml-therapy-shows-promise-in-phase-1-2-trial/) - Aptose Biosciences reported promising early results from its Phase 1/2 TUSCANY trial, testing a triplet therapy of tuspetinib, venetoclax, and azacitidine (TUS+VEN+AZA) in newly diagnosed acute myeloid leukemia (AML) patients ineligible for standard induction chemotherapy. Early data from the first cohort receiving the lowest dose of tuspetinib (40mg) shows positive clinical safety and anti-leukemic activity.
- [Escharex's Pivotal Trial for Venous Leg Ulcers](https://www.clinicaltrialvanguard.com/news/escharexs-pivotal-trial-for-venous-leg-ulcers/) - MediWound has launched VALUE, a pivotal Phase III trial for EscharEx®, its enzymatic treatment for venous leg ulcers (VLUs). The global, double-blind, placebo-controlled trial will assess EscharEx's efficacy in debridement and wound closure in 216 patients across the U.S. and Europe, with an interim analysis expected in mid-2026. The company has partnered with Solventum, Mölnlycke,
- [Updated Phase 2 Agent-797 Gastric Cancer Data at AACR IO](https://www.clinicaltrialvanguard.com/news/updated-phase-2-agent-797-gastric-cancer-data-at-aacr-io/) - MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer at the AACR IO Annual Meeting, February 23-26 in Los Angeles. The presentation, titled "Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1
- [Bio-Path Holdings Announces Promising Phase 1/1b AML Trial Results](https://www.clinicaltrialvanguard.com/news/bio-path-holdings-announces-promising-phase-1-1b-aml-trial-results/) - Bio-Path Holdings announced positive findings from its Phase 1/1b clinical trial of BP1002, a drug designed to treat refractory/relapsed acute myeloid leukemia (AML), including cases resistant to venetoclax. One patient in the third cohort demonstrated stable disease and a significant reduction in blast count after a single treatment cycle. The trial has now advanced to
- [Neuphoria Therapeutics Gets $15M Milestone Payment from Merck](https://www.clinicaltrialvanguard.com/news/neuphoria-therapeutics-gets-15m-milestone-payment-from-merck/) - Neuphoria Therapeutics (Nasdaq: NEUP) will receive a $15 million milestone payment from Merck due to the initiation of a Phase 2 clinical trial for MK-1167. MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator, targets the symptoms of Alzheimer’s disease dementia. This marks the second milestone payment in their collaboration. This Phase 2 trial initiation
- [Bio-Path Holdings' Key Clinical Breakthroughs](https://www.clinicaltrialvanguard.com/news/bio-path-holdings-key-clinical-breakthroughs/) - Bio-Path Holdings provided updates on two clinical trials: BP1001-A for solid tumors and prexigebersen for acute myeloid leukemia (AML). A patient with gynecologic cancer in the BP1001-A trial experienced tumor reduction and stable disease after multiple rounds of treatment. Two elderly AML patients in the prexigebersen trial remain in complete remission after two years. The
- [NKGen Biotech Publishes Promising Alzheimer’s Drug Trial Results](https://www.clinicaltrialvanguard.com/news/nkgen-biotech-publishes-promising-alzheimers-drug-trial-results/) - NKGen Biotech announced the publication of Phase 1 clinical trial results for troculeucel, an NK cell therapy for Alzheimer's disease. The trial showed stable or improved outcomes in 90% of evaluable participants with no drug-related adverse events. The research highlights the potential of troculeucel to address neuroinflammation and protein aggregates, key factors in Alzheimer's disease
- [AskBio Gene Therapy Trial for Heart Failure Begins in Europe](https://www.clinicaltrialvanguard.com/news/askbio-gene-therapy-trial-for-heart-failure-begins-in-europe/) - AskBio, a Bayer subsidiary, has initiated the European arm of its Phase 2 GenePHIT trial for AB-1002, a gene therapy for congestive heart failure (CHF). This follows the commencement of the US arm in 2024 and marks a significant step towards potentially offering this one-time treatment to European patients. The therapy targets non-ischemic cardiomyopathy with
- [BioCardia Completes Low-Dose Cohort Enrollment in CardiALLO Trial](https://www.clinicaltrialvanguard.com/news/biocardia-completes-low-dose-cohort-enrollment-in-cardiallo-trial/) - BioCardia completed enrollment and dosing in the low-dose cohort of its CardiALLO™ Phase I/II trial. This trial investigates allogeneic mesenchymal stem cell (MSC) therapy for patients with ischemic heart failure and reduced ejection fraction (HFrEF) who also exhibit elevated markers of heart stress and systemic inflammation. The trial incorporates the Morph DNA steerable guide for
- [UCB Bimzelx Poised to Disrupt Psoriatic Arthritis Market](https://www.clinicaltrialvanguard.com/news/ucb-bimzelx-poised-to-disrupt-psoriatic-arthritis-market/) - UCB’s Bimzelx (bimekizumab), a dual IL-17A/IL-17F inhibitor for psoriatic arthritisarthritis (PsA), is demonstrating strong early adoption among rheumatologists just three months post-launch. A Spherix Global Insights study indicates that Bimzelx's uptake and positive perception among rheumatologists surpass those of similar drug launches, driven by its dual mechanism of action and perceived efficacy. While early prescription
- [Allogene Therapeutics Publishes Durable Response Data from Phase 1 Trials of ALLO-501 in R/R LBCL](https://www.clinicaltrialvanguard.com/news/allogene-therapeutics-publishes-durable-response-data-from-phase-1-trials-of-allo-501-in-r-r-lbcl/) - Allogene Therapeutics announced positive results from its Phase 1 ALPHA and ALPHA2 clinical trials of cema-cel, an allogeneic CAR T therapy for relapsed/refractory large B-cell lymphomaB-cell lymphoma (LBCL). The therapy demonstrated comparable efficacy to approved autologous CD19 CAR T treatments, with a manageable safety profile and rapid treatment initiation. Data from the trials, published in
- [Pfizer Talzenna & Xtandi Improve Survival in mCRPC](https://www.clinicaltrialvanguard.com/news/pfizer-talzenna-xtandi-improve-survival-in-mcrpc/) - Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant prostate cancer (mCRPC). The combination therapy showed a statistically significant improvement in overall survival compared to XTANDI plus placebo, regardless of homologous recombination repair (HRR) gene mutation status. The findings were presented at the American Society
- [ImmunityBio Anktiva® for BCG-Unresponsive Bladder Cancer: MHRA Accepts Marketing Authorization Application](https://www.clinicaltrialvanguard.com/news/immunitybio-anktiva-for-bcg-unresponsive-bladder-cancer-mhra-accepts-marketing-authorization-application/) - ImmunityBio announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its marketing authorization application for ANKTIVA, a treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This follows recent acceptance by the European Medicines Agency and FDA approval ten months prior. The MHRA's validation initiates the formal
- [Relativity-098 Trial Update: BMS Provides Insights](https://www.clinicaltrialvanguard.com/news/relativity-098-trial-update-bms-provides-insights/) - Bristol Myers Squibb announced that the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for adjuvant treatment of completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival. The safety profile of Opdualag remained consistent with previous studies. The company acknowledges that LAG-3 inhibition in the adjuvant setting did not
- [Cabometyx® & Opdivo® in Kidney Cancer: 5-Year CheckMate -9ER Results](https://www.clinicaltrialvanguard.com/news/cabometyx-opdivo-in-kidney-cancer-5-year-checkmate-9er-results/) - Final results from the phase 3 CheckMate-9ER trial show that cabozantinib (CABOMETYX) combined with nivolumab (Opdivo) continues to demonstrate a survival benefit compared to sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC) after more than five years of follow-up. The combination therapy improved both progression-free survival (PFS) and overall survival (OS) compared
- [StemSpine® Procedure Significantly Reduces Opioid Use in Chronic Lower Back Pain Patients](https://www.clinicaltrialvanguard.com/news/stemspine-procedure-significantly-reduces-opioid-use-in-chronic-lower-back-pain-patients/) - Creative Medical Technology Holdings (CELZ) announced positive mid-term results from its StemSpine pilot study using AlloStem cells to treat chronic lower back pain. The study showed significant reductions in opioid use, pain levels, and functional disability three years post-procedure, with a strong safety profile. StemSpine is a patented, non-surgical, ultrasound-guided procedure utilizing AlloStem, an "off-the-shelf"
- [Medicus Pharma Announces SKNJC-003 Phase 2 Nodular BCC Study Update](https://www.clinicaltrialvanguard.com/news/medicus-pharma-announces-sknjc-003-phase-2-nodular-bcc-study-update/) - Medicus Pharma Ltd. (NASDAQ: MDCX) announced that its Phase 2 clinical trial (SKNJCT-003) for D-MNA, a treatment for basal cell carcinoma (BCC), has randomized over half of its targeted 60 patients. The company anticipates completing an interim data analysis by the end of Q1 2025 and will submit the findings to the FDA, requesting a
- [Next-Gen Nectin-4 Targeting ADC Shows Promise in Phase 1 Study](https://www.clinicaltrialvanguard.com/news/next-gen-nectin-4-targeting-adc-shows-promise-in-phase-1-study/) - Corbus Pharmaceuticals announced positive data from its US and UK Phase 1 dose escalation study of CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4. The study mirrored the highest doses of a previous China study and showed comparable safety, tolerability, and pharmacokinetic profiles, including low rates of peripheral neuropathy and skin toxicity. Clinical responses were observed
- [Benitec Biopharma's BB-301 Study at MDA Conference](https://www.clinicaltrialvanguard.com/news/benitec-biopharmas-bb-301-study-at-mda-conference/) - Benitec Biopharma announced interim clinical study updates for the first three subjects in its Phase 1b/2a trial of BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). These updates will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19th. The presentation will focus on the therapy's impact on dysphagia,
- [ORYZON Announces Journal Publication of Final Phase IIa REimagine Results with Vafidemstat](https://www.clinicaltrialvanguard.com/news/oryzon-announces-journal-publication-of-final-phase-iia-reimagine-results-with-vafidemstat/) - Oryzon Genomics announced the publication of final Phase IIa REIMAGINE study results, demonstrating the safety and efficacy of vafidemstat in reducing agitation and aggression in patients with borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD). The study provided crucial data for advancing vafidemstat’s clinical development, specifically in BPD, leading to a
- [EU Approves First Self-Amplifying mRNA COVID-19 Vaccine](https://www.clinicaltrialvanguard.com/news/eu-approves-first-self-amplifying-mrna-covid-19-vaccine/) - CSL and Arcturus Therapeutics announced that the European Commission has approved KOSTAIVE (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for adults. This marks the first approval of an sa-mRNA COVID-19 vaccine by the European Commission, following its existing use in Japan. The approval hinges on positive clinical trial data demonstrating superior immunogenicity and antibody persistence compared
- [ICON Discusses How AI is Changing Clinical Trial Recruitment and Diversity](https://www.clinicaltrialvanguard.com/executiveinterviews/icon-discusses-how-ai-is-changing-clinical-trial-recruitment-and-diversity/) - In this discussion with Kathleen Mandziuk, Vice President of eClinical Development & Delivery at ICON, we explore the dynamic world of clinical trials. Kathleen offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion. As the industry shifts towards patient-centric
- [Dupixent® FDA Priority Review for Bullous Pemphigoid Treatment](https://www.clinicaltrialvanguard.com/news/dupixent-fda-priority-review-for-bullous-pemphigoid-treatment/) - Regeneron and Sanofi announced that the FDA accepted for Priority Review their supplemental Biologics License Application for Dupixent (dupilumab) to treat bullous pemphigoid (BP) in adults. The application is supported by positive pivotal trial data showing significantly improved sustained disease remission rates with Dupixent compared to placebo. Specifically, five times more Dupixent patients achieved sustained
- [Lacutamab Gets FDA Breakthrough Therapy for Sézary Syndrome](https://www.clinicaltrialvanguard.com/news/lacutamab-gets-fda-breakthrough-therapy-for-sezary-syndrome/) - Innate Pharma received Breakthrough Therapy Designation from the FDA for lacutamab, its anti-KIR3DL2 antibody, for treating relapsed or refractory Sézary Syndrome (SS) in adults. This designation is based on promising Phase 1 and 2 trial results showing efficacy and a favorable safety profile in patients previously treated with mogamulizumab. This rare and aggressive form of
- [Revolutionary New Prostate Cancer Super Test Developed in UK](https://www.clinicaltrialvanguard.com/news/revolutionary-new-prostate-cancer-super-test-developed-in-uk/) - Scientists in Cambridge developed a new prostate cancer test designed to revolutionize screening, diagnosis, and personalized treatment. The test analyzes blood and urine samples for over 100 clinically-validated prostate-related biomarkers, using an AI-driven algorithm to identify cancer presence, stage, aggressiveness, and genetic risks. This "super test" aims to address the high incidence of prostate cancer
- [Innocare Announces BCL2 Inhibitor & Orelabrutinib for CLL/SLL](https://www.clinicaltrialvanguard.com/news/innocare-announces-bcl2-inhibitor-orelabrutinib-for-cll-sll/) - InnoCare Pharma received approval from China's CDE to begin a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax), combined with the BTK inhibitor orelabrutinib. This trial will evaluate the combination as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients in China. The company believes this fixed-duration combination therapy
- [DeepSon Bio at Korean Society of Brain Neuromodulation Therapy](https://www.clinicaltrialvanguard.com/news/deepson-bio-at-korean-society-of-brain-neuromodulation-therapy/) - Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio's NEUCLARE therapeutic ultrasound device to treat normal pressure hydrocephalus (NPH). The trial demonstrated statistically significant improvements in the mobility of NPH patients after undergoing ultrasound therapy. This research explores a novel, non-invasive approach to treating NPH, a condition currently reliant on
- [Vaxxas HD-MAP Vaccine Delivery Clinical Trial Sets Record](https://www.clinicaltrialvanguard.com/news/vaxxas-hd-map-vaccine-delivery-clinical-trial-sets-record/) - Vaxxas, a clinical-stage biotech company, has completed enrollment for its Phase I clinical trial of an avian influenza A (H7N9) vaccine delivered via its high-density microarray patch (HD-MAP). This 258-participant trial, the largest Phase I study conducted by Vaxxas to date, compares the HD-MAP’s efficacy against traditional needle-and-syringe delivery. The study is partially funded by
- [Miist Therapeutics: Pioneering Inhaled Therapies for Rapid Smoking Cessation and Migraine Relief](https://www.clinicaltrialvanguard.com/executiveinterviews/miist-therapeutics-pioneering-inhaled-therapies-for-rapid-smoking-cessation-and-migraine-relief/) - Discover how Miist Therapeutics is revolutionizing migraine and smoking cessation treatment with innovative inhaled therapies.
- [Sellas Announces Positive Data from Phase 2a Trial of SLS009](https://www.clinicaltrialvanguard.com/news/sellas-announces-positive-data-from-phase-2a-trial-of-sls009/) - SELLAS Life Sciences announced positive Phase 2a trial data for SLS009 (tambiciclib), a CDK9 inhibitor, combined with Brukinsa (zanubrutinib) in relapsed/refractory diffuse large B-cell lymphomaB-cell lymphoma (r/r DLBCL). The trial, conducted by GenFleet Therapeutics in China, showed a 67% overall response rate, significantly exceeding the anticipated response rate of zanubrutinib alone. This combination therapy also
- [Neurona's Epic Nrtx-1001 Cell Therapy Epilepsy Study](https://www.clinicaltrialvanguard.com/news/neuronas-epic-nrtx-1001-cell-therapy-epilepsy-study/) - Neurona Therapeutics, a clinical-stage biotherapeutics company, is initiating its Phase 3 EPIC clinical trial for NRTX-1001, a regenerative cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) in adults. This marks the first investigational human cell therapy to reach Phase 3 for this indication and is based on the regulatory pathway established through the Regenerative
- [Phoenix Molecular Designs Doses First Patient with PMD-026 in Dauntless-1 Trial](https://www.clinicaltrialvanguard.com/news/phoenix-molecular-designs-doses-first-patient-with-pmd-026-in-dauntless-1-trial/) - Phoenix Molecular Designs (PhoenixMD) has initiated Phase 2 clinical trials (Dauntless-1) for PMD-026, a first-in-class pan-RSK inhibitor, in combination with fulvestrant. The trial targets patients with locally advanced or metastatic HR+/HER2-/RSK2-high breast cancer who have progressed after CDK4/6 inhibitor treatment. This approach aims to address CDK4/6 inhibitor resistance, a significant challenge in treating this type
- [EG 427 Gets €27M in Series B Funding for Clinical Study](https://www.clinicaltrialvanguard.com/news/eg-427-gets-e27m-in-series-b-funding-for-clinical-study/) - EG 427, a biotech company developing targeted genetic medicines for neurological conditions, secured €27 million in Series B funding. The round was co-led by Andera Partners and Bpifrance, with participation from SCI Ventures and existing investors. The funding will primarily support the Phase 1b/2a clinical trial of EG110A, a treatment for neurogenic detrusor overactivity (NDO)
- [Komen Calls for Urgent Action on Racial Disparities in Breast Cancer](https://www.clinicaltrialvanguard.com/news/komen-calls-for-urgent-action-on-racial-disparities-in-breast-cancer/) - New data reveals that Black women in the U.S. have a significantly higher mortality rate from breast cancer than white women, despite having a lower incidence rate. This disparity is attributed to systemic inequities in healthcare access, quality of care, and social determinants of health, not solely biological factors. Susan G. Komen emphasizes the urgent
- [Samsung Bioepis Launches Stelara® Biosimilar Pyzchiva® in US](https://www.clinicaltrialvanguard.com/news/samsung-bioepis-launches-stelara-biosimilar-pyzchiva-in-us/) - Samsung Bioepis launched PYZCHIVA (ustekinumab-ttwe), a biosimilar to Stelara, in the United States. The drug is approved to treat plaque psoriasis, psoriatic arthritis, Crohn's diseaseCrohn's disease, and ulcerative colitis and will be available in various formulations through their partner, Sandoz. This launch follows a 2023 commercialization agreement with Sandoz, with Samsung Bioepis retaining responsibility for
- [Duvakitug Shows Promise in Ulcerative Colitis and Crohn's Disease](https://www.clinicaltrialvanguard.com/news/duvakitug-shows-promise-in-ulcerative-colitis-and-crohns-disease/) - Teva Pharmaceuticals and Sanofi announced positive Phase 2b results for duvakitug, a novel antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's diseaseCrohn's disease (CD). The RELIEVE UCCD study demonstrated that duvakitug achieved clinical remission in a significant portion of UC patients and endoscopic response in CD patients, exceeding placebo rates. The
- [Preparing and Upskilling the Clinical Trial Workforce for AI Innovation](https://www.clinicaltrialvanguard.com/conference-coverage/preparing-and-upskilling-the-clinical-trial-workforce-for-ai-innovation/) - Discover how AI is reshaping the clinical trial workforce, emphasizing new skills and collaboration. Insights from Syneos and Sanofi.
- [FDA Grants Auron Therapeutics Fast Track Designation for AUTX-703 to Treat AML](https://www.clinicaltrialvanguard.com/news/fda-grants-auron-therapeutics-fast-track-designation-for-autx-703-to-treat-aml/) - Auron Therapeutics received FDA Fast Track designation for AUTX-703, an oral KAT2A/B degrader, for treating relapsed or refractory acute myelogenous leukemia (AML). The company plans to initiate clinical development in Q1 2025, following recent IND application clearance. This designation follows promising preclinical data demonstrating AUTX-703's potential to improve survival rates in AML. This Fast Track
- [Leti-101 Shows Promise in Preclinical Huntington's Disease Study](https://www.clinicaltrialvanguard.com/news/leti-101-shows-promise-in-preclinical-huntingtons-disease-study/) - ElevateBio has unveiled preclinical data for LETI-101, a CRISPR-based therapy for Huntington's Disease (HD) being developed by its subsidiary, Life Edit. The therapy utilizes an AAV5 vector to deliver a CRISPR nuclease targeting a specific single nucleotide polymorphism (SNP) in the huntingtin gene (HTT) responsible for HD. Preclinical studies show LETI-101 successfully reduced mutant HTT
- [Brain Exercise Lowers Fatigue in MS Study](https://www.clinicaltrialvanguard.com/news/brain-exercise-lowers-fatigue-in-ms-study/) - Researchers at New York University (NYU) found that brain exercises from the BrainHQ app, developed by Posit Science, reduced fatigue in Multiple Sclerosis (MS) patients. This is the first study to demonstrate BrainHQ's positive impact on MS-related fatigue, adding to existing research showing improvements in processing speed and cognitive function. The study, published in Nature:
- [Calidi Starts High-Grade Glioma Trial Recruitment](https://www.clinicaltrialvanguard.com/news/calidi-starts-high-grade-glioma-trial-recruitment/) - Calidi Biotherapeutics has begun enrolling patients at Northwestern University/Northwestern Memorial Hospital for a clinical trial of CLD-101, an immunotherapy for newly diagnosed high-grade glioma (HGG). The therapy utilizes allogeneic neural stem cells carrying an oncolytic adenovirus, CRAd-S-pk7, and builds upon promising Phase 1 single-dose results published in •The Lancet Oncology•. This Phase 1B/2 trial will
- [Versamune® HPV Clinical Cancer Research Results](https://www.clinicaltrialvanguard.com/news/versamune-hpv-clinical-cancer-research-results/) - PDS Biotechnology Corporation announced positive clinical trial results for its lead immunotherapy candidate, Versamune® HPV, in the treatment of locally advanced cervical cancer. The trial demonstrated that combining Versamune® HPV with standard chemoradiation (CRT) led to a faster and more complete clearance of HPV16-positive cancer cells from the bloodstream compared to CRT alone. This clearance
- [Leronlimab Shows Promise in mTNBC Patient Survival](https://www.clinicaltrialvanguard.com/news/leronlimab-shows-promise-in-mtnbc-patient-survival/) - CytoDyn Inc. announced encouraging survival outcomes in a group of patients with metastatic triple-negative breast cancer (mTNBC) treated with leronlimab, a CCR5 antagonist. Some patients who had failed prior treatments for metastatic disease survived beyond 36 months, are currently alive, and show no evidence of active disease. Following the resolution of a dispute with its
- [Allo-Inkt Combination Data in 2L Gastric Cancer at AACR](https://www.clinicaltrialvanguard.com/news/allo-inkt-combination-data-in-2l-gastric-cancer-at-aacr/) - MiNK Therapeutics presented Phase 2 data at the AACR IO Annual Meeting showcasing the potential of its allogeneic iNKT cell therapy, agenT-797, combined with botensilimab and balstilimab (BOT/BAL) for refractory gastroesophageal cancer. Early results indicate this combination therapy triggers significant immune activation within the tumor microenvironment. The study demonstrates the importance of treatment sequencing, with
- [Synergia Medical Announces Strong Results for nao.vns First-in-Human Study](https://www.clinicaltrialvanguard.com/news/synergia-medical-announces-strong-results-for-nao-vns-first-in-human-study/) - Synergia Medical's NAO.VNS™ device, implanted in five patients in Belgium, has met its primary safety endpoint in the AURORA first-in-human clinical study. The implantable device, designed to treat drug-resistant epilepsy (DRE) via vagus nerve stimulation (VNS), demonstrated no serious adverse events or device failures over three months. This next-generation neuromodulation platform eliminates metal components found
- [EMA and EU-Medicines for All Validate Lenacapavir HIV Prevention Application](https://www.clinicaltrialvanguard.com/news/ema-and-eu-medicines-for-all-validate-lenacapavir-hiv-prevention-application/) - Gilead Sciences announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir, a twice-yearly injectable HIV prevention drug. The EMA granted accelerated assessment based on the potential public health impact of lenacapavir. This follows the FDA's acceptance of similar applications under priority review.
- [LTZ-301: First-in-Class Myeloid Engager Immunotherapy IND Cleared by FDA](https://www.clinicaltrialvanguard.com/news/ltz-301-first-in-class-myeloid-engager-immunotherapy-ind-cleared-by-fda/) - LTZ Therapeutics received FDA clearance for its Investigational New Drug (IND) application for LTZ-301. LTZ-301, a first-in-class myeloid engager immunotherapy, will be investigated for the treatment of relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The company plans to initiate a Phase 1 clinical trial in Q2 2025. This IND clearance is a crucial step in
- [PrecivityAD2 Blood Test Certified in UK](https://www.clinicaltrialvanguard.com/news/precivityad2-blood-test-certified-in-uk/) - C2N Diagnostics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its PrecivityAD2 blood test, designed to aid in the diagnosis of Alzheimer's diseaseAlzheimer's disease in patients aged 55 and older experiencing cognitive decline. This marks the first global regulatory approval for a blood test specifically for Alzheimer's disease
- [How AstraZeneca and Mass General Brigham are Enhancing Clinical Trial Protocol Design](https://www.clinicaltrialvanguard.com/conference-coverage/how-astrazeneca-and-mass-general-brigham-are-enhancing-clinical-trial-protocol-design/) - Revolutionizing Clinical Research: Mass General Brigham Partnership with AstraZeneca and Evinova sets a new standard in clinical trials efficiency.
- [Candel Therapeutics Announces Positive CAN-2409 Trial Data](https://www.clinicaltrialvanguard.com/news/candel-therapeutics-announces-positive-can-2409-trial-data/) - Candel Therapeutics announced positive final overall survival data from its Phase 2 trial of CAN-2409 in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The experimental treatment, combined with standard chemotherapy and radiation, showed a significant increase in median overall survival to 31.4 months compared to 12.5 months for the control group. Three of the
- [Alzamend Neuro Starts Phase 2 Trial of AL001 at Mass General](https://www.clinicaltrialvanguard.com/news/alzamend-neuro-starts-phase-2-trial-of-al001-at-mass-general/) - Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system, in healthy human subjects during the second quarter of 2025. This study, conducted in partnership with Massachusetts General Hospital, will compare AL001 to currently available lithium treatments, focusing on lithium’s pharmacokinetics in the brain and blood.
- [Ampligen and Imfinzi in Phase 2 Pancreatic Cancer Trial](https://www.clinicaltrialvanguard.com/news/ampligen-and-imfinzi-in-phase-2-pancreatic-cancer-trial/) - AIM ImmunoTech has dosed the first patient in Phase 2 of its Phase 1b/2 clinical trial, DURIPANC, evaluating Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) for late-stage pancreatic cancer. Several participants from Phase 1 who received the highest dose of Ampligen will continue into Phase 2. The open-label, single-center study, conducted at Erasmus Medical Center
- [Silexion Announces Promising Pancreatic Cancer Study Results](https://www.clinicaltrialvanguard.com/news/silexion-announces-promising-pancreatic-cancer-study-results/) - Silexion Therapeutics (NASDAQ: SLXN) has completed data collection for its first study of SIL-204 in orthotopic pancreatic cancer models. This study examined the drug's ability to shrink primary tumors and limit metastasis after systemic administration. The company expects to release initial results in March 2025. This study is important because orthotopic models, where tumor cells
- [FemBloc Permanent Birth Control: Positive Safety and Efficacy Results](https://www.clinicaltrialvanguard.com/news/fembloc-permanent-birth-control-positive-safety-and-efficacy-results/) - Femasys Inc. announced positive clinical trial data for FemBloc, a non-surgical permanent birth control method, published in the Journal of Gynecology & Reproductive Medicine. The trials demonstrated a 0% pregnancy rate among participants three months post-procedure, significantly outperforming traditional surgical sterilization. The five-year data also highlighted a strong safety profile, with no serious adverse events
- [Trethera & UCLA Publish Data on TRE-515 in Mice with MS](https://www.clinicaltrialvanguard.com/news/trethera-ucla-publish-data-on-tre-515-in-mice-with-ms/) - Trethera Corporation announced research published in Immunology demonstrating that their drug, TRE-515, effectively inhibits the hyperactive lymphocytes responsible for multiple sclerosis (MS) symptoms in mouse models. TRE-515 targets deoxycytidine kinase (dCK), an enzyme crucial for cell division, specifically within the overactive T and B cells driving MS. This targeted approach reduces the number of these
- [FDA Accepts Medincell and Teva Uzedy for Bipolar I Disorder Treatment](https://www.clinicaltrialvanguard.com/news/fda-accepts-medincell-and-teva-uzedy-for-bipolar-i-disorder-treatment/) - Teva Pharmaceuticals and Medincell announced that the FDA accepted their supplemental New Drug Application for UZEDY, a long-acting injectable risperidone formulation, for the maintenance treatment of bipolar I disorder in adults. UZEDY is already approved in the US for schizophrenia treatment and is administered subcutaneously every one or two months. This application leverages existing UZEDY
- [Oric Pharmaceuticals Announces Development Plans, Cash Runway, and Milestones](https://www.clinicaltrialvanguard.com/news/oric-pharmaceuticals-announces-development-plans-cash-runway-and-milestones/) - ORIC Pharmaceuticals announced focused development plans for its lead programs, ORIC-944 and ORIC-114, extending its cash runway into 2027. The company will prioritize indications with the strongest clinical validation and highest unmet need, specifically metastatic castration-resistant prostate cancer (mCRPC) for ORIC-944 and first-line non-small cell lung cancersmall cell lung cancer (NSCLC) for ORIC-114. Favorable enrollment
- [Castle Creek Biosciences Secures $75M Royalty Financing](https://www.clinicaltrialvanguard.com/news/castle-creek-biosciences-secures-75m-royalty-financing/) - Ligand Pharmaceuticals has invested $50 million and led a syndicate of co-investors, including Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corporation, in a $25 million royalty financing agreement with Castle Creek Biosciences. This funding will support the Phase 3 clinical trial of Castle Creek's lead gene therapy candidate, D-Fi (FCX-007), for the treatment of
- [Coya Therapeutics in BTIG KOL Call on Alzheimer's & GLP-1](https://www.clinicaltrialvanguard.com/news/coya-therapeutics-in-btig-kol-call-on-alzheimers-glp-1/) - Coya Therapeutics is advancing COYA 303, a combination therapy of low-dose interleukin-2 (COYA 301) and a GLP-1 receptor agonist, for inflammatory diseases. CEO Arun Swaminathan and Dr. Stanley H. Appel will discuss the potential of GLP-1 agonists and combination therapies for Alzheimer's disease in a webcast hosted by BTIG. This discussion will also cover Coya's
- [FDA Accepts Regeneron Odronextamab Resubmission for Follicular Lymphoma Review](https://www.clinicaltrialvanguard.com/news/fda-accepts-regeneron-odronextamab-resubmission-for-follicular-lymphoma-review/) - Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended to treat relapsed/refractory follicular lymphoma (FL) after patients have undergone at least two other systemic therapies. The FDA is expected to make a decision by July 30, 2025. This resubmission is a critical step for Regeneron
- [Lucid-21-302 Phase 1 Trial Complete: Quantum Biopharma's MS Drug Shows Promise](https://www.clinicaltrialvanguard.com/news/lucid-21-302-phase-1-trial-complete-quantum-biopharmas-ms-drug-shows-promise/) - Quantum BioPharma Ltd. announced the successful completion of a Phase 1 clinical trial for Lucid-MS, a novel neuroprotective compound for multiple sclerosis (MS). The safety review committee confirmed that Lucid-MS was well-tolerated by healthy participants, with no safety concerns or serious adverse events. This first-in-class compound is designed to stabilize the myelin sheath surrounding nerve
- [Pyx-201 Gets FDA Fast Track for Head & Neck Cancer](https://www.clinicaltrialvanguard.com/news/pyx-201-gets-fda-fast-track-for-head-neck-cancer/) - Pyxis Oncology's PYX-201, an antibody-drug conjugate targeting Extradomain-B Fibronectin (EDB+FN), received Fast Track Designation from the FDA for treating recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in patients whose disease progressed after platinum-based chemotherapy and anti-PD-(L)1 antibody treatment. PYX-201 is the first ADC to target EDB+FN, a component of the tumor
- [PDS Biotech's HPV Cancer Data in JAMA Oncology: Positive Survival, Clinical Responses](https://www.clinicaltrialvanguard.com/news/pds-biotechs-hpv-cancer-data-in-jama-oncology-positive-survival-clinical-responses/) - PDS Biotechnology Corporation announced promising clinical trial results for a triple combination therapy targeting HPV-associated cancers, published in JAMA Oncology. The therapy combines Versamune® HPV, PDS01ADC (an IL-12 fused antibody-drug conjugate), and a PD-L1 immune checkpoint inhibitor. The trial involved patients with recurrent or metastatic HPV-positive anal, cervical, head and neck, penile, vaginal, and vulvar
- [First Participant Dosed in Phase 1a Study of Oral HDV Entry Inhibitor](https://www.clinicaltrialvanguard.com/news/first-participant-dosed-in-phase-1a-study-of-oral-hdv-entry-inhibitor/) - Assembly Biosciences has dosed the first participant in a Phase 1a clinical trial for ABI-6250, an oral HDV entry inhibitor. The trial will assess the safety, tolerability, pharmacokinetics, and serum bile acid levels (a biomarker for target engagement) of ABI-6250 in healthy individuals. Data from this trial is anticipated in Q3 2025. This clinical trial
- [Sonnet BioTherapeutics Son-1010: Improved Solid Tumor Treatment](https://www.clinicaltrialvanguard.com/news/sonnet-biotherapeutics-son-1010-improved-solid-tumor-treatment/) - Sonnet BioTherapeutics presented data at the 2025 AACR:IO Conference on its Fully Human Albumin Binding (FHAB) platform, which enhances tumor targeting and retention of immunomodulators. The platform links mono- or bifunctional immunomodulators to an albumin-binding domain, improving the pharmacokinetic profile and reducing toxicity risk. The presentation focused on SON-1010, a rhIL-12 configured with FHAB, and
- [Derm-Biome's DB-007-5 Highly Effective in Atopic Dermatitis Study](https://www.clinicaltrialvanguard.com/news/derm-biomes-db-007-5-highly-effective-in-atopic-dermatitis-study/) - Derm-Biome Pharmaceuticals announced positive preclinical results for its topical drug DB-007-5 in treating atopic dermatitis (AD). The drug significantly reduced inflammation and outperformed the current leading AD treatment, Opzelura, in reducing itch, a key symptom of AD. DB-007-5 also demonstrated a favorable safety profile in previous studies. This development holds substantial promise for patients suffering
- [DM Clinical Research Data Breach Exposes Over 1.6M Records, Raising Patient Privacy Concerns](https://www.clinicaltrialvanguard.com/news/dm-clinical-research-data-breach-exposes-over-1-6m-records-raising-patient-privacy-concerns/) - DM Clinical Research, a Texas-based clinical trial site network, has suffered a major data breach, exposing over 1.6 million personal and medical records. The unprotected database, discovered by cybersecurity researcher Jeremiah Fowler, was publicly accessible without password protection or encryption. The breach involved 1,674,218 records, totaling 2 terabytes of data. Details of the Exposure The
- [Lexicon Announces Pilavapan Results for Diabetic Nerve Pain](https://www.clinicaltrialvanguard.com/news/lexicon-announces-pilavapan-results-for-diabetic-nerve-pain/) - Lexicon Pharmaceuticals will announce topline results from its Phase 2b PROGRESS study of pilavapadin (LX9211) for diabetic peripheral neuropathic pain (DPNP) on March 3, 2025. The study evaluated the efficacy and safety of this oral, non-opioid, AAK1 inhibitor in adults with moderate to severe DPNP. The company hopes this novel approach to pain management will
- [Apg990 Interim Phase 1 Results Show Potential for Maintenance Dosing](https://www.clinicaltrialvanguard.com/news/apg990-interim-phase-1-results-show-potential-for-maintenance-dosing/) - Apogee Therapeutics announced positive interim Phase 1 results for APG990, a novel, half-life extended OX40L antibody, demonstrating an approximately 60-day half-life. This achievement paves the way for a Phase 1b head-to-head study of APG279 (a combination of APG777 and APG990) against Dupixent, planned for later this year with results expected in the second half of
- [Deucrictibant Data at AAAAI/WAO 2025: HAE Prevention & Treatment](https://www.clinicaltrialvanguard.com/news/deucravacitinib-data-at-aaaai-wao-2025-hae-prevention-treatment/) - Pharvaris released positive long-term data for its oral bradykinin B2 receptor antagonist, deucrictibant, at the 2025 AAAAI/WAO Joint Congress. The data highlighted sustained efficacy and safety in both prophylactic and on-demand treatment of Hereditary Angioedema (HAE) from extension studies of previous Phase 2 trials. The findings demonstrate the potential of deucrictibant to address unmet needs
- [Voyager Reports Positive Topline Anti-Tau Antibody Data, Initiates Next Trial](https://www.clinicaltrialvanguard.com/news/voyager-reports-positive-topline-anti-tau-antibody-data-initiates-next-trial/) - Voyager Therapeutics announced positive topline data from its single ascending dose (SAD) trial of VY7523, an investigational anti-tau antibody for Alzheimer's diseaseAlzheimer's disease. The data showed VY7523 was safe, tolerable, and exhibited dose-proportional pharmacokinetics in healthy volunteers. Based on these results, Voyager has initiated a multiple ascending dose (MAD) trial in early Alzheimer's patients, with
- [Aura Biosciences NMIBC Data at EAU Congress](https://www.clinicaltrialvanguard.com/news/aura-biosciences-nmibc-data-at-eau-congress/) - Aura Biosciences announced Phase 1 data from its trial of bel-sar (AU-011) for non-muscle invasive bladder cancer (NMIBC) will be presented at the 40th Annual European Association of Urology (EAU) Congress, March 21-24, 2025. The company will also participate in the EAU Research Forum and host a virtual investor event on March 24th, featuring key
- [Transforming Oncology with Real World Data: Insights from COTA's Miruna Sasu](https://www.clinicaltrialvanguard.com/executiveinterviews/transforming-oncology-with-real-world-data-insights-from-cotas-miruna-sasu/) - In this conversation with Miruna Sasu, President and CEO of COTA Healthcare, we explore the transformative power of real world data (RWD) in oncology. With a background spanning pharmaceutical giants and health tech innovators, Sasu shares her vision for leveraging RWD to accelerate drug development and enhance patient outcomes. This interview delves into COTA's cutting-edge
- [Oryzon Defines Phase III Trial Endpoints for Agitation & Aggression in BPD](https://www.clinicaltrialvanguard.com/news/oryzon-defines-phase-iii-trial-endpoints-for-agitation-aggression-in-bpd/) - Oryzon Genomics has established primary and key secondary endpoints for its Phase III clinical trial of vafidemstat for Borderline Personality Disorder (BPD). This was achieved with input from a newly formed Clinical Advisory Board comprised of leading psychiatric experts. The company anticipates submitting the Phase III protocol to the FDA in the first half of
- [NKgen Biotech Administers First Troculeucel Dose to Stroke Patient](https://www.clinicaltrialvanguard.com/news/nkgen-biotech-administers-first-troculeucel-dose-to-stroke-patient/) - NKGen Biotech administered its expanded autologous NK cell therapy, troculeucel, to a stroke patient under an FDA-cleared compassionate use IND. This marks the first step towards a potential full IND application for troculeucel in the post-stroke setting, building on NKGen’s research into neuroinflammation in stroke and traumatic brain injury. The collaboration with George Washington University
- [Adverum Launches Phase 3 Study of Ixo-Vec for Wet AMD](https://www.clinicaltrialvanguard.com/news/adverum-launches-phase-3-study-of-ixo-vec-for-wet-amd/) - Adverum Biotechnologies has launched the ARTEMIS Phase 3 study, a pivotal trial evaluating the efficacy and safety of a single intravitreal injection of Ixo-vec (ixoberogene soroparvovec) for wet age-related macular degeneration (AMD). The study compares Ixo-vec to the current standard of care, aflibercept administered every eight weeks, in approximately 284 patients, encompassing both treatment-naïve and
- [Onward Medical Advances Parkinson's Pipeline with DoD, MJFF Support](https://www.clinicaltrialvanguard.com/news/onward-medical-advances-parkinsons-pipeline-with-dod-mjff-support/) - ONWARD Medical received two grants to support early clinical feasibility studies of its ONWARD ARC-IM System for Parkinson's disease. The Michael J. Fox Foundation awarded a $1 million grant for a study on mobility challenges, while the US Department of Defense granted approximately $1.5 million to study blood pressure instability. Both studies aim to expand
- [Transforming Clinical Trials: Medable's Approach to Diversity and Inclusion](https://www.clinicaltrialvanguard.com/executiveinterviews/transforming-clinical-trials-medables-approach-to-diversity-and-inclusion/) - In this interview, we explore clinical trial technology's impact on diversity and inclusion. Ali Holland from Medable shares insights on how digital trials enhance diverse participation. This discussion explores Medable's strategies for engaging underrepresented populations, the role of digital solutions in patient engagement, and the future of decentralized clinical trials (DCTs) in addressing healthcare disparities.
- [Pelareorep: A Game-Changer in Oncolytic Virus Therapy](https://www.clinicaltrialvanguard.com/executiveinterviews/pelareorep-a-game-changer-in-oncolytic-virus-therapy/) - In this conversation, we engage with Dr. Thomas Heineman, Chief Medical Officer of Oncolytics Biotech, to explore the innovative cancer treatment, pelareorep (pela). This proprietary oncolytic virus is making waves in the field of immuno-oncology, particularly in breast and pancreatic cancers. Dr. Heineman shares insights into pela's unique mechanisms, administration, and potential to redefine therapeutic
- [Revolutionizing NSCLC Treatment: Insights from ImmunityBio's CMO](https://www.clinicaltrialvanguard.com/executiveinterviews/revolutionizing-nsclc-treatment-insights-from-immunitybios-cmo/) - In this discussion with Bobby Reddy, Chief Medical Officer of ImmunityBio, we delve into the innovative immunotherapy strategies targeting non-small cell lung cancer (NSCLC). Reddy discusses the promising combination of ANKTIVA's IL-15 super agonist with tislelizumab PD-1 inhibition, aimed at reactivating immune responses in patients resistant to prior therapies. This conversation explores the mechanisms, clinical
- [New Obesity Treatment Mechanisms: Dr. Bolz on Aphaia Pharma's Innovative Approach](https://www.clinicaltrialvanguard.com/executiveinterviews/new-obesity-treatment-mechanisms-dr-bolz-on-aphaia-pharmas-innovative-approach/) - In this discussion with Steffen-Sebastian Bolz, MD, PhD, we explore Aphaia's groundbreaking work in obesity treatment. With his dual expertise in clinical and molecular biology, Dr. Bolz shares insights on Aphaia's novel oral coated glucose formulation. This innovative approach has the potential to transform current treatment paradigms by emphasizing physiological mechanisms and minimizing side effects.
- [2025 SCOPE Summit: Transforming Clinical Trials with Pragmatic Trial Approaches](https://www.clinicaltrialvanguard.com/conference-coverage/2025-scope-summit-transforming-clinical-trials-with-pragmatic-trial-approaches/) - Understand the role of pragmatic trials in providing substantial evidence for drug approvals and advancing drug development.
- [Cybrexa Unveils Promising Preclinical Data on Tumor-Selective PDCs at ESMO 2025](https://www.clinicaltrialvanguard.com/news/cybrexa-unveils-promising-preclinical-data-on-tumor-selective-pdcs-at-esmo-2025/) - Cybrexa Therapeutics presented preclinical data at the ESMO Targeted Anticancer Therapies Congress 2025, showcasing their alphalex™ peptide-drug conjugates (PDCs). These PDCs demonstrate tumor-selective delivery of potent microtubule inhibitors, resulting in significant tumor suppression and a durable anti-tumor immune response. This approach leverages tumor acidity for precise drug delivery, potentially mitigating the toxicities associated with antigen-based
- [Reunion Neuroscience Raises Post Pardum Depression at MMH Forum](https://www.clinicaltrialvanguard.com/news/reunion-neuroscience-raises-post-pardum-depression-at-mmh-forum/) - Reunion Neuroscience is participating in the 2025 Maternal Mental Health (MMH) FORUM to discuss RE104, its lead product candidate for treating postpartum depression (PPD). The company's participation highlights the ongoing Phase 2 RECONNECT clinical trial, which is evaluating the safety and efficacy of a single dose of RE104 for moderate-to-severe PPD. This forum allows Reunion
- [Nuvectis Pharma: Combination Therapy Improves EGFR Inhibitor Efficacy](https://www.clinicaltrialvanguard.com/news/nuvectis-pharma-combination-therapy-improves-egfr-inhibitor-efficacy/) - Nuvectis Pharma announced promising preclinical research demonstrating the synergistic effects of combining its drug candidate, NXP900, with osimertinib (Tagrisso®) in treating EGFR-mutated non-small cell lung cancersmall cell lung cancer (NSCLC). The research, conducted at the Lerner Research Institute, Cleveland Clinic, showed the combination therapy outperformed osimertinib alone in preclinical models, leading to reduced cancer cell
- [Tiziana Life Sciences Files IND Application with FDA for ALS Phase 2 Trial](https://www.clinicaltrialvanguard.com/news/tiziana-life-sciences-files-ind-application-with-fda-for-als-phase-2-trial/) - Tiziana Life SciencesLife Sciences has submitted an Investigational New Drug (IND) application to the FDA for a phase 2 clinical trial of intranasal foralumab for Amyotrophic Lateral Sclerosis (ALS). This application follows a grant award from the ALS Association's Hoffman ALS Clinical Trial Awards Program, supporting Tiziana’s focus on intranasal foralumab for three neurodegenerative diseases:
- [Celon Pharma Promising Phase 2 Data for PDE10A Inhibitor in Parkinson's Dyskinesia](https://www.clinicaltrialvanguard.com/news/celon-pharma-promising-phase-2-data-for-pde10a-inhibitor-in-parkinsons-dyskinesia/) - Celon Pharma announced positive Phase 2 clinical trial results for its oral, once-daily PDE10A inhibitor, CPL’36, for treating Levodopa-Induced Dyskinesia (LID) in Parkinson’s disease. The study achieved its primary endpoint and several secondary endpoints, demonstrating significant efficacy in reducing LID symptoms. CPL’36 had previously shown promise in Phase 2 trials for schizophrenia. This development is
- [Enlivex Therapeutics Announces Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis](https://www.clinicaltrialvanguard.com/news/enlivex-therapeutics-announces-positive-interim-data-from-phase-i-ii-allocetra-trial-in-knee-osteoarthritis/) - Enlivex Therapeutics announced positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis. The trial showed statistically significant reductions in pain and improvements in joint function, with a sustained response at six months and no serious adverse events. The company will host a webinar on March 5, 2025, to discuss these results.
- [Invivyd Announces Neutralizing Activity of Pemigarda Against Dominant SARS-CoV-2 Variant](https://www.clinicaltrialvanguard.com/news/invivyd-announces-neutralizing-activity-of-pemigarda-against-dominant-sars-cov-2-variant/) - Invivyd announced positive in vitro neutralization data for its COVID-19 antibody treatment, PEMGARDA (pemivibart), against the dominant LP.8.1 variant. The company also highlighted the consistent susceptibility of prevalent variants like KP.3.1.1 and XEC to PEMGARDA, attributing this to the structural integrity of the targeted epitope. Additionally, Invivyd’s next-generation antibody candidate, VYD2311, demonstrated similar stability and
- [Zyversa Demonstrates NLRP3 Inhibition Improves Heart Function, Glucose Homeostasis, and Insulin Sensitivity in Obese Animal Model](https://www.clinicaltrialvanguard.com/news/zyversa-demonstrates-nlrp3-inhibition-improves-heart-function-glucose-homeostasis-and-insulin-sensitivity-in-obese-animal-model/) - ZyVersa Therapeutics highlighted newly published data demonstrating the cardioprotective and metabolic benefits of inhibiting NLRP3 inflammasome pathways in an obese animal model with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. The company's Inflammasome ASC Inhibitor, IC 100, showed promising results in reducing inflammation and improving cardiac and metabolic function. This research
- [Silexion Therapeutics Reports Positive Initial Data from Sil204 in Pancreatic Cancer Models](https://www.clinicaltrialvanguard.com/news/silexion-therapeutics-reports-positive-initial-data-from-sil204-in-pancreatic-cancer-models/) - Silexion Therapeutics (NASDAQ: SLXN) has released positive preclinical data for SIL204, its RNAi therapy targeting KRAS-driven cancers. The study used orthotopic pancreatic cancer models, a more clinically relevant setting, and demonstrated that subcutaneously administered SIL204 reduced both primary tumor growth and metastasis. This is the first time the company has shown SIL204’s efficacy in an
- [Tenax Advances Oral Levosimendan in Phase 3 PH-HFpEF Studies](https://www.clinicaltrialvanguard.com/news/tenax-advances-oral-levosimendan-in-phase-3-ph-hfpef-studies/) - Tenax Therapeutics announced the FDA's acceptance of an amendment to expand its Phase 3 LEVEL study for TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The LEVEL study will now enroll 230 patients, increasing its statistical power, and a second global Phase 3 trial, LEVEL-2, will
- [Journey Medical's Emrosi™ Rosacea Trial Results Published in JAMA Dermatology](https://www.clinicaltrialvanguard.com/news/journey-medicals-emrosi-rosacea-trial-results-published-in-jama-dermatology/) - Journey Medical Corporation announced positive Phase 3 trial results for its rosacea treatment, Emrosi (DFD-29), published in JAMA Dermatology. The drug, a modified-release minocycline capsule, demonstrated statistically superior efficacy compared to both Oracea (doxycycline) and placebo in reducing inflammatory lesions and erythema. The FDA approved Emrosi in November 2024, with a planned launch in early
- [Sernova Secures $1M Convertible Debt Financing](https://www.clinicaltrialvanguard.com/news/sernova-secures-1m-convertible-debt-financing/) - Sernova Biotherapeutics secured a CAD$1,000,000 convertible debenture financing from existing shareholder and board member, Dr. Steven Sangha. The proceeds will bolster the company's working capital. The debenture, repayable by March 4, 2027, has a 15% interest rate and includes warrants exercisable into common shares at CAD$0.20 per share. This financing is crucial for Sernova as
- [Rhenium Obisbemeda Gets FDA Orphan Drug Designation](https://www.clinicaltrialvanguard.com/news/rhenium-obisbemeda-gets-fda-orphan-drug-designation/) - Plus Therapeutics received Orphan Drug Designation from the FDA for its Rhenium (¹⁸⁶Re) Obisbemeda, a treatment for leptomeningeal metastases (LM) in lung cancer patients. This designation follows the successful completion of the Phase 1 single-dose trial, which identified the recommended Phase 2 dose. The company is also pursuing a Fast Track designation for the drug.
- [Clearside Biomedical CLS-AX Phase 3 Wet AMD Trial Announced](https://www.clinicaltrialvanguard.com/news/clearside-biomedical-cls-ax-phase-3-wet-amd-trial-announced/) - Clearside Biomedical announced positive results from a meeting with the FDA regarding its Phase 3 clinical trial plans for CLS-AX, a treatment for wet age-related macular degeneration (wet AMD). The FDA agreed with Clearside’s proposed Phase 3 program design, signaling a crucial step toward potential approval of this new therapy. CLS-AX, administered via Clearside’s patented
- [Medicus Pharma: Positive Interim Analysis of SKNJC-003 in BCC Treatment](https://www.clinicaltrialvanguard.com/news/medicus-pharma-positive-interim-analysis-of-sknjc-003-in-bcc-treatment/) - Medicus Pharma (NASDAQ: MDCX) announced positive interim results from its Phase 2 clinical study of SKNJCT-003, a non-invasive treatment for basal cell carcinoma (BCC). The interim analysis, conducted after randomizing over half of the targeted 60 patients, revealed a complete clinical clearance rate exceeding 60%. The investigational product, D-MNA, demonstrated good tolerability at both low
- [Chemomab's Nebakitug Shows Promise in Systemic Sclerosis Treatment](https://www.clinicaltrialvanguard.com/news/chemomabs-nebakitug-shows-promise-in-systemic-sclerosis-treatment/) - Chemomab Therapeutics announced new scientific data supporting the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc). The data, presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025), further validates the mechanism of action of nebokitug, a monoclonal antibody that blocks CCL24, a protein implicated in SSc.
- [Study Shows Increased Cardiometabolic Risk After Switching to Integrase Inhibitors](https://www.clinicaltrialvanguard.com/news/study-shows-increased-cardiometabolic-risk-after-switching-to-integrase-inhibitors/) - The AIDS Clinical Trials Group (ACTG) presented data from the REPRIEVE study at the 2025 Conference on Retroviruses and Opportunistic Infections. The study found that switching to an integrase inhibitor-based antiretroviral regimen in people living with HIV increased the risk of weight gain, diabetes, hypertension, and metabolic syndrome over five years, compared to those who
- [Late-Breaking ESK-001 Phase 2 Data Presented at AAD Meeting](https://www.clinicaltrialvanguard.com/news/late-breaking-esk-001-phase-2-data-presented-at-aad-meeting/) - Alumis announced positive 52-week data from the open-label extension of its Phase 2 STRIDE trial for ESK-001, an oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. Results presented at the 2025 American Academy of Dermatology meeting showed sustained and increasing clinical responses in patients receiving 40mg twice daily. The therapy continued to be well-tolerated with no
- [Regeneron and Sanofi: Dupixent® Bullous Pemphigoid Data at AAD](https://www.clinicaltrialvanguard.com/news/regeneron-and-sanofi-dupixent-bullous-pemphigoid-data-at-aad/) - Regeneron and Sanofi announced positive Phase 2/3 trial results for Dupixent (dupilumab) in treating moderate-to-severe bullous pemphigoid (BP), a chronic skin disease. The ADEPT trial showed Dupixent significantly improved sustained disease remission, reduced disease severity and itch, and lessened the need for oral corticosteroids and rescue medication compared to placebo. This is particularly relevant as
- [BioXcel's Serenity Trial: At-Home Agitation Treatment](https://www.clinicaltrialvanguard.com/news/bioxcels-serenity-trial-at-home-agitation-treatment/) - BioXcel Therapeutics has reached 33% enrollment (67 patients) in its 200-patient Phase 3 SERENITY At-Home trial for BXCL501 (dexmedetomidine sublingual film). The trial aims to evaluate the safety of the lowest approved dose (120mcg) of BXCL501 for at-home treatment of agitation related to bipolar disorders or schizophrenia. Topline data is anticipated in the latter half
- [Givastomig Phase 1b Study Sees Accelerated Progress](https://www.clinicaltrialvanguard.com/news/givastomig-phase-1b-study-sees-accelerated-progress/) - I-Mab, a global biotech company, announced the completion of enrollment, ahead of schedule, in the first dose expansion cohort of a Phase 1b study for givastomig. Givastomig is a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody being studied for first-line treatment of gastric cancer. The first patient in the second expansion cohort has also been
- [Briumvi Data at AAN 2025 Meeting: TG Therapeutics MS Treatment](https://www.clinicaltrialvanguard.com/news/briumvi-data-at-aan-2025-meeting-tg-therapeutics-ms-treatment/) - TG Therapeutics announced upcoming presentations of Briumvi (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting. The presentations will cover various aspects of Briumvi, including long-term safety, infusion tolerability, real-world efficacy, and a modified regimen. The data will be presented via posters between April 7th and 9th, 2025.
- [MindRank's MRANK-106 Gets FDA Clearance for Oncology Trials](https://www.clinicaltrialvanguard.com/news/mindranks-mrank-106-gets-fda-clearance-for-oncology-trials/) - MindRank, an AI-driven drug discovery company, has received FDA Investigational New Drug (IND) application clearance for MRANK-106. MRANK-106 is an orally available dual inhibitor of WEE1 and YES1 kinases, intended to treat various cancers, including pancreatic, small cell lung, ovarian, breast, and colorectal cancers. The upcoming Phase I clinical trial will assess its safety, tolerability,
- [AskBio Doses First Limb-Girdle Muscular Dystrophy Patient](https://www.clinicaltrialvanguard.com/news/askbio-doses-first-limb-girdle-muscular-dystrophy-patient/) - AskBio, a Bayer subsidiary, announced the advancement of its Phase 1/Phase 2 LION-CS101 clinical trial for AB-1003, a gene therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The first participant in the second cohort has been dosed following a positive safety review by the Data Safety Monitoring Board (DSMB) of the first cohort's data. The
- [PDS Biotech Launches Phase 3 Trial of Versamune® in HPV16+ Head and Neck Cancer](https://www.clinicaltrialvanguard.com/news/pds-biotech-launches-phase-3-trial-of-versamune-in-hpv16-head-and-neck-cancer/) - PDS Biotechnology Corporation has launched VERSATILE-003, a Phase 3 clinical trial for its immunotherapy drug, Versamune® HPV. The trial will evaluate Versamune® HPV combined with pembrolizumab as a first-line treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). The trial aims to enroll approximately 350 patients, comparing the combination therapy to pembrolizumab alone.
- [Artax Biopharma Unveils Promising Preclinical Data on NCK Modulators at 2025 AAD Annual Meeting](https://www.clinicaltrialvanguard.com/news/artax-biopharma-unveils-promising-preclinical-data-on-nck-modulators-at-2025-aad-annual-meeting/) - Artax Biopharma presented preclinical data on Nck modulators for atopic dermatitis at the 2025 American Academy of Dermatology Annual Meeting. The data demonstrate the potential of Nck modulation to treat autoimmune skin diseases by regulating T cell activation. Specifically, the research highlighted the reduction of inflammation markers in animal models and the controlled release of
- [Merck on Investigator-Initiated Studies and Budgeting Practices at 2025 SCOPE Summit](https://www.clinicaltrialvanguard.com/conference-coverage/merck-on-investigator-initiated-studies-and-budgeting-practices-at-2025-scope-summit/) - The 2025 SCOPE Summit's panel discussion on investigator-initiated studies (IIS) delved into the complexities of budgeting practices, highlighting the growing importance of IIS in clinical research. Industry experts Meghan Harrington, Karen Hartman, and Michael Salvatore Jr. explored the nuances of IIS, the challenges in budgeting, and the collaborative efforts needed to streamline processes. Understanding their
- [Calidi Delivers Transient Gene Therapy to Tumors](https://www.clinicaltrialvanguard.com/news/calidi-delivers-transient-gene-therapy-to-tumors/) - Calidi Biotherapeutics announced preclinical success with its systemic RTNova platform, demonstrating effective delivery of gene therapy payloads to targeted tumors and killing over 60 tumor cell lines. The platform utilizes a modified vaccinia virus enveloped in a human cell membrane, enabling systemic delivery and targeted tumor destruction while also acting as a viral vector for
- [4DMT Announces First Patients in Phase 3 Trial of 4D-150 for Wet AMD](https://www.clinicaltrialvanguard.com/news/4dmt-announces-first-patients-in-phase-3-trial-of-4d-150-for-wet-amd/) - 4D Molecular Therapeutics (4DMT) has initiated its Phase 3 clinical trial, 4FRONT-1, for 4D-150, a potential treatment for wet age-related macular degeneration (wet AMD). The trial aims to evaluate the efficacy and safety of 4D-150 compared to the current standard treatment, aflibercept. The company expects to release topline data from this trial and a second
- [ACTG Reveals Promising SLIM Liver Findings at CROI](https://www.clinicaltrialvanguard.com/news/actg-reveals-promising-slim-liver-findings-at-croi/) - The AIDS Clinical Trials Group (ACTG) presented findings from their SLIM LIVER study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI). The study investigated the use of semaglutide, a medication commonly used for weight loss and diabetes, to treat metabolic dysfunction-associated steatotic liver disease (MASLD) in people living with HIV. Researchers discovered that
- [Neflamapimod Shows Promise in Dementia with Lewy Bodies Study](https://www.clinicaltrialvanguard.com/news/neflamapimod-shows-promise-in-dementia-with-lewy-bodies-study/) - CervoMed announced positive 16-week results from the extension phase of its Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB). A new batch of neflamapimod capsules, addressing prior bioavailability issues, showed significant improvement in cognitive function and a lower incidence of falls compared to the old capsules and placebo. The positive data
- [Citeline's Strategic Vision: Bridging Clinical Trials and Real-World Healthcare](https://www.clinicaltrialvanguard.com/executiveinterviews/citelines-strategic-vision-bridging-clinical-trials-and-real-world-healthcare/) - In this discussion with Claire Riches, a veteran in clinical development, we explore Citeline's strategic initiatives. As a leader in pharma intelligence, Citeline is redefining how clinical trials integrate with real-world healthcare. Claire shares insights on leveraging data and AI to enhance patient-focused solutions and maintain industry leadership amid evolving challenges. Moe: How does Citeline's
- [Transforming Clinical Trials with AI: Insights from the Frontline](https://www.clinicaltrialvanguard.com/executiveinterviews/transforming-clinical-trials-with-ai-insights-from-the-frontline/) - In the rapidly evolving landscape of clinical trials, technology is a game-changer. Dr. Michelle Papka, Ph.D., Founder and President of The Cognitive And Research Center and a leader in Alzheimer's research, discusses the integration of AI to enhance participant recruitment and engagement. Alongside Tran Le, CEO of Grove AI, they explore the transformative potential of
- [Revolutionizing Clinical Trials with AI and Decentralization](https://www.clinicaltrialvanguard.com/executiveinterviews/revolutionizing-clinical-trials-with-ai-and-decentralization/) - In the evolving world of clinical trials, AI and decentralization are key drivers of change. Iddo Peleg, CEO of Yonalink, shares insights on how these innovations enhance trial efficiency, reduce costs, and improve patient recruitment. Peleg discusses the challenges and successes of implementing AI-driven solutions and the future of decentralized trials, offering a glimpse into
- [CLENE CNM-Au8® Shows ALS Survival Benefit](https://www.clinicaltrialvanguard.com/news/clene-cnm-au8-shows-als-survival-benefit/) - Clene Inc. announced positive results from a new analysis of the HEALEY ALS Platform Trial data. The analysis showed that CNM-Au8® 30 mg significantly improved survival in ALS patients, particularly those with moderate to severe disease and those meeting the criteria for Clene's upcoming Phase 3 RESTORE-ALS trial. The results support earlier findings from the
- [Soquelitinib in Phase 2 Trial for ALPS](https://www.clinicaltrialvanguard.com/news/soquelitinib-in-phase-2-trial-for-alps/) - The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS). This rare genetic disorder, often manifesting in early childhood, causes a buildup of T cells due to a faulty Fas protein, leading to immune system disruption
- [PDS Biotech gets FDA Clearance for Trial on Metastatic Colorectal Cancer Combo Therapy](https://www.clinicaltrialvanguard.com/news/pds-biotech-gets-fda-clearance-for-trial-on-metastatic-colorectal-cancer-combo-therapy/) - PDS Biotechnology Corporation has received FDA clearance for its Investigational New Drug (IND) application to evaluate a combination therapy for MUC1-positive metastatic colorectal cancer (mCRC). The therapy combines Versamune® MUC1, a novel MUC1-targeted immunotherapy candidate, with PDS01ADC, an IL-12 fused antibody drug conjugate. This Phase 1/2 trial will be conducted in collaboration with the National
- [Promising FAP Treatment: Phase 2 Trial of TPST-1495 Approved by FDA](https://www.clinicaltrialvanguard.com/news/promising-fap-treatment-phase-2-trial-of-tpst-1495-approved-by-fda/) - Tempest Therapeutics has received FDA clearance for a Phase 2 clinical trial of TPST-1495, a dual prostaglandin E2 (PGE2) receptor inhibitor, for Familial Adenomatous Polyposis (FAP). The trial, funded by the National Cancer Institute and conducted by the Cancer Prevention Clinical Trials Network, will begin in 2025 with data expected in 2026. This marks Tempest’s
- [Groundbreaking mRNA Biomarkers for Pancreatic Cancer Detection](https://www.clinicaltrialvanguard.com/news/groundbreaking-mrna-biomarkers-for-pancreatic-cancer-detection/) - Mainz Biomed has secured an exclusive license agreement with Liquid Biosciences for a portfolio of mRNA biomarkers aimed at developing a blood test for pancreatic cancer. The companies plan to refine the test and pursue FDA approval. This agreement centers around promising biomarkers that have demonstrated 95% sensitivity and 98% specificity in detecting pancreatic cancer
- [EnnoDC Presents Positive Phase I AMV Data at CROI 2025](https://www.clinicaltrialvanguard.com/news/ennodc-presents-positive-phase-i-amv-data-at-croi-2025/) - EnnoDC's Phase I ANRS VRI06 trial demonstrated that its Antibody Mediated Vaccine (AMV) technology induces a safe, durable, and robust immune response against HIV in human volunteers. The trial's positive data, presented at CROI 2025, showcases the platform’s potential in treating infectious diseases and, notably, its expanding application in oncology. The study’s findings confirm the
- [Dyne-251 Shows Unprecedented Functional Improvement in DMD Trial](https://www.clinicaltrialvanguard.com/news/dyne-251-shows-unprecedented-functional-improvement-in-dmd-trial/) - Dyne Therapeutics announced positive long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD). The data shows sustained functional improvement in patients amenable to exon 51 skipping at the 20 mg/kg dose. The company plans to submit a Biologics License Application for accelerated approval in the U.S. in early
- [FDA Approves Expanded Label for Iluvien®](https://www.clinicaltrialvanguard.com/news/fda-approves-expanded-label-for-iluvien/) - ANI Pharmaceuticals received FDA approval for an expanded label for ILUVIEN, adding chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) to its existing indication for diabetic macular edema (DME). The company plans to launch ILUVIEN in the U.S. with the combined label later this year. This approval also incorporates updates to the
- [Gain Therapeutics Doses First Patient in Phase 1b Parkinson's Trial](https://www.clinicaltrialvanguard.com/news/gain-therapeutics-doses-first-patient-in-phase-1b-parkinsons-trial/) - Gain Therapeutics has dosed the first Parkinson's disease patient in a Phase 1b clinical trial of its lead candidate, GT-02287. The trial will assess the drug's safety and tolerability in patients with Parkinson's disease, both with and without a GBA1 mutation. Interim analysis is expected by the end of Q2 2025. This trial initiation is
- [KRRO-110 FDA Orphan Drug Designation for A1AD Deficiency](https://www.clinicaltrialvanguard.com/news/krro-110-fda-orphan-drug-designation-for-a1ad-deficiency/) - Korro Bio announced that its investigational medicine, KRRO-110, received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is the first RNA editing candidate from Korro’s OPERA™ platform and is currently in a Phase 1/2a clinical trial called REWRITE. This designation recognizes the unmet need for AATD treatments and provides Korro
- [Gradalis Unveils Clonal Tumor Mutation Burden Pipeline](https://www.clinicaltrialvanguard.com/news/gradalis-unveils-clonal-tumor-mutation-burden-pipeline/) - Gradalis, a clinical-stage biotech company, published a peer-reviewed article in Scientific Reports detailing their novel exome sequencing procedure and bioinformatics pipeline for identifying clonal cancer signals. This process focuses on clonal Tumor Mutation Burden (cTMB), clonal Neoantigens (cNEO), and Intratumoral Heterogeneity (ITH) to identify optimal targets for immunotherapy and predict patient response. The study validated
- [Bitterroot Bio Presents Phase 1 BRB-002 Results at ACC.25](https://www.clinicaltrialvanguard.com/news/bitterroot-bio-presents-phase-1-brb-002-results-at-acc-25/) - Bitterroot Bio will present Phase 1 study results for BRB-002, a novel anti-CD47 therapy for atherosclerotic cardiovascular disease (ASCVD), at the American College of Cardiology's 2025 Scientific Session. The study in healthy volunteers met its primary safety objective, showing no serious adverse events and demonstrating dose-dependent target engagement with up to 100% CD47 receptor occupancy
- [Radiopharm Theranostics: Rad202 Shows Positive Tumor Uptake & Biodistribution](https://www.clinicaltrialvanguard.com/news/radiopharm-theranostics-rad202-shows-positive-tumor-uptake-biodistribution/) - Radiopharm Theranostics presented data at EMIM 2025 demonstrating the effectiveness of RAD202, a HER2-targeting single domain antibody, for both imaging and therapy. Preclinical studies showed 68Ga-RAD202 effectively imaged HER2-positive tumors and 177Lu-RAD202, in both single and fractionated doses, reduced tumor volume and improved survival in mouse models. This research builds on previous studies that established
- [PEP-010 Awarded FDA Orphan Drug Status for Pancreatic Cancer](https://www.clinicaltrialvanguard.com/news/pep-010-awarded-fda-orphan-drug-status-for-pancreatic-cancer/) - PEP-Therapy's lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer. The peptide is currently in a Phase Ib clinical trial assessing its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in combination with chemotherapy for pancreatic cancer patients. This designation is based on the
- [Cellphire Therapeutics gets FDA Fast Track for CLPH-511](https://www.clinicaltrialvanguard.com/news/cellphire-therapeutics-gets-fda-fast-track-for-clph-511/) - Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat acute hemorrhage when conventional platelets are unavailable. This designation expedites the development and review process for CLPH-511, potentially leading to faster approval and addressing a critical unmet medical need. The FDA granted this designation because of
- [Deramiocel Shows Long-Term Efficacy in Duchenne Muscular Dystrophy Treatment](https://www.clinicaltrialvanguard.com/news/deramiocel-shows-long-term-efficacy-in-duchenne-muscular-dystrophy-treatment/) - Capricor Therapeutics announced positive three-year data from its open-label extension of the HOPE-2 clinical trial for deramiocel, a cell-based therapy for Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD). The trial demonstrated a 52% slower decline in upper limb function for patients treated with deramiocel compared to an external comparator group. This positive data was presented at
- [2025 SCOPE Summit: Advancing Patient-Centric Clinical Trials](https://www.clinicaltrialvanguard.com/conference-coverage/2025-scope-summit-advancing-patient-centric-clinical-trials/) - The 2025 SCOPE Summit brought together industry leaders to explore patient-centric approaches in clinical trials, addressing the critical issue of low enrollment rates. With 80% of trials failing to enroll on time, the summit focused on strategies to engage healthcare providers and patients effectively. Key discussions revolved around modernizing protocols, leveraging data, and fostering trust
- [Bio-Path Holdings Announces Promising Pre-clinical Results for BP1001-A in Obesity Treatment for Type 2 Diabetes Patients](https://www.clinicaltrialvanguard.com/news/bio-path-holdings-announces-promising-pre-clinical-results-for-bp1001-a-in-obesity-treatment-for-type-2-diabetes-patients/) - Bio-Path Holdings announced positive pre-clinical results for BP1001-A, a potential obesity treatment. The drug candidate successfully reversed fatty acid-induced insulin resistance and improved insulin sensitivity in muscle cell models. These findings suggest BP1001-A could be effective in treating obesity and related metabolic issues, particularly in patients with Type 2 diabetes. Current obesity treatments often fall
- [Clearmind Medicine Initiates First Human Trial for Alcohol Use Disorder](https://www.clinicaltrialvanguard.com/news/clearmind-medicine-initiates-first-human-trial-for-alcohol-use-disorder/) - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD). This trial, taking place at IMCA in Israel, Yale School of Medicine, and Johns Hopkins University School of Medicine, will evaluate the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy in reducing alcohol cravings and
- [Ocu200 DME Trial: Cohort 2 Dosing Approved After Safety Review](https://www.clinicaltrialvanguard.com/news/ocu200-dme-trial-cohort-2-dosing-approved-after-safety-review/) - Ocugen, a biotechnology company, announced positive safety data from the first cohort of its Phase 1 clinical trial for OCU200, a novel fusion protein designed to treat diabetic macular edema (DME). The Data and Safety Monitoring Board approved the trial's progression to the second cohort after finding no serious adverse events related to OCU200. The
- [Fruquintinib & Sintilimab Trial Meets Primary Endpoint in Advanced RCC](https://www.clinicaltrialvanguard.com/news/fruquintinib-sintilimab-trial-meets-primary-endpoint-in-advanced-rcc/) - HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined with sintilimab as a second-line treatment for advanced renal cell carcinoma (RCC) in China and successfully met its primary endpoint of progression-free survival. The combination also showed improvement in secondary endpoints, including objective response rate and
- [Arbor Biotechnologies Secures $73.9M Series C Funding for Gene Editing](https://www.clinicaltrialvanguard.com/news/arbor-biotechnologies-secures-73-9m-series-c-funding-for-gene-editing/) - Arbor Biotechnologies secured $73.9 million in Series C funding, led by ARCH Venture Partners and TCGX, to advance its gene editing therapies for liver and central nervous system (CNS) diseases. The funding will propel the clinical development of ABO-101 for primary hyperoxaluria type 1 (PH1) and progress other programs towards Investigational New Drug (IND) applications,
- [Acumen Announces Results for Sabirnetug Formulation Study](https://www.clinicaltrialvanguard.com/news/acumen-announces-results-for-sabirnetug-formulation-study/) - Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of its Alzheimer's drug, sabirnetug. The study compared subcutaneous (SC) and intravenous (IV) delivery methods in healthy volunteers, finding weekly SC injections were well-tolerated and achieved systemic exposure sufficient for further development. This is particularly relevant as the company's lead candidate is currently being
- [Protara Therapeutics: Choline Deficiency and Liver Injury in Parenteral Support Patients: Encore Presentation of THRIVE-1 Results](https://www.clinicaltrialvanguard.com/news/protara-therapeutics-choline-deficiency-and-liver-injury-in-parenteral-support-patients-encore-presentation-of-thrive-1-results/) - Protara Therapeutics announced results from THRIVE-1, a study on choline deficiency and liver injury in patients dependent on parenteral support (PS). The study found that 78% of PS patients were choline deficient and 63% of those deficient also experienced liver dysfunction. Protara plans to start the THRIVE-3 registrational trial for their intravenous (IV) Choline Chloride
- [Conduit Pharmaceuticals Pipeline Update: AZD1656, AZD5658, & AZD5904](https://www.clinicaltrialvanguard.com/news/conduit-pharmaceuticals-pipeline-update-azd1656-azd5658-azd5904/) - Conduit Pharmaceuticals announced progress in its preclinical and clinical pipeline, including studies for AZD5658 in lupus, Phase IIa trial design for AZD1656, formulation optimization, and intellectual property expansion. The company is evaluating glucokinase inhibitors for autoimmune diseases, with a focus on lupus, anticipating results in Q2 2025. Conduit is also optimizing the Phase II trial
- [Tenaya Therapeutics Unveils Breakthrough Cardiac Data at ACC Conference](https://www.clinicaltrialvanguard.com/news/tenaya-therapeutics-unveils-breakthrough-cardiac-data-at-acc-conference/) - Tenaya Therapeutics will present new clinical data from the MyPEAK-1 Phase 1b/2 trial of TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the American College of Cardiology’s Annual Scientific Session. The data will include one-year assessments of the first two adult patients treated with TN-201 and six-month data from the third patient. A
- [Savolitinib Shines in HutchMed Phase II Lung Cancer Trial](https://www.clinicaltrialvanguard.com/news/savolitinib-shines-in-hutchmed-phase-ii-lung-cancer-trial/) - HUTCHMED announced new data from studies of savolitinib and surufatinib, two compounds it discovered, will be presented at the European Lung Cancer Congress 2025. The SAVANNAH Phase II trial demonstrated promising results for savolitinib combined with TAGRISSO (osimertinib) in patients with MET-high EGFR-mutated non-small cell lung cancer (NSCLC) whose disease progressed after initial TAGRISSO treatment.
- [Genenta Secures €20M, Brain Tumor Trial Shows Promising Survival](https://www.clinicaltrialvanguard.com/news/genenta-secures-e20m-brain-tumor-trial-shows-promising-survival/) - Genenta Science secured €20 million (approximately $21.9 million) in financing from ENEA Tech and Biomedical (ETB) to support the expansion of its clinical pipeline, specifically for Temferon in metastatic Renal Cell Carcinoma (mRCC). ETB, a prominent Italian foundation managing substantial assets, conducted extensive due diligence before investing in Genenta, demonstrating confidence in the company's potential.
- [WuGen Announces Dosing in Wu-CART-007 Trial](https://www.clinicaltrialvanguard.com/news/wugen-announces-dosing-in-wu-cart-007-trial/) - Wugen, Inc. has begun its pivotal Phase 2 trial of WU-CART-007, an off-the-shelf CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) in pediatric and adult patients. This follows promising Phase 1/2 results, which showed a 91% overall response rate and a 73% composite complete remission rate in heavily pre-treated patients. The
- [Celz-201-DDT FDA Clearance for Chronic Lower Back Pain Trial](https://www.clinicaltrialvanguard.com/news/celz-201-ddt-fda-clearance-for-chronic-lower-back-pain-trial/) - Creative Medical Technology Holdings (CELZ) announced positive interim data from its Phase 1/2 trial of StemSpine using AlloStem (CELZ-201-DDT), a donor cell therapy for chronic lower back pain due to degenerative disc disease (DDD). The FDA cleared an expanded dose escalation for the trial following statistically significant pain reduction and mobility improvement in participants. The
- [Pathos AI Doses First Patient in Pocenbrodib Trial](https://www.clinicaltrialvanguard.com/news/pathos-ai-doses-first-patient-in-pocenbrodib-trial/) - Pathos AI has initiated a Phase 1b/2a clinical trial for its CBP/p300 inhibitor, pocenbrodib, in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will evaluate pocenbrodib as a monotherapy and in combination with existing treatments like abiraterone acetate, olaparib, or 177Lu-PSMA-617. This marks the first clinical-stage asset for Pathos AI. This trial is significant
- [Soquelitinib Data in T-Cell Lymphoma: Promising Results Unveiled](https://www.clinicaltrialvanguard.com/news/soquelitinib-data-in-t-cell-lymphoma-promising-results-unveiled/) - Corvus Pharmaceuticals released additional data from its Phase 1/1b clinical trial of soquelitinib, an oral ITK inhibitor, for T-cell lymphoma (TCL). The data, presented at the 16th Annual T-Cell Lymphoma Forum, showed promising anti-tumor activity and a reduction in T-cell exhaustion. Based on these positive results, Corvus is currently enrolling patients in a registrational Phase
- [Briacell's Phase 3 Breast Cancer Study Gets Positive Recommendation](https://www.clinicaltrialvanguard.com/news/briacells-phase-3-breast-cancer-study-gets-positive-recommendation/) - BriaCell Therapeutics Corp. announced positive safety results from the second review of its Phase 3 study of Bria-IMT™ combined with an immune checkpoint inhibitor in patients with metastatic breast cancer. The independent Data Safety Monitoring Board (DSMB) found no safety concerns and recommended the continuation of the study, which has Fast Track Designation from the
- [Nanobiotix Data from Two Phase 1 NBTXR3 Studies at ELC](https://www.clinicaltrialvanguard.com/news/nanobiotix-data-from-two-phase-1-nbtxr3-studies-at-elc/) - Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900 (NBTXR3) in patients with non-small cell lung cancersmall cell lung cancer (NSCLC). One study evaluated the safety and efficacy of re-irradiation with NBTXR3 in patients with unresectable, locoregional recurrent NSCLC. The other explored the safety and
- [Opthea Coast Phase 3 Trial Fails to Meet Primary Endpoint](https://www.clinicaltrialvanguard.com/news/opthea-coast-phase-3-trial-fails-to-meet-primary-endpoint/) - Opthea Limited's Phase 3 COAST trial for sozinibercept, a combination therapy with aflibercept for wet age-related macular degeneration (wet AMD), failed to meet its primary endpoint of improved best corrected visual acuity (BCVA). The trial showed no significant difference in BCVA improvement between patients receiving sozinibercept combined with aflibercept and those receiving aflibercept alone. This
- [Silexion Unveils Sil204 Plan at NEAUXCancer 2025](https://www.clinicaltrialvanguard.com/news/silexion-unveils-sil204-plan-at-neauxcancer-2025/) - Silexion Therapeutics has developed an expanded plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The company will present this plan, along with recent groundbreaking preclinical data, at the 2025 NeauxCancer Conference in New Orleans. This new strategy builds on promising preclinical results and explores multiple delivery methods for SIL204. This development is particularly
- [Clearmind's Psychedelic CMND-100 Arrives in US for Yale Trial](https://www.clinicaltrialvanguard.com/news/clearminds-cmnd-100-arrives-in-us-for-fda-trial/) - Clearmind Medicine Inc. (Nasdaq: CMND) has shipped its novel psychedelic-derived drug candidate, CMND-100, to the United States for its upcoming Phase I/IIa clinical trial targeting Alcohol Use Disorder (AUD). This trial, approved by the FDA, will be conducted at Yale School of Medicine, Johns Hopkins University School of Medicine, and IMCA in Israel. CMND-100, an
- [Move Over Pharma: Patient-Led Organizations Advance Rare Disease Clinical Trials](https://www.clinicaltrialvanguard.com/conference-coverage/move-over-pharma-patient-led-organizations-advance-rare-disease-clinical-trials/) - At the 2025 SCOPE Summit, industry leaders and patient advocates discussed a transformative shift in the pharmaceutical industry: patient-led disruption in clinical trials. The panel, featuring Craig Lipset from the Decentralized Trials & Research Alliance, Deirdre BeVard of CSL Innovation GmbH, Heidi Bjornson-Pennell from the Chan Zuckerberg Initiative, Nasha Fitter of Citizen Health Inc, Craig
- [Tonix Pharmaceuticals Advances NDA: TNX-102 SL for Fibromyalgia](https://www.clinicaltrialvanguard.com/news/tonix-pharmaceuticals-advances-nda-tnx-102-sl-for-fibromyalgia/) - Tonix Pharmaceuticals announced that the FDA will not require an advisory committee meeting for their New Drug Application (NDA) for TNX-102 SL, a sublingual cyclobenzaprine tablet for fibromyalgia management. The FDA set a PDUFA goal date of August 15, 2025, and if approved, TNX-102 SL would be the first new fibromyalgia treatment in 15 years.
- [Clearside Biomedical Announces Six ARVO 2025 Abstracts](https://www.clinicaltrialvanguard.com/news/clearside-biomedical-announces-six-arvo-2025-abstracts/) - Clearside Biomedical announced the acceptance of six abstracts for presentation at the 2025 ARVO meeting. These abstracts cover topics ranging from clinical trial results for CLS-AX, a treatment for wet age-related macular degeneration (AMD), to advancements in suprachoroidal drug delivery technology and training. The company highlights its suprachoroidal drug delivery platform as a transformative approach

## Pages

- [SUBSCRIBE](https://www.clinicaltrialvanguard.com/subscribe/) - You will get our reporting on clinical trials, drug development and the business behind them. One email, and you can unsubscribe from any issue.
- [Video Page](https://www.clinicaltrialvanguard.com/video-page/)
- [Log In](https://www.clinicaltrialvanguard.com/login/)
- [Your Profile](https://www.clinicaltrialvanguard.com/membership-account/your-profile/)
- [Membership Cancel](https://www.clinicaltrialvanguard.com/membership-account/membership-cancel/) - [pmpro_cancel]
- [Membership Checkout](https://www.clinicaltrialvanguard.com/membership-checkout/) - [pmpro_checkout]
- [Membership Confirmation](https://www.clinicaltrialvanguard.com/membership-checkout/membership-confirmation/) - [pmpro_confirmation]
- [Membership Orders](https://www.clinicaltrialvanguard.com/membership-account/membership-orders/) - [pmpro_invoice]
- [Membership Levels](https://www.clinicaltrialvanguard.com/membership-levels/) - [pmpro_levels]
- [Membership Account](https://www.clinicaltrialvanguard.com/membership-account/)
- [Membership Billing](https://www.clinicaltrialvanguard.com/membership-account/membership-billing/) - [pmpro_billing]
- [TERMS AND CONDITIONS OF ACCESS AND USE](https://www.clinicaltrialvanguard.com/terms-and-conditions-of-access-and-use/) - PLEASE CAREFULLY REVIEW THESE TERMS AND CONDITIONS OF ACCESS AND USE ("TERMS") BEFORE UTILIZING THIS WEBSITE ("WEBSITE") AND ASSOCIATED DIGITAL PLATFORMS, INCLUDING ANY SUBDOMAINS AND MOBILE APPLICATIONS, MANAGED BY ANNEX CLINICAL CORPORATION AND ITS SUBSIDIARIES ("ANNEX"). THESE TERMS GOVERN YOUR ACCESS AND USE OF THE WEBSITE AND ESTABLISH A LEGAL AGREEMENT BETWEEN YOU AND ANNEX.
- [ABOUT US](https://www.clinicaltrialvanguard.com/about-us/) - Welcome to Clinical Trial Vanguard, the premier platform for in-depth insights, current news, and thorough analysis in the world of clinical trials.
- [PRIVACY POLICY](https://www.clinicaltrialvanguard.com/privacy-policy-2/) - This Privacy Policy (“Policy”) outlines the information we collect, how we use it, who we might share it with, & choices you have regarding this information.

## Video Sliders

- [Interview with Dr. Olga Kubassova: Imaging in Clinical Trials](https://www.clinicaltrialvanguard.com/video-slider/interview-with-dr-olga-kubassova-imaging-in-clinical-trials/) - https://www.youtube.com/watch?v=NQjAk9zT2iY&t=1s
- [Standardizing on the Veeva Vault Platform](https://www.clinicaltrialvanguard.com/video-slider/25815/) - https://www.youtube.com/watch?v=Tlq__IuLr3k
- [GLP-1 Trials Have an Imaging Problem | Prof. Mikael Boesen, MSK Radiology](https://www.clinicaltrialvanguard.com/video-slider/glp-1-trials-have-an-imaging-problem-prof-mikael-boesen-msk-radiology/) - https://www.youtube.com/watch?v=eaR-vVN-_zQ
- [Interview with Northwell Health's Christina Brennan](https://www.clinicaltrialvanguard.com/video-slider/interview-with-northwell-healths-christina-brennan/) - https://www.youtube.com/watch?v=LXxSDXEDhRE
- [Redefining Imaging Workflows in Clinical Trials](https://www.clinicaltrialvanguard.com/video-slider/redefining-imaging-workflows-in-clinical-trials/) - https://www.youtube.com/watch?v=EVUdx7HYAik
- [Interview with Luca Manfro, Recordati](https://www.clinicaltrialvanguard.com/video-slider/interview-with-luca-manfro-recordati/) - https://www.youtube.com/watch?v=y4TEX0nRSkA
- [Interview with Novo Nordisk](https://www.clinicaltrialvanguard.com/video-slider/interview-with-novo-nordisk/) - https://www.youtube.com/watch?v=Plhq4ctKZ1s
- [Interview with AstraZeneca](https://www.clinicaltrialvanguard.com/video-slider/interview-with-astrazeneca/) - https://www.youtube.com/watch?v=bLbSd-73MiA
- [Interview with Martin Helling Boehringer Ingelheim](https://www.clinicaltrialvanguard.com/video-slider/interview-with-martin-helling-boehringer-ingelheim/) - https://www.youtube.com/watch?v=VuW8UwbT_NQ
- [Interview with Skylight Health Research Alisha Garibaldi](https://www.clinicaltrialvanguard.com/video-slider/interview-with-skylight-health-research-alisha-garibaldi/) - https://www.youtube.com/watch?v=6bZ2uxx6Vo8&t
- [Interview with Veeva's Kenny Kong](https://www.clinicaltrialvanguard.com/video-slider/interview-with-veevas-kenny-kong/) - https://youtu.be/1igRKXWt6Hg
- [Interview with Carolyn Jin from Kura Oncology](https://www.clinicaltrialvanguard.com/video-slider/interview-with-carolyn-jin-from-kura-oncology/) - https://www.youtube.com/watch?v=7P2smAnlU2g&t=1s
- [Interview with Bonne Adams of Inhibrx](https://www.clinicaltrialvanguard.com/video-slider/interview-with-bonne-adams-of-inhibrx/) - https://youtu.be/dEdS73wfVxo?si=Wixpq6yngLUqfD92
- [Raviv Pryluk from Phase V](https://www.clinicaltrialvanguard.com/video-slider/raviv-pryluk-from-phase-v/) - https://youtu.be/aZZdwIiMB_s?si=YRKT5uWMQDff3qTh
- [Mumbi Kairu on FDA's Guidance on Diversity Inclusion in Clinical Trials](https://www.clinicaltrialvanguard.com/video-slider/mumbi-kairu-on-fdas-guidance-on-diversity-inclusion-in-clinical-trials/) - https://www.youtube.com/watch?v=y1M8Yfz1Qa8&t=17s
- [Interview with Parexel Peyton Howell](https://www.clinicaltrialvanguard.com/video-slider/interview-with-parexel-peyton-howell/) - https://www.youtube.com/watch?v=C1E3Qb2VuMo&t=17s
- [Interview with Veeva's Rylan Collins](https://www.clinicaltrialvanguard.com/video-slider/interview-with-veevas-rylan-collins/) - https://youtu.be/mIS5E98eaL0
- [Interview with Veeva's Richard Young](https://www.clinicaltrialvanguard.com/video-slider/interview-with-veevas-richard-young/) - https://www.youtube.com/watch?v=uICB_ECFUdg
- [Advancing Real-World Data to Generate Regulatory Grade Real-World Evidence in Oncology](https://www.clinicaltrialvanguard.com/video-slider/video-1/) - https://www.youtube.com/watch?v=UfrAdbHiSZA
- [Translating QbD Principles to Risk-Proportionate Oversight Including RBM: Successes and Challenges](https://www.clinicaltrialvanguard.com/video-slider/video-2/) - https://www.youtube.com/watch?v=Kqo2UWDcXz0
- [Enhancing Adoption of Innovative Clinical Trial Approaches](https://www.clinicaltrialvanguard.com/video-slider/video-3/) - https://www.youtube.com/watch?v=rLOKp0XBfrA&t=3837s
- [Integrating QBD and RBM Approaches in Clinical Trials](https://www.clinicaltrialvanguard.com/video-slider/video-4/) - https://www.youtube.com/watch?v=3e-DqXu2Mmo

## Episode

- [What are Pragmatic Trials?](https://www.clinicaltrialvanguard.com/podcast/what-are-pragmatic-trials/) - Pragmatic trials are a transformative approach in clinical research designed to integrate real-world data into clinical trials. They aim to bridge the gap between clinical research and practice by ensuring that trial results are applicable to broader, real-world populations. Here are some key aspects of pragmatic trials: Real-world applicability: Pragmatic trials are designed to determine
- [Key Takeaways from SCOPE Summit 2025: Budget Negotiations, Protocol Design, and AI in Clinical TrialsSCOPE Summit Summary](https://www.clinicaltrialvanguard.com/podcast/key-takeaways-from-scope-summit-2025-budget-negotiations-protocol-design-and-ai-in-clinical-trialsscope-summit-summary/) - The SCOPE Summit 2025 addressed key areas in clinical trials: budget negotiations, protocol design, and AI integration. Clinical Trial Budget Negotiations: The summit addressed unresponsive sites and budget discrepancies3. It promoted clear communication, thorough feasibility assessments, and flexible fair market value (FMV) parameters to improve negotiation efficiency and fairness. Enhancing Clinical Trial Protocol Design: Collaboration
- [Is Big Pharma in Decline?](https://www.clinicaltrialvanguard.com/podcast/is-big-pharma-in-decline/) - Explore the financial challenges facing the pharmaceutical industry in light of declining performance indicators and the impact on innovation.
- [FDA’s Diversity in Clinical Trials Plan: Why It Fails to Address Key Barriers for Underrepresented Communities](https://www.clinicaltrialvanguard.com/podcast/fdas-diversity-in-clinical-trials-plan-why-it-fails-to-address-key-barriers-for-underrepresented-communities/) - This is an AI-Generated podcast. This podcast discusses the FDA's recent guidance on inclusion and diversity in clinical trials and features an interview with Mumbi Kairu, a nurse practitioner at the Pamoja Research Institute. Kairu discusses the crucial need for diversity in clinical trials, noting that while the FDA guidance is a step in the

## Categories

- [Uncategorized](https://www.clinicaltrialvanguard.com/category/uncategorized/)
- [Clinical Trials](https://www.clinicaltrialvanguard.com/category/clinicaltrials/)
- [Article: Executive Interviews](https://www.clinicaltrialvanguard.com/category/executiveinterviews/)
- [News](https://www.clinicaltrialvanguard.com/category/news/)
- [Article](https://www.clinicaltrialvanguard.com/category/article/)
- [Analysis](https://www.clinicaltrialvanguard.com/category/analysis/)
- [Article: Conference Coverage](https://www.clinicaltrialvanguard.com/category/conference-coverage/)
- [Clinical Trial Quality Assurance](https://www.clinicaltrialvanguard.com/category/clinical-trial-quality-assurance/)
- [Patient Engagement](https://www.clinicaltrialvanguard.com/category/patient-engagement/)
- [Article: Opinion](https://www.clinicaltrialvanguard.com/category/opinion/)
- [Decentralized Clinical Trials](https://www.clinicaltrialvanguard.com/category/clinicaltrials/decentralized-clinical-trials/)
- [Article: Deep Dive](https://www.clinicaltrialvanguard.com/category/article/article-deep-dive/)
- [Intel Brief](https://www.clinicaltrialvanguard.com/category/article/intel-brief/)
- [Trend Watch](https://www.clinicaltrialvanguard.com/category/article/trend-watch/)
- [Psych Pulse](https://www.clinicaltrialvanguard.com/category/article/psych-pulse/)
- [Clinical Trial Ops Brief](https://www.clinicaltrialvanguard.com/category/clinical-trial-ops-brief/)
- [Clinops Watchdog](https://www.clinicaltrialvanguard.com/category/clinops-watchdog/)
- [Inclusion Brief](https://www.clinicaltrialvanguard.com/category/inclusion-brief/)
- [Clinical Bellwether](https://www.clinicaltrialvanguard.com/category/clinical-bellwether/)
- [The Billing Grid](https://www.clinicaltrialvanguard.com/category/the-billing-grid/) - A weekly column on research billing and coverage analysis, by Krishma Shah.
- [eClinical Vendor Watch](https://www.clinicaltrialvanguard.com/category/eclinical-vendor-watch/) - Vendor announcements read closely: what was said, what was left out, and what the evidence would need to show.

## Tags

- [Clinical Trials](https://www.clinicaltrialvanguard.com/tag/clinicaltrials/)
- [Opinion](https://www.clinicaltrialvanguard.com/tag/opinion/)
- [News](https://www.clinicaltrialvanguard.com/tag/news/)
- [Data Analysis](https://www.clinicaltrialvanguard.com/tag/dataanalysis/)
- [sponsor](https://www.clinicaltrialvanguard.com/tag/sponsor/)
- [Article](https://www.clinicaltrialvanguard.com/tag/article/)
- [Conference Coverage](https://www.clinicaltrialvanguard.com/tag/conference-coverage/)
- [AI in Clinical Trials](https://www.clinicaltrialvanguard.com/tag/ai-in-clinical-trials/)
- [Artificial Intelligence in Clinical Trials](https://www.clinicaltrialvanguard.com/tag/artificial-intelligence-in-clinical-trials/)
- [Clinical Research](https://www.clinicaltrialvanguard.com/tag/clinical-research/)
- [Executive Interviews](https://www.clinicaltrialvanguard.com/tag/executive-interviews/)
- [CTMS](https://www.clinicaltrialvanguard.com/tag/ctms/)
- [Clinical Trial Management System](https://www.clinicaltrialvanguard.com/tag/clinical-trial-management-system/)
- [Analysis](https://www.clinicaltrialvanguard.com/tag/analysis/)
- [Clinical Trial Patient Engagement](https://www.clinicaltrialvanguard.com/tag/clinical-trial-patient-engagement/)
- [Decentralized Clinical Trials](https://www.clinicaltrialvanguard.com/tag/decentralized-clinical-trials/)
- [Clinical Trial Quality](https://www.clinicaltrialvanguard.com/tag/clinical-trial-quality/)
- [ICH E6](https://www.clinicaltrialvanguard.com/tag/ich-e6/)
- [Clinical Trial Diversity](https://www.clinicaltrialvanguard.com/tag/clinical-trial-diversity/)
- [Compliance](https://www.clinicaltrialvanguard.com/tag/compliance/)
- [FDA](https://www.clinicaltrialvanguard.com/tag/fda/)
- [Acquisitions](https://www.clinicaltrialvanguard.com/tag/acquisitions/)
- [Patient Centricity](https://www.clinicaltrialvanguard.com/tag/patient-centricity/)
- [Site Selection](https://www.clinicaltrialvanguard.com/tag/site-selection/)
- [RWE](https://www.clinicaltrialvanguard.com/tag/rwe/)
- [RWD](https://www.clinicaltrialvanguard.com/tag/rwd/)
- [RBQM](https://www.clinicaltrialvanguard.com/tag/rbqm/)
- [AI](https://www.clinicaltrialvanguard.com/tag/ai/)
- [Mental Health](https://www.clinicaltrialvanguard.com/tag/mental-health/)
- [Psychedelics](https://www.clinicaltrialvanguard.com/tag/psychedelics/)
- [Clinical Trial News](https://www.clinicaltrialvanguard.com/tag/clinical-trial-news/)
- [eSource](https://www.clinicaltrialvanguard.com/tag/esource/)
- [GCP](https://www.clinicaltrialvanguard.com/tag/gcp/)
- [Data Management](https://www.clinicaltrialvanguard.com/tag/data-management/)
- [Protocol](https://www.clinicaltrialvanguard.com/tag/protocol/)
- [FDA Guidance](https://www.clinicaltrialvanguard.com/tag/fda-guidance/)
- [eCOA](https://www.clinicaltrialvanguard.com/tag/ecoa/)
- [Clinical Trial Tech](https://www.clinicaltrialvanguard.com/tag/clinical-trial-tech/)
- [Clinical Trial Innovation](https://www.clinicaltrialvanguard.com/tag/clinical-trial-innovation/)
- [Clinical Trial Risk Management](https://www.clinicaltrialvanguard.com/tag/clinical-trial-risk-management/)
- [Clinical Trial Payments](https://www.clinicaltrialvanguard.com/tag/clinical-trial-payments/)
- [EDC](https://www.clinicaltrialvanguard.com/tag/edc/)
- [Liver Clinical Trials](https://www.clinicaltrialvanguard.com/tag/liver-clinical-trials/)
- [Pfizer](https://www.clinicaltrialvanguard.com/tag/pfizer/)
- [eConsent](https://www.clinicaltrialvanguard.com/tag/econsent/)
- [DHT](https://www.clinicaltrialvanguard.com/tag/dht/)
- [Digital Health Technologies](https://www.clinicaltrialvanguard.com/tag/digital-health-technologies/)
- [DCT](https://www.clinicaltrialvanguard.com/tag/dct/)
- [Thyroid](https://www.clinicaltrialvanguard.com/tag/thyroid/)
- [Oncology](https://www.clinicaltrialvanguard.com/tag/oncology/)
- [Solid Tumors](https://www.clinicaltrialvanguard.com/tag/solid-tumors/)
- [Tufts CSDD](https://www.clinicaltrialvanguard.com/tag/tufts-csdd/)
- [Stanford](https://www.clinicaltrialvanguard.com/tag/stanford/)
- [eClinical Tech News](https://www.clinicaltrialvanguard.com/tag/eclinical-tech-news/)
- [FDA Regulatory Strategy](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-strategy/)
- [CBER](https://www.clinicaltrialvanguard.com/tag/cber/)
- [Biologics](https://www.clinicaltrialvanguard.com/tag/biologics/)
- [Clinical Trial Design](https://www.clinicaltrialvanguard.com/tag/clinical-trial-design/)
- [Rare Disease](https://www.clinicaltrialvanguard.com/tag/rare-disease/)
- [DOGE FDA Cuts](https://www.clinicaltrialvanguard.com/tag/doge-fda-cuts/)
- [Drug Approval](https://www.clinicaltrialvanguard.com/tag/drug-approval/)
- [Patient Safety](https://www.clinicaltrialvanguard.com/tag/patient-safety/)
- [Site Infrastructure](https://www.clinicaltrialvanguard.com/tag/site-infrastructure/)
- [FDA Strategy](https://www.clinicaltrialvanguard.com/tag/fda-strategy/)
- [Global Competition](https://www.clinicaltrialvanguard.com/tag/global-competition/)
- [Inclusive Trial Design](https://www.clinicaltrialvanguard.com/tag/inclusive-trial-design/)
- [Biomarker Strategy](https://www.clinicaltrialvanguard.com/tag/biomarker-strategy/)
- [Adaptive Trial Design](https://www.clinicaltrialvanguard.com/tag/adaptive-trial-design/)
- [Pediatric Oncology](https://www.clinicaltrialvanguard.com/tag/pediatric-oncology/)
- [FDA Regulation](https://www.clinicaltrialvanguard.com/tag/fda-regulation/)
- [Complete Response Letter](https://www.clinicaltrialvanguard.com/tag/complete-response-letter/)
- [Oncology Trials](https://www.clinicaltrialvanguard.com/tag/oncology-trials/)
- [FDA Regulatory Guidance](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-guidance/)
- [Biomarker Validation](https://www.clinicaltrialvanguard.com/tag/biomarker-validation/)
- [Algorithmic Bias](https://www.clinicaltrialvanguard.com/tag/algorithmic-bias/)
- [Health Equity](https://www.clinicaltrialvanguard.com/tag/health-equity/)
- [Real-World Evidence](https://www.clinicaltrialvanguard.com/tag/real-world-evidence/)
- [Patient Stratification](https://www.clinicaltrialvanguard.com/tag/patient-stratification/)
- [Multiple Myeloma](https://www.clinicaltrialvanguard.com/tag/multiple-myeloma/)
- [Oncology Clinical Trials](https://www.clinicaltrialvanguard.com/tag/oncology-clinical-trials/)
- [Drug Safety](https://www.clinicaltrialvanguard.com/tag/drug-safety/)
- [CNS/Psychiatry Trials](https://www.clinicaltrialvanguard.com/tag/cns-psychiatry-trials/)
- [FDA Regulatory Pathway](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-pathway/)
- [Phase 1 Trials](https://www.clinicaltrialvanguard.com/tag/phase-1-trials/)
- [eClinical Technology](https://www.clinicaltrialvanguard.com/tag/eclinical-technology/)
- [Data Integrity](https://www.clinicaltrialvanguard.com/tag/data-integrity/)
- [GCP Compliance](https://www.clinicaltrialvanguard.com/tag/gcp-compliance/)
- [Endpoint Selection](https://www.clinicaltrialvanguard.com/tag/endpoint-selection/)
- [Biomarker Stratification](https://www.clinicaltrialvanguard.com/tag/biomarker-stratification/)
- [Endpoint Strategy](https://www.clinicaltrialvanguard.com/tag/endpoint-strategy/)
- [FDA Regulatory Policy](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-policy/)
- [Biomarkers](https://www.clinicaltrialvanguard.com/tag/biomarkers/)
- [Alzheimer's Disease](https://www.clinicaltrialvanguard.com/tag/alzheimers-disease/)
- [CNS Trials](https://www.clinicaltrialvanguard.com/tag/cns-trials/)
- [CAR-T Therapy](https://www.clinicaltrialvanguard.com/tag/car-t-therapy/)
- [Autoimmune Disease](https://www.clinicaltrialvanguard.com/tag/autoimmune-disease/)
- [EMA](https://www.clinicaltrialvanguard.com/tag/ema/)
- [Antipsychotics](https://www.clinicaltrialvanguard.com/tag/antipsychotics/)
- [Clinical Trial Technology](https://www.clinicaltrialvanguard.com/tag/clinical-trial-technology/)
- [eClinical Platforms](https://www.clinicaltrialvanguard.com/tag/eclinical-platforms/)
- [Cardiovascular Trials](https://www.clinicaltrialvanguard.com/tag/cardiovascular-trials/)
- [Immuno-Oncology](https://www.clinicaltrialvanguard.com/tag/immuno-oncology/)
- [Clinical Trial Operations](https://www.clinicaltrialvanguard.com/tag/clinical-trial-operations/)
- [Phase 3 Trials](https://www.clinicaltrialvanguard.com/tag/phase-3-trials/)
- [Parkinson's Disease](https://www.clinicaltrialvanguard.com/tag/parkinsons-disease/)
- [Deep Brain Stimulation](https://www.clinicaltrialvanguard.com/tag/deep-brain-stimulation/)
- [Neuroimaging](https://www.clinicaltrialvanguard.com/tag/neuroimaging/)
- [Cell and Gene Therapy](https://www.clinicaltrialvanguard.com/tag/cell-and-gene-therapy/)
- [Manufacturing Changes](https://www.clinicaltrialvanguard.com/tag/manufacturing-changes/)
- [Phase III Trials](https://www.clinicaltrialvanguard.com/tag/phase-iii-trials/)
- [FDA Regulatory Compliance](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-compliance/)
- [GLSI-100](https://www.clinicaltrialvanguard.com/tag/glsi-100/)
- [FDA Approval](https://www.clinicaltrialvanguard.com/tag/fda-approval/)
- [Hidradenitis Suppurativa](https://www.clinicaltrialvanguard.com/tag/hidradenitis-suppurativa/)
- [Drug Development Pipeline](https://www.clinicaltrialvanguard.com/tag/drug-development-pipeline/)
- [Infectious Disease](https://www.clinicaltrialvanguard.com/tag/infectious-disease/)
- [Preclinical Development](https://www.clinicaltrialvanguard.com/tag/preclinical-development/)
- [Global Trial Design](https://www.clinicaltrialvanguard.com/tag/global-trial-design/)
- [Enrollment Strategy](https://www.clinicaltrialvanguard.com/tag/enrollment-strategy/)
- [INTEL BRIEF](https://www.clinicaltrialvanguard.com/tag/intel-brief/)
- [Opioid Use Disorder](https://www.clinicaltrialvanguard.com/tag/opioid-use-disorder/)
- [Biomarker-Selected Trials](https://www.clinicaltrialvanguard.com/tag/biomarker-selected-trials/)
- [Gastric Cancer](https://www.clinicaltrialvanguard.com/tag/gastric-cancer/)
- [Adaptive Trial Strategy](https://www.clinicaltrialvanguard.com/tag/adaptive-trial-strategy/)
- [Registrational Trial Design](https://www.clinicaltrialvanguard.com/tag/registrational-trial-design/)
- [Breast Cancer Screening](https://www.clinicaltrialvanguard.com/tag/breast-cancer-screening/)
- [GLP-1 Receptor Agonists](https://www.clinicaltrialvanguard.com/tag/glp-1-receptor-agonists/)
- [Trial Emulation](https://www.clinicaltrialvanguard.com/tag/trial-emulation/)
- [Label Expansion](https://www.clinicaltrialvanguard.com/tag/label-expansion/)
- [Biomarker Enrichment](https://www.clinicaltrialvanguard.com/tag/biomarker-enrichment/)
- [Addiction Psychiatry](https://www.clinicaltrialvanguard.com/tag/addiction-psychiatry/)
- [Heart Failure Trials](https://www.clinicaltrialvanguard.com/tag/heart-failure-trials/)
- [Precision Oncology](https://www.clinicaltrialvanguard.com/tag/precision-oncology/)
- [Wearable Technologies](https://www.clinicaltrialvanguard.com/tag/wearable-technologies/)
- [Digital Biomarkers](https://www.clinicaltrialvanguard.com/tag/digital-biomarkers/)
- [Clinical Operations](https://www.clinicaltrialvanguard.com/tag/clinical-operations/)
- [CNS Clinical Trials](https://www.clinicaltrialvanguard.com/tag/cns-clinical-trials/)
- [GLP-1 agonists](https://www.clinicaltrialvanguard.com/tag/glp-1-agonists/)
- [dual diagnosis](https://www.clinicaltrialvanguard.com/tag/dual-diagnosis/)
- [semaglutide](https://www.clinicaltrialvanguard.com/tag/semaglutide/)
- [Non-Small Cell Lung Cancer](https://www.clinicaltrialvanguard.com/tag/non-small-cell-lung-cancer/)
- [Immunotherapy Resistance](https://www.clinicaltrialvanguard.com/tag/immunotherapy-resistance/)
- [DOGE FDA Budget Cuts](https://www.clinicaltrialvanguard.com/tag/doge-fda-budget-cuts/)
- [Companion Diagnostics](https://www.clinicaltrialvanguard.com/tag/companion-diagnostics/)
- [Biomarker-Driven Trials](https://www.clinicaltrialvanguard.com/tag/biomarker-driven-trials/)
- [CAR-T Cell Therapy](https://www.clinicaltrialvanguard.com/tag/car-t-cell-therapy/)
- [Pancreatic Cancer](https://www.clinicaltrialvanguard.com/tag/pancreatic-cancer/)
- [HRD Stratification](https://www.clinicaltrialvanguard.com/tag/hrd-stratification/)
- [Blood-Brain Barrier](https://www.clinicaltrialvanguard.com/tag/blood-brain-barrier/)
- [Phase 3 Trial Design](https://www.clinicaltrialvanguard.com/tag/phase-3-trial-design/)
- [Anti-IL-5 Therapy](https://www.clinicaltrialvanguard.com/tag/anti-il-5-therapy/)
- [Clinical Trial Endpoints](https://www.clinicaltrialvanguard.com/tag/clinical-trial-endpoints/)
- [EMA Guidance](https://www.clinicaltrialvanguard.com/tag/ema-guidance/)
- [Virtual Control Groups](https://www.clinicaltrialvanguard.com/tag/virtual-control-groups/)
- [Animal Testing Alternatives](https://www.clinicaltrialvanguard.com/tag/animal-testing-alternatives/)
- [Obesity Trials](https://www.clinicaltrialvanguard.com/tag/obesity-trials/)
- [Patient Adherence](https://www.clinicaltrialvanguard.com/tag/patient-adherence/)
- [Treatment-Resistant Depression](https://www.clinicaltrialvanguard.com/tag/treatment-resistant-depression/)
- [Ketamine Therapy](https://www.clinicaltrialvanguard.com/tag/ketamine-therapy/)
- [CHMP](https://www.clinicaltrialvanguard.com/tag/chmp/)
- [Postpartum Depression](https://www.clinicaltrialvanguard.com/tag/postpartum-depression/)
- [Perinatal Psychiatry](https://www.clinicaltrialvanguard.com/tag/perinatal-psychiatry/)
- [CNS Pipeline](https://www.clinicaltrialvanguard.com/tag/cns-pipeline/)
- [Adaptive Trials](https://www.clinicaltrialvanguard.com/tag/adaptive-trials/)
- [Orphan Oncology](https://www.clinicaltrialvanguard.com/tag/orphan-oncology/)
- [Single-Arm Trials](https://www.clinicaltrialvanguard.com/tag/single-arm-trials/)
- [Basket Trials](https://www.clinicaltrialvanguard.com/tag/basket-trials/)
- [Lipid Disorders](https://www.clinicaltrialvanguard.com/tag/lipid-disorders/)
- [Phase 3 Design](https://www.clinicaltrialvanguard.com/tag/phase-3-design/)
- [MRD Endpoints](https://www.clinicaltrialvanguard.com/tag/mrd-endpoints/)
- [Protocol Innovation](https://www.clinicaltrialvanguard.com/tag/protocol-innovation/)
- [Psychedelic & Ketamine Research](https://www.clinicaltrialvanguard.com/tag/psychedelic-ketamine-research/)
- [Expedited Review Pathways](https://www.clinicaltrialvanguard.com/tag/expedited-review-pathways/)
- [PSYCH PULSE](https://www.clinicaltrialvanguard.com/tag/psych-pulse/)
- [Suicidal Crisis](https://www.clinicaltrialvanguard.com/tag/suicidal-crisis/)
- [Drug Development Strategy](https://www.clinicaltrialvanguard.com/tag/drug-development-strategy/)
- [Phase 2 Trial Design](https://www.clinicaltrialvanguard.com/tag/phase-2-trial-design/)
- [Pharmacovigilance](https://www.clinicaltrialvanguard.com/tag/pharmacovigilance/)
- [EMA PRAC](https://www.clinicaltrialvanguard.com/tag/ema-prac/)
- [Cenobamate](https://www.clinicaltrialvanguard.com/tag/cenobamate/)
- [Safety Monitoring](https://www.clinicaltrialvanguard.com/tag/safety-monitoring/)
- [AI in clinical research](https://www.clinicaltrialvanguard.com/tag/ai-in-clinical-research/)
- [EU regulatory landscape](https://www.clinicaltrialvanguard.com/tag/eu-regulatory-landscape/)
- [Biotech Act](https://www.clinicaltrialvanguard.com/tag/biotech-act/)
- [digital endpoints](https://www.clinicaltrialvanguard.com/tag/digital-endpoints/)
- [China biotech competition](https://www.clinicaltrialvanguard.com/tag/china-biotech-competition/)
- [trial simulation](https://www.clinicaltrialvanguard.com/tag/trial-simulation/)
- [QuantHealth](https://www.clinicaltrialvanguard.com/tag/quanthealth/)
- [probability of technical success](https://www.clinicaltrialvanguard.com/tag/probability-of-technical-success/)
- [real-world data](https://www.clinicaltrialvanguard.com/tag/real-world-data/)
- [Novartis](https://www.clinicaltrialvanguard.com/tag/novartis/)
- [patient recruitment](https://www.clinicaltrialvanguard.com/tag/patient-recruitment/)
- [operating model](https://www.clinicaltrialvanguard.com/tag/operating-model/)
- [scalability](https://www.clinicaltrialvanguard.com/tag/scalability/)
- [site engagement](https://www.clinicaltrialvanguard.com/tag/site-engagement/)
- [patient matching](https://www.clinicaltrialvanguard.com/tag/patient-matching/)
- [MindMed](https://www.clinicaltrialvanguard.com/tag/mindmed/)
- [LSD](https://www.clinicaltrialvanguard.com/tag/lsd/)
- [large language models](https://www.clinicaltrialvanguard.com/tag/large-language-models/)
- [generalized anxiety disorder](https://www.clinicaltrialvanguard.com/tag/generalized-anxiety-disorder/)
- [major depression](https://www.clinicaltrialvanguard.com/tag/major-depression/)
- [central raters](https://www.clinicaltrialvanguard.com/tag/central-raters/)
- [Hamilton Anxiety Scale](https://www.clinicaltrialvanguard.com/tag/hamilton-anxiety-scale/)
- [MADRS](https://www.clinicaltrialvanguard.com/tag/madrs/)
- [phase three](https://www.clinicaltrialvanguard.com/tag/phase-three/)
- [psychiatric trials](https://www.clinicaltrialvanguard.com/tag/psychiatric-trials/)
- [Clinical Trial Innovation Summit 2025](https://www.clinicaltrialvanguard.com/tag/clinical-trial-innovation-summit-2025/)
- [Medical Imaging](https://www.clinicaltrialvanguard.com/tag/medical-imaging/)
- [Rare Cancer Trials](https://www.clinicaltrialvanguard.com/tag/rare-cancer-trials/)
- [Phase 1/2 Trial Design](https://www.clinicaltrialvanguard.com/tag/phase-1-2-trial-design/)
- [Biomarker-Driven Stratification](https://www.clinicaltrialvanguard.com/tag/biomarker-driven-stratification/)
- [Magnetic Seizure Therapy](https://www.clinicaltrialvanguard.com/tag/magnetic-seizure-therapy/)
- [Electroconvulsive Therapy](https://www.clinicaltrialvanguard.com/tag/electroconvulsive-therapy/)
- [Neuromodulation](https://www.clinicaltrialvanguard.com/tag/neuromodulation/)
- [ICU Research](https://www.clinicaltrialvanguard.com/tag/icu-research/)
- [Protocol Design](https://www.clinicaltrialvanguard.com/tag/protocol-design/)
- [Bispecific Antibodies](https://www.clinicaltrialvanguard.com/tag/bispecific-antibodies/)
- [FDA Regulatory Authority](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-authority/)
- [Synthetic Biology](https://www.clinicaltrialvanguard.com/tag/synthetic-biology/)
- [Loper Bright](https://www.clinicaltrialvanguard.com/tag/loper-bright/)
- [site readiness](https://www.clinicaltrialvanguard.com/tag/site-readiness/)
- [enrollment timelines](https://www.clinicaltrialvanguard.com/tag/enrollment-timelines/)
- [protocol deviations](https://www.clinicaltrialvanguard.com/tag/protocol-deviations/)
- [CAPA](https://www.clinicaltrialvanguard.com/tag/capa/)
- [trial execution](https://www.clinicaltrialvanguard.com/tag/trial-execution/)
- [Pragmatic Trial Design](https://www.clinicaltrialvanguard.com/tag/pragmatic-trial-design/)
- [Protocol Optimization](https://www.clinicaltrialvanguard.com/tag/protocol-optimization/)
- [Site Startup](https://www.clinicaltrialvanguard.com/tag/site-startup/)
- [Contract Negotiation](https://www.clinicaltrialvanguard.com/tag/contract-negotiation/)
- [CRO Consolidation](https://www.clinicaltrialvanguard.com/tag/cro-consolidation/)
- [Vendor Integration](https://www.clinicaltrialvanguard.com/tag/vendor-integration/)
- [Digital Twins](https://www.clinicaltrialvanguard.com/tag/digital-twins/)
- [Observational Studies](https://www.clinicaltrialvanguard.com/tag/observational-studies/)
- [SaMD](https://www.clinicaltrialvanguard.com/tag/samd/)
- [pediatric clinical trials](https://www.clinicaltrialvanguard.com/tag/pediatric-clinical-trials/)
- [FDA Accelerated Approval](https://www.clinicaltrialvanguard.com/tag/fda-accelerated-approval/)
- [Surrogate Endpoints](https://www.clinicaltrialvanguard.com/tag/surrogate-endpoints/)
- [Rare Disease Trials](https://www.clinicaltrialvanguard.com/tag/rare-disease-trials/)
- [Biomarker Endpoints](https://www.clinicaltrialvanguard.com/tag/biomarker-endpoints/)
- [Immunology](https://www.clinicaltrialvanguard.com/tag/immunology/)
- [Phase 1/2 Trials](https://www.clinicaltrialvanguard.com/tag/phase-1-2-trials/)
- [alcohol use disorder](https://www.clinicaltrialvanguard.com/tag/alcohol-use-disorder/)
- [FDA drug approval](https://www.clinicaltrialvanguard.com/tag/fda-drug-approval/)
- [protocol complexity](https://www.clinicaltrialvanguard.com/tag/protocol-complexity/)
- [site activation](https://www.clinicaltrialvanguard.com/tag/site-activation/)
- [protocol amendments](https://www.clinicaltrialvanguard.com/tag/protocol-amendments/)
- [IRB timelines](https://www.clinicaltrialvanguard.com/tag/irb-timelines/)
- [CNS trial design](https://www.clinicaltrialvanguard.com/tag/cns-trial-design/)
- [IRB review burden](https://www.clinicaltrialvanguard.com/tag/irb-review-burden/)
- [study startup](https://www.clinicaltrialvanguard.com/tag/study-startup/)
- [Head and Neck Cancer](https://www.clinicaltrialvanguard.com/tag/head-and-neck-cancer/)
- [RWE Methodology](https://www.clinicaltrialvanguard.com/tag/rwe-methodology/)
- [CAR-T trials](https://www.clinicaltrialvanguard.com/tag/car-t-trials/)
- [post-M&A integration](https://www.clinicaltrialvanguard.com/tag/post-ma-integration/)
- [sponsor consolidation](https://www.clinicaltrialvanguard.com/tag/sponsor-consolidation/)
- [Digital Pathology](https://www.clinicaltrialvanguard.com/tag/digital-pathology/)
- [Oncology Trial Design](https://www.clinicaltrialvanguard.com/tag/oncology-trial-design/)
- [FDA AI Guidance](https://www.clinicaltrialvanguard.com/tag/fda-ai-guidance/)
- [FDA Inspections](https://www.clinicaltrialvanguard.com/tag/fda-inspections/)
- [BIMO](https://www.clinicaltrialvanguard.com/tag/bimo/)
- [RAS Inhibitors](https://www.clinicaltrialvanguard.com/tag/ras-inhibitors/)
- [Agitation](https://www.clinicaltrialvanguard.com/tag/agitation/)
- [Auvelity](https://www.clinicaltrialvanguard.com/tag/auvelity/)
- [Dextromethorphan](https://www.clinicaltrialvanguard.com/tag/dextromethorphan/)
- [Geriatric Psychiatry](https://www.clinicaltrialvanguard.com/tag/geriatric-psychiatry/)
- [Tardive Dyskinesia](https://www.clinicaltrialvanguard.com/tag/tardive-dyskinesia/)
- [Axsome Therapeutics](https://www.clinicaltrialvanguard.com/tag/axsome-therapeutics/)
- [SLE](https://www.clinicaltrialvanguard.com/tag/sle/)
- [Dose-Finding Trials](https://www.clinicaltrialvanguard.com/tag/dose-finding-trials/)
- [Phase 2 Failures](https://www.clinicaltrialvanguard.com/tag/phase-2-failures/)
- [FDA Endpoints](https://www.clinicaltrialvanguard.com/tag/fda-endpoints/)
- [Phase 3 Evidence](https://www.clinicaltrialvanguard.com/tag/phase-3-evidence/)
- [BRIDGE Pilot](https://www.clinicaltrialvanguard.com/tag/bridge-pilot/)
- [MicroRNA Therapeutics](https://www.clinicaltrialvanguard.com/tag/microrna-therapeutics/)
- [Cardior Pharmaceuticals](https://www.clinicaltrialvanguard.com/tag/cardior-pharmaceuticals/)
- [DIPG](https://www.clinicaltrialvanguard.com/tag/dipg/)
- [Site Operations](https://www.clinicaltrialvanguard.com/tag/site-operations/)
- [Sponsor Transitions](https://www.clinicaltrialvanguard.com/tag/sponsor-transitions/)
- [Contract Management](https://www.clinicaltrialvanguard.com/tag/contract-management/)
- [Remote Informed Consent](https://www.clinicaltrialvanguard.com/tag/remote-informed-consent/)
- [Early-Phase Trials](https://www.clinicaltrialvanguard.com/tag/early-phase-trials/)
- [CRO Networks](https://www.clinicaltrialvanguard.com/tag/cro-networks/)
- [IRB Workflows](https://www.clinicaltrialvanguard.com/tag/irb-workflows/)
- [Satellite Clinics](https://www.clinicaltrialvanguard.com/tag/satellite-clinics/)
- [CLINOPS WATCHDOG](https://www.clinicaltrialvanguard.com/tag/clinops-watchdog/)
- [FDA Enforcement](https://www.clinicaltrialvanguard.com/tag/fda-enforcement/)
- [Pharmaceutical Advertising](https://www.clinicaltrialvanguard.com/tag/pharmaceutical-advertising/)
- [Brukinsa](https://www.clinicaltrialvanguard.com/tag/brukinsa/)
- [OPDP](https://www.clinicaltrialvanguard.com/tag/opdp/)
- [China Clinical Trials](https://www.clinicaltrialvanguard.com/tag/china-clinical-trials/)
- [NMPA Regulatory Reform](https://www.clinicaltrialvanguard.com/tag/nmpa-regulatory-reform/)
- [IND Applications](https://www.clinicaltrialvanguard.com/tag/ind-applications/)
- [Theta Burst Stimulation](https://www.clinicaltrialvanguard.com/tag/theta-burst-stimulation/)
- [Emerging Pathogens](https://www.clinicaltrialvanguard.com/tag/emerging-pathogens/)
- [Surgical Site Infection](https://www.clinicaltrialvanguard.com/tag/surgical-site-infection/)
- [Orthopedic Trauma](https://www.clinicaltrialvanguard.com/tag/orthopedic-trauma/)
- [Antibiotic Prophylaxis](https://www.clinicaltrialvanguard.com/tag/antibiotic-prophylaxis/)
- [Infection Prevention](https://www.clinicaltrialvanguard.com/tag/infection-prevention/)
- [digital outcome measures](https://www.clinicaltrialvanguard.com/tag/digital-outcome-measures/)
- [Antimicrobial Resistance](https://www.clinicaltrialvanguard.com/tag/antimicrobial-resistance/)
- [Beta-Lactamase Inhibitors](https://www.clinicaltrialvanguard.com/tag/beta-lactamase-inhibitors/)
- [Clinical Hold](https://www.clinicaltrialvanguard.com/tag/clinical-hold/)
- [Prader-Willi Syndrome](https://www.clinicaltrialvanguard.com/tag/prader-willi-syndrome/)
- [Cardiovascular Safety](https://www.clinicaltrialvanguard.com/tag/cardiovascular-safety/)
- [iCBT](https://www.clinicaltrialvanguard.com/tag/icbt/)
- [Hispanic Mental Health](https://www.clinicaltrialvanguard.com/tag/hispanic-mental-health/)
- [post-market surveillance](https://www.clinicaltrialvanguard.com/tag/post-market-surveillance/)
- [FDA Leadership](https://www.clinicaltrialvanguard.com/tag/fda-leadership/)
- [CDER](https://www.clinicaltrialvanguard.com/tag/cder/)
- [CRISPR](https://www.clinicaltrialvanguard.com/tag/crispr/)
- [Intellia Therapeutics](https://www.clinicaltrialvanguard.com/tag/intellia-therapeutics/)
- [Clinical Trial Regulation](https://www.clinicaltrialvanguard.com/tag/clinical-trial-regulation/)
- [EU 2030 Targets](https://www.clinicaltrialvanguard.com/tag/eu-2030-targets/)
- [ACT EU](https://www.clinicaltrialvanguard.com/tag/act-eu/)
- [Site Management](https://www.clinicaltrialvanguard.com/tag/site-management/)
- [Data Quality](https://www.clinicaltrialvanguard.com/tag/data-quality/)
- [COPD](https://www.clinicaltrialvanguard.com/tag/copd/)
- [Astegolimab](https://www.clinicaltrialvanguard.com/tag/astegolimab/)
- [ST2/IL-33](https://www.clinicaltrialvanguard.com/tag/st2-il-33/)
- [Roche/Genentech](https://www.clinicaltrialvanguard.com/tag/roche-genentech/)
- [IL-33/ST2 Pathway](https://www.clinicaltrialvanguard.com/tag/il-33-st2-pathway/)
- [Drug Approvals](https://www.clinicaltrialvanguard.com/tag/drug-approvals/)
- [CAR-T Safety](https://www.clinicaltrialvanguard.com/tag/car-t-safety/)
- [data governance](https://www.clinicaltrialvanguard.com/tag/data-governance/)
- [Long-Term Safety](https://www.clinicaltrialvanguard.com/tag/long-term-safety/)
- [Adverse Events](https://www.clinicaltrialvanguard.com/tag/adverse-events/)
- [Clinical Trial Monitoring](https://www.clinicaltrialvanguard.com/tag/clinical-trial-monitoring/)
- [AstraZeneca](https://www.clinicaltrialvanguard.com/tag/astrazeneca/)
- [Etcamah](https://www.clinicaltrialvanguard.com/tag/etcamah/)
- [FDA Advisory Committee](https://www.clinicaltrialvanguard.com/tag/fda-advisory-committee/)
- [EMA CHMP](https://www.clinicaltrialvanguard.com/tag/ema-chmp/)
- [FGFR Inhibition](https://www.clinicaltrialvanguard.com/tag/fgfr-inhibition/)
- [Rare Tumor Trials](https://www.clinicaltrialvanguard.com/tag/rare-tumor-trials/)
- [coordinator burnout](https://www.clinicaltrialvanguard.com/tag/coordinator-burnout/)
- [patient enrollment](https://www.clinicaltrialvanguard.com/tag/patient-enrollment/)
- [clinical trial retention](https://www.clinicaltrialvanguard.com/tag/clinical-trial-retention/)
- [Clinical AI](https://www.clinicaltrialvanguard.com/tag/clinical-ai/)
- [Regulatory Sandbox](https://www.clinicaltrialvanguard.com/tag/regulatory-sandbox/)
- [Clinical Decision Support](https://www.clinicaltrialvanguard.com/tag/clinical-decision-support/)
- [AI Oversight](https://www.clinicaltrialvanguard.com/tag/ai-oversight/)
- [Clinical Trial Ops Brief](https://www.clinicaltrialvanguard.com/tag/clinical-trial-ops-brief/)
- [Neuroscience Trials](https://www.clinicaltrialvanguard.com/tag/neuroscience-trials/)
- [AI Clinical Trials](https://www.clinicaltrialvanguard.com/tag/ai-clinical-trials/)
- [CTMS Integration](https://www.clinicaltrialvanguard.com/tag/ctms-integration/)
- [Real-Time Data](https://www.clinicaltrialvanguard.com/tag/real-time-data/)
- [Veeva Systems](https://www.clinicaltrialvanguard.com/tag/veeva-systems/)
- [agentic AI](https://www.clinicaltrialvanguard.com/tag/agentic-ai/)
- [regulatory technology](https://www.clinicaltrialvanguard.com/tag/regulatory-technology/)
- [Vault](https://www.clinicaltrialvanguard.com/tag/vault/)
- [drug development technology](https://www.clinicaltrialvanguard.com/tag/drug-development-technology/)
- [life sciences software](https://www.clinicaltrialvanguard.com/tag/life-sciences-software/)
- [digital transformation](https://www.clinicaltrialvanguard.com/tag/digital-transformation/)
- [Regulatory Affairs](https://www.clinicaltrialvanguard.com/tag/regulatory-affairs/)
- [Platform Trials](https://www.clinicaltrialvanguard.com/tag/platform-trials/)
- [Neurodegenerative Disease](https://www.clinicaltrialvanguard.com/tag/neurodegenerative-disease/)
- [FDA Master Protocols](https://www.clinicaltrialvanguard.com/tag/fda-master-protocols/)
- [ADHD](https://www.clinicaltrialvanguard.com/tag/adhd/)
- [Pharmacotherapy](https://www.clinicaltrialvanguard.com/tag/pharmacotherapy/)
- [Dose Optimization](https://www.clinicaltrialvanguard.com/tag/dose-optimization/)
- [Tumor-Agnostic Trials](https://www.clinicaltrialvanguard.com/tag/tumor-agnostic-trials/)
- [CRO Oversight](https://www.clinicaltrialvanguard.com/tag/cro-oversight/)
- [Site Payments](https://www.clinicaltrialvanguard.com/tag/site-payments/)
- [Budget Reconciliation](https://www.clinicaltrialvanguard.com/tag/budget-reconciliation/)
- [ICON plc](https://www.clinicaltrialvanguard.com/tag/icon-plc/)
- [Clinical High Risk for Psychosis](https://www.clinicaltrialvanguard.com/tag/clinical-high-risk-for-psychosis/)
- [Tobacco Use Comorbidity](https://www.clinicaltrialvanguard.com/tag/tobacco-use-comorbidity/)
- [NAPLS2](https://www.clinicaltrialvanguard.com/tag/napls2/)
- [Diversity Action Plans](https://www.clinicaltrialvanguard.com/tag/diversity-action-plans/)
- [Psychosis Prevention Trials](https://www.clinicaltrialvanguard.com/tag/psychosis-prevention-trials/)
- [340B Drug Pricing Program](https://www.clinicaltrialvanguard.com/tag/340b-drug-pricing-program/)
- [Eli Lilly](https://www.clinicaltrialvanguard.com/tag/eli-lilly/)
- [Hospital Compliance](https://www.clinicaltrialvanguard.com/tag/hospital-compliance/)
- [Drug Discount Enforcement](https://www.clinicaltrialvanguard.com/tag/drug-discount-enforcement/)
- [DCT Strategy](https://www.clinicaltrialvanguard.com/tag/dct-strategy/)
- [Psychedelic Clinical Trials](https://www.clinicaltrialvanguard.com/tag/psychedelic-clinical-trials/)
- [Blinding Integrity](https://www.clinicaltrialvanguard.com/tag/blinding-integrity/)
- [FDA Regulatory Science](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-science/)
- [Psilocybin MDMA](https://www.clinicaltrialvanguard.com/tag/psilocybin-mdma/)
- [Neurological Disease](https://www.clinicaltrialvanguard.com/tag/neurological-disease/)
- [MAMS](https://www.clinicaltrialvanguard.com/tag/mams/)
- [CNS Drug Development](https://www.clinicaltrialvanguard.com/tag/cns-drug-development/)
- [Breast Cancer Research](https://www.clinicaltrialvanguard.com/tag/breast-cancer-research/)
- [CDK4/6 inhibitors](https://www.clinicaltrialvanguard.com/tag/cdk4-6-inhibitors/)
- [Tenecteplase](https://www.clinicaltrialvanguard.com/tag/tenecteplase/)
- [Endovascular Treatment](https://www.clinicaltrialvanguard.com/tag/endovascular-treatment/)
- [Ischemic Stroke](https://www.clinicaltrialvanguard.com/tag/ischemic-stroke/)
- [Phase 3 RCT](https://www.clinicaltrialvanguard.com/tag/phase-3-rct/)
- [Psychedelic-Assisted Therapy](https://www.clinicaltrialvanguard.com/tag/psychedelic-assisted-therapy/)
- [Mebufotenin](https://www.clinicaltrialvanguard.com/tag/mebufotenin/)
- [obesity clinical trials](https://www.clinicaltrialvanguard.com/tag/obesity-clinical-trials/)
- [oral small molecule](https://www.clinicaltrialvanguard.com/tag/oral-small-molecule/)
- [Phase 2b trial design](https://www.clinicaltrialvanguard.com/tag/phase-2b-trial-design/)
- [metabolic disease endpoints](https://www.clinicaltrialvanguard.com/tag/metabolic-disease-endpoints/)
- [MASLD](https://www.clinicaltrialvanguard.com/tag/masld/)
- [Survodutide](https://www.clinicaltrialvanguard.com/tag/survodutide/)
- [Liver Fibrosis](https://www.clinicaltrialvanguard.com/tag/liver-fibrosis/)
- [manufacturing compliance](https://www.clinicaltrialvanguard.com/tag/manufacturing-compliance/)
- [FDA 483](https://www.clinicaltrialvanguard.com/tag/fda-483/)
- [drug supply chain](https://www.clinicaltrialvanguard.com/tag/drug-supply-chain/)
- [site enrollment](https://www.clinicaltrialvanguard.com/tag/site-enrollment/)
- [Neuroprotection](https://www.clinicaltrialvanguard.com/tag/neuroprotection/)
- [Acute Ischaemic Stroke](https://www.clinicaltrialvanguard.com/tag/acute-ischaemic-stroke/)
- [EMPHASIS Trial](https://www.clinicaltrialvanguard.com/tag/emphasis-trial/)
- [ADC Therapeutics](https://www.clinicaltrialvanguard.com/tag/adc-therapeutics/)
- [Zynlonta](https://www.clinicaltrialvanguard.com/tag/zynlonta/)
- [post-authorization studies](https://www.clinicaltrialvanguard.com/tag/post-authorization-studies/)
- [conditional marketing authorization](https://www.clinicaltrialvanguard.com/tag/conditional-marketing-authorization/)
- [CRO acquisition](https://www.clinicaltrialvanguard.com/tag/cro-acquisition/)
- [sponsor-CRO integration](https://www.clinicaltrialvanguard.com/tag/sponsor-cro-integration/)
- [Pilot Scaling](https://www.clinicaltrialvanguard.com/tag/pilot-scaling/)
- [Clinical Data Standards](https://www.clinicaltrialvanguard.com/tag/clinical-data-standards/)
- [Site Burden](https://www.clinicaltrialvanguard.com/tag/site-burden/)
- [spatial biology](https://www.clinicaltrialvanguard.com/tag/spatial-biology/)
- [solid tumor trials](https://www.clinicaltrialvanguard.com/tag/solid-tumor-trials/)
- [antibody therapeutics](https://www.clinicaltrialvanguard.com/tag/antibody-therapeutics/)
- [pharmacobiology](https://www.clinicaltrialvanguard.com/tag/pharmacobiology/)
- [eClinical Monitoring](https://www.clinicaltrialvanguard.com/tag/eclinical-monitoring/)
- [Phase 1 Trial Design](https://www.clinicaltrialvanguard.com/tag/phase-1-trial-design/)
- [Cebranopadol](https://www.clinicaltrialvanguard.com/tag/cebranopadol/)
- [NOP Receptor](https://www.clinicaltrialvanguard.com/tag/nop-receptor/)
- [spatial transcriptomics](https://www.clinicaltrialvanguard.com/tag/spatial-transcriptomics/)
- [preclinical models](https://www.clinicaltrialvanguard.com/tag/preclinical-models/)
- [Valproate](https://www.clinicaltrialvanguard.com/tag/valproate/)
- [AAV Vectors](https://www.clinicaltrialvanguard.com/tag/aav-vectors/)
- [Clinical Trial Recruitment](https://www.clinicaltrialvanguard.com/tag/clinical-trial-recruitment/)
- [Enrollment Delays](https://www.clinicaltrialvanguard.com/tag/enrollment-delays/)
- [Sponsor-Site Operations](https://www.clinicaltrialvanguard.com/tag/sponsor-site-operations/)
- [Adaptive Neurostimulation](https://www.clinicaltrialvanguard.com/tag/adaptive-neurostimulation/)
- [Zepzelca](https://www.clinicaltrialvanguard.com/tag/zepzelca/)
- [Jazz Pharmaceuticals](https://www.clinicaltrialvanguard.com/tag/jazz-pharmaceuticals/)
- [Clinical Trial Governance](https://www.clinicaltrialvanguard.com/tag/clinical-trial-governance/)
- [Sponsor Accountability](https://www.clinicaltrialvanguard.com/tag/sponsor-accountability/)
- [Small Biotech](https://www.clinicaltrialvanguard.com/tag/small-biotech/)
- [Adaptive Clinical Trial Design](https://www.clinicaltrialvanguard.com/tag/adaptive-clinical-trial-design/)
- [CNS Device Regulation](https://www.clinicaltrialvanguard.com/tag/cns-device-regulation/)
- [Bayesian statistics](https://www.clinicaltrialvanguard.com/tag/bayesian-statistics/)
- [clinical trial startup](https://www.clinicaltrialvanguard.com/tag/clinical-trial-startup/)
- [FDA Medical Devices](https://www.clinicaltrialvanguard.com/tag/fda-medical-devices/)
- [MAMS design](https://www.clinicaltrialvanguard.com/tag/mams-design/)
- [progressive MS](https://www.clinicaltrialvanguard.com/tag/progressive-ms/)
- [adaptive enrollment](https://www.clinicaltrialvanguard.com/tag/adaptive-enrollment/)
- [Dementia Prevention](https://www.clinicaltrialvanguard.com/tag/dementia-prevention/)
- [Shingles Vaccine](https://www.clinicaltrialvanguard.com/tag/shingles-vaccine/)
- [Repurposed Vaccines](https://www.clinicaltrialvanguard.com/tag/repurposed-vaccines/)
- [PTSD](https://www.clinicaltrialvanguard.com/tag/ptsd/)
- [Dementia Agitation](https://www.clinicaltrialvanguard.com/tag/dementia-agitation/)
- [Behavioral Endpoints](https://www.clinicaltrialvanguard.com/tag/behavioral-endpoints/)
- [AI Validation](https://www.clinicaltrialvanguard.com/tag/ai-validation/)
- [FDA AI Governance](https://www.clinicaltrialvanguard.com/tag/fda-ai-governance/)
- [FDA CDS Guidance](https://www.clinicaltrialvanguard.com/tag/fda-cds-guidance/)
- [Regulatory Brief](https://www.clinicaltrialvanguard.com/tag/regulatory-brief/)
- [FDA Warning Letter](https://www.clinicaltrialvanguard.com/tag/fda-warning-letter/)
- [Medical Device Reporting](https://www.clinicaltrialvanguard.com/tag/medical-device-reporting/)
- [Quality Control](https://www.clinicaltrialvanguard.com/tag/quality-control/)
- [Sponsor Oversight](https://www.clinicaltrialvanguard.com/tag/sponsor-oversight/)
- [Autonomous AI Agents](https://www.clinicaltrialvanguard.com/tag/autonomous-ai-agents/)
- [AI Endpoints](https://www.clinicaltrialvanguard.com/tag/ai-endpoints/)
- [Regulated AI](https://www.clinicaltrialvanguard.com/tag/regulated-ai/)
- [GLP-1 trial design](https://www.clinicaltrialvanguard.com/tag/glp-1-trial-design/)
- [FDA obesity guidance](https://www.clinicaltrialvanguard.com/tag/fda-obesity-guidance/)
- [semaglutide endpoints](https://www.clinicaltrialvanguard.com/tag/semaglutide-endpoints/)
- [Sponsor Acquisitions](https://www.clinicaltrialvanguard.com/tag/sponsor-acquisitions/)
- [IND Transfer](https://www.clinicaltrialvanguard.com/tag/ind-transfer/)
- [Eosinophilic Esophagitis](https://www.clinicaltrialvanguard.com/tag/eosinophilic-esophagitis/)
- [Vonoprazan](https://www.clinicaltrialvanguard.com/tag/vonoprazan/)
- [Clinical Trial Enrollment](https://www.clinicaltrialvanguard.com/tag/clinical-trial-enrollment/)
- [Phathom Pharmaceuticals](https://www.clinicaltrialvanguard.com/tag/phathom-pharmaceuticals/)
- [Rare GI Disease](https://www.clinicaltrialvanguard.com/tag/rare-gi-disease/)
- [CRO Technology](https://www.clinicaltrialvanguard.com/tag/cro-technology/)
- [Site Monitoring](https://www.clinicaltrialvanguard.com/tag/site-monitoring/)
- [Clinical Trial Integrity](https://www.clinicaltrialvanguard.com/tag/clinical-trial-integrity/)
- [MHRA Inspection](https://www.clinicaltrialvanguard.com/tag/mhra-inspection/)
- [Mammography Screening](https://www.clinicaltrialvanguard.com/tag/mammography-screening/)
- [MASAI Trial](https://www.clinicaltrialvanguard.com/tag/masai-trial/)
- [Overdiagnosis](https://www.clinicaltrialvanguard.com/tag/overdiagnosis/)
- [Intermediate Endpoints](https://www.clinicaltrialvanguard.com/tag/intermediate-endpoints/)
- [Health AI](https://www.clinicaltrialvanguard.com/tag/health-ai/)
- [Adversarial Robustness](https://www.clinicaltrialvanguard.com/tag/adversarial-robustness/)
- [CRO Operations](https://www.clinicaltrialvanguard.com/tag/cro-operations/)
- [Risk-Based Monitoring](https://www.clinicaltrialvanguard.com/tag/risk-based-monitoring/)
- [Trauma-Focused CBT](https://www.clinicaltrialvanguard.com/tag/trauma-focused-cbt/)
- [Stroke Rehabilitation](https://www.clinicaltrialvanguard.com/tag/stroke-rehabilitation/)
- [Wearables and DHTs](https://www.clinicaltrialvanguard.com/tag/wearables-and-dhts/)
- [Gout Therapy](https://www.clinicaltrialvanguard.com/tag/gout-therapy/)
- [Psychedelic Therapy](https://www.clinicaltrialvanguard.com/tag/psychedelic-therapy/)
- [Tuberculosis](https://www.clinicaltrialvanguard.com/tag/tuberculosis/)
- [Rifampicin-Resistant TB](https://www.clinicaltrialvanguard.com/tag/rifampicin-resistant-tb/)
- [Adaptive Trial Methodology](https://www.clinicaltrialvanguard.com/tag/adaptive-trial-methodology/)
- [CNS Tumors](https://www.clinicaltrialvanguard.com/tag/cns-tumors/)
- [clinical trial supply chain](https://www.clinicaltrialvanguard.com/tag/clinical-trial-supply-chain/)
- [GMP compliance](https://www.clinicaltrialvanguard.com/tag/gmp-compliance/)
- [Altuviiio](https://www.clinicaltrialvanguard.com/tag/altuviiio/)
- [Bundibugyo virus](https://www.clinicaltrialvanguard.com/tag/bundibugyo-virus/)
- [PARTNERS trial](https://www.clinicaltrialvanguard.com/tag/partners-trial/)
- [WHO clinical trials](https://www.clinicaltrialvanguard.com/tag/who-clinical-trials/)
- [rare infectious disease](https://www.clinicaltrialvanguard.com/tag/rare-infectious-disease/)
- [Biomarker Qualification](https://www.clinicaltrialvanguard.com/tag/biomarker-qualification/)
- [Geroscience](https://www.clinicaltrialvanguard.com/tag/geroscience/)
- [Immunosenescence](https://www.clinicaltrialvanguard.com/tag/immunosenescence/)
- [Data Rights](https://www.clinicaltrialvanguard.com/tag/data-rights/)
- [Manufacturing Quality](https://www.clinicaltrialvanguard.com/tag/manufacturing-quality/)
- [Sanofi](https://www.clinicaltrialvanguard.com/tag/sanofi/)
- [AI Drug Discovery](https://www.clinicaltrialvanguard.com/tag/ai-drug-discovery/)
- [Insilico Medicine](https://www.clinicaltrialvanguard.com/tag/insilico-medicine/)
- [HIV](https://www.clinicaltrialvanguard.com/tag/hiv/)
- [bispecific antibody](https://www.clinicaltrialvanguard.com/tag/bispecific-antibody/)
- [adaptive randomization](https://www.clinicaltrialvanguard.com/tag/adaptive-randomization/)
- [broadly neutralizing antibody](https://www.clinicaltrialvanguard.com/tag/broadly-neutralizing-antibody/)
- [Fentanyl Vaccine](https://www.clinicaltrialvanguard.com/tag/fentanyl-vaccine/)
- [Addiction Immunotherapy](https://www.clinicaltrialvanguard.com/tag/addiction-immunotherapy/)
- [serotonin 1B receptor](https://www.clinicaltrialvanguard.com/tag/serotonin-1b-receptor/)
- [PET biomarker](https://www.clinicaltrialvanguard.com/tag/pet-biomarker/)
- [Pivotal Trial Design](https://www.clinicaltrialvanguard.com/tag/pivotal-trial-design/)
- [Recurrent Glioblastoma](https://www.clinicaltrialvanguard.com/tag/recurrent-glioblastoma/)
- [LAG-3](https://www.clinicaltrialvanguard.com/tag/lag-3/)
- [Checkpoint Inhibitors](https://www.clinicaltrialvanguard.com/tag/checkpoint-inhibitors/)
- [Schizophrenia](https://www.clinicaltrialvanguard.com/tag/schizophrenia/)
- [Functional Unblinding](https://www.clinicaltrialvanguard.com/tag/functional-unblinding/)
- [Multiple Sclerosis](https://www.clinicaltrialvanguard.com/tag/multiple-sclerosis/)
- [McDonald Criteria](https://www.clinicaltrialvanguard.com/tag/mcdonald-criteria/)
- [FDA Biomarker Policy](https://www.clinicaltrialvanguard.com/tag/fda-biomarker-policy/)
- [CMC Compliance](https://www.clinicaltrialvanguard.com/tag/cmc-compliance/)
- [Hepatocellular Carcinoma](https://www.clinicaltrialvanguard.com/tag/hepatocellular-carcinoma/)
- [Compass Pathways](https://www.clinicaltrialvanguard.com/tag/compass-pathways/)
- [Clinical Trial Simulation](https://www.clinicaltrialvanguard.com/tag/clinical-trial-simulation/)
- [Trial Optimization](https://www.clinicaltrialvanguard.com/tag/trial-optimization/)
- [recruitment inefficiency](https://www.clinicaltrialvanguard.com/tag/recruitment-inefficiency/)
- [Tourette Syndrome](https://www.clinicaltrialvanguard.com/tag/tourette-syndrome/)
- [Cannabinoid Therapeutics](https://www.clinicaltrialvanguard.com/tag/cannabinoid-therapeutics/)
- [Phase IIb Clinical Trial](https://www.clinicaltrialvanguard.com/tag/phase-iib-clinical-trial/)
- [NeuroThera Labs](https://www.clinicaltrialvanguard.com/tag/neurothera-labs/)
- [Site Recruitment](https://www.clinicaltrialvanguard.com/tag/site-recruitment/)
- [non-Hodgkin lymphoma](https://www.clinicaltrialvanguard.com/tag/non-hodgkin-lymphoma/)
- [T-cell exhaustion](https://www.clinicaltrialvanguard.com/tag/t-cell-exhaustion/)
- [substance use disorder](https://www.clinicaltrialvanguard.com/tag/substance-use-disorder/)
- [Ambient AI](https://www.clinicaltrialvanguard.com/tag/ambient-ai/)
- [Clinical Documentation](https://www.clinicaltrialvanguard.com/tag/clinical-documentation/)
- [Pharmacokinetics](https://www.clinicaltrialvanguard.com/tag/pharmacokinetics/)
- [B-cell Lymphoma](https://www.clinicaltrialvanguard.com/tag/b-cell-lymphoma/)
- [Dose Escalation](https://www.clinicaltrialvanguard.com/tag/dose-escalation/)
- [Phase 3 Termination](https://www.clinicaltrialvanguard.com/tag/phase-3-termination/)
- [Study Closeout](https://www.clinicaltrialvanguard.com/tag/study-closeout/)
- [Sponsor-Site Relations](https://www.clinicaltrialvanguard.com/tag/sponsor-site-relations/)
- [combination therapy](https://www.clinicaltrialvanguard.com/tag/combination-therapy/)
- [Remote Patient Monitoring](https://www.clinicaltrialvanguard.com/tag/remote-patient-monitoring/)
- [FDA Compliance](https://www.clinicaltrialvanguard.com/tag/fda-compliance/)
- [CMS 2027 Physician Fee Schedule](https://www.clinicaltrialvanguard.com/tag/cms-2027-physician-fee-schedule/)
- [AtaiBeckley](https://www.clinicaltrialvanguard.com/tag/ataibeckley/)
- [Rare Disease Clinical Trials](https://www.clinicaltrialvanguard.com/tag/rare-disease-clinical-trials/)
- [Osteosarcoma](https://www.clinicaltrialvanguard.com/tag/osteosarcoma/)
- [Phase 1/2 Oncology](https://www.clinicaltrialvanguard.com/tag/phase-1-2-oncology/)
- [Bioequivalence Studies](https://www.clinicaltrialvanguard.com/tag/bioequivalence-studies/)
- [spinal cord injury](https://www.clinicaltrialvanguard.com/tag/spinal-cord-injury/)
- [iPSC](https://www.clinicaltrialvanguard.com/tag/ipsc/)
- [regenerative medicine](https://www.clinicaltrialvanguard.com/tag/regenerative-medicine/)
- [Vaccine Trials](https://www.clinicaltrialvanguard.com/tag/vaccine-trials/)
- [Clinical Trial Methodology](https://www.clinicaltrialvanguard.com/tag/clinical-trial-methodology/)
- [Inherited Retinal Disease](https://www.clinicaltrialvanguard.com/tag/inherited-retinal-disease/)
- [eClinical Innovation](https://www.clinicaltrialvanguard.com/tag/eclinical-innovation/)
- [JAK inhibitors](https://www.clinicaltrialvanguard.com/tag/jak-inhibitors/)
- [dermatology trials](https://www.clinicaltrialvanguard.com/tag/dermatology-trials/)
- [povorcitinib](https://www.clinicaltrialvanguard.com/tag/povorcitinib/)
- [Diversity & Inclusion](https://www.clinicaltrialvanguard.com/tag/diversity-inclusion/)
- [Genetic Trials](https://www.clinicaltrialvanguard.com/tag/genetic-trials/)
- [AI Regulation](https://www.clinicaltrialvanguard.com/tag/ai-regulation/)
- [Medical AI Benchmarking](https://www.clinicaltrialvanguard.com/tag/medical-ai-benchmarking/)
- [Duchenne Muscular Dystrophy](https://www.clinicaltrialvanguard.com/tag/duchenne-muscular-dystrophy/)
- [Long COVID](https://www.clinicaltrialvanguard.com/tag/long-covid/)
- [cluster randomized trial](https://www.clinicaltrialvanguard.com/tag/cluster-randomized-trial/)
- [integrated care pathway](https://www.clinicaltrialvanguard.com/tag/integrated-care-pathway/)
- [Diversity Enrollment](https://www.clinicaltrialvanguard.com/tag/diversity-enrollment/)
- [Biomarker Screening](https://www.clinicaltrialvanguard.com/tag/biomarker-screening/)
- [maternal vaccines](https://www.clinicaltrialvanguard.com/tag/maternal-vaccines/)
- [Group B Streptococcus](https://www.clinicaltrialvanguard.com/tag/group-b-streptococcus/)
- [immunogenicity endpoints](https://www.clinicaltrialvanguard.com/tag/immunogenicity-endpoints/)
- [biometrics CRO](https://www.clinicaltrialvanguard.com/tag/biometrics-cro/)
- [eClinical stack](https://www.clinicaltrialvanguard.com/tag/eclinical-stack/)
- [decentralized trials](https://www.clinicaltrialvanguard.com/tag/decentralized-trials/)
- [NaV1.8 inhibitors](https://www.clinicaltrialvanguard.com/tag/nav1-8-inhibitors/)
- [acute pain](https://www.clinicaltrialvanguard.com/tag/acute-pain/)
- [non-opioid analgesics](https://www.clinicaltrialvanguard.com/tag/non-opioid-analgesics/)
- [Deescalation Trials](https://www.clinicaltrialvanguard.com/tag/deescalation-trials/)
- [Low-Value Care](https://www.clinicaltrialvanguard.com/tag/low-value-care/)
- [Deprescribing](https://www.clinicaltrialvanguard.com/tag/deprescribing/)
- [Behavioral Science](https://www.clinicaltrialvanguard.com/tag/behavioral-science/)
- [RSV Vaccine Trial](https://www.clinicaltrialvanguard.com/tag/rsv-vaccine-trial/)
- [Genetic Stratification](https://www.clinicaltrialvanguard.com/tag/genetic-stratification/)
- [Site Enrollment Strategy](https://www.clinicaltrialvanguard.com/tag/site-enrollment-strategy/)
- [GBA1 LRRK2](https://www.clinicaltrialvanguard.com/tag/gba1-lrrk2/)
- [Diversity Recruitment Operations](https://www.clinicaltrialvanguard.com/tag/diversity-recruitment-operations/)
- [Antipsychotic Trials](https://www.clinicaltrialvanguard.com/tag/antipsychotic-trials/)
- [PANSS](https://www.clinicaltrialvanguard.com/tag/panss/)
- [Statistical Analysis](https://www.clinicaltrialvanguard.com/tag/statistical-analysis/)
- [Clinical Guidelines](https://www.clinicaltrialvanguard.com/tag/clinical-guidelines/)
- [EDC Workflows](https://www.clinicaltrialvanguard.com/tag/edc-workflows/)
- [ICON Anthropic](https://www.clinicaltrialvanguard.com/tag/icon-anthropic/)
- [Dronabinol](https://www.clinicaltrialvanguard.com/tag/dronabinol/)
- [Cannabinoids](https://www.clinicaltrialvanguard.com/tag/cannabinoids/)
- [intracranial delivery](https://www.clinicaltrialvanguard.com/tag/intracranial-delivery/)
- [CNS oncology](https://www.clinicaltrialvanguard.com/tag/cns-oncology/)
- [FDA Regulatory Validation](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-validation/)
- [Cell & Gene Therapy](https://www.clinicaltrialvanguard.com/tag/cell-gene-therapy/)
- [Digital Mental Health](https://www.clinicaltrialvanguard.com/tag/digital-mental-health/)
- [AI Safety](https://www.clinicaltrialvanguard.com/tag/ai-safety/)
- [eTMF](https://www.clinicaltrialvanguard.com/tag/etmf/)
- [NMOSD](https://www.clinicaltrialvanguard.com/tag/nmosd/)
- [B-cell depletion](https://www.clinicaltrialvanguard.com/tag/b-cell-depletion/)
- [rare neurological diseases](https://www.clinicaltrialvanguard.com/tag/rare-neurological-diseases/)
- [CNS autoimmune trials](https://www.clinicaltrialvanguard.com/tag/cns-autoimmune-trials/)
- [Contract Manufacturing](https://www.clinicaltrialvanguard.com/tag/contract-manufacturing/)
- [Phase II Success Rates](https://www.clinicaltrialvanguard.com/tag/phase-ii-success-rates/)
- [ctDNA biomarkers](https://www.clinicaltrialvanguard.com/tag/ctdna-biomarkers/)
- [Causal Inference](https://www.clinicaltrialvanguard.com/tag/causal-inference/)
- [Difference-in-Differences](https://www.clinicaltrialvanguard.com/tag/difference-in-differences/)
- [FDA Real-World Evidence](https://www.clinicaltrialvanguard.com/tag/fda-real-world-evidence/)
- [AI Clinical Monitoring](https://www.clinicaltrialvanguard.com/tag/ai-clinical-monitoring/)
- [Phase 3 Oncology](https://www.clinicaltrialvanguard.com/tag/phase-3-oncology/)
- [CliniBiz](https://www.clinicaltrialvanguard.com/tag/clinibiz/)
- [AI Decision Support](https://www.clinicaltrialvanguard.com/tag/ai-decision-support/)
- [Clinical Trial Data Integrity](https://www.clinicaltrialvanguard.com/tag/clinical-trial-data-integrity/)
- [FDA AI/ML Guidance](https://www.clinicaltrialvanguard.com/tag/fda-ai-ml-guidance/)
- [AI Clinical Decision Support](https://www.clinicaltrialvanguard.com/tag/ai-clinical-decision-support/)
- [FDA AI Regulation](https://www.clinicaltrialvanguard.com/tag/fda-ai-regulation/)
- [Digital Health Technology](https://www.clinicaltrialvanguard.com/tag/digital-health-technology/)
- [AI Monitoring](https://www.clinicaltrialvanguard.com/tag/ai-monitoring/)
- [NIH funding](https://www.clinicaltrialvanguard.com/tag/nih-funding/)
- [K awards](https://www.clinicaltrialvanguard.com/tag/k-awards/)
- [clinical trial workforce](https://www.clinicaltrialvanguard.com/tag/clinical-trial-workforce/)
- [clinician-scientists](https://www.clinicaltrialvanguard.com/tag/clinician-scientists/)
- [research training pipeline](https://www.clinicaltrialvanguard.com/tag/research-training-pipeline/)
- [vitiligo](https://www.clinicaltrialvanguard.com/tag/vitiligo/)
- [upadacitinib](https://www.clinicaltrialvanguard.com/tag/upadacitinib/)
- [Phase 3 clinical trials](https://www.clinicaltrialvanguard.com/tag/phase-3-clinical-trials/)
- [FDA dermatology](https://www.clinicaltrialvanguard.com/tag/fda-dermatology/)
- [Contract Harmonization](https://www.clinicaltrialvanguard.com/tag/contract-harmonization/)
- [CTMS Migration](https://www.clinicaltrialvanguard.com/tag/ctms-migration/)
- [AI in Drug Development](https://www.clinicaltrialvanguard.com/tag/ai-in-drug-development/)
- [Antibody Discovery](https://www.clinicaltrialvanguard.com/tag/antibody-discovery/)
- [Computational Biology](https://www.clinicaltrialvanguard.com/tag/computational-biology/)
- [Cannabinoid Therapy](https://www.clinicaltrialvanguard.com/tag/cannabinoid-therapy/)
- [Epigenetic Clocks](https://www.clinicaltrialvanguard.com/tag/epigenetic-clocks/)
- [Longevity Trials](https://www.clinicaltrialvanguard.com/tag/longevity-trials/)
- [KRYSTAL-12](https://www.clinicaltrialvanguard.com/tag/krystal-12/)
- [adagrasib](https://www.clinicaltrialvanguard.com/tag/adagrasib/)
- [patient-reported outcomes](https://www.clinicaltrialvanguard.com/tag/patient-reported-outcomes/)
- [KRASG12C NSCLC](https://www.clinicaltrialvanguard.com/tag/krasg12c-nsclc/)
- [community-based research](https://www.clinicaltrialvanguard.com/tag/community-based-research/)
- [sponsor-CRO collaboration](https://www.clinicaltrialvanguard.com/tag/sponsor-cro-collaboration/)
- [genomic sequencing](https://www.clinicaltrialvanguard.com/tag/genomic-sequencing/)
- [Patient Safety Monitoring](https://www.clinicaltrialvanguard.com/tag/patient-safety-monitoring/)
- [Regenxbio](https://www.clinicaltrialvanguard.com/tag/regenxbio/)
- [Precision Psychiatry](https://www.clinicaltrialvanguard.com/tag/precision-psychiatry/)
- [Veeva Vault CRM](https://www.clinicaltrialvanguard.com/tag/veeva-vault-crm/)
- [sponsor technology](https://www.clinicaltrialvanguard.com/tag/sponsor-technology/)
- [eClinical systems](https://www.clinicaltrialvanguard.com/tag/eclinical-systems/)
- [Conversion Therapy](https://www.clinicaltrialvanguard.com/tag/conversion-therapy/)
- [FDA Oncology](https://www.clinicaltrialvanguard.com/tag/fda-oncology/)
- [cyberattack](https://www.clinicaltrialvanguard.com/tag/cyberattack/)
- [eDC systems](https://www.clinicaltrialvanguard.com/tag/edc-systems/)
- [site continuity](https://www.clinicaltrialvanguard.com/tag/site-continuity/)
- [CAR T cell therapy](https://www.clinicaltrialvanguard.com/tag/car-t-cell-therapy-2/)
- [rheumatoid arthritis](https://www.clinicaltrialvanguard.com/tag/rheumatoid-arthritis/)
- [genomic diagnostics](https://www.clinicaltrialvanguard.com/tag/genomic-diagnostics/)
- [precision medicine](https://www.clinicaltrialvanguard.com/tag/precision-medicine/)
- [clinical data integration](https://www.clinicaltrialvanguard.com/tag/clinical-data-integration/)
- [ATTR-CM](https://www.clinicaltrialvanguard.com/tag/attr-cm/)
- [eplontersen](https://www.clinicaltrialvanguard.com/tag/eplontersen/)
- [trial stratification](https://www.clinicaltrialvanguard.com/tag/trial-stratification/)
- [CARDIOTTRansform](https://www.clinicaltrialvanguard.com/tag/cardiottransform/)
- [enrollment acceleration](https://www.clinicaltrialvanguard.com/tag/enrollment-acceleration/)
- [investigator readiness](https://www.clinicaltrialvanguard.com/tag/investigator-readiness/)
- [WEE1 inhibitor](https://www.clinicaltrialvanguard.com/tag/wee1-inhibitor/)
- [Clinical Data Synthesis](https://www.clinicaltrialvanguard.com/tag/clinical-data-synthesis/)
- [DOJ Settlement](https://www.clinicaltrialvanguard.com/tag/doj-settlement/)
- [Opioid Marketing](https://www.clinicaltrialvanguard.com/tag/opioid-marketing/)
- [Regulatory Accountability](https://www.clinicaltrialvanguard.com/tag/regulatory-accountability/)
- [Pharma Compliance](https://www.clinicaltrialvanguard.com/tag/pharma-compliance/)
- [Clinical AI Governance](https://www.clinicaltrialvanguard.com/tag/clinical-ai-governance/)
- [AI Accountability](https://www.clinicaltrialvanguard.com/tag/ai-accountability/)
- [New Approach Methodologies](https://www.clinicaltrialvanguard.com/tag/new-approach-methodologies/)
- [Triple-Negative Breast Cancer](https://www.clinicaltrialvanguard.com/tag/triple-negative-breast-cancer/)
- [Atezolizumab](https://www.clinicaltrialvanguard.com/tag/atezolizumab/)
- [Phase I Operations](https://www.clinicaltrialvanguard.com/tag/phase-i-operations/)
- [CNS Autoimmune Disease](https://www.clinicaltrialvanguard.com/tag/cns-autoimmune-disease/)
- [FDA Rare Disease](https://www.clinicaltrialvanguard.com/tag/fda-rare-disease/)
- [Neuromyelitis Optica](https://www.clinicaltrialvanguard.com/tag/neuromyelitis-optica/)
- [siRNA therapeutics](https://www.clinicaltrialvanguard.com/tag/sirna-therapeutics/)
- [lipoprotein(a)](https://www.clinicaltrialvanguard.com/tag/lipoproteina/)
- [cardiovascular clinical trials](https://www.clinicaltrialvanguard.com/tag/cardiovascular-clinical-trials/)
- [RNA interference](https://www.clinicaltrialvanguard.com/tag/rna-interference/)
- [Addiction Neuroscience](https://www.clinicaltrialvanguard.com/tag/addiction-neuroscience/)
- [Novel Targets](https://www.clinicaltrialvanguard.com/tag/novel-targets/)
- [data monitoring committees](https://www.clinicaltrialvanguard.com/tag/data-monitoring-committees/)
- [early termination](https://www.clinicaltrialvanguard.com/tag/early-termination/)
- [Solute Carrier Transporters](https://www.clinicaltrialvanguard.com/tag/solute-carrier-transporters/)
- [FDA Drug-Drug Interactions](https://www.clinicaltrialvanguard.com/tag/fda-drug-drug-interactions/)
- [Vendor Management](https://www.clinicaltrialvanguard.com/tag/vendor-management/)
- [Phase 2a](https://www.clinicaltrialvanguard.com/tag/phase-2a/)
- [Proteomic Aging Clocks](https://www.clinicaltrialvanguard.com/tag/proteomic-aging-clocks/)
- [remote monitoring](https://www.clinicaltrialvanguard.com/tag/remote-monitoring/)
- [MS trials](https://www.clinicaltrialvanguard.com/tag/ms-trials/)
- [eCOA validation](https://www.clinicaltrialvanguard.com/tag/ecoa-validation/)
- [Generative AI](https://www.clinicaltrialvanguard.com/tag/generative-ai/)
- [clinical data management](https://www.clinicaltrialvanguard.com/tag/clinical-data-management/)
- [FDA regulatory framework](https://www.clinicaltrialvanguard.com/tag/fda-regulatory-framework/)
- [Psychedelic Drugs](https://www.clinicaltrialvanguard.com/tag/psychedelic-drugs/)
- [CNS Therapies](https://www.clinicaltrialvanguard.com/tag/cns-therapies/)
- [mitapivat](https://www.clinicaltrialvanguard.com/tag/mitapivat/)
- [thalassaemia](https://www.clinicaltrialvanguard.com/tag/thalassaemia/)
- [ENERGIZE-T](https://www.clinicaltrialvanguard.com/tag/energize-t/)
- [pyruvate kinase activator](https://www.clinicaltrialvanguard.com/tag/pyruvate-kinase-activator/)
- [transfusion-dependent](https://www.clinicaltrialvanguard.com/tag/transfusion-dependent/)
- [sponsor operations](https://www.clinicaltrialvanguard.com/tag/sponsor-operations/)
- [Biohaven](https://www.clinicaltrialvanguard.com/tag/biohaven/)
- [BHV-7000](https://www.clinicaltrialvanguard.com/tag/bhv-7000/)
- [Preclinical Safety](https://www.clinicaltrialvanguard.com/tag/preclinical-safety/)
- [ibogaine](https://www.clinicaltrialvanguard.com/tag/ibogaine/)
- [provider training](https://www.clinicaltrialvanguard.com/tag/provider-training/)
- [data standardization](https://www.clinicaltrialvanguard.com/tag/data-standardization/)
- [drug regulation](https://www.clinicaltrialvanguard.com/tag/drug-regulation/)
- [veterans health](https://www.clinicaltrialvanguard.com/tag/veterans-health/)
- [REMS](https://www.clinicaltrialvanguard.com/tag/rems/)
- [underrepresented populations](https://www.clinicaltrialvanguard.com/tag/underrepresented-populations/)
- [digital cognitive assessment](https://www.clinicaltrialvanguard.com/tag/digital-cognitive-assessment/)
- [remote screening](https://www.clinicaltrialvanguard.com/tag/remote-screening/)
- [anti-amyloid therapy](https://www.clinicaltrialvanguard.com/tag/anti-amyloid-therapy/)
- [HIV functional cure](https://www.clinicaltrialvanguard.com/tag/hiv-functional-cure/)
- [broadly neutralizing antibodies](https://www.clinicaltrialvanguard.com/tag/broadly-neutralizing-antibodies/)
- [analytical treatment interruption](https://www.clinicaltrialvanguard.com/tag/analytical-treatment-interruption/)
- [phase 2 clinical trial](https://www.clinicaltrialvanguard.com/tag/phase-2-clinical-trial/)
- [bNAb resistance](https://www.clinicaltrialvanguard.com/tag/bnab-resistance/)
- [Bipolar Disorder](https://www.clinicaltrialvanguard.com/tag/bipolar-disorder/)
- [Mood Stabilizers](https://www.clinicaltrialvanguard.com/tag/mood-stabilizers/)
- [liquid biopsy](https://www.clinicaltrialvanguard.com/tag/liquid-biopsy/)
- [EEG biomarkers](https://www.clinicaltrialvanguard.com/tag/eeg-biomarkers/)
- [site network operations](https://www.clinicaltrialvanguard.com/tag/site-network-operations/)
- [eCOA standardization](https://www.clinicaltrialvanguard.com/tag/ecoa-standardization/)
- [brain medicine](https://www.clinicaltrialvanguard.com/tag/brain-medicine/)

## Podcasts

- [The Clinical Trial Vanguard](https://www.clinicaltrialvanguard.com/podcasts/the-clinical-trial-vanguard/)
- [CliniCast](https://www.clinicaltrialvanguard.com/podcasts/clinicast/)